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Abstract 
Background: Polymyalgia rheumatica (PMR) is one of the most common inflammatory 
arthritic disorders seen in older people and is closely related to giant cell arteritis (GCA). 
Most PMR patients are diagnosed and managed in general practice yet primary care 
focused research is lacking.   
Methods:  Three complimentary studies were undertaken to investigate PMR and GCA in 
primary care.  
1. A systematic review investigating the diagnosis and diagnostic criteria for PMR 
2. A national questionnaire survey of 5000 randomly selected general practitioners 
(GPs)  
3. Qualitative telephone interview study of GPs. 
Results:  No validated diagnostic criteria or combination of investigations were identified 
that could be used for definitive PMR diagnosis. 1249 (25%) GPs responded to the 
questionnaire survey. 24 GPs were interviewed for the qualitative study. Features used by 
GPs to identify PMR were largely in-line with current guidance. Diagnosis was found to be 
challenging with GPs relying heavily on response to treatment with glucocorticoids. 
Guideline advised investigations were not routinely requested. Concerns surrounding 
long term treatment with glucocorticoids were widespread in relation to both potential 
adverse effects and on-going monitoring. 
Headache was the main symptom used to identify potential patients with GCA. Other 
symptoms indicative of GCA were less frequently used. Significant fears relating to 
missing a diagnosis of GCA exist as well as frustrations in forward treatment and 
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investigation of potential GCA patients with clear regional variations in assessment and 
referral pathways.  
Conclusion: For PMR, focused GP educational strategies are needed to promote the need 
to exclude relevant differential diagnoses and on-going vigilance for treatment 
complications. Raising awareness of the range of potential features that GCA can present 
with could aid and improve diagnosis. To complement this, a national standard for fast 
track pathways for suspected GCA patients to relevant expertise could help to improve 
care and outcomes for patients with GCA. 
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“There is, perhaps, no disease as to which professional opinion 
differs more than as to rheumatic gout. This diversity of views is 
unfortunate, as it affects the kind of treatment and mode of life of 
the patient, and it disturbs the lay mind and gives occasion for 
remarks as to the uncertainties of medicine.” 
 
William Bruce 1888 p811 
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Chapter 1: The history and epidemiology of polymyalgia rheumatica 
1.1 Introduction 
This thesis is concerned with polymyalgia rheumatica (PMR), and the attitudes and beliefs 
that general practitioners (GPs) have towards its diagnosis and management.  In this 
chapter, the content of the thesis will be introduced with a specific focus on the central 
disease being studied: polymyalgia rheumatica. Specific areas that will be covered include 
an introduction to PMR, the history of PMR, PMR in general practice and the 
epidemiology of PMR.   
 
1.2 Introduction to the disease polymyalgia rheumatica 
Polymyalgia rheumatica (PMR) is a relatively common inflammatory rheumatic condition 
that affects older people. [Michet and Matteson 2008] It is estimated that over 700,000 
Americans live with the condition. [Lawrence et al 2008] Patients presenting with PMR 
are typically over 60 years of age [Smeeth et al 2006] and classically suffer with bilateral 
shoulder and/or hip girdle pain, morning stiffness and muscle aches, although the 
presenting features can be non-specific and vary widely. [Dasgupta et al 2008] Patients 
with PMR commonly have elevated inflammatory markers (including the erythrocyte 
sedimentation rate (ESR), C Reactive Protein (CRP), plasma viscosity (PV) or fibrinogen 
[Dasgupta et al 2010, McCarthy et al 2013]). Typically, patients with PMR respond rapidly 
to treatment with low dose glucocorticoids (e.g. 15mg of prednisolone daily). [Dasgupta 
et al 2010] No diagnostic test exists for PMR, therefore diagnosis can be challenging in 
view of the non-specific nature of the presentation of PMR and because of a wide range 
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of differential diagnoses which also respond to low dose glucocorticoids and can present 
in a similar way. The differential diagnosis of PMR is discussed in more detail later in this 
chapter. 
PMR is closely associated with giant cell arteritis (GCA). Around 1 in 5 patients with PMR 
develop GCA during their illness and between 40 and 60% of patients with GCA report 
symptoms of PMR. [Salvarani et al 2008] GCA is the most common large vessel vasculitis 
with over a quarter of a million Americans living with the disease. [Lawrence et al 2008] 
The features of GCA are caused by inflammation, predominantly of the branches of the 
external carotid artery, ciliary artery and retinal arteries. [Barraclough et al 2012] If 
treatment is delayed, GCA can potentially lead to irreversible blindness. Because of this 
intimate overlap between PMR and GCA, practitioners treating PMR have to be vigilant to 
the possibility of co-existing GCA. It is also important to discuss and investigate GCA when 
researching PMR. This thesis will therefore address issues surrounding the diagnosis and 
management of GCA as a secondary research question.  
In the United Kingdom PMR is a condition which is diagnosed and managed 
predominantly in primary care [Barraclough et al 2008, Helliwell et al 2013] yet there has 
been limited research undertaken in this setting. Given the paucity of research in this 
setting, this thesis has been undertaken to investigate the diagnosis and management of 
PMR in a primary care setting. The following sections describe the history of PMR (Section 
1.3), the epidemiology of PMR (section 1.4) and PMR in a primary care context (Section 
1.5). Section 1.6 focuses on GCA. 
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1.3 The History of PMR 
William Bruce in his article entitled “Senile Rheumatic Gout” published in the BMJ in 1888 
is often attributed with publishing the first description of what we now consider to be 
polymyalgia rheumatica. In this paper he notes that: 
“There is, perhaps, no disease as to which professional opinion differs more than as to 
rheumatic gout. This diversity of views is unfortunate, as it affects the kind of treatment 
and mode of life of the patient, and it disturbs the lay mind and gives occasion for remarks 
as to the uncertainties of medicine.” Bruce 1888 p811 
 
In this seminal work on polymyalgia rheumatica, he described five cases that appeared to 
be distinct from rheumatoid arthritis and gout. [Bruce 1888] All five cases however were 
male and, as we know now, polymyalgia rheumatica tends to affect women more than 
men.  
In post Second World War Europe, several case series of potential polymyalgia 
rheumatica patients that were published, with different terms for PMR being coined. 
These included descriptors such as periarthrosis humeroscapularis and peri-extra-articular 
rheumatism. [Hunder 2006] 
Barber (1957) has been attributed as being the first person to use the term “polymyalgia 
rheumatica.” His case series entitled “Myalgic syndrome with constitutional effects: 
polymyalgia rheumatica” was published in the Annals of Rheumatic Diseases in 1957. 
[Barber 1957] This article identified morning stiffness as one of the cardinal features of 
PMR. It also identified other features which have been shown to be consistently 
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associated with PMR. These include anaemia, raised erythrocyte sedimentation rate 
(ESR), and bilateral shoulder and hip girdle pain and/or discomfort, which are now widely 
accepted as symptoms typical of PMR. Most case series agree that given time, patients 
would eventually improve. Barber however noted the rapid response demonstrated by 
patients who were given cortisone treatment. 
“no doubt of their immediate response to corticosteroids” Barber 1957 p231 
 
Barber also recognised the quite significant impacts that PMR could have on patient’s 
everyday life saying, 
“The somewhat melodramatic description of their pain by these patients tends to 
suggest a diagnosis of psychoneurosis until the E.S.R. has been measured.”  
Barber 1957 p232 
 
Barber also advised that the diagnosis be based largely on negative findings (i.e. the 
absence of joint involvement, muscle weakness or atrophy, after a lengthy period of 
observation). Barber’s case series of 12 patients included 2 men and 10 women. [Barber 
1957] 
Gordon (1960) in the Quarterly Journal of Medicine confirmed Barber’s finding in relation 
to corticosteroid treatment noting that: 
“In every case, if an adequate dose was given, a remarkable and rapid remission of 
symptoms was induced within 48 hours.” Gordon 1960 p482 
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This paper also highlighted that all pain and stiffness had completely or almost completely 
disappeared with treatment. [Gordon 1960] 
Boyle was the first to advocate the use of low dose glucocorticoids for the treatment of 
PMR. [Boyle and Beatty 1961] 
“Six patients had symptoms severe enough to warrant a trial of steroids, and all of 
them made a good response to prednisone in doses of 15 mg per day or less. Once 
again, however, there was a prompt relapse of symptoms if the drug was 
withdrawn” Boyle 1961 p22 
 
An editorial written in the BMJ in December of 1957 further highlighted that patients with 
PMR tended to be middle or old age women and highlighted the controversies and 
difficulties in diagnosing PMR in view of its lack of clear physical signs or symptoms adding 
that: 
“often the patients’ symptoms were wrongly attributed to psychogenic causes”  
BMJ 1957 (editorial)  p1483 
 
Bruce’s case series of PMR patient was described over 125 years ago but sadly, much of 
the original writing of Bruce, particularly the ‘diversity of views’ still holds true today. ESR 
remains the predominant investigation used to help diagnose patients, glucocorticoids 
remain the mainstay of treatment and it still causes significant impacts on patients’ lives 
both prior to diagnosis and during treatment.  
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1.4 The epidemiology of PMR  
1.4.1 Introduction and methods used to investigate the epidemiology of PMR 
The incidence of PMR (number of new cases per population at risk in a given time period) 
varies geographically, and with age. PMR is rare in patients under the age of 50. [Smeeth 
2006] The epidemiological study of PMR is challenging, as it is difficult to determine and 
compare incidence and prevalence (proportion of the population having the condition) 
rates between geographical regions, as standardised methodologies and uniform 
diagnostic classification criteria are not widely used. There is currently no gold standard 
diagnostic test for PMR, however, classification criteria that conform to the American 
College of Rheumatology (ACR) standards have now been developed for use in future 
research. [Dasgupta et al 2012] This section reviews the literature concerning the 
epidemiology of PMR and was undertaken as part of the initial phases of the PhD in 
November 2011. 
In order to identify relevant evidence on the epidemiology of PMR, a literature search of 
Medline and EMBASE was undertaken using the thesaurus explode function and the 
search terms polymyalgia rheumatica, epidemiology, incidence and prevalence. Titles and 
abstracts were screened and the reference lists from identified citations reviewed for 
other additional publications that were potentially relevant. 
The majority of the studies identified related to the incidence of PMR and the findings of these 
incidence studies are summarised in Table 1.1. The identified studies were usually undertaken 
in North America or Europe and are described in more detail the following sections.  
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Table 1.1 Summary of the epidemiology of polymyalgia rheumatica 
Reference Setting Study Type Population Inclusion Criteria Female: Male 
Ratio 
 
Epidemiological results 
 
Chuang   
1982  
Minnesota,  
USA 
Prospective 
observational 
study 
 
 
n=96 Chuang/Hunder classification 
criteria  
1.7:1 Age Group 
(years) 
Incidence 
(per 100,000 
patient years) 
0-49 0.1 
50-59 19.8 
60-69 48.1 
70-79 112.2 
80+ 86.2 
All ages 11.1 
 
 
Doran 
2002  
Minnesota, 
USA 
Prospective 
observational 
study 
n=378  Chuang/Hunder classification 
criteria  
2:1 In patients over 50 years of 
age, incidence was 58.7 per 
100,000 patient years 
 
Gonzalez-Gay 
1999  
 
Xeral Lugo 
Hospital, 
Spain 
Retrospective 
observational 
study 
n=185 Clinical records of patients 
diagnosed with PMR between 
January 1987 and December 1996 
Excluded patients with conditions 
mimicking PMR 
Patients sub-grouped into total 
PMR (PMR patients including 
PMR  with associated GCA) and 
isolated PMR (only PMR patients 
with no associated GCA)  
Not given Total PMR (PMR  with 
associated GCA): 
18.67 per 100,000 patient 
years 
 
Isolated PMR (no evidence of 
associated giant cell arteritis): 
13.52 per 100,000 patient 
years 
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Reference Setting Study Type Population Inclusion Criteria Female: Male 
Ratio 
 
Epidemiological results 
 
Gran 
1997 
 
Aust Agder, 
Norway 
Prospective 
observational 
study 
n=322 All physicians suspecting PMR 
asked to refer patients to 
rheumatology.  
Bird1 classification criteria used as 
inclusion criteria for study. 
 
1.65:1 Incidence in the population of 
50 years and above 
112.6 per 100,000 patient 
years 
Kyle  
1985 
 
Cambridge, 
UK 
Cross sectional 
study 
n=650 650 patients over the age of 65 
invited to an interview to 
undertake a previously validated 
(specificity 97%) screening 
questionnaire1 administered by 
interview. 
Positively identified patients were 
then assessed by a 
rheumatologist and included the 
study if the Jones/Hazelman 
criteria were achieved 
 
Not given Incidence in patients over the 
age of 65 years old 4/1000 
patient years. (400 per 100,000 
patient years) 
Salvarani   
1991 
 
Reggio 
Imilia,  
Italy 
Retrospective 
observational 
study 
n=99 Persistent pain for more than one 
month involving two of the 
following: neck, shoulder or 
pelvic girdle 
EMSb for more than one hour 
Rapid response to prednisolone 
of less than 20mg per day 
Absence of other diseases which 
could mimic these symptoms 
2:1 Incidence in patients over the 
age 50 years: 
12.7 per 100,000 patient years 
 
 
9  
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Reference Setting Study Type Population Inclusion Criteria Female: Male 
Ratio 
 
Epidemiological results 
 
Schaufelberger 
1995   
 
Goteburg, 
Sweden 
Prospective 
observational 
study 
 
 
n=220 Pain and stiffness affecting at 
least  two groups of: neck, 
shoulders, upper arms, hips and 
thighs for  two weeks 
Absence of inflammatory arthritis 
Elevated ESRa  of more than 40 
Age of 50 or more 
No evidence of: rheumatoid 
arthritis, systemic lupus 
erythematosis, periarteritis 
nodosa, infection or malignant 
disease. 
2.49:1 Incidence in patients with PMR 
with negative temporal artery 
biopsy2 was: 
17 per 100,000 patient years  
 
Incidence in patients older than 
50 with PMR with negative 
temporal artery biopsy2 was: 
50 per 100,000 patient years 
 
       
Smeeth  
2006 
 
UK General 
Practice 
Research 
Database 
(GPRD) UK 
Retrospective 
observational 
study  
n=15013 Older than 40 years of age 
First diagnosis of PMR entered 
into their general practice record 
2 prescriptions for oral 
corticosteroids, one within six 
months of diagnosis and the two 
prescriptions being within six 
months of each other 
 
2:1 Age Group 
(years) 
Incidence 
(per 100,000 
patient years) 
40-49 4.1 
50-59 27 
60-69 98 
70-79 229 
80+ 222 
All ages  84 
 
a ESR: erythrocyte sedimentation rate,  bEMS: early morning stiffness 
11) Have you at any time had arthritis or rheumatism, 2) Do you have stiffness around the neck and both shoulder, 3) Do you wake up with stiffness or aching 
around your shoulder. Does this stiffness last for more than one hour 4) Do you wake up with stiffness or aching in your joints 5) Have you ever had any swelling in 
any joints 6) Symptoms of temporal arteritis: Scalp tenderness, Severe headaches, Visual loss. 
1
0 
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Two prevalence studies were identified. A study conducted by Lawrence (2008), derived 
the prevalence of PMR using published data from small scale studies and the 
corresponding 2005 United States Census Bureau population estimates. They concluded 
that the number of people with PMR in the United States was 711,000. [Lawrence et al 
2008] Salaffi (2005) in Marches, Italy conducted a cross-sectional study of 3664 patients. 
Patients identified with a possible musculoskeletal disorder were then formally assessed 
by a rheumatologist and diagnosed according to internationally accepted classification 
criteria (Bird classification criteria were used for PMR patients. [Bird et al 1979]) The 
study had a 58.8% response rate and the prevalence of PMR above the age of 50 years 
old was 0.7%. This was equivalent to rheumatoid arthritis in patients over 50 years old. 
[Salaffi et al 2005] 
 
1.4.3 Age 
Studies suggest that PMR is rare in patients under the age of 50. Smeeth (2006) found 
that the age adjusted incidence of PMR in the 40-49 year group was 4.1 per 100,000 
patient years which compared to an age adjusted incidence of 229 per 100,000 patient 
years in the 70 to 79 year old group. [Smeeth et al 2006] Chuang (1982) described only 
one patient younger than 50 years of age (who was excluded from the main analysis in 
view of their age) resulting in an incidence of 0.1 per 100,000 patient years in people 
younger than 50. Those presenting with suspected PMR under the age of 50 years are 
often excluded from research studies as they may have atypical disease. The 
epidemiology of PMR in patients under the age of 50 has therefore not been widely 
studied. [Chuang et al 1982] 
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1.4.4 Incidence 
The highest incidence rate reported in the identified studies was 112.6 per 100,000 
patient years in patients aged over 50 years in Aust Agder, Southern Norway. [Gran and 
Myklebust 1997] By contrast the lowest reported incidence rate was found in Reggio 
Imilia, Northern Italy which had an incidence of 12.7 per 100,000 patient years in those 
aged over 50 years. [Salvarani et al 1991] Of particular note is the increasing incidence of 
PMR with increasing latitude. This has in part been attributed to genetic and 
environmental factors [Cimmino et al 1997], but may also be due to varying 
methodological approaches which will be discussed in more detail in Section 1.4.4.  
Most relevant to this thesis however, is the paper published by Smeeth (2006) as it is a 
study focusing on the epidemiology of PMR in the UK. This study used one of the largest 
cohorts of patients diagnosed with PMR. Data were extracted from the General Practice 
Research Database (GPRD). This database consists of the electronic medical records of 
patients registered with contributing UK general practices and relied on the appropriate 
diagnostic code for PMR being used in the database to identify patients with PMR. 
Patients who were younger than 40 years old were excluded. One limitation of this 
dataset is uncertainty around the diagnostic accuracy and the lack of a standardised 
approach to diagnosis. Therefore, as a proxy to improve diagnostic accuracy, cases 
included in the analysis also had to have had two prescriptions for glucocorticoids, the 
first within 6 months of the diagnosis date and the second within six months of the first 
prescription being issued. The overall incidence of PMR was 8.42 per 10,000 person years 
with a female to male ratio of 2:1. As other epidemiological studies of PMR have also 
demonstrated, incidence rates increase sharply with increasing age such that the highest 
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incidence of PMR in this study was found in women in the 70 to 79-year-old group (22.9 
per 10,000 patient years). [Smeeth et al 2006] 
PMR occurs more frequently in women. The female to male ratio for patients with PMR 
varies between 1.65 to 1 to 2.49 to 1. [Gran and Myklebust 1997, Schaufelberger et al 
1995] 
 
1.4.4 Factors impacting on the epidemiological research of PMR 
 The published incidence of PMR ranges from a low of 12.7/100,000 patient years in Italy 
[Salvarani et al 1991] to a high of 112.6/100,000 patient years in Norway. [Gran and 
Myklebust 1997] This variation in incidence has led some researchers to hypothesise that 
PMR is linked to latitude. [Cimmino et al 2000] However, differences in incidence are also 
likely to reflect a lack of standardised recruitment methodologies and participant 
classification. Studies identified recruited patients predominately from secondary care 
settings [Gonzalez-Gay et al 1999], although an attempt was made by some to include 
primary care patients. [Gran and Myklebust 1997]  Whilst the diagnostic accuracy in 
general practice has been questioned [Bahlas et al 2000], the recently published 
classification criteria highlight the challenges of diagnosing PMR in all settings. [Dasgupta 
et al 2012] Studies only including those from secondary care are likely to underestimate 
the true incidence of PMR, as patients with classical disease are seldom referred to 
specialist services [Barraclough et al 2008, Helliwell et al 2013] and will not be included in 
incidence estimates based on hospital studies. It is also a possibility that for some studies 
conducted in some regions of the world, the availability of high quality and accurate 
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primary care data may simply not be available and so secondary care data has to be relied 
upon to conduct such studies again resulting in lower overall incidence estimates. 
Conversely, primary care database studies, may result in over or under-estimates of 
incidence and or prevalence of PMR due to diagnostic inaccuracy. As such, the true 
population level burden associated with PMR is largely an estimate.   
 
1.5 Polymyalgia rheumatica and primary care  
1.5.1 Introduction 
Primary care in the UK remains, for most patients, the first point of access to medical 
care. General practitioners (GPs) are defined by WONCA Europe (World Organization of 
National Colleges, Academies and Academic Associations of General Practitioners/Family 
Physicians) as: 
“specialist physicians trained in the principles of the discipline. They are personal 
doctors, primarily responsible for the provision of comprehensive and continuing 
care to every individual seeking medical care irrespective of age, sex and illness. In 
negotiating management plans with their patients they integrate physical, 
psychological, social, cultural and existential factors, utilising the knowledge and 
trust engendered by repeated contacts.” 
[http://www.woncaeurope.org/sites/default/files/documents/Definition%203rd%20ed%
202011%20with%20revised%20wonca%20tree.pdf. Accessed 7/12/2015] 
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GPs undertake over 90% of medical contacts in the UK National Health Service (NHS) and 
are therefore key to the early identification and on-going management of many chronic 
diseases. PMR and GCA are no exception to this, and as such GPs need to be aware of the 
possible diagnosis of PMR or GCA, given that they are likely to be the first clinicians to see 
patients presenting with these conditions. GPs are also well placed to provide follow up 
and continuing care and support for patients with PMR and GCA. 
PMR can be challenging to diagnose, as early symptoms can be non-specific and there is 
currently no gold standard diagnostic test. Guidelines on the diagnosis and management 
of PMR were published by the British Society of Rheumatology and British Health 
Professionals in Rheumatology in 2010.[Dasgupta et al 2010] These guidelines, 
summarised in Figure 1.1, represent a significant step forward for clinicians, as no widely 
accepted guidelines describing diagnosis and management previously existed. The 
guidelines however, are largely based on secondary care expert opinion. This reflects the 
lack of research surrounding PMR and suggests difficulties in the integration of primary 
and secondary care for the management of rheumatological disorders. Expert opinion is 
often considered to be low quality evidence. [Greenhalgh 1997] Furthermore, expert 
consensus evidence is less likely to be relevant in a different healthcare setting where 
patients typically have a different range of symptoms and a different response to 
treatment.    
Jordan (2010) reported that a general practitioner working full-time with a list size of 
approximately 2500 patients could expect to consult with five patients with PMR 
annually. [Jordan 2010] These findings relate to an average per general practitioner 
calculated from pooled consultation data obtained from twelve general practices and 
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assumes a practice size of 10,000 patients with four full time general practitioners. The 
data does not however, specify whether the encounter was a first encounter, new 
encounter or follow up encounter and compared to osteoarthritis (180 consultations 
annually) or gout (35 consultations annually) in the same study, the workload associated 
with PMR in primary care is relatively small. [Jordan 2010]  
The frequency with which PMR is encountered by GPs will vary depending on the 
demographic of the practice population. However, based on the overall incidence rates 
given by Smeeth [Smeeth et al 2006] a full time GP can expect to see one or two new 
cases annually.  
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Figure 1.1. Summary of BSR/BHPR guidelines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure developed from BSR and BHPR guidelines [Dasgupta et al 2010]
1) Safe, stepped, diagnostic 
process 
 
2) Documentation of a 
minimum data set 
6) Bone protection 
3) Suggested criteria for early 
specialist referral 
5) Regular follow up 
4) Tailored tapering of steroid 
dose 
Core inclusion 
 Age greater than 50 years 
 Bilateral shoulder and or hip girdle pain 
 Morning stiffness less than 45 minutes 
 Evidence of an acute phase response 
Core Exclusion 
 Active infection 
 Evidence of malignancy 
 Active GCA 
Exclusion of other causes 
Assess response to standard dose of 
steroids (15mg) 
FBC, U&E, LFT, Bone, ESR/CRP, protein 
electrophoresis, RF, TFT, Urinary Bence Jones 
protein, CK, Dipstick urinalysis. Consider ANA, 
anti CCP, Chest Xray 
 Age less than 60 
 Chronic onset ( more than 2 months) 
 Lack of shoulder involvement 
 Lack of inflammatory stiffness 
 Prominent systemic features 
 Features of other rheumatic disease 
 Normal or very high inflammatory markers 
 Also consider referral if - poor 
response/sustained response to treatment, 
prolonged treatment ( more than 2 years), 
contraindications to treatment, inability to 
reduce steroid dose 
Advised prednisolone dose: 15 mg for 3 weeks, 
12.5 mg for 3 weeks, 10mg for 4-6 weeks, then 
reduce by 1mg every 4-8 weeks 
Suggested follow-up 
 Weeks 0, 1, 3 6 
 Months 3, 6, 9, 12 
 High Risk: prophylaxis indicated 
 Low risk: Calcium and Vitamin D 
supplementations and Dexa scan. Treatment 
indicated if T score less than -1.5 
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1.5.2 Brief review and summary of the literature investigating PMR in the primary care 
setting 
The following section describes in brief a scoping investigation of the literature relating to 
PMR in primary care. 
 
1.5.3 Methods used in identifying the literature investigating PMR in the primary care 
setting 
To understand the extent of research conducted on PMR in primary care and to inform 
the original research planned for this thesis, an exploratory scoping literature search of 
Medline and Embase was conducted for primary care focused studies (September 2011). 
The search term “polymyalgia rheumatica” and the thesaurus explode function (which 
allows all related terms to be included in the search) was used for both Medline and 
Embase to identify PMR studies. This was combined with a search undertaken again using 
the thesaurus explode function searching for “primary care”, “general practice” and 
“family medicine”.  The abstracts of identified studies were then reviewed to identify 
original research studies with a focus on general practice. 14 full text studies were 
identified, three of which have already been discussed, as they were epidemiology 
studies. An additional study [Helliwell et al 2013] was identified subsequently to the initial 
search and is included in these findings. 
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1.5.4 Review findings of scoping literature search 
The highlights of the identified studies are summarised under the two main themes of 
diagnosis and management. Articles by Kyle (1985), Salaffi (2005) and Smeeth (2006) 
were identified but have been presented in the sections relating to epidemiology and 
Table 1.1 and will not be discussed again. 
 
1.5.4.1 Diagnosis 
Studies relating to the diagnosis of PMR in general practice are summarised in Table 1.2.  
Barraclough (2008) undertook a study using routinely collected GP consultation data from 
three general practices in Gloucester, UK. This study aimed to investigate the diagnosis 
and management of PMR in general practice. 183 patients with PMR were identified. The 
most common feature used in diagnosis was shown to be proximal muscle pain, which 
was documented in 82% of patients identified with PMR. Raised inflammatory markers 
and a significant response to glucocorticoid were other important features used for 
diagnosis. The study also highlighted that GPs were not using established diagnostic 
criteria. [Barraclough et al 2008]  
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Table 1.2 Summary of primary-care based studies relating to the diagnosis of PMR. 
Reference Title Study Design Aim Study Findings 
 
Bahlas 
2000 
Utilisation and costs of 
investigations, and 
accuracy of diagnosis 
of PMR by family 
physicians 
 
Retrospective chart review of 
123 patients referred to a 
tertiary rheumatology clinic  
 
To ascertain the costs of PMR 
investigations and accuracy of 
diagnosis of family physicians 
 
An accurate diagnosis of PMR was made in 24% of 
cases 
There was a high cost associated with investigations 
for PMR 
Barraclough 
2008 
Polymyalgia 
rheumatica in primary 
care: a cohort 
study of the diagnostic 
criteria and outcome 
Retrospective notes review, 
three general practices in 
Gloucester UK between  
1994-2003 
To identify the features used 
to diagnose PMR, benchmark 
these against diagnostic 
criteria and identify features 
of diagnostic importance 
 
11% of patients had a normal ESR
a 
Most common features documented were: 
Proximal muscle pain (82%) 
Raised inflammatory markers (87%) 
A clinical response to glucocorticoids (91%)  
Being female and raised inflammatory markers were 
associated with longer treatment duration. 
17% were referred for specialist review 
 
Coomes  
1976 
A prospective study of 
102 patients with the 
polymyalgia 
rheumatica syndrome 
Prospective observational 
study 
To study prospectively a 
cohort of patients referred by 
GPs to a secondary care 
rheumatology clinic who 
were  diagnosed with either 
PMR or GCA 
 
Diagnosis mentioned in referral letter correct was 
correct 4% of the time between 1964-69 and 10% of 
the time between 1970-74  
 
Cope 
1969 
 
Polymyalgia 
rheumatica in general 
practice 
 
Case series of 5 PMR patients 
seen in general practice 
To describe 5 cases of PMR 
encountered in a rural 
general practice 
PMR is a more common disease than expected and in 
the five cases described, raised ESR
a 
and weight loss 
were constant findings 
 
 
 
2
0 
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Reference Title Study Design Aim Study Findings 
 
Gamez-Nava 
1998 
Referral and diagnosis 
of common rheumatic 
diseases by primary 
care physicians 
 
Retrospective observational 
study 
To describe the primary care 
patterns of referral for 
musculoskeletal disorders.  
Probability of a GP detecting PMR (sensitivity) 60%, 
Probability of a GP excluding PMR (specificity) 98% 
 
 
Helliwell 
2013 
Polymyalgia 
rheumatica: diagnosis, 
prescribing, and 
monitoring in general 
practice 
Retrospective observational  
study  
To investigate the diagnostic 
processes, management, and 
monitoring of patients with 
PMR in UK primary care. 
 
Identification and initial management is appropriate. 
Documentation of a process of exclusion of mimicking 
disorders and consideration of prophylaxis for 
potential treatment adverse effects could be improved 
upon. 
Referral for specialist review was made in  44.4% of 
cases 
 
Jones 
1981 
Polymyalgia 
rheumatica and giant 
cell arteritis. a difficult 
diagnosis 
Prospective observational 
study 
To identify the difficulties and 
challenges associated with 
diagnosing PMR 
Referral of PMR patients to specialist settings are 
more likely to be those with an atypical presentation 
and will consequently be more likely to cause 
diagnostic difficulty.  
Cohorts of patients from hospital practice alone 
cannot be considered to present a typical picture of 
the disease. 
 
Jordan 
2010 
 
Consultations for 
selected diagnoses 
and regional problems 
 
 
Retrospective observational 
study 
To illustrate the frequency of 
consultations in general 
practice every year  for 
selected musculoskeletal 
disorders 
 
 
 
 
 
 
12 practices contributing consultation data to the 
Keele GP research partnership. Results presented per 
10,000 patients.  
12% of all consultations with a diagnosis were for 
musculoskeletal disorders. 20 were for PMR 
2
1 
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Reference Title Study Design Aim Study Findings 
 
Kremers 
2005 
Use of physician 
services in a 
population-based 
cohort of patients with 
polymyalgia 
rheumatica 
over the course of 
their disease 
 
Prospective observational 
study 
Describe the use of generalist 
and specialist services in a 
cohort of patients with PMR  
39.6% exclusively managed by a general physician 
28% had 1 rheumatology review early in the illness  
There was a trend towards younger patients, patients 
with a normal/near normal ESR
a 
and patients with 
multi-morbidity being referred for specialist review 
Majority of care (67%) provided by generalists 
 
Turner 
1983 
Polymyalgia 
rheumatica: a general 
practice 
experience 
Case series review To describe the natural 
history, diagnostic challenges 
and outcomes of 10 patients 
diagnosed with PMR in 
general practice. 
Only descriptive findings of typical PMR features 
presented. Author concluded that with an aging 
population PMR would be more often encountered 
and that research should include patients recruited 
from general practice 
 
a ESR: erythrocyte sedimentation rate
2
2 
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Helliwell (2013) identified 304 PMR patients from the CiPCA (Consultations in Primary 
Care Archive) and PiPCA (Prescriptions in Primary Care Archive) databases. These 
databases consists of frozen consultation, prescribing and investigation data from local 
participating general practices which are part of the Keele GP Research Partnership 
(Staffordshire, UK) and undergo on-going training, assessment and feedback to ensure 
the quality of data and morbidity coding. [Porcheret et al 2004] This study investigated 
both diagnostic and management issues in general practice. Recording of diagnosis, 
identification and initial treatment appeared to be in-line with current guidance. 
However, documentation of a process of exclusion of other diagnoses could be improved 
upon. [Helliwell et al 2013] 
 
1.5.4.2 Referral for specialist review 
PMR in the UK is usually diagnosed and managed in non-specialist settings with referral 
for specialist review being made for between 17% [Barraclough et al 2008] and 44.4% 
[Helliwell et al 2013] of potential PMR patients (table 1.3). This finding however, is not 
confined to the UK. Kremers (2005) showed that 67% of care for PMR patients was 
provided by generalists in the Olmstead County area in the USA [Kremers et al 2005] 
whilst Binard (2009) demonstrated that over 40% of GPs who took part in their French 
study on PMR did not request rheumatology reviews for their patients. [Binard et al 2009]  
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Table 1.3 Referral rates 
Author 
(Year) 
Country  
(Region) 
Proportion referred for 
specialist review 
 
Barraclough  
2008 
UK 
Gloucestershire 
 
17% 
Binard 
2009 
 
France 
 
41.7% 
Helliwell 
2013 
UK  
Staffordshire 
 
44.4% 
Kremers 
2005 
USA 
Minnesota 
 
61.4% 
 
 
Much has been written about the diagnostic accuracy of a primary care PMR diagnosis. 
Coomes (1976) suggested that general practitioners diagnosis of PMR was correct in just 
4% of cases in their study conducted between 1964 and 1969. This had risen to a 
diagnostic accuracy of 10% when replicated between 1970 and 1974. This study reviewed 
102 patients referred to the rheumatology clinic from general practice over a 13 year 
period, assessing diagnostic accuracy by reviewing the referral letter to see if PMR had at 
all been suggested. [Coomes et al 1976]  
In a more recent study Gamez-Nava (1998) investigated the referral and diagnosis of 
common rheumatic diseases by primary-care physicians. They examined referrals made 
by 305 primary-care physicians (711 consecutive patients) at a university-based 
outpatients department in Alberta, Canada. They considered the final rheumatologist’s 
diagnosis as the gold standard. Out of the 711 patients referred with different rheumatic 
disorders, 10 were referred with potential PMR and five patients had a final formal 
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diagnosis of PMR made, resulting in a calculated sensitivity of 50%. [Gamez-Nava et al 
1998] 
However, in part this may be explained by differences in reasons for referral. GPs may be 
less likely to refer patients where they are confident of the diagnosis and as such the PMR 
patients included in this study are likely to represent diagnostic uncertainty rather than 
diagnostic error. [Gamez-Nava et al 1998] 
Bahlas and colleagues conducted a study investigating the utilisation and costs of 
investigation and accuracy of diagnosis of PMR by family physicians. This was a 
retrospective chart review of 123 PMR patients referred to a tertiary rheumatology clinic 
again in Alberta, Canada. They reported that an accurate diagnosis of PMR was made in 
24% of cases and that there was a high cost of investigations associated with its diagnosis. 
[Bahlas et al 2000] As these were patients finally seen in a tertiary referral centre, it is 
likely that many were significantly atypical in presentation and so more extensively 
investigated with accompanying higher costs. As such, it would seem possible that these 
referrals were appropriate, but that this sample does not reflect the general PMR 
population.  
Kremers (2005) reviewed the use of physician services in a population-based cohort of 
patients with PMR over the course of their disease. This was based on the previously 
described Olmstead County cohort, USA. They found that 39.6% of the cohort was 
exclusively managed by a generalist and there was a trend to refer younger patients, 
patients with more comorbidities and patients with a normal or near normal ESR. They 
concluded that referral to a rheumatologist is driven by diagnostic uncertainty. Referral at 
times of diagnostic uncertainty is reflected in the current UK guidance which advises 
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referral for specialist review in younger patients, patients without shoulder involvement, 
normal or very high inflammatory markers, features suggestive of other rheumatic 
disease, prominent systemic features (for example significant weight loss or neurological 
signs) and treatment dilemmas (for example poor response to initial treatment or an 
inability to reduce the dose). [Dasgupta et al 2010] 
An alternative estimate of diagnostic accuracy is made by Quick (2012) who presented 
data from a rapid access specialist PMR clinic based in Bristol, UK. The clinic protocol 
encouraged referral of all potential cases of PMR from local general practices prior to 
treatment with glucocorticoids so that the patients’ presenting symptoms were not 
affected. 55% of patients referred to this clinic were confirmed cases of PMR. [Quick and 
Kirwan 2012] However, GPs may well have excluded PMR (as did the clinic) based on a 
poor response to treatment. Additionally, because of the low threshold for accepting 
potential suspected PMR patients, referrals may be done early and without a period of 
consideration that may have happened prior to the service becoming available. This 
therefore impacts on the accuracy of the study findings but does give a closer and more 
accurate estimate of clinical diagnostic accuracy when compared to the secondary care 
focused studies already described. 
 
1.5.3 Management 
UK published guidelines recommend that in uncomplicated cases of PMR management 
should be undertaken in the community. [Dasgupta et al 2010]  It was not however, until 
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these guidelines were published that a complete management process was brought 
together in a single guideline.  
Currently, the most accepted form of treatment is with low-dose glucocorticoids, typically 
at an initiating dose of 15mg of prednisolone followed by a slow reduction in dose over a 
period of 18-24 months. This suggested treatment regimen is summarised in Box 1.1  
Box 1.1 Suggested glucocorticoid treatment and dose reduction regimen 
 
 
 
 
Adapted from BSR/BHPR guidance [Dasgupta et al 2010] 
Treatment with glucocorticoids may be required for two years or more and as such 
management strategies need to account for any potential adverse treatment effects (Box 
1.2). Appropriate prophylaxis for example bone protection (with calcium and vitamin D 
supplementation and bisphosphonates if indicated) or gastric protection (with proton 
pump inhibitors) in high risk groups to prevent glucocorticoid adverse effects should be 
therefore considered and instigated if indicated for patients taking long term 
glucocorticoid treatment. This is especially important as patients are particularly 
concerned about glucocorticoid side effects. [Twohig et al 2015, Helliwell et al 2015] Box 
1.2 summarises some of the identified adverse effects of glucocorticoids. 
 
Initial dose 15mg prednisolone for 3 weeks 
Reducing in prednisolone dose 
- 12.5mg for 3 weeks 
- 10mg for  4 to 6 weeks 
- Reduction of 1mg every 4-8 weeks 
Symptom flares managed by increasing dose of 
prednisolone to previous dose that controlled symptoms 
 28 
 
 
 
Box 1.2 Potential adverse effects of glucocorticoid therapy 
 
 
 
 
 
 
 
Source: British National Formulary [BNF.org] 
The studies relating to the management of PMR are summarised in Table 1.4. Chantler 
(2003) found that the most common rheumatological indications for prescribing long-
term glucocorticoids in women over 50 years of age were PMR and rheumatoid arthritis. 
In patients aged over 70 the most common reason for long-term glucocorticoids was 
PMR. [Chantler et al 2003] 
Gastrointestinal 
 Dyspepsia, Pancreatitis, Peptic ulceration and perforation, Oesophageal 
ulceration and Candidiasis. 
Musculoskeletal 
 Muscle weakness, Osteoporosis, Vertebral/long bone fracture, Tendon 
rupture 
Endocrine 
 Diabetes, Menstrual irregularities, Hirsutism, Weight gain, Raised 
cholesterol, Hyperlipidaemia,  
 Increased susceptibility to infections. 
Neuro-psychiatric 
 Psychological dependence, Insomnia, Raised intracranial pressure, 
Aggravation of schizophrenia and epilepsy 
Opthalmic 
 Glaucoma, Papilloedema, Cataracts, Ophthalmic viral or fungal disease, 
Raised intra-ocular pressure 
Additional 
 Impaired healing, Ecchymosis, Urticaria, Hyperhydrosis, Skin atrophy, 
Bruising, Myocardial rupture post recent myocardial infarction, Congestive 
cardiac failure, Leucocytosis, Headache, Vertigo 
 
[BNF.org] 
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Table 1.4 Studies investigating the management of PMR in primary care 
Reference Title Study Design Aim Study Findings 
Binard 
2009 
Validity of the 
polymyalgia 
rheumatica activity 
score (PMR-AS) 
in primary care 
practice 
 
Clinical vignettes study  
 
To assess the reliability of the 
PMR-AS for assessing relapse 
of PMR in primary care. 
 
 
35.8% of GPs routinely referred PMR patients to 
rheumatology for diagnosis 
41.7% reported that they do not routinely arrange a  
rheumatology review for PMR patients 
PMR-AS is valid to be used by GPs (previously only 
valid for use by rheumatologists) in identifying relapse 
of PMR 
 
Chakravarty 
1994 
A district audit on the 
management of PMR 
and GCA  
 
Cross sectional regional 
questionnaire survey of 
rheumatologists and GPs 
To evaluate the role of ESR
a
 
and CRP
b
 in diagnosis and 
monitoring of PMR; and the 
dose and duration of 
corticosteroid treatment to 
help develop regional 
consensus guidelines.  
 
Initiating steroid dose and steroid tapering varied 
widely (same for consultants).  
Wide variation in community and hospital use of 
diagnostic tests.  
There was an over reliance on ESR
a
 in identifying 
relapse 
 
Chantler 
2003 
Oral glucolcorticoid 
prescribing in women 
over the age of 50 
years and the use of 
fracture prevention 
therapy, and bone 
densitometry 
Retrospective observational 
study 
To identify the most common 
diseases that are being 
treated with corticosteroid 
therapy in women over 50 
years old 
Most common diseases treated with long term 
glucocorticoids are PMR/GCA and rheumatoid 
arthritis. 
PMR and GCA was the most common reason for 
treatment with glucocorticoids in patients over 70 
years of age  
 
 
a ESR: erythrocyte sedimentation rate, b CRP: C-reactive protein 
2
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Chakravarty (1994) undertook a district audit on the management of PMR. 
Questionnaires focusing on the management of PMR were sent to both rheumatology 
consultants and general practitioners .This study achieved a high response rate of 78% 
from GPs. The study found that there was great variation in the initiating dose of 
prednisolone and the reduction in prednisolone dose over time by both GPs and 
specialists. Additionally in both groups it was found that clinicians were over relying on 
ESR results and not symptoms to identify PMR relapse.  [Chakravarty et al 1994] The 
management of PMR was also investigated by Helliwell (2013) (discussed above in section 
1.5.4.1) and although initial treatment was largely in line with current guidance, 
prophylactic treatment for osteoporosis and or gastric protection was found to not be 
routine practice. [Helliwell et al 2013] 
 
1.5.4.4 Summary 
From the studies identified, it would appear that the accuracy of PMR diagnosis in 
primary care is variable and that published classification/diagnostic criteria are not 
frequently used outside secondary care and/or research settings. The reasons for this are 
not understood and are likely to be multifactorial.  Many of these studies were 
undertaken prior to the publication of clinical guidelines that encompassed all aspects of 
care. The majority of studies reporting diagnostic accuracy were based on referrals made 
by GPs to secondary care, yet PMR is predominantly diagnosed and managed in the 
community with referrals for specialist review being made at times of diagnostic 
uncertainty or non-response to treatment.  
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As such, studies of secondary care patient populations will undoubtedly report high rates 
of diagnostic inaccuracy.  [Kremers et al 2005, Gamez Nava et al 1998]  
 
1.6 Giant Cell Arteritis (GCA) 
Giant cell arteritis (GCA) or temporal arteritis (TA) is the most common large vessel 
vasculitis [Dasgupta (GCA) et al 2010] and has a clear association with PMR. [Salvarani et 
al 2008] Up to 21% of patients with PMR patients will develop evidence of GCA and 40-
60% of patients with GCA report PMR symptoms. [Salvarani et al 2008] It is however less 
common than PMR with an estimated incidence of 2.2 per 10000 patient years. [Smeeth 
et al 2006] Barraclough (2012) estimated that a full-time general practitioner can expect 
to see one new case every 1-2 years. [Barraclough et al 2012] However, given the 
estimates of incidence given by Smeeth, it is likely that GPs will encounter it less often 
depending on the patient demographic of the practice population.   
 Classical presenting symptoms of GCA include headache (which may be unilateral and 
often temporal), scalp pain, jaw and tongue claudication (pain on talking or chewing), 
constitutional symptoms (for example lethargy and weight loss) and visual symptoms 
including blurring of vision, amaurosis fugax (temporary, usually unilateral visual loss), 
diplopia (double vision) and ultimately (if left untreated) blindness. Clinical signs include a 
clinically abnormal superficial temporal artery (tender or thickened with reduced or 
absent pulsation), scalp tenderness, upper cranial nerve palsies and pale swollen optic 
discs on fundoscopy with associated haemorrhages. [Dasgupta et al 2010] These 
symptoms are usually accompanied by a significant inflammatory response (classically a 
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raised ESR).  Prompt identification, treatment with high dose glucocorticoids and early 
referral of potential patients with GCA is imperative to prevent potential irreversible 
blindness. 
The diagnosis is frequently clinical, although the gold standard diagnostic test remains 
temporal artery biopsy (TAB). However, 13% to 19% of patients with typical features of 
GCA have a negative temporal artery biopsy. [Niederkohr et al 2007, Breuer et al 2008] 
Ultrasound scanning is increasingly being developed as a diagnostic test for GCA since it is 
less invasive and thus more acceptable for patients.  It has been shown to have a 
sensitivity of 69% and specificity of 82% when compared to temporal artery biopsy. 
[Karassa et al 2005] Positron Emission Tomography (PET) scanning is an alternative, 
promising imaging technique with a sensitivity of 80% and specificity of 79% when 
compared to biopsy. [Prieto-Gonzalez et al 2014] However, owing to lack of its general 
availability and high cost, it is unlikely that PET scanning will become a mainstream 
imaging modality in the near future for GCA.  
Initial treatment is with high dose glucocorticoids typically between 40 and 60 mg of 
prednisolone per day although intravenous methylprednisolone under ophthalmology 
observation is advised in patients presenting with visual symptoms [Dasgupta (GCA) et al 
2010]. The role of the GP in the diagnosis of GCA involves keeping a high index of 
suspicion for the disorder and in potential cases initiating early therapy and referring on 
to appropriate specialist services for diagnostic confirmation. Subsequent to formal 
diagnosis GPs are often involved in the on-going glucocorticoid reduction and regular 
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assessment, screening and if indicated, treatment for glucocorticoid related adverse 
effects. 
This thesis is predominantly concerned with the diagnosis and management of PMR in 
primary care and its associated challenges. However, given its close association with PMR, 
it would be remiss not to investigate GCA as part of a wider investigation of PMR. The 
results obtained from the GCA investigation undertaken as part of the PMR research are 
presented in detail in Chapter 7. 
 
1.7 Conclusions 
Despite PMR being described more than 125 years ago, clear gaps continue to exist in the 
evidence base for this painful and disabling condition. This is especially pertinent in the primary 
care setting, where the majority of patients are diagnosed and managed. A lack of accepted 
standard classification criteria and the use of different research methodologies have made 
comparisons of the identified epidemiological studies challenging, since spectrum bias is a 
significant limitation of much of the published literature. Primary care research is needed if we 
are to improve outcomes for all patients with PMR. The following chapter describes the aims 
and objectives of this thesis. 
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Chapter 2: Thesis Aims and objectives 
2.1 Introduction 
This chapter introduces and justifies the overall purpose of the Ph.D., detailing the 
specific aims and objectives of the thesis. 
 
2.2 Thesis aims  
The overall aim of this PhD is to describe the current diagnostic and management 
practices used by general practitioners caring for patients with polymyalgia rheumatica, 
to identify the perceived barriers to effective care, and to determine targets for future 
interventions and educational initiatives that could lead to improvements in patient care. 
As GCA has a considerable association with PMR a secondary aim of this Ph.D. is to also 
investigate the identification, diagnosis and management of GCA in general practice.  
 
2.3 Thesis objectives 
The aims of the Ph.D. will be achieved through the following specific objectives: 
1) To review the published diagnostic and classification criteria available to clinicians 
working with patients with PMR and explore their utility  
 
Clinicians diagnosing PMR rely on a set of features that can be used to confidently and 
accurately diagnose the condition. The objective of this review is to perform a systematic 
literature review of existing research focussing on the diagnosis of PMR  
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The review will identify the differences between established diagnostic and classification 
criteria and how they are used in a clinical setting. 
2) To determine the current practice for the diagnosis and management of PMR in 
general practice 
 
 
This objective will be achieved by conducting a large national cross-sectional 
questionnaire postal survey of 5000 randomly selected UK general practitioners to 
investigate the diagnosis and management of PMR in the community.  
3) To explore in-depth the barriers and potential solutions to successful primary care 
diagnosis and management of PMR. 
 
The final objective of this PhD will be realised using semi-structured telephone qualitative 
interviews with general practitioners focusing on the perceived challenges encountered 
with diagnosing and managing PMR. Findings from the cross sectional survey be used to 
inform the topic guide for the qualitative study. 
 
2.4 Thesis novelty and originality 
It has been shown that up to 80% of patients with PMR are diagnosed and managed 
exclusively by their general practitioner [Barraclough 2008], yet most studies have 
focused on patients recruited from secondary care settings. As highlighted in Chapter 1, 
the extent of primary care focused research on PMR is very limited. This thesis will 
contribute new knowledge to the existing literature on PMR by focussing specifically on 
primary care. By using a combination of quantitative and qualitative methods this thesis 
will not only determine GPs current clinical practice but will also identify challenges and 
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barriers in the optimal diagnosis and management of PMR and GCA. Such a mixed 
methods approach will allow for a more in-depth exploration of the relevant issues and 
will provide the opportunity to improve patient care and enhance professional education. 
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Chapter 3: Literature review of diagnostic and classification criteria for 
PMR and their use in clinical practice 
Diagnosis is the process through which a disease is identified and confirmed using 
distinctive collections of symptoms, signs and investigation results (for example blood 
tests and imaging). This chapter seeks to investigate the best available evidence and tools 
available to GPs to accurately diagnose PMR. 
 
3.1. Introduction 
Most rheumatic disorders do not have a single distinguishing feature or ‘gold standard’ 
diagnostic test that can be used by practitioners to make a definitive diagnosis. PMR is no 
exception. There is no ‘gold standard’ diagnostic test and as such clinicians have to rely 
upon a collection of clinical features, laboratory findings, the exclusion of other 
pathology, and response to treatment to diagnose the disorder. Classically, PMR presents 
with bilateral shoulder pain and or hip girdle pain, muscle pain (myalgia) and morning 
stiffness with raised inflammatory markers and a significant response to low dose 
corticosteroids. This cluster of clinical features has long been recognised as typical of 
PMR. [Barber 1957] However, PMR can also present atypically (in around 20% of cases) 
and given the significant overlap with presenting symptoms with both rheumatological 
and non-rheumatological disorders, making an accurate diagnosis challenging.  
A British Society of Rheumatology (BSR) and British Health Professional in Rheumatology 
(BHPR) guideline exists to support the diagnosis and management of PMR. [Dasgupta et al 
2010] This guideline outlines a stepwise approach to identifying patients with PMR. 
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However, the diagnostic aspects of the guideline rely on the exclusion of other disorders 
(for example “other inflammatory disorders”) which may be challenging, especially for 
generalist clinicians. 
Fries (1994) noted that criteria sets used in research created a “uniform language,” which 
allowed comparisons between studies to be more meaningful and that “classification and 
sub-classification criteria define the presence of a particular disease or specific subsets of 
that disease” [Fries et al 1994 p454] and aim to separate patients with the disease from 
those with “confusable” disease. However classification criteria are designed for research 
purposes and whilst published study inclusion criteria have become used as proxy 
diagnostic criteria for practising clinicians, this may not be appropriate.  This is a 
particularly pertinent issue for PMR where no ‘gold standard’ test exists. Whilst 
classification criteria are important for research purposes (as they are helpful in 
identifying a standard participant or definite case), they may not be so helpful clinically, 
as more atypical cases may not be covered by classification criteria and those with 
multimorbidity may be excluded. 
Despite the publication of clinical guidelines and classification criteria some of the 
published studies identified and described in Chapter 1 have highlighted how accurate 
diagnosis is a particular problem in general practice. [Bahlas et al 2000] A review of 
patients seen in a fast track PMR clinic in Bristol (UK) suggests that approximately 50% of 
patients referred to the clinic had a diagnosis of PMR. [Quick et al 2012] However, it is 
important to note that this is not a typical secondary care clinic, as GPs were encouraged 
to refer all potential PMR cases and were discouraged from initiating treatment 
(something that would not be usual clinic practice). Response to glucocorticoids can be 
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helpful in making an accurate diagnosis. [Dasgupta et al 2010] Indeed making a diagnosis 
of PMR can be a challenge even for experts. In studies developing classification criteria for 
PMR international experts identified 68 potential criteria [Dasgupta et al 2008] and 10 of 
128 PMR study participants identified by a panel of international rheumatology PMR 
experts were reclassified as not having PMR by the end of the study. [Dasgupta et al 
2012] 
Diagnosis therefore is a key challenge for PMR and this review is intended to identify 
potential diagnostic strategies for general practitioners. Additionally the findings will 
contribute to the development of the PMR GP questionnaire postal survey and support 
developing themes for exploration in the qualitative telephone study of general 
practitioners. 
 
3.2. Aims and objectives 
The aim of this systematic literature review is to identify the most useful clinical features 
in diagnosing PMR.  
This will be achieved using the following methods: 
1) Perform a systematic literature search of bibliographical databases to identify 
relevant studies reporting the diagnosis and classification of PMR 
2) Systematically review each identified article 
3) Collate relevant data to identify appropriate features for clinical diagnosis  
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3.3. Methods 
3.3.1. Medical Databases 
The following bibliographical databases were searched to identify relevant articles. 
 MEDLINE. MEDLINE is a database of articles from a wide range of academic 
journals that cover medicine, nursing, dentistry, veterinary science and health care as well 
pure science fields including biology and biochemistry. 
[http://www.nlm.nih.gov/pubs/factsheets/medline.html]  
 
 AMED. AMED is a healthcare database produced by the Health Care Information 
Service of the British Library. It covers subject areas allied to medical professions 
including physiotherapy, occupational therapy, podiatry, rehabilitation medicine, 
palliative care and complementary medicine. It indexes relevant articles from 596 
journals, mainly from Europe many of which are often not indexed in other databases. 
Key journals can also be found on the database. 
[http://www.ovid.com/webapp/wcs/stores/servlet/ProductDisplay?storeId=13051&catal
ogId=13151&langId=-1&partNumber=Prod-12] 
 
 CINAHL. CINAHL is a research database providing details of articles from journals 
relevant to nursing, allied health, healthcare and biomedicine. 
[http://www.ebscohost.com/academic/cinahl-plus-with-full-text] 
 
 EMBASE. EMBASE is a bibliographic database of over 7600 biomedical journals 
from 90 countries that was designed to “support information managers and 
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pharmacovigilance in complying with the regulatory requirements of a licensed drug”. Its 
design allows detailed searches for specific drug adverse events and 
tracking.[http://www.elsevier.com/online-tools/embase] 
 
3.3.2. Search Strategy 
MEDLINE, CINAHL, EMBASE and AMED databases were individually searched. The search 
terms used for Medline and EMBASE can be found in [Appendix 1]. These specific search 
terms were also used for CINAHL and AMED and the searches were repeated using the 
search engine thesaurus “explode” option. This is a tool that allows all associated terms 
to also be included in the search.  
Particular challenges have arisen with this literature search. The condition of interest is 
PMR, however there isn’t an outcome of interest other than the accurate diagnosis of 
PMR, making the use of traditional search structures such as PICO (population, 
intervention, control, outcome) and established search filters unhelpful.   
The resulting searches for PMR and diagnosis/classification were combined using the 
“AND” command and the resulting citations were limited to studies published in English, 
studies involving humans and studies using participants over the age of 18 years. No 
limits were imposed on the type of study at the stage of the review. The resulting 
citations for each database were imported into a Refworks file and then combined, with 
all identified duplicates being removed. The results of articles identified are summarised 
in Figure 3.1. 
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Figure 3.1 Unique citations identified in each database
 
3.3.3. Selection of relevant articles from identified citations 
Identified titles were screened by two reviewers (Toby Helliwell (TH) and Sara Muller 
(SM)). The following inclusion and exclusion criteria were used to identify studies for 
abstract review. 
Inclusion Criteria 
1) The study reported on patients, or a sub-group of patients, with PMR. 
2) The study was specifically reporting diagnostic or classification criteria. 
3) The study was researching features (clinical, genetic, imaging and laboratory) that 
may be used to diagnose PMR or distinguish it from other diseases that may 
present in a similar way. 
4) The study was original research or a systematic review using human participants.  
5) The study was published in English. 
 
 
 
 
 
 
 
 
 Medline 
615 
 
 
 
Embase 
419 
 
Cinahl  
72 
 
Amed 
17 
 
 
 Final Total 
1123 
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Exclusion Criteria 
1) Articles reporting on disorders other than PMR 
2) Articles that did not research diagnosis or features of PMR at the onset of the 
disease 
3) Articles that were editorials, case reports or case series. 
4) Articles not in English 
 
Any title identified as potentially relevant by one or more reviewer was carried forward to 
the abstract screening stage. The abstracts of titles that met the inclusion/exclusion 
criteria were obtained for abstract review. Abstracts were then screened (by both TH and 
SM) to identify studies for full text review. Any study abstract included by one reviewer 
was reviewed in full text. Finally, of the full text articles identified, the reference lists were 
further reviewed to identify any additional articles that had not been identified using the 
formal process described above. This process is summarised in Figure 3.2. 
 
3.3.4. Data extraction and synthesis 
A standard data extraction form was created to extract relevant information from the 
articles including data relating to the objectives, methods, results and conclusions of the 
article. Information on geographical location, number of patients studied, criteria used 
and a quality assessment score (discussed below) was also included on the form. The data 
extraction form can be found in Appendix 2. 
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 Figure 3.2 Identification of citations for review 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
Articles included after title 
screening 
335 
 
Articles included after 
abstract screening 
113 
 
Articles included for full-
text review 
67 
 
Articles included for full 
text analysis  
49 
 
 
 
 
Reasons for Exclusion 
 Article type 
 Case reports 4 
 Editorial/guideline 4 
 Letter 2 
 Epidemiology study 3 
 Treatment study 1 
 Monitoring Article 4 
 
Additional articles included 
through article 
assessment and article 
reference review  (n=2) 
2 
 
Total full text articles 
included 
51 
 
Initial citation included 
1123 
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3.3.5. Quality assessment 
The majority of identified studies in this review were observational studies and so a 
quality assessment tool specifically designed for observational research of 
musculoskeletal disorders was used. This quality assessment tool derived common 
themes that were included in identified checklists for observational studies and those 
used in previous musculoskeletal systematic reviews. [Mallen et al 2007] This instrument 
has been widely used in musculoskeletal systematic reviews. The quality of each study 
was assessed using this 15 item checklist which can be found in full on the data extraction 
form in Appendix 2. Examples of criteria include rates of participation (including 
descriptions of losses and completers), appropriateness of study question and associated 
study population. Quality scores (from a maximum score of 15) are presented in the first 
column in each table.   
 
3.4. Results 
3.4.1 Methodological Quality assessment 
All studies included in this review were assessed for methodological quality. Studies were 
not excluded on the basis of the quality score, however this was taken into account when 
synthesising the evidence. The majority of quality assessment scores were high, with Li 
(2010) recording the lowest scoring study (10/15) and Dasgupta (2012) the highest 
scoring (14/15).  No studies undertook a formal sample size calculation, however this may 
not have been appropriate for some of the studies identified. Studies recruiting 
participants solely from secondary care were deemed to be non-representative as 
 46 
 
patients referred to secondary care have been shown to have different characteristics to 
primary care patients (e.g. more severe disease, non-response to treatment, atypical 
presenting features) and as such these studies are unlikely to be representative. [Kremers 
et al 2005] 
 
3.4.2. Study review 
51 studies were included for full text review. Of these studies, only five studies recruited 
participants from a primary care setting. Broadly the studies cover five domains that 
might be of interest in helping to diagnose PMR in primary care. These are discussed in 
detail in the following sections. 
 
3.4.3 Classification research studies 
These studies relate to investigations that specifically validate existing or new 
classification criteria or studies that have developed classification criteria which 
subsequently have been used in other studies investigating PMR and are summarised in 
Table 3.1.  
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Table 3.1 Summary of studies investigating classification criteria for PMR  
Citation Overview of study 
 
Bird  
(1979) 
 
 
 
Bird  
(2005) 
  
 
Dasgupta 
(2008)  
 
Dasgupta  
(2012) 
 
 
Nobunaga  
(1989) 
 
 
 
Chuang 
(1982)  
 
Jones/Hazelman 
(1981) 
UK (Multi-centre)  
146 secondary care “unequivocal PMR” patients 
253 controls 
Criteria tested on submitted data 
 
International multi-centre study 
213 secondary care patients 
Criteria tested on recruited participants diagnosed with PMR by expert.  
 
International 3 stage hybrid consensus approach 
27 World experts consulted to identify key features for classification of PMR 
 
International multi-centre study 
128 PMR patients, 184 controls 
Primary and secondary care 
 
Japan 
29 PMR 119 controls 
Retrospective case review and development of criteria from identified common 
features 
 
USA Community epidemiology project of PMR 
No detail of how criteria were developed for use in this study 
 
UK 
Criteria developed for inclusion of patients to their study on PMR and GCA 
No detail of how criteria were developed for use in this study 
 
 
3.4.3.1 Key findings 
Seven studies were identified from the literature that specifically presented research 
related to classification criteria. These are summarised in Table 3.2. Bird (1979) was the 
first to propose a standard set of classification criteria.  This study is summarised in Table 
3.2 and whilst achieving three of the criteria performs well at identifying definite PMR 
cases, the authors stress that their use should be confined to research settings rather 
than clinical settings. This is because the criteria were not developed and validated for 
diagnostic purposes but to identify an acceptable research standard with a high 
probability of having PMR.  
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Table 3.2 Studies investigating classification criteria for PMR 
First Author 
(quality assessment 
score) 
 
Objective Findings or criteria identified 
Bird 1979 
(12/15) 
 
To identify a reproducible 
means of identifying PMR 
for research 
Bilateral Shoulder Pain and or stiffness  
Onset of illness less than 2 weeks duration  
Initial ESR
a
 more than 40 mm/hour  
Morning stiffness  more than 1hour  
Age greater than 65  
Depression and or loss of weight 
Upper arm tenderness bilaterally  
The presence of 3 criteria achieves a sensitivity of 92% for PMR 
 
Dasgupta 2008 
(NA: consensus study of 
world experts, patients 
not recruited) 
To identify classification 
criteria for PMR 
 
Candidate criteria identified for a prospective PMR study investigation.  
These included for further study: 
Age greater than or equal to 50 years 
Duration of more than 2 weeks 
Bilateral shoulder and/or pelvic girdle aching 
Duration of morning stiffness of more than 45 minutes 
Elevated ESR
a 
or CRP
b 
Rapid steroid response (greater than 75% global response within 1 week to prednisolone/prednisone 15 to 
20 mg daily) 
 
Dasgupta 2012 
(14/15) 
 
To develop a EULAR/ACR 
classification criteria for 
PMR 
Morning stiffness (2point) 
Hip pain/limited range of movement (1 point) 
Absence of RF
c
/Anti CCP
d
  (2 points)  
No other Joint pain (1 point) 
Score greater than or equal to 𝟒:-Sensitivity 68%,Specificity 78% (PMR versus other similar disorders)  
Inclusion of positive relevant ultrasound findings Sensitivity 66% Specificity 81% 
 
 
4
8 
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First Author 
(quality assessment 
score) 
 
Objective Findings or criteria identified 
Nobunaga 1989  
12/15 
 
To propose specific criteria 
sets for PMR in Japanese 
patients. 
Bilateral myalgia for 2 weeks and symptoms of at least 2 of neck, shoulders, shoulder girdle, upper arms, 
hips or pelvic girdle and thighs  
Normal serum myogenic enzymes  
ESR
1 
greater than 40  
No swelling in the hand joints 
Presence of all 4 features: 93.1% sensitivity 98.3% specificity 
 
Jones/Hazelman 1982 
(N/A: study did not relate 
to the criteria used) 
 
 
Classification criteria 
developed for recruitment 
of patients to their study 
investigating the link 
between PMR and GCA 
Shoulder or hip girdle pain  
Morning stiffness  
Disease duration 2 months or more  
ESR
a
 greater than 30 or CRP
b
 greater than 6,  
Absence of rheumatoid arthritis  
Absence of muscle disease 
Age greater than 50 year 
 
Chuang 1982 
(N/A: study did not relate 
to the criteria used) 
Classification criteria 
developed for recruitment 
of patients to their 
epidemiology study of PMR 
Age greater than 50 years 
Bilateral aching /tenderness for 1 month or more of: neck or torso, shoulders or upper arms, hips or thighs 
ESR greater than 40 
Exclusion of other causes 
 
Bird 2005 
(12/15) 
To compare performance of 
different criteria sets for 
PMR 
Bird criteria (3 or more) Sensitivity 99.5%,  
Jones Hazelman (All criteria) Sensitivity 84.9% 
Hunder/Chuang (All criteria) Sensitivity 93.3%  
Nobunga (4 or more) Sensitivity 67.8% 
a
ESR: Erythrocyte sedimentation rate 
b
CRP: C-reactive protein 
c
RF: Rheumatoid factor 
d
Anti CCP: Anti-cyclic citrullinated peptide antibody 
4
9 
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Additionally the author highlights that the study does not identify any new, unknown or 
novel features of PMR that may be important in diagnosing PMR but rather is a validation 
of a set of existing recognised features as a standard for research purposes. [Bird et al 
1979]   
Nobunaga (1989) proposed that Japanese patients with PMR may need different criteria 
since previously described classification criteria were largely based on patients of white 
Caucasian ethnicity.  They identified patients with a diagnosis of PMR and retrospectively 
reviewed their medical records identifying the relevant clinical features, investigations, 
imaging and responses to treatment.  This allowed them to develop specific classification 
criteria for Japanese patients that differ from other criteria in that they include the 
presence of normal myogenic enzymes (for example creatinine kinase) and the absence of 
swelling in the hand joint. These are summarised in Table 3.2. [Nobunag et al a 1989] 
A consensus process undertaken in Dasgupta (2008) informed the design and domains of 
interest for a future prospective study by assessing the reliability of identified criteria. 
This study identified 68 different features of PMR deemed important by international 
experts when diagnosing PMR. [Dasgupta et al 2008] This large number of items is likely 
in part to reflect the wide variation in PMR presentation and the lack of agreement, even 
amongst experts, as to the defining features of PMR. The subsequent international 
prospective study tested the identified criteria and developed a scoring system that had a 
sensitivity of 68% and specificity of 78% for identifying PMR. [Dasgupta et al 2012] The 
study challenged the response to glucocorticoid treatment as a reliable feature for 
classifying PMR, as it did not significantly add to the overall sensitivity of the criteria and 
did not alter the specificity.  
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The authors conclude that:  
“patients aged 50 years and older presenting with bilateral shoulder pain and 
elevated CRP and or ESR can be classified as having PMR in the presence of 
morning stiffness for more than 45 minutes, and new hip pain in the absence of 
peripheral synovitis or positive rheumatoid arthritis serology”  
Dasgupta et al 2012.P491 
 
They also stress that whilst their classification criteria are useful for research purposes, 
they should not yet be used for clinical purposes and should be viewed as provisional 
even though the criteria set presented achieved a C statistic of 81% (a C statistic of 
greater than 80% is, conventionally acceptable for use in clinical decision making).  
Two further studies are presented in this section. These were not identified from the 
formal literature search but found from the wider literature. Chuang (1982) and Jones 
(1981) were not identified in the initial literature search but were identified on review of 
the studies discussed above. It is likely that these studies were not identified despite the 
wide inclusion criteria and search terms as the criteria were developed to standardise 
inclusion to their respective studies (epidemiology of PMR (Chuang) and investigating the 
link between PMR and GCA (Jones)).  
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Chuang/Hunder criteria [Chuang et al 1982] were developed to identify patients to recruit 
to their PMR epidemiology research in Rochester (Minnesota, USA). Their criteria were: 
1) Age greater than 50 years 
2) Bilateral moderate/severe aching and stiffness for more than 1 month involving 2 
or more of the following areas: neck or torso, shoulder or upper arms, hip or 
proximal thigh. 
3) ESR >40 mm/hr (although if this criterion was not met but other features to 
suggest the diagnosis were present (e.g. a significant and prompt response to 
corticosteroids) then PMR should be considered). 
4) No other cause for symptoms (e.g. the presence of rheumatoid arthritis or 
multiple myeloma). 
 
These criteria were also used in their follow up studies and have been employed by many 
other studies subsequently (e.g. Ceccato (2006), Proven (1999)). However, no discussion 
or validation description is given explaining how the criteria were derived. 
Jones and Hazelman undertook a study to retrospectively investigate the association 
between PMR and GCA.  
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The criteria that they used were: 
1) Shoulder and pelvic girdle pain (primarily muscular) 
2) Morning Stiffness (duration not defined) 
3) Duration of at least 2 months if not treated 
4) ESR of > 30mm/hour or CRP > 6 μg/ml 
5) Absence of inflammatory arthritis or malignant disease 
6) Absence of objective signs of muscle disease 
7) Prompt and dramatic response to systemic corticosteroids 
[Jones  and Hazelman 1981] 
 
Again, no details were given as to how these classification criteria were developed.  These 
criteria have been used in many PMR studies despite lacking important details on their 
derivation and a lack of definition for the various criteria for example what constitutes a 
dramatic response to glucocorticoids or how long do you need morning stiffness for?  
Bird (2005) revisited the commonly used classification criteria to assess the sensitivity of 
each set in identifying PMR. 213 patients with PMR were identified by rheumatology 
experts and each of the criteria assessed for sensitivity in identifying PMR. The Nobunaga 
(1989) criteria were the worst performing set but this is unsurprising given that they were 
developed specifically for a Japanese population. The Bird (1979) criteria had the highest 
sensitivity however, all participants were recruited from secondary care and they point 
out that there may be a bias towards their criteria in classifying PMR clinically as it is one 
of the most commonly used classification criteria and the one that was developed first. 
[Bird et al 2005] 
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 3.4.4 Clinical Features 
Studies relating to the investigation of the presenting signs and symptoms that suggest 
PMR are presented in Table 3.3. 
Table 3.3 Summary of studies investigating the presenting features of PMR  
Citation 
(Year) 
 
Overview of study 
 
Andrews  
(1965)  
 
 
Barraclough  
(2008)  
 
 
Caporali  
(2001)  
 
 
Fauchald 
(1972)  
 
 
Gonzalez-Gay 
(1997)  
 
 
Gonzalez-Gay  
(1998) 
 
Gran  
(2000)  
 
 
Kimura 
(2012)  
 
Li  
(2010)  
 
Little  
(2004)  
 
 
Narvaez 
(2001)  
 
 
Olivio 
(1996)  
 
UK. Secondary care 
Mixed prospective (10 PMR patients) and retrospective (34 PMR patients) study  
Three years of follow-up 
 
UK. Primary Care 
183 PMR patients. Retrospective cohort study 
Two years post diagnosis follow-up 
 
Italy. Secondary care 
116 PMR patients. Prospective cohort 
18 months follow-up 
 
Norway. Secondary care  
94 PMR patients. Prospective cohort  
8-96 month follow-up 
 
Spain. Secondary care 
201 PMR patients. Retrospective case review 
18 months of follow-up or greater 
 
Spain. Secondary care 
225 patients. Retrospective case review 
 
Norway. Community and secondary care 
231 PMR patients. Prospective cohort 
Follow-up until disease remission 
 
Japan. Secondary care  
151 patients (RS3PE
a
 and PMR). Retrospective cohort case review 
 
Hong Kong. Secondary care  
44 patients. Retrospective case review 
 
UK. Secondary care  
183 patients with small vessel vasculitis. Retrospective case review 
Follow up, up to 12 years 
 
Spain. Secondary care 
163 PMR patients. Retrospective case review 
Follow-up until death or cessation of treatment 
 
Italy. Secondary care.  
75 PMR patients and 22 EORA
b
 with PMR like onset. Retrospective case review 
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Citation 
(Year) 
 
Overview of study 
 
Pease  
(2005)  
 
 
Pease  
(2009)  
 
 
Pege-Regosa  
(2005)  
 
 
Salvarani  
(1998) 
UK. Secondary care 
349 PMR patients. Prospective cohort  
Minimum follow up of two years 
 
UK. Secondary care.  
147 patients with EORA
b
/PMR. Prospective  cohort 
Five year follow up 
 
Spain. Secondary care.  
118 patients with PMR, 112 patients with CPDD
c
. Prospective  cohort 
Follow up for at least 12 months 
 
Italy.  Secondary care. 
177 PMR patients. Prospective cohort. 
Follow up 23 months 
 
 
a
RS3PE: Remitting seronegative symmetrical synovitis with pitting edema 
b
EORA: Elderly onset rheumatoid arthritis 
c
CPDD: Calcium pyrophosphate deposition disease 
 
3.4.4.1 Key findings 
The key findings of the studies relating to clinical features are summarised in Table 3.4. All 
but one of the identified studies investigating clinical features were undertaken using 
data obtained (whether prospectively or retrospectively) from patients recruited from 
secondary care settings. These studies broadly describe either the clinical manifestations 
of PMR or focus on distinguishing PMR from other selected disorders that can mimic PMR 
(including elderly onset rheumatoid arthritis (EORA), RS3PE (remitting seronegative 
symmetrical synovitis with pitting oedema and small vessel vasculitis (SVV)). 
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Table 3.4 Studies investigating the presenting features of PMR 
First Author  
(quality assessment) 
Objective Summary of main conclusions of the study 
 
Classification criteria 
used 
 
Andrews  
1965 
(11/15) 
To review the PMR “Syndrome” and its 
relationship with GCA 
Features of PMR: 
Abrupt onset 
Early morning stiffness 
Night Sweats 
Depression 
Raised ESR
a
 
Females affected more than men 
PMR and GCA appear to be separate entities 
 
Own criteria 
Barraclough 
2008 
(12/15) 
Identify features used to diagnose PMR by GPs 
and compare to recognised diagnostic criteria. 
Features used by GPs to diagnose PMR 
Muscle Pain 82%  
Raised Inflammatory markers 87% 
Response to glucocorticoids 91% 
Normalization of inflammatory markers 81%  
 
Bird 
Hunder 
Healy 
Hazelman 
Caporali  
2001 
(12/15) 
To investigate if PMR patients and patients with 
RA with a PMR-onset show distinctive 
clinical/laboratory features 
 
No clinical or laboratory feature found , which 
identifies patients who present like PMR who will 
develop RA  
For PMR:  
Jones/ Hazelman  
For RA
b
: American 
College of Rheumatology 
RA
b
 criteria 
 
Fauchald  
1972 
(11/15) 
 
To compare clinical, lab findings and clinical 
course in patients with GCA and PMR 
All patients felt symptomatically ‘weak’  
(not further defined) 
Weight loss in PMR (49%),  
Fever in PMR (85%) 
 
No stated criteria 
5
6 
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First Author  
(quality assessment) 
Objective Summary of main conclusions of the study 
 
Classification criteria 
used 
 
Gonzalez-Gay  
1997 
(12/15) 
 
To investigate the role of ESR
a
 in the diagnosis 
and prognosis of patients with PMR 
20.4% of patients had a low ESR
a
 (less than 40mm/hr) 
Low ESR
a
 found in men, younger patients and had a 
less severe disease  
Also, less abnormalities in other investigations for 
example haemoglobin levels 
 
Own Criteria` 
Gonzalez-Gay  
1998 
(13/15) 
 
To describe features to identify PMR, PMR with 
biopsy proven GCA and GCA with no features of 
PMR 
Patients with GCA and PMR were significantly older 
than the other 2 groups 
Patients with GCA and PMR  had more constitutional 
symptoms, anaemia was more frequent and had 
higher platelets and higher ESR
a
 compared to other 
groups 
 
No quoted classification 
criteria 
Gran  
2000 
(13/15) 
To evaluate incidence and peripheral arthritis in 
PMR & incidence of RA
b
 among such cases 
4.8% developed RA
b
, 38.5% of PMR patients 
developed peripheral arthritis at some point 
No clinical or laboratory features identified to 
distinguish PMR patients subsequently developing RA
b
  
For PMR: Bird   
For RA
b
: American 
College of Rheumatology 
RA
b
 criteria 
 
Kimura  
2012 
(12/15) 
To compare the clinical features of RS3PE
c
  with 
PMR patients 
All RS3PE
c
 patients  identified (n=28) fulfilled the 
diagnostic PMR criteria  
RS3PE
c
 patients were more likely to be male and have 
pitting oedema of their hands compared to PMR 
patients 
 
Hunder 
Li  
2010 
(10/15) 
 
 
To examine clinical characteristic of PMR in a 
Chinese cohort and compare this to Caucasian 
series 
Chinese patients have a significantly longer duration 
of symptoms prior to diagnosis 
Bird (Caucasians) 
ICD10 for Chinese 
5
7 
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First Author  
(quality assessment) 
Objective Summary of main conclusions of the study 
 
Classification criteria 
used 
 
Little  
2004 
(11/15) 
To review patients with SVV
d
 misdiagnosed as 
having PMR 
13% of SVV
d
 patients had a prior diagnosis of PMR 
Patients with PMR symptoms and microscopic 
haematuria/proteinuria should be referred to 
nephrology 
 
No quoted classification 
criteria 
Narvaez  
2001 
(12/15) 
To evaluate the incidence and characteristics of 
musculoskeletal manifestations in PMR and GCA 
 
20% of PMR patients had clinically detectable 
peripheral synovitis  
Distal musculoskeletal manifestations were not 
uncommon in PMR patients but are in GCA 
For PMR: Chuang   
For GCA: American 
College of Rheumatology 
GCA criteria 
 
Olivio D 1996 
(12/15) 
Examine at onset the clinical and laboratory 
features of PMR and EORA
e
 with PMR like 
presentation 
 
More Fever and asthenia in PMR, No differences in 
laboratory tests but RF+ve good predictor of EORA
e
, 
Arthritis of peripheral joints more common in EORA
e
 
For PMR: Bird   
For RA
b
: American 
College of Rheumatology 
RA
b 
criteria for EORA
e
 
  
Pease 2005 
(12/15) 
To ascertain demographic and clinical differences 
between EORA
e
, PMR, GCA in patients with 
polymyalgic symptoms  
9 PMR patients developed RA (diagnostic delay of 13 
months)  
No single lab or clinical feature to distinguish EORA
e
 
from PMR 
RhF +ve status is a strong indicator of EORA
e
 but is not 
diagnostic 
 
For PMR: Bird   
For RA
b
: American 
College of Rheumatology 
RA
b 
criteria for EORA
e
 
For GCA: American 
College of Rheumatology 
GCA criteria 
 
Pease 2009 
(13/15) 
To attempt to develop a diagnostic algorithm that 
could help distinguish PMR from EORA
e
 
 
Combination of Wrist and proximal interphalangeal 
and or metacarpophalangeal joint disease at onset 
was highly suggestive of EORA
e
 
For PMR: Bird   
For RA
b
: American 
College of Rheumatology 
RA
b 
criteria for EORA
e 
 
Pege-Regosa  
2005 
(13/15) 
To describe 
f
CPDD mimicking PMR Proximal symptoms of 
f
CPDD can mimic PMR  
Tibio-femoral OA, tendinous calcifications, ankle 
arthritis are suggestive of 
f
CPDD 
For PMR: Chuang 
For 
f
CPDD: McCarty 
criteria [McCarty 1975] 
5
8 
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First Author  
(quality assessment) 
Objective Summary of main conclusions of the study 
 
Classification criteria 
used 
 
Salvarani  
1998 
(12/15) 
Determine the frequency and characteristics of 
distal musculoskeletal manifestations in PMR 
45% of PMR patients have distal musculoskeletal 
manifestations 
25% have peripheral arthritis,  
14% have carpal tunnel syndrome 
12% distal extremity swelling and peripheral arthritis 
These manifestations were more common in women  
For PMR: Healy   
For RA
b
: American 
College of Rheumatology 
RA
b 
criteria 
aESR: Erythrocyte sedimentation rate 
bRA: Rheumatoid arthritis 
cRS3PE: Remitting seronegative symmetrical synovitis with pitting edema 
dSVV: Small vessel vasculitis 
eEORA: Elderly onset rheumatoid arthritis 
fCPDD: Calcium pyrophosphate deposition disease
5
9 
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There are no specific laboratory tests or clinical manifestations that can be used to 
accurately distinguish EORA with a PMR like onset from PMR. There are features that are 
“suggestive of EORA” (e.g. being positive for rheumatoid factor [Pease et al 2005] and 
having distal joint involvement, particularly wrist and proximal inter-phalangeal or 
metacarpo-phalangeal joint involvement [Pease 2009]), but these are neither sensitive 
(the proportion of  “true” positives people who test positive for the disease among those 
who have the disease) or specific (“true” negatives ie the proportion of patients known 
not to have the disease, who will test negative for it)  enough for accurate early diagnosis. 
Similar conclusions have been made for remitting seronegative symmetrical synovitis with 
pitting oedema (RS3PE) although this disorder (unlike PMR) is more likely to occur in men 
presenting with PMR like symptoms with associated pitting oedema of their hands. 
[Kimura et al 2012]  
Pease and colleagues identified that just over 6% of the patients who were diagnosed by 
a rheumatologist using established classification criteria as having PMR were 
subsequently re-classified as having EORA (mean delay in diagnosis of 13 months (range 
1-30 months)). [Pease et al 2005] This has several important implications for primary care. 
First, careful and regular follow up has to be undertaken, with clinicians being aware of 
the association of other disorders presenting in a similar manner to PMR and referring on 
for specialist review if the clinical picture changes (e.g. developing oedema or peripheral 
arthritis). For GPs this is a challenging area especially as some disorders, (such as 
remitting seronegative symmetrical synovitis with pitting edema (RS3PE) or calcium 
pyrophosphate deposition disease (CPDD)) are very rare and the clinician may not have 
the awareness of these illnesses. The key issue however, is to recognise that the patient is 
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not following the expected clinical trajectory and to refer early for expert review in such 
circumstances. Second, research studies need to have adequate frequency and duration 
of follow up of patients with the same careful assessment and flexibility to change a 
diagnosis should the need arise.   
 
3.4.5 Laboratory investigations and unique biomarkers 
Table 3.5 illustrates the research studies identified from the literature search 
investigating laboratory tests (including potential novel biomarkers) that could be used to 
help more definitively diagnose PMR. 
Table 3.5 Summary of studies researching laboratory investigations and unique biomarkers 
in PMR diagnosis 
Citation 
(year) 
 
Overview of study 
Arnold  
(1993) 
 
 
Boiardi  
(1996)  
 
 
Cats 
(1993)  
 
 
Ceccato  
(2006)  
 
 
Chakravarty 
(1995)  
 
 
Corrigall 1995  
 
 
 
 
Australia. Secondary care  
Prospective cohort.  
Serum from 30 PMR and 20 control patients to investigate CD8 +ve T lymphocytes 
 
Italy. Secondary care 
Prospective cohort. 18 PMR and controls (healthy ≥60, EORA
a
 and RA
b
 ≤ 50) 
To assess CD8. Follow up 2 years 
 
Netherlands. Secondary care  
Prospective cohort. 11 GCA, 9 PMR and 25 healthy blood donors 
To study ANCA
c
 in PMR and GCA. 
  
Argentina. Secondary care. 
Prospective cohort. 16 EORA
a
, 13 PMR patients. 
To study Anti CCP
d 
in PMR. Mean follow up 20.1 months 
 
UK. Primary care 
 Prospective cohort. 98 PMR, 100 healthy controls  
To study aCL
e
 antibodies in PMR 
 
UK. Secondary care 
Prospective cohort. 37 PMR patients and controls  (21 rheumatoid arthritis and 27 non 
inflammatory arthritis eg osteoarthritis) 
To study CD8 positive T lymphocytes in PMR in comparison to other rheumatic diseases 
Italy. Secondary care 
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Citation 
(year) 
 
Overview of study 
Cutolo  
(2006)  
 
Dasgupta 
(1990)  
 
 
Elling 
(1989)  
 
 
Garcia Unzueta 
(2006)  
 
 
Hachulla  
(1991)  
 
 
Helfgott  
(1996)  
 
 
Kassimos 
(1995)  
 
 
Lopez-Hoyos 
(2004)  
 
 
Pawlowski, 
(1990) 
 
 
 
 
Proven  
(1999)  
 
 
Pulsatelli 
(1998)  
 
 
Salvarani 
(1994)  
 
 
Uddhammar 
(1995)  
 
 
Prospective cohort. Serum of 14 PMR and 15 EORA
a
 patients. 
To investigate serum cytokines in PMR.  
 
UK. Secondary care  
Prospective cohort. Serum from 12 PMR and 3 GCA patients  
To study IL6
f
 in PMR. Follow up 1 year 
 
Denmark. Secondary care 
Prospective cohort. Serum from 55 with PMR and or GCA, 25 controls  
To study serum CD4 lymphocyte subsets
 
in PMR. Follow up 1 year 
 
Spain. Secondary care. 
Prospective cohort study. Serum obtained from  17 PMR patients 
To investigate adrenomedullin in PMR 
 
France.  Secondary care 
Prospective cohort study. Serum obtained from 23 PMR patients. 
To study serum amyloid A in PMR 
 
USA. Secondary care.  
Prospective cohort study. 117 PMR patients. 
Describe the outcomes of patients with a normal ESR
g
 
 
UK. Secondary care 
Prospective cohort study. Serum from 20  PMR and RhF
h
 positive controls 
To study the significance of cytidine deaminase in PMR patients. 
 
Spain. Secondary care  
Prospective cohort. Serum from 57 EORA
a
 patients, 49 PMR and 24 healthy individuals. 
To Study anti-CCP antibodies
d
 in PMR.  
 
Switzerland. Secondary care 
Prospective cohort. 15 PMR, 17  dermatomyositis and polymyositis patients, 12 healthy 
subjects  
Study investigating serum AGP
j
  and ACHT
k
, to distinguish PMR from dermatomyositis 
and polymyositis 
  
USA. Community based cohort 
Prospective cohort. 232 PMR patients  
Study of PMR patients with low ESR
g 
 
Italy. Secondary care 
Prospective cohort study. 16 PMR subjects  
Study of RANTES
m
 in PMR. Follow up 6 months 
 
Italy. Secondary care. 
Prospective cohort. Serum from 19 PMR and 41 healthy controls 
Study of CD4 positive lymphocytes. Follow up 6 months 
 
Sweden. Secondary care. 
Prospective cohort. Serum from 23 PMR and 14 Healthy elderly controls 
Study of CD4 positive lymphocytes.  
Sweden. Secondary care  
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Citation 
(year) 
 
Overview of study 
Udehammer 
(1998) 
Prospective cohort. Serum from 15 patients with PMR  
Investigation of Inflammatory cytokine levels in PMR patients 
 
a
EORA: Elderly onset rheumatoid arthritis 
b
RA: Rheumatoid arthritis 
c
ANCA: Anti-neutrophil cytoplasmic antibody 
d
Anti CCP: anti-cyclic citrullinated peptide antibody 
e
aCL antibodies: Anti cardiolipin antibody 
f
IL6: Interleukin 6 
g
ESR: Erythrocyte sedimentation rate 
h
RhF: Rheumatoid factor 
j
AGP: Alpha-1-acid glycoprotein 
k
ACHT: Antichymotrypsin
  
m
RANTES: Regulated on Activation, Normal T Expressed and Secreted 
 
 
3.4.5.1 Key findings 
20 studies were identified that investigated the role of laboratory investigations or 
biomarkers and their potential utility in diagnosing PMR. The studies reviewed in this 
section can be broadly split into 2 groups. First, investigating currently available 
laboratory tests that can be used to help diagnose and differentiate PMR from other 
rheumatological disorders (in particular elderly onset rheumatoid arthritis, 4 studies) and 
second studies that investigate novel biomarkers that could potentially be used to 
diagnose PMR (n=16). All but one study (Chakravarty 1995) recruited patients exclusively 
from a secondary care setting using a variety of different classification criteria to identify 
eligible participants. These studies are summarised in Table 3.6. 
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Table 3.6 Studies researching laboratory investigations and unique biomarkers in PMR diagnosis 
First Author  
(quality assessment) 
 
 Objective  Summary of main conclusions of the study Criteria 
Arnold 
1993 
(12/15) 
To assess whether levels of CD8 
positive T lymphocytes are useful in 
diagnosing PMR or GCA 
 
With a CD8 positive T lymphocyte count of 
less than 22% you have an 88% chance of 
having PMR. 
With a CD8 positive count of less than 
<22% you have a sensitivity of 73% and a 
specificity of 85% 
 
Jones/ Hazelman 
Boiardi 
1996 
(13/15) 
Evaluate the role of CD8 positive T lymphocytes 
in active PMR and if these can be used to 
differentiate PMR from EORA
a 
 
CD8 positive T lymphocytes subsets 
studied significantly lower in PMR 
compared to controls 
Not helpful in distinguishing PMR from 
EORA
a 
  
For PMR: Healy 
For EORA
a
: 
American College of 
Rheumatology RA
b 
criteria
 
 
Cats  
1993 
(12/15) 
To investigate the diagnostic utility of ANCA
b
 in 
patients with GCA and PMR 
All patients with GCA positive for ANCA
b
 
No difference in ANCA
b
 between PMR and 
healthy volunteers 
For PMR: Jones/ 
Hazelman 
For GCA: American 
College of 
Rheumatology GCA 
criteria 
 
Ceccato  
2006 
(12/15) 
To investigate anti CCP antibodies
c
 in 
differentiating EORA
a 
from PMR and anti CCP 
antibodies
c
  in RhF
d
 negative EORA
a 
 patients 
In patients with EORA
a
, anti CCP 
antibodies
c
 present had a sensitivity of 
56%, a specificity of 92% a positive 
predictive value of 63% and a negative 
predictive value of 90%
 
A positive anti CCP
c
 antibody in patients 
with PMR symptoms is highly suggestive 
For PMR: Chuang 
For EORA: 
American College of 
Rheumatology RA
b
 
criteria 
 
6
4 
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First Author  
(quality assessment) 
 
 Objective  Summary of main conclusions of the study Criteria 
of EORA
a
 
Chakravarty 1995 
(13/15) 
 
Assess anti-cardiolipin antibodies aCL
e
 in 98 
consecutive patients with newly diagnosed 
PMR with or without GCA 
Increased aCL
e
 levels found in 20 patients 
These had a relative risk of 4.82 in 
developing GCA at some point during their 
illness 
For PMR: Bird 
Corrigall  
1995 
(13/15) 
To assess CD8 positive T lymphocytes in PMR 
and its potential as a new diagnostic criteria for 
disease 
Reduced percentage of CD8 positive T 
lymphocytes found in patients with PMR.  
Specificity of reduced CD8 positive T 
lymphocytes in PMR 85% (compared to 
controls with RA
b
) 
 
 
For PMR: Jones/ 
Hazelman 
For RA
b
: American 
College of 
Rheumatology RA
b
 
criteria 
Cutolo  
2006 
(11/15) 
To investigate serum cytokines and steroidal 
hormones in PMR and EORA
a 
 
TNFα
f
 raised in all study groups (PMR, 
EORA
a
 and a group of combined PMR/ 
EORA
a
) 
IL6
g
 was raised in all three groups and 
significantly raised in the isolated PMR 
and EORA
a
 groups 
No marker was able to differentiate 
between the three groups 
 
For PMR: Chuang 
For EORA
a
: 
American College of 
Rheumatology RA
b
 
criteria 
 
 
Dasgupta  
1990 
(12/15) 
To investigate IL6
g
 in patients with PMR and 
GCA and to establish additional disease activity 
markers 
 
IL6
g
 raised in PMR/GCA compared to non-
inflammatory disorders  
Known to be raised in RA
b
 so unclear how 
helpful it is in distinguishing from other 
inflammatory disorders  
 
 
 
 
 
For PMR: Jones/ 
Hazelman 
6
5 
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First Author  
(quality assessment) 
 
 Objective  Summary of main conclusions of the study Criteria 
Elling  
1989 
(11/15) 
To assess CD8 positive T lymphocytes in PMR 
patients with low or normal inflammatory 
markers 
CD8 positive T lymphocytes lower in PMR 
with low ESR
h
 or CRP
j
 compared to 
controls.  
T lymphocytes lower in PMR/GCA when 
inflammatory markers are low or normal 
 
None given 
Garcia Unzueta 
(13/15) 
 
To investigate plasma levels AM
k
 in patients 
with PMR and patients with GCA 
AM
k
 significantly increased in GCA 
compared with PMR and controls 
No differences in AM
k
 between PMR and 
controls 
 
For PMR: Chuang 
For GCA: American 
College of 
Rheumatology GCA 
criteria 
 
Hachulla  
1991 
(11/15) 
 
To assess serum amyloid A in the induction of 
PMR and disease remission with prednisolone 
 
Serum amyloid A: Sensitivity for disease 
activity (97%) 
Specificity for inactive disease (86%)  
None given 
Helfgott  
1996 
(12/15) 
 
To ascertain the frequency of PMR with a 
normal ESR
h
 and determine defining features 
22% of participants had an ESR
h
 of less 
than 30 mm/hr  
Patients with a high ESR
h 
had a 
significantly lower haemoglobin 
Low ESR
h
 was found to be more common 
in males  
Low ESR
h
 was associated with a potential 
delay in diagnosis  
 
For PMR: 
Jones/Hazelman 
Kassimos  
1995 
(12/15) 
 
To assess cytidine de-aminase in PMR & EORA
a 
  
Baseline cytidine de-aminase was higher 
in established pure RA
b
 compared to PMR 
or GCA  
For PMR: 
Jones/Hazeleman  
For EORA
a
: 
American College of 
Rheumatology RA
b
 
criteria 
6
6 
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First Author  
(quality assessment) 
 
 Objective  Summary of main conclusions of the study Criteria 
Lopez-Hoyos 2004  
(12/15) 
To assess the utility of anti CCP antibodies
c
 and 
RhF
d
 in the diagnosis of PMR and EORA 
No positive anti CCP antibodies
c
  found in 
PMR patients 
Anti CCP antibodies
c
 positive in EORA
a 
Anti CCP antibodies
c
 in the presence of 
PMR Symptoms is highly suggestive of 
EORA
a 
 
For PMR: Chuang 
For EORA
a
: 
American College of 
Rheumatology RA
b
 
criteria 
 
 
Pawlowski  
1990 
(11/15) 
 
To study the role of α-1-acid glycoprotein and 
α-1 antichymotrypsin in patients with 
dermatomyositis/ polymyositis PMR, GCA and 
healthy controls studied 
Presence α-1-acid glycoprotein  had a 
sensitivity of 100% and specificity 88%. 
Only useful in suspected dermatomyositis/ 
polymyositis 
 
For PMR: Bird 
For 
dermatomyositis/ 
polymyositis: 
Bohan 1988 
 
Proven  
1999 
(13/15) 
 
Determine clinical characteristics of PMR with 
low ESR in a community based cohort of 232 
patients 
17 (7.3%) had an ESR
h
 <40 
No difference in clinical features between 
the 2 groups 
For PMR: Chuang 
Pulsatelli  
1998 
(11/15) 
 
To evaluate the chemokine RANTES
l
 in PMR  
patients at disease diagnosis therapy 
Increase levels of RANTES
l
 compared to 
normal Controls, No correlation with 
clinical and routine lab findings 
 
For PMR: Healey 
Salvarani  
1994 
(13/15) 
 
To measure the levels of soluble CD4 and 
soluble CD8 in active PMR 
Soluble CD8 and soluble interleukin-2R 
levels were significantly raised in PMR 
compared to controls (healthy patients). 
Soluble CD4 decreased in the active phase 
of the disease 
 
 
 
 
 
For PMR: Healey 
6
7 
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First Author  
(quality assessment) 
 
 Objective  Summary of main conclusions of the study Criteria 
Uddhammar 1995 
(11/15) 
To investigate abnormalities in CD4+ T cell 
subsets in peripheral blood described for 
patients with PMR 
No difference in number or percentage of 
T Lymphocytes, HLA DR activated T cells or 
B Cells 
CD16 positive CD56 positive lymphocytes 
suppressed compared to controls until 2 
years 
 
For PMR: Bird 
aEORA:  Elderly onset rheumatoid arthritis 
bRA Rheumatoid arthritis 
cANCA: Anti-neutrophil cytoplasmic antibodies 
canti CCP antibodies: anti-cyclic citrullinated peptide antibody 
dRhF: Rheumatoid factor 
eaCL anti-cardiolipin antibodies  
fTNFα: Tumour necrosis factor alpha 
gIL6: Interleukin 6 
hESR: Erythrocyte sedimentation rate 
jCRP: C-reactive protein 
kAM: adrenomedullin  
lRANTES: Regulated on Activation, Normal T Expressed and Secreted 
6
8 
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3.4.5.2. Investigations and biomarkers currently available in clinical practice 
Ceccato (2006) and Lopez Hoyos (2004) demonstrated that the presence of PMR 
symptoms in patients with positive anti-CCP antibodies should be highly suspicious of 
elderly onset rheumatoid arthritis (EORA) [Ceccato et al 2006, Lopez-Hoyos et al 2004] 
with Lopez-Hoyos and colleagues highlighting, that rheumatoid factor was poor at 
differentiating PMR from EORA. However, these studies used different classification 
criteria for recruiting their PMR participants making comparison difficult. Furthermore, 
their utility in a primary care setting might be limited by different availability of these 
tests for primary care.  
Helfgott (1996) and Proven (1999) investigated having a normal ESR in the presence of 
typical PMR symptoms. These studies differed in their definition of a “normal” ESR 
(Helfgott defining it as an ESR of less than 30mm/hr and Proven defining it as an ESR of 
less than 40mm/hr). Helfgott and Kieval noted that patients with a raised ESR tended to 
have lower haemoglobin levels on laboratory testing whilst both studies failed to 
demonstrate any difference in the clinical features (duration of morning stiffness, site of 
stiffness or pain and systemic features for example fever and weight loss)  between those 
with a normal or raised ESR. [Helfgott and Kieval 1996, Proven et al 1999] 
 
3.4.5.3 Novel and experimental investigations and biomarkers  
Investigating the utility of new biomarkers is a two stage process. First it is necessary 
ascertain if the biomarkers level is different in PMR patients compared to healthy 
controls, and second it is important to assess whether the biomarker is helpful in 
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differentiating PMR from other rheumatic or mimicking disorders. No novel biomarker 
has been identified that can accurately diagnose or differentiate PMR from other 
disorders which commonly present with similar features. The only possible exception to 
this is α-1-acid glycoprotein (AGP) which is an acute phase protein synthesized by 
hepatocytes. Pawlowski (1990) demonstrated in a small study comparing 15 PMR patients 
with 17 patients with dermatomyositis (an autoimmune condition which causes 
inflammation of the skin and underlying muscle) or polymyositis (an autoimmune 
condition which causes inflammation of skeletal muscle) and 12 healthy volunteers that 
the presence of AGP had a sensitivity of 100% for dermatomyositis/polymyositis and a 
specificity of 88% suggesting that the presence of AGP is likely to exclude a diagnosis of 
PMR. Dermatomyositis and polymyositis are rare disorders and larger studies are 
required to replicate these findings and these findings are relevant only to patients with 
PMR symptoms where there is a possibility of dermatomyositis or polymyositis are being 
considered. [Pawlowski et al 1990] 
The utility of interleukin 6 (IL-6) has been investigated by Dasgupta (1990) and Cutolo 
(2006). Dasgupta and colleagues in their study of 12 PMR patients demonstrated levels of 
IL-6 to be raised in patients with PMR which helped differentiate PMR from non-
inflammatory disorders (for example osteoarthritis). [Dasgupta et al 1990] IL-6 levels are 
known to be raised in rheumatoid arthritis [Houssiau et al 1988] but this study failed to 
compare PMR and other inflammatory rheumatic disorders and clinical utility may be 
limited.  
There has previously been interest in the role of lymphocyte subsets in patients with 
PMR. Studies have investigated whether the absolute number and percentage of CD8 
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positive T lymphocytes when compared to controls are useful in diagnosing PMR.  
However, data is conflicting on the usefulness of CD8 positive T lymphocyte levels in 
differentiating PMR from EORA. Boiardi (1996) suggest that a reduction in CD8 
lymphocytes was not helpful in distinguishing PMR from EORA as only 55% of PMR 
patients had a reduced number whilst this was also observed in 23% of EORA patients.   
[Boiardi et al 1996] Corrigall (1995) suggested that participants with normal levels of CD8 
positive T lymphocytes and a polymyalgic presentation were more likely to develop 
seronegative rheumatoid arthritis. [Corrigall et al 1995] Neither of these studies 
investigated how useful these novel biomarkers would be in conjunction with other 
laboratory or clinical features. These studies are however limited by the use of different 
PMR classification criteria (Healy and Jones/Hazelman respectively), and small sample size 
(18 and 37 respectively). More research in this area needs to be undertaken to clarify 
these findings further. Furthermore, as neither of these tests is definitively diagnostic or 
widely available, it is unlikely that they would be useful in everyday clinical practice on 
the basis of currently published data. 
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3.4.6 The research of different imaging modalities used in PMR diagnosis 
Table 3.7 summarises studies identified that have investigated the role and effectiveness 
of different imaging modalities to help diagnose PMR. 
Table 3.7 Summary of studies investigating different imaging modalities for PMR diagnosis 
Citation 
(year) 
 
Overview of study 
Cantini  
(1999)  
 
Cantini 
(2001(a)) 
 
Cantini 
(2001 (b))  
 
 
Cantini 
(2005)  
 
Falsetti  
(2002)  
 
 
Falsetti  
(2011)  
 
Lange  
(1998)  
 
Lange  
(2000) 
Italy. Secondary care  
Prospective cohort. 23 Pure RS3PE
a
, 177 PMR patients assessed by MRI
b 
 
Italy. Secondary care. 
 Prospective cohort. 57 Patients with PMR MRI
b
 versus ultrasound assessed 
 
Italy. Secondary care 
Prospective cohort. 72 patients  with PMR 6 case patients with PMR an 
normal ESR
c
 (USS
d
 and MRI
b
) 
 
Italy. Secondary care. 
Prospective cohort. 20 patients with PMR, 40 controls assessed by MRI
b
 
 
Italy.  Secondary care   
Prospective cohort. Ultrasound scans of  50  patients with PMR compared 
with controls 
 
Italy.  Secondary care. 
Prospective cohort. 61 patients with PMR, multi-site ultrasound scans 
 
Germany.  Secondary care. 
 Prospective cohort. Ultrasound scans of 32 patients with PMR 
 
Germany. Secondary care 
Prospective cohort. 51 PMR patients,  ultrasound scans of glenohumeral 
joints 
 
a
RS3PE: Remitting seronegative symmetrical synovitis with pitting edema 
b
MRI: Magnetic resonance imaging 
c
ESR: Erythrocyte sedimentation rate 
d
USS: Ultrasound scan 
 
 
 
 
 
 73 
 
0 
3.4.6.1. Key findings 
Eight studies were identified investigating the use of imaging in the diagnosis of PMR: 
four studies considering ultrasound scanning (USS) alone, one study considering magnetic 
resonance imaging (MRI) alone and three studies investigating MRI and USS. These 
studies are summarised in Table 3.8.Three studies investigated the effectiveness of 
imaging at identifying relevant abnormalities that could be used to help diagnose PMR. 
[Frediani et al 2002, Cantini et al 2005, Cantini et al 2001a] The remaining studies looked 
at ultrasound scanning as a diagnostic tool to try and help to distinguish between patients 
with PMR and other rheumatic diseases. (Cantini 1999 (RS3PE), Lange 2000 and 1998 and 
Falsetti 2011 (EORA)). 
For identifying PMR related imaging abnormalities (typically reported as being 
subdeltoid/subacromial bursitis) ultrasound is as effective as MRI [Cantini et al 2000a & b, 
Cantini et al 2005] and potentially could be the imaging modality of choice for patients 
with PMR given its lower cost and relative ease of use. However, the question remains as 
to whether the presence of these imaging abnormalities, however detected, is sufficient 
to confidently diagnose PMR and able to differentiate PMR from other rheumatic 
disorders that present in a similar manner. All of the studies highlighted above attempted 
to distinguish PMR from elderly onset rheumatoid arthritis (EORA) which can present with 
a very similar clinical picture to PMR. As an isolated finding it would appear that the 
presence of subacromial/subdeltoid bursitis is not adequate in reliably distinguishing PMR 
from EORA [Lange et al 1998, Lange et al 2000] but may be helpful in making a more 
accurate diagnosis of PMR in conjunction with other clinical laboratory and imaging 
features. [Falsetti et al 2011]. 
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Table 3.8 Studies investigating different imaging modalities for PMR diagnosis 
First Author 
(quality assessment) 
 
Objective Summary of main conclusions of the study Criteria 
Cantini  
1999  
12/15 
 
To compare clinical and MRI
a
 characteristics 
of PMR and RS3PE
b
  
 
No significant difference in MRI
a 
findings between PMR and 
RS3PE
b 
 
For PMR: Healy 
 
Cantini  
2001 
12/15 
 
Investigation of shoulder structures of PMR 
patients using USS
c 
in patients with normal 
ESR
d
 at diagnosis 
 
Bilateral subacromial/ subdeltoid bursitis represents USS
c
 
imaging hallmark of PMR both in cases of raised ESR
d
 and 
normal ESR
d
 
For PMR: Healy 
For RA: American 
College of Rheumatology 
RA criteria 
 
Cantini 
2001(a)  
12/15 
 
To compare shoulder USS
c
 and MRI
a
 in 
patients with PMR 
USS
c 
detection of glenohumoral joint synovitis: sensitivity 78.7 
specificity 93.3 
USS
c 
detection of glenohumoral joint bursitis: sensitivity 93.7% 
specificity 100% 
USS
c 
evidence long head biceps tenosynovitis: sensitivity 100% 
specificity 100%  
USS
c 
evidence bursitis bilaterally: sensitivity 92.9%, specificity 
98.1% 
USS
c 
equally effective with MRI
a
 at identifying sub-
acromial/subdeltoid synovitis  
 
 
 
 
 
 
For PMR: Healy  
For RA: American 
College of Rheumatology 
RA criteria 
 
7
4 
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First Author 
(quality assessment) 
 
Objective Summary of main conclusions of the study Criteria 
Cantini 
2005 
12/15 
 
To investigate hip inflammatory features 
and evaluate accuracy of examination 
compared to MRI
a
 in patients with PMR 
53.4% had pelvic girdle involvement, USS
c
 and MRI
a
 detected 
trochanteric bursitis in 100% 
MRI better for detecting hip synovitis  
Trochanteric bursitis was the most common hip lesion found 
on MRI
a 
USS
c
 was as good as MRI
a
 at detecting this 
 
For PMR: Healy  
For RA: American 
College of Rheumatology 
RA criteria 
 
 
 
Frediani  
2002  
12/15 
Localization of synovitis in untreated PMR High prevalence of articular and peri-articular synovitis  at 
onset of PMR 
Subacromial-subdeltoid synovitis in 70%, 
Tenosynovitis long head of biceps 68% 
Glenohumoral joint effusion 66% 
No significant difference in findings comparing PMR and RA 
 
For PMR: Healy  
For RA: American 
College of Rheumatology 
RA criteria 
 
Falsetti  
2011 
13/15 
Effectiveness of USS
c
 at predicting 
diagnostic outcome in PMR patients 
Presence of subacromial subdeltoid bursitis gave an odds ratio 
of 5.603 for PMR 
Subacromial bursitis for PMR had a sensitivity of 79% and 
specificity 59% with a positive predictive value of 64% 
EORA
e
 and the presence of Anti CCP antibodies
f
 were found to 
have more erosions.  
 
For PMR: Bird 
 
Lange  
1998  
11/15 
 
 61.5% demonstrated inflammation of the glenohumoral joints 
in PMR  
63.2%  demonstrated inflammation of the glenohumoral joints 
in the EORA
e
 group 
USS
c
 was unable to differentiate between PMR and EORA
e 
 
For PMR: Healy  
For EORA
e
: no specific 
criteria quoted 
Lange  
2000 
12/15 
To investigate the usefulness of USS
c
 of the 
glenohumeral joint in PMR and EORA
e
 
Glenohumoral joint inflammation found in 40.9% of PMR 
participants and 65.5% of EORA
e
 patients 
Typical PMR findings: unilateral glenohumoral joint 
inflammation and discrete biceps tendon sheath effusion 
For PMR: Healy  
For EORA
e
: no specific 
criteria quoted 
 
7
5 
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aMRI 
bRS3PE: Remitting seronegative symmetrical synovitis with pitting edema 
cUSS: ultrasound scanning 
dESR: Erythrocyte sedimentation rate 
eEORA:  Elderly onset rheumatoid arthritis 
fAnti CCP antibodies: anti-cyclic citrullinated peptide antibody 
7
6  
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3.5. Discussion 
The overall aim of this systematic literature review was to identify and synthesise the 
available evidence regarding the diagnosis and classification of PMR, and to consider the 
findings in order to identify potential challenges in developing a diagnostic algorithm that 
could be used clinically in primary care. This section brings together the summarised 
findings for each domain above and will review the strengths and limitations of the 
systematic review. 
 
3.5.1. Evaluation of the methods used for the review 
3.5.1.1. Strengths  
Search Strategy  
The main strength of this literature review was the systematic approach that was 
employed to ensure that all studies relevant to classification, or diagnosis of PMR, were 
included. Search terms were identified from previous PMR based literature reviews and 
with the help of an experienced health librarian. To ensure maximum coverage, the 
“explode” feature was used to ensure all relevant and associated search terms were 
included. 
Two reviewers were also used at the title screening stage and all titles identified by either 
reviewer were kept for abstract screening even where disagreements were present.  
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Quality  
An assessment of the quality of each article was also made using a recognised quality 
assessment tool. However no studies undertook any sample size calculations and the 
range of quality scores was between 10 and 14 out of 15. It could be argued that all 
studies were of high quality. However criticisms include: 
 Lack of item weighting as each item is considered equivalent. For example, “an 
appropriate setting” has an equivalent weight to, “a more than 70% participation”.  
 Some items may be viewed as subjective for the assessor for example “an 
appropriate measure of outcome,” especially in circumstances where there may 
be a wide variety of outcome measures that could be used. 
 
3.5.1.2 Limitations 
Identified citations were limited in the original searches to studies written in English. The 
general aim of systematic reviews and meta-analyses is to attempt and assimilate all of 
the evidence available relating to the subject in question. Therefore excluding studies 
based solely on language goes, in part, against this principle. However, Juni (2002) 
demonstrated that including all languages has little impact on overall conclusions [Juni et 
al 2002] although Gregoire (1995) in their review of 36 identified meta-analyses 
concluded that at least one of the studies would have had different conclusions if all 
languages had been included. [Gregoire et al 1995] This systematic review may therefore 
have benefitted from having no language limits, however the risk of a significant citation 
being missed that would have greatly affected the findings was potentially low, given that 
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the citations papers identified were submitted from research centres from around the 
world. 
The Cochrane handbook defines publication bias as “The publication or non-publication of 
research findings, depending on the nature and direction of the results” 
[http://handbook.cochrane.org]. All systematic reviews are at risk of publication bias and 
therefore a search of un-published articles should have been undertaken. For this 
systematic review however, most of the published research identified above did not 
demonstrate significant findings and owing to the limited amount of published research 
in each area it is unlikely that a significant body of relevant un-published research exists 
that would alter any conclusions.  
Data extraction was undertaken by a single person (TH) and therefore there is the 
possibility of human error. However, each citation was reviewed twice, first at initial data 
extraction and then, during citation summary to minimise errors.  
 
3.5.2. Synthesis of results 
Owing to the wide variation of the question and the different recruitment strategies used, 
a meta-analysis was not appropriate and so a narrative approach was taken to data 
synthesis. Whilst this could be subject to reviewer bias it is the most suitable approach for 
a review with such a broad focus.  
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3.5.3 Implications for Practice 
This systematic review did not identify any validated diagnostic criteria for PMR nor were 
there any existing or experimental biomarkers or imagining modality that had diagnostic 
potential for use in general practice. The GP’s approach to diagnosis (in particular for 
disorders like PMR where no gold standard diagnostic test exists) evolves over time, 
sometimes through multiple consultations and assessments, which may include 
responses to trials of treatment in conjunction with relevant investigations, history and 
examination findings. This contrasts with recruitment into clinical trials where 
classification criteria are used to identify “standard participants” with a high probability of 
the disorder whilst excluding atypical patients who still need to be treated in routine 
clinical practice. 
 
3.5.4. Implications for PMR research  
This review has identified several areas that have implications for future PMR research. 
1) The lack of a historically recognised and universally accepted classification criteria 
means that a unified formal definition of PMR for research purposes has been lacking. 
This means that it has been impossible to formally benchmark laboratory tests, 
imaging or clinical features against a recognised and agreed “PMR patient”. However, 
the publication of validated and accepted provisional classification criteria should help 
standardise PMR identification for research, in the future. 
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2) As no gold standard agreed set of classification criteria exist, at least four different 
sets of classification criteria have been used. It is also not uncommon for unique 
criteria to be developed for individual studies. This makes comparison of studies 
difficult. 
3) Most of the studies included in the review have recruited participants from single 
specialist centres. The question remains however as to how representative patients 
recruited in secondary care alone are. Future studies should therefore recruit patients 
from a range of settings and not rely on secondary care samples which are not likely 
to be generalisable to the wider PMR population. 
4) Whilst traditional classification criteria (for example Bird (1979) and Chuang (1982)) 
may identify definite cases of PMR, it is clear that PMR exists as a spectrum and can 
present atypically.  Future studies therefore may need to include “outliers” to 
represent this wide spectrum of disease so that results can be generalizable to the 
wider PMR community.  
5) Future prospective studies should ensure adequate long-term follow-up. Disorders 
mimicking PMR may reveal themselves many months after the PMR diagnosis is 
originally made, as demonstrated by Pease (2005) where the mean diagnosis of EORA 
presenting with PMR symptoms was 13 months after symptom onset. [Pease et al 
2005] 
 
3.6. Summary 
The conclusions of the review are limited in view of the heterogeneity of studies and the 
small sample sizes of many of the studies identified. No novel or commonly available 
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group of biomarkers or imaging feature that typically characterises PMR and can be used 
to definitively diagnose PMR has been identified. Neither is there a single definitive 
clinical feature or group of features that can be used for reliable diagnosis. 
Guidance published by the British Society of Rheumatology and British Health 
Professionals in Rheumatology in 2010 advocate undertaking an extensive process of 
exclusion of other causes that may mimic PMR before making a definitive diagnosis. 
[Dasgupta et al 2010] Whilst for some conditions this requires a simple blood test other 
differential diagnoses require a certain amount of expertise that generalists may not 
have. Even with specialist expertise differentiating PMR from other very similarly 
presenting disorders  can be difficult, as demonstrated by the 2012 classification criteria, 
in which 8% of expert diagnosed PMR was eventually re-classified with an alternative 
disorder. [Dasgupta et al 2012] 
For the generalist, the 2010 clinical guidelines remain the standard process for diagnosis. 
[Dasgupta et al 2010] Since undertaking this review, up-dated guidance on the 
management of PMR has been published. [Dejaco et al 2015] Whilst these guidelines 
focus on the management of PMR, they do reinforce the 2010 guidance advocating a safe 
and specific approach to diagnosing PMR with a focus on the exclusion of relevant 
mimicking disorders. This involves undertaking a minimum set of investigations and 
constant re-assessment at follow up consultations, searching for alternative diagnoses. 
[Dejaco et al 2015] As no diagnostic feature or group of features have yet been identified 
to definitively diagnose PMR it may be more appropriate to consider PMR as “suspected” 
until a sufficient time has lapsed to allow other disorders to present. The existing 
evidence discussed relies in the majority on assessing the effectiveness of currently 
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accepted features yet there are a whole range of features that experts use to diagnose 
PMR [Dasgupta et al 2008] and, as Bird (1979) highlighted, these types of studies do not 
allow for the identification of new and unique features that might typify PMR. [Bird et al 
1979] Given that there is little evidence for specific tests and diagnosis remains 
challenging, what is needed in the first instance is to investigate the current practices of 
clinicians. This could be achieved through a large in-depth consultation record review or a 
large questionnaire study of clinicians involved in identifying and formally diagnosing 
PMR. For this thesis, and given that there is evidence suggesting that the majority of 
patients are identified in primary care [Barraclough et al 2008, Helliwell et al 2013] a 
national PMR questionnaire survey of GPs was undertaken and is described in more detail 
in Chapters 4 and 5. Specific areas of foci that will be investigated, given the findings of 
this review, will surround the processes that GPs undertake in making a formal diagnosis 
for PMR, what alerts them to thinking about potential alternative diagnoses and the kind 
of investigations used to confirm or exclude PMR.
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Chapter 4: PMR National Cross-sectional Survey: methodology 
The second objective of this thesis is “to describe the current diagnostic and management 
practices used by general practitioners caring for patients with polymyalgia rheumatica, 
to identify the perceived barriers to effective care, and to determine targets for future 
interventions and educational initiatives that could lead to improvements in patient care”. 
This will be achieved by undertaking a nationwide cross-sectional postal questionnaire 
survey of general practitioners.  
 
4.1. Introduction 
This chapter will review the methods used in developing the questionnaire survey and 
describe the practical aspects of delivering the survey to 5000 participants (GPs), the 
advantages and disadvantages of this method and potential sources of bias. Finally, the 
chapter will describe the methods used to analyse the survey data.   
 
4.2. Surveys 
Cross-sectional surveys have been widely used for research purposes and range from 
simple market research to national population based censuses. They can be performed in 
a variety of ways from individual face-to-face interviews to telephone and self-completion 
questionnaires. The aim of survey research is to gather standard information from a 
representative sample. [Aldridge and Levine 2001] 
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By obtaining data from a representative sample, the conclusions made from the survey 
findings should reflect the population as a whole. 
 They are particularly effective if:- 
1) new data on a subject are needed; 
2) the questions that need to be asked to generate these data are known; 
3) the target population is willing to tell you what you need to know; 
4) you want to generalise to a whole population. 
[Buckingham and Saunders 2009] 
 
4.2.1 Mode of questionnaire administration  
Questionnaires can be administered using a number of different methods including face 
to face interview, telephone interview, self-completion postal questionnaire and 
increasingly by electronic or on-line methods. The advantages and disadvantages of these 
different methods are summarised in Table 4.1, however, the choice of method may be 
limited by the type of research being undertaken. For example face to face interviews 
may not be practical for a national survey and telephone or electronic methods may be 
limited if the appropriate contact information is not available.  
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Table 4.1 Advantages and disadvantages of different survey methods.  
Type of Survey General advantages 
 
General disadvantages 
Postal Relative low cost Relatively low response rates 
Quick to perform Relatively high non-Response bias 
Can be used to target specific populations Volunteer bias 
Can cover large numbers of respondents 
Can cover large geographical area 
Difficult to control context of 
response 
No interviewer bias Gauging salience of responses 
No interviewer effects Restricts questionnaire length 
Effective for sensitive subjects Missing data 
Specific questions can be asked  
Responses can be controlled  
Anonymity  
Ample time to complete questionnaire  
Complexity  
Visual aids can be used  
Convenience  
  
Web Based 
Surveys 
Convenience for both participants and 
researcher 
Limited respondents if contact 
email addresses not available 
Rapid data collection Self-selection 
Cost effective Lack of interviewer involvement 
Visual aids can be used  
Ease of follow up  
Specialist populations can be targeted  
Complex question processes and decision 
making tools can be used aided by specific 
survey software 
 
  
Telephone 
Surveys 
Rapid data collection Potential for:  
Possible cost savings Less control, 
Anonymity  
Assurance that instructions are followed and 
survey completed appropriately 
Less credibility,  
Less complexity 
  
Face to Face 
Interviews 
Flexibility and opportunity to probe detail and 
meaning 
High costs 
Greater complexity Interviewer-induced bias 
Ability to contact hard to reach populations Participant reluctance to cooperate 
Assurance that instructions are appropriately 
followed 
Greater stress 
Less Anonymous 
  
[Adapted from Rea and Parker 2005]
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As part of their study examining recruitment strategies in GP surveys, Bonevski (2011) 
also questioned participants as to their preferred mode of questionnaire. 81.1% indicated 
that postal questionnaires were the most preferred format of survey, followed by online 
(17.1%), face to face (1.7%) and telephone (0.2%). [Bonevski et al 2011] 
With increasing use of the internet and the availability of contact electronic details it is 
likely that on-line and electronic methods (email, on-line questionnaire hosting site e.g. 
SurveyMonkey and social media portals e.g. Facebook and Twitter) for survey research 
will be used more frequently in the future.  
 
4.2.2 Postal Questionnaires 
Postal questionnaire surveys have the potential to investigate areas of research interest 
in a population by obtaining data from only a small fraction of that population [Dillman et 
al 2007] 
Postal surveys remain a popular survey method and it was this method that was chosen 
for the cross-sectional GP survey. The option to complete an on-line electronic version of 
the questionnaire as an alternative to the traditional paper self-completion questionnaire 
was also offered to participants in an attempt to improve response from harder to reach 
groups of clinicians (for example locum doctors).   
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4.2.3 Advantages and disadvantages of postal questionnaires 
Advantages 
Postal questionnaires possess several advantages. Costs for undertaking a postal 
questionnaire survey are relatively low when compared to other methods of obtaining 
data. This is especially relevant if large numbers of participants are required or 
participants need to be recruited from either specific populations or from hard to reach 
geographical areas. 
Postal questionnaires also have the practical benefits that they can be quick to perform, 
completed at a convenient time for the participant and can allow the participant ample 
time to complete the questionnaire. There are also methodological advantages for postal 
questionnaires. As postal questionnaires are self-completed, there is no interviewer bias 
and there are no interviewer effects, which makes them effective for sensitive subjects, 
as they create a certain amount of anonymity for the participant. [Rea and Parker 2005]   
 
Disadvantages 
Many of the disadvantages surrounding questionnaire surveys can be controlled and 
minimised given careful development of the questionnaire to be used. However 
questionnaires have clear and recognised disadvantages with the main disadvantage 
surrounding problems associated with bias. Bias in questionnaire surveys is a significant 
issue and is discussed specifically in Section 4.6 along with methods to try to limit bias in 
survey questionnaires. 
 89 
 
0 
Questionnaires often use fixed response answers or short open response answers. Whilst 
this can be an advantage, it can also be difficult to gauge the relevance and context of 
responses. Practical considerations include how to manage missing data or incomplete 
questionnaire responses as well as the recognition that sometimes questionnaires will not 
be completed and returned immediately, if ever, and so reminder methods to encourage 
response are recommended to minimise this. [Rea and Parker 2005] 
The main disadvantage specifically relevant to postal questionnaires surrounds the 
administration burden that they create. Printing the relevant paperwork and address 
labels, envelope stuffing and sending the questionnaires out to participants can be a 
physically onerous and time consuming process, often involving large amounts of staff 
and resources to undertake. Additionally, large postal questionnaire surveys may require 
special arrangements with the postal services. Arrangement and processes also need to 
be in place to manage further mail outs and to manage returned questionnaires, including 
data extraction. 
 
4.2.4 Sources of bias in survey methodology 
Bias can be defined as: 
 “Any trend in the collection, analysis, interpretation, publication, or review of data 
that can lead to conclusions that differ systematically from the truth; deviation of 
results or inferences from the truth, or processes leading to deviation.” [bias. (n.d.) 
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Farlex Partner Medical Dictionary. (2012). Retrieved April 25 2016 from 
http://medical-dictionary.thefreedictionary.com/bias].  
In survey research, bias can occur at many different stages. Choi and Pak(2005) 
categorized 48 different types of potential bias that can occur with questionnaire 
research relating to the design of individual questions, the way that the entire 
questionnaire is designed and the manner in which the questionnaire is delivered. [Choi 
and Pak 2005] Bias can also occur subsequent to data collection in the way that the data 
are analysed, interpreted and reported (reporting bias). [McGaura et al n 2010] 
 
4.2.5 Questionnaire design 
The aim of the study presented in this thesis is to investigate the current practice of 
general practitioners with regards to diagnosis, investigation and management of 
polymyalgia rheumatica and giant cell arteritis. A large representative population that is 
geographically diverse and accounts for all levels of clinical seniority and experience is 
ideally required to make robust conclusions from the data collected. Postal 
questionnaires are ideal for this purpose, as they specifically have the advantage of low 
cost, they can be performed quickly and large amounts of data from a wide, 
geographically diverse, targeted population can be obtained.  
The questionnaires used however, have to be developed with care in order to limit bias 
and maximise the accuracy of the data being provided, whilst ensuring that the greatest 
possible response is achieved. 
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There are certain forms of bias that cannot be controlled for in survey questionnaires. 
These include false reporting (giving information that did not happen), social desirability 
issues (indicating what the participant thinks the right answers are, rather than what they 
actually do or think) and issues surrounding recall. [Choi and Pak 2005] 
Bias and response rates can be influenced by questionnaire design. Methods for 
improving response rates are discussed in more detail in Section 4.9. To maximise the 
accuracy of the data, careful consideration of the overall design and format of the 
questionnaire has to be made. Each question needs careful construction to avoid 
ambiguity (by avoiding double barrelled questions, technical jargon and vague or 
inaccurate words). The accuracy of the data obtained from questionnaires is also 
dependent on the order of the questions (participants may learn in response to 
subsequent questions how they should have responded and may change answers) and 
the manner in which participants are able to answer the questions set. If participants are 
given a set of answers for a question to choose from then too few categories may cause 
participants to be forced into making a decision that they may not want to. Too many 
categories may lead to end aversion (not wanting to give the best or worst mark because 
it is at the end of the scale), response fatigue, and yes or no saying (ticking the same 
response whether accurate or inaccurate). [Choi and Pak 2005] 
  
4.2.6 Survey response and non-response bias 
The principal challenges of survey methods in order to make robust conclusions from data 
extracted from a completed survey are to ensure that the sample of participants that you 
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intend to survey is representative of the population as a whole and that this sampled 
population responds adequately. 
If responders are significantly different from non-responders, then bias can occur.  
Significant effort therefore needs to be invested in ensuring that response rates are 
maximised. 
Unfortunately levels of response are often used as a proxy indicator to judge whether or 
not the data is likely to be biased or not. Low response rates increase the risk of bias 
(although studies with a low response are not automatically biased), however studies 
where response is high may still be biased. 
Studies will often compare baseline characteristics (e.g. age, gender, years of experience) 
between responders and non-responders to demonstrate that no differences exist 
between the groups and hence that no bias exists. However this does not necessarily 
guarantee the absence of bias, as Jenkins et al demonstrated in their questionnaire study 
on health status. Whilst two groups (initial responders and late responder) were identical 
in terms of baseline demographics, their responses to the specific questions were actually 
very different. [Jenkins et al 2004] 
 
4.2.7 Response rates of questionnaires used in General Practice research 
There is an increasing body of evidence that suggests that GPs are participating less and 
less in survey research and as such, response rates to surveys are declining despite 
employing evidence-based methods that have been demonstrated to improve response 
rates, for example reminder cards and further questionnaires or incentives (Section 
4.2.10). [Creavin et al 2011] There has been some investigation into the reasons for this 
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declining participation in survey research and also much research into ways that survey 
response rates can be improved, both in commercial and medical survey research. 
 
4.2.8 Characteristics of non-responders in surveys of general practitioners 
Stocks and Gunnell (2000) investigated in depth, serial non-responders to postal surveys 
in the Avon area of the UK. They found that serial non-responders were likely to be older, 
were less likely to have a postgraduate degree and were less likely to be involved in 
undergraduate training. [Stocks and Gunnell 2000] This finding was confirmed by 
Hummers-Pradiera (2008) who also found that responders were more likely to be 
members of a Royal College. [Hummers-Pradiera et al 2008]. Bonevski (2011) found that 
responders in their study were more likely to be female and work part-time [Bonevski et 
al 2011] and finally Barclay (2002) found that non-UK graduates were a third less likely to 
respond to questionnaires, whilst UK graduates responded to surveys quicker if they were 
more recently qualified.[Barclay 2002] No correlation however has been demonstrated 
between response and measures of clinical care, such as the Quality and Outcomes 
Framework (QOF) score achieved by the practice. [Muller et al 2012] Unfortunately, 
survey non-responders have the potential to possess a wealth of knowledge and opinion 
that may be important and which could feasibly bias any conclusions made from a survey. 
Therefore, every effort has to be made to encourage potential participants to respond. 
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4.2.9 Why are people reluctant to take part in surveys? 
Aldridge and Levine (2001) state several reasons why people are reluctant to take part in 
surveys. 
These include choice, competition from other surveys, survey fatigue, intensification of 
social life, dislike of form filling and privacy.  More and more individuals feel that it is their 
choice not to participate in surveys and it appears that there is an increasing trend to 
choose not to participate given that that response rates to surveys are declining. Because 
of the benefits of survey research as outlined above, surveys remain a popular 
methodology with more and more being conducted. Participants are likely therefore, to 
complete only surveys that they feel are relevant to them or that they are interested in. 
Associated with this is the impact on the probability of filling in future surveys given the 
amount of form filling that often accompanies questionnaires, which potentially could 
impact on the time, taken at work and at home becoming ever more limited. As a result 
surveys may be viewed as an intrusion of spare time affecting whether or not they are 
completed. The amount of paperwork that certain professions are required to undertake 
(healthcare professions being no exception) is ever increasing. Adding to this workload, 
especially if optional, is likely to reduce the chance of the questionnaire being completed. 
Finally, concerns over the use of personal data and opinions, have become an increasingly 
important problem.  Surveys, even if completely anonymous may be viewed as an 
intrusion of privacy, impacting on a participant’s decision to respond or not. [Aldridge and 
Levine 2001] 
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All of the points made above are also relevant to general practitioners, the target group 
for this research. Kaner (1998) followed up the non-responders to a postal questionnaire 
survey with a telephone interview to ascertain the reasons for their non-response. [Kaner 
et al 1998] The three most common reasons for non-response were: 
1) Questionnaire was lost in pile of paperwork (24%) 
2) Too busy to complete the questionnaire (21%) 
3) I don’t do any questionnaires (16%) 
 
McAvoy and Kaner (1996) cited additional reasons for nonresponse including, the volume 
of questionnaires received, the length of the questionnaire, the time taken to participate 
in completing a questionnaire, resentment due to the interference that the questionnaire 
imposed, non-interest in the subject, issues surrounding confidentiality, disruption of 
workload, lack of provided information before completing the survey and lack of feedback 
offered. [McAvoy and Kaner 1996] These echo the general findings by Aldridge (2001) 
discussed above. By addressing the reasons why participants do not respond, surveys can 
be developed to maximise response. These methods are discussed in the following 
section. 
 
4.2.10 Methods shown to improve response rate 
Much research has been undertaken, particularly by those interested in commercial 
research, investigating ways to improve response rates to questionnaire surveys.  
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4.2.10.1 Questionnaire format 
Length of questionnaire 
As identified above, the length of questionnaire was an often cited reason for not 
responding to surveys. [McEvoy and Kaner 1996] This was supported by a Cochrane 
review by Edwards (2009) that showed that the odds of response was almost 75% higher 
with shorter questionnaires (although no optimal questionnaire length was 
offered).[Edwards et al 2009] Contrary to this, Grava-Gubins and Scott (2008) in their 
study on survey response amongst Canadian physicians, found no difference in response 
relative to length of questionnaire. [Grava-Gubins and Scott 2008]  Nakash in their meta-
analysis specifically relating to survey response in health care research found that shorter 
questionnaires improved response (OR 1.4, 95% CI 1.19 to 1.54). [Nakash et al 2006] 
The length of questionnaire however, is highly dependent on the amount of information 
that is being sought or required to answer the research question, and although the 
optimal length of questionnaire is not known, data suggest that the length should be 
minimised to improve response. [Edwards et al 2009] 
 
Appearance of questionnaire 
Having a reputable university, organisational logo or sponsorship and a signed 
accompanying letter has been shown to improve response rates [Edwards et al 2002] yet 
other studies looking specifically at questionnaires for general practitioners found no 
effect on response rate when the survey was endorsed by a GP. [Bonevski et al 2011] 
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Coloured paper has not been shown to have any effect on response rates [Edwards et al 
2002], although this seems quite surprising considering a common reason given for not 
responding is that the questionnaire had got lost in paperwork and presumably coloured 
paper would make it more identifiable. Font size used in survey questionnaires has been 
shown to improve response rates in older people and although paper thickness did not, it 
did improve completeness of the data collected. [Mallen et al 2008] 
 
Delivery of questionnaire 
Methods of delivery that have been shown to increase response rates include including 
stamped return envelopes, using brown envelopes, and using special delivery services 
and first class return of questionnaire. No differences in response rates have been shown 
with, different types of stamps, windowed envelopes or whether the questionnaire was 
sent to the participants work or home. [Edwards et al 2002] 
 
4.2.10.2 Incentives 
It is well recognised that incentives improve response rates whether they are gifts, 
monetary incentives or the chance to win a prize in a lottery. [Thomson et al 2004] The 
timing of when the incentive is given can also have an impact on response rates. In 
general, large monetary incentives appear to be the most effective at increasing odds of 
response (by up to a third). This can be further improved by enclosing the incentive with 
the questionnaire rather than giving it “if” the survey is completed. [Edwards et al 2002] 
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Specifically, when looking at response rates amongst GPs, small monetary incentives can 
boost response rates [Nakash et al 2006, Brealy et al 2007, Thorpe  et al 2009], but the 
opportunity to win a large single prize has also been shown to be effective, particularly 
using champagne as the prize. [Thomson et al 2004] Despite incentives being a potential 
method of improving response, local research ethics committees are often reluctant to 
allow their use.  
 
4.2.10.3 Relevance and interest in the subject  
Several studies have shown that participants who are interested in the subject of the 
survey are more likely to respond. This has been highlighted in several investigations 
[McAvoy and Kaner 1996, Kaner et al 1998] with Edwards showing a doubling of odds of 
response in surveys with “more interesting questions.” [Edwards et al 2002] 
This aspect of survey research is difficult to control for, as it is difficult to predict what 
participants may be interested in and whether or not they would be interested in the 
research being conducted. Whilst selecting a cohort of interested participants may 
improve response rates and may for some studies be appropriate, it could have significant 
effects on any conclusions made. Uninterested participants represent a potentially 
important group that could yield important data, which if absent could introduce bias. 
Table 4.2 summarises some of the literature investigating questionnaire response rates in 
medical research. 
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Table 4.2 Summary of research investigating questionnaire response rates  
Lead Author 
 
Aim Study findings 
Barclay 
2002 
 
To review of response 
rates from mailed 
questionnaires and the 
characteristics of non-
responders 
 
Non UK graduates less likely to respond compared to UK 
graduates 
RCGP members twice as likely to respond 
The more recent the qualification the faster the response 
 
Bonevski  
2011 
 
To investigate 
strategies for 
improving response 
rates in surveys 
Response rate overall 30.3% 
Higher proportion of responders are females and part 
time GPs 
No difference in response if the questionnaire is endorsed 
No difference in response with telephone reminder 
 
Preference of mode of questionnaire 
81.1% postal  
17.1 online 
1.7% face to face 
0.2% telephone 
 
Brealey  
2007 
 
To investigate if  
monetary incentives 
improve response 
rates  
 
Adjusted odds ratio of response 2.2 with a monetary 
incentive 
Speed of response was increased 
 
Creavin  
2011 
 
To conduct a 
comprehensive review 
of primary care 
literature surrounding 
GP response rates to 
questionnaire surveys 
Total average response rate 61% 
Higher mean response rate associated with journals in the 
higher quartile of impact factor. 
 
No evidence of increase in response rate between 2000 
and 2009 despite the increased use of strategies to 
enhance response rate  
 
 
Edwards  
2002 
 
 
To conduct a 
systematic review to 
determine the best 
methods of increasing 
response rates to 
postal questionnaires 
 
Examples of methods to increase response rates: 
Monetary incentive (OR 2.02 95% CI 1.79 to 2.27 
Short questionnaire (OR 1.86 95% CI 1.55 to 2.24) 
More interest in subject (OR 2.44 95% CI 1.99 to 3.01) 
Grava-Gubins  
2008 
 
To assess the effects of 
various methodologic 
strategies on survey 
response rates  
 
No difference between longer and shorter questionnaires 
No difference in mode of questionnaire delivery 
Monetary lottery incentive did not increase response 
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Lead Author 
 
Aim Study findings 
Hummers-
Pradiera  
2008  
 
To investigate the 
barriers to GPs’ 
participation in 
primary health care 
research 
 
Respondents more likely to have higher level vocational 
training 
More likely to be members of a college 
More likely to be involved in teaching medical students 
 
Jones  
1999  
 
To compare postal, 
email and world wide 
web health survey 
methods 
 
Email response rate 34% 
Postal 72% 
Kaner  
1998 
 
 
 
To conduct a 
telephone survey of 
general 
practitioners' reasons 
for not participating in 
postal questionnaire 
surveys 
 
Most common reasons for non-response: 
Questionnaire lost in pile of paperwork (24%) 
Too busy (21%) 
Don’t do questionnaires (16%) 
 
McAvoy  
1996 
 
To review general 
practice postal surveys 
Reasons for non-response 
Volume of questionnaires 
Length of questionnaire 
Time taken to participate 
Resenting interference 
Uninterested in subject 
Issues surrounding confidentiality 
Disruption to work load 
Lack of information before hand 
Insufficient feed back 
 
Nakash  
2006 
 
To conduct a 
systematic review on 
how to maximise 
responses to postal 
questionnaires 
 
Impact of reminder systems (OR 3.71 95% CI 2.30 to 5.97) 
Shorter questionnaires  (OR 1.35 95% CI 1.19 to 1.54) 
Incentive (OR 1.09 95% CI 0.94 to 1.27) 
Stocks 
2000 
 
 
To determine the 
characteristics of 
general practitioners 
who routinely do not 
return postal 
questionnaires 
 
Serial non responders are: 
Likely to be older 
Less likely to have a post graduate qualification 
Less likely to be involved in undergraduate training 
Thorpe 
2009 
 
A review methods to 
improve response 
rates when surveying 
physicians 
 
Improved response rates with: 
Dillman total design method
1
  
Personalised incentives 
Recorded delivery 
First class post 
a
OR: Odds ration 
b
CI: Confidence interval 
1
Dillman total design method to maximise postal response: 1) Respondent friendly questionnaire 2) Total of 
4 contacts using first class mail and a special contact for example registered post or telephone contact 3) 
Return envelope with a real stamp on it 4) Personalised documentation with each contact 5) Financial 
incentive to be included irrespective of whether the questionnaire is completed or not 
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4.2.10.4 Contact and communication 
Covering letters outlining benefits to the sponsor or participant have not been shown to 
have any effect on response rates although indicating a benefit to society has a small 
impact on response but more significantly, assurances on confidentiality appear to have 
the greatest impact. [Edwards et al 2002] In addition, surveys with covering letters with a 
personalised approach with good quality explanatory information are likely to result in 
improved response rates. [Kaner et al 1998]  
Pre-notification improved odds of response [Edwards et al 2002], but reminder systems 
have been shown to be the most effective method at increasing response rates to 
questionnaire surveys involving general practitioners (OR 3.71). [Nakash et al 2006] 
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4.3 Discussion 
Although as highlighted above, a large Cochrane review was undertaken to explore how 
to improve response rates to postal questionnaires, [Edwards et al 2002] This review has 
its limitations, including the fact that only a few studies included are related specifically 
to medical settings and so its application in this area may be limited.  
Medical questionnaires surrounding specific disorders such as PMR provide several 
challenges. There is a fine balance between the need for the data required to answer 
the research question and fulfil the aims of the research project with encouraging the 
participant to respond to the questionnaire and not making them feel tested or judged 
by the questions that are asked.  
Interest in the subject is difficult to control for and there will always be a certain 
proportion of people that will not respond to surveys in which they have no interest. 
Additionally a certain proportion of potential participants, as a matter of routine, do not 
complete any surveys. [Kaner et al 1998] This is unfortunate as questionnaire surveys 
may be conducted in order to influence and improve health provision. Poor response 
however may lead to weakened conclusions, which may therefore have less influence. 
[McAvoy and Kaner 1996]  
Addressing non-response remains a significant challenge in healthcare research as non-
responders are a potentially significant source of important information and their views 
may have had a substantial impact on the overall study conclusions. For some 
investigations it may be practical to contact non-responders on an individual basis. For 
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most large scale surveys however, this is not feasible and as such the potential source of 
bias resulting from low response rates has to be acknowledged.    
 
4.4 Development of the national GP PMR research survey 
The following section describes the processes undertaken in developing the national GP 
PMR research survey. This section will review the application process for ethical 
approval, questionnaire design, obtaining contact details for potential participants and 
the practical aspects that need to be considered when conducting large scale surveys for 
example, mail-out, database development and data extraction processes.  
 
4.4.1 Ethical Approval 
Recent legislation has altered the process for ethical approval for studies that are 
undertaken involving health care professionals. As such ethical approval was sought 
from the Keele University Ethics Panel, rather than from the NHS National Research 
Ethics Service. 
[www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh
_126614.pdf]. Ethical approval was requested for a cross sectional survey of general 
practitioners and subsequently granted from the Keele University Ethics Review Panel 
on the 23rd of January 2012. [Appendix 3] 
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4.4.2 Questionnaire design 
Using the evidence outlined above on improving response rates and the findings from 
the systematic review discussed in Chapter 3, a questionnaire was developed that built 
on findings from my previously published work examining GP management of PMR 
using the CiPCA dataset [Helliwell et al 2013] but also included relevant primary care 
related aspects from available national PMR guidelines. [Dasgupta et al 2010] This 
process is summarised in Appendix 4. The questionnaire underwent a process of review 
and refinement by relevant stakeholders (general practitioners, rheumatologists, PMR 
patients) for content and usability.  
The final agreed questionnaire was eight pages long and endorsed with both Keele 
University and the Arthritis Research UK logos. Yellow paper was used (to reduce the 
risk of loss in a pile of paperwork) of 100g/m2 thickness which has been shown to reduce 
the chance of missed pages and therefore increase the chance of a fully completed 
questionnaire. [Mallen et al 2008]  
A single prize of a bottle of Dom Perignon champagne was offered as an incentive for 
completing the survey with all respondents being entered into a prize draw. Table 4.3 
summarises the questions and domains of the questionnaire. The full questionnaire can 
be found in Appendix 3. 
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Table 4.3 Summary of questions and domains from the PMR National cross-sectional 
survey questionnaire 
Domain Question 
Number 
 
Question theme 
Diagnosis   
 1 Age at which the diagnosis of PMR would be excluded? 
 2 Importance of key features  
 3 Use of inflammatory markers 
 4 Actions undertaken if inflammatory markers are normal 
 5 Disorders routinely excluded before making a diagnosis 
 6 Initial dose of prednisolone used 
 7 Investigations routinely performed 
 
Management   
 8 Action undertaken if response to treatment is poor 
 9 Previous use of methylprednisolone 
 10 Follow up of PMR patients 
 11 Additional interventions or medications offered 
 12 Indications for referral 
 13 Management of relapse 
 14 Impact on patients’ lives 
 
Challenges   
 15 Challenges of PMR diagnosis 
 16 Challenges of PMR treatment 
 17 General challenges associated with PMR 
 
Giant cell 
arteritis (GCA) 
  
 18 Experience of managing GCA 
 19 Symptoms indicative of GCA 
 20 Signs indicative of GCA 
 21 Management of suspected GCA  
 22 Specialist to whom GCA patients routinely referred 
 23 Initiating dose of prednisolone 
 
Responder 
demographic 
questions 
 Age 
Gender 
Seniority 
Year of qualification 
List size 
Educational resources used 
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4.4.3 Sampling frame 
The Binleys database [http://www.binleys.com/] was used as a sampling frame for this 
study. This large database contains the names and addresses of general practitioners 
working in the UK. In addition, it also contains other forms of information including the 
type of practice, the practice population size, practitioner seniority, and some of the 
clinical services that they provide. A random sample of 5000 general practitioners from 
across the United Kingdom (England, Wales, Scotland and Northern Ireland) was 
purchased. The data were imported into a specially created mailing database. The 
databases created for the PMR survey are described in more detail in the following 
section.  
 
4.4.4 Database development for the PMR survey  
Two databases were created specifically for this study. The first database was a mailing 
database and contained information from Binleys regarding the 5000 randomly selected 
general practitioners. This was used for the mail-out process described later. The second 
database contained the completed questionnaire response data.  
 
4.4.5 On-line option for questionnaire completion. 
To try and maximise questionnaire response, an on-line option was offered as an 
alternative method of questionnaire completion. Little research has been undertaken 
into the effectiveness of web based questionnaire methodology, especially when both 
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traditional postal and on-line options are offered in parallel. Whilst Hohwu (2013) 
suggested that internet questionnaire surveys are a promising and cost-effective 
method, when compared with postal questionnaires [Hohwu et al 2013], others have 
found that they are inferior in terms of response rate. [Leece et al 2004] However, Lusk 
(2007) found that an option to complete a survey online was in general favoured by 
younger males in particular. [Lusk et al 2007] The on-line version of the questionnaire 
was hosted by Survey Monkey [http://www.surveymonkey.com/]. This is a user-friendly 
and straight forward service, which provided the opportunity to test the questionnaire 
prior to it going ‘live’. The online version also would not allow you to continue without 
completing each page and indicated to participants their progress through the 
questionnaire. Details of how to use this option were included on the covering letters 
and reminder card and could be accessed from the PMR survey home page. A unique 
study identification number was required in order to access the survey. Regular data up-
dates were provided by Survey Monkey and imported onto the database created for 
participant questionnaire responses. Internet responses were specifically coded on the 
database. 
The project also has a news webpage that participants and the general public are able to 
access should they wish to learn more about the study and its updates. 
[http://www.keele.ac.uk/pmr/gpstudy/news/] 
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4.4.6 Mail-out procedure 
An initial survey pack containing a covering letter, study information leaflet, survey 
questionnaire and business return addressed envelope was sent to each of the 
randomly selected general practitioners.  Non-responders were sent a reminder post 
card after two weeks, reminding them of the survey and also providing the website link 
to complete the questionnaire on-line if preferred. These documents can be reviewed in 
Appendix 3. After two weeks, non-responders were sent a further questionnaire and 
covering letter. This mail-out process has been shown to be effective at maximising the 
response rate in questionnaire surveys of health professionals. [Glidewell et al 2012]  
The survey was open for a total of six weeks after the second survey pack had been sent 
out to non-responders. 
 
4.5 Data Entry 
Data were entered into the database designed specifically for the postal questionnaire. 
This was undertaken by administration staff trained in data entry. The data for every 
tenth questionnaire was reviewed by a second person to ensure quality control. Medical 
queries and uncertain entries were reviewed by TH when needed. 
 
 
 
 
 109 
 
0 
4.6 Data Analysis  
4.6.1 Description of data obtained from the PMR National cross-sectional survey 
Broadly the questionnaire survey contained two formats of questions, fixed /closed 
response questions (where participants would choose the option most appropriate for 
them) and open response questions that allowed participants to enter free text 
answers. Participants were given the opportunity for some fixed response questions to 
add free text as well. These different forms of data required different types of analysis 
methods and these will be described in the next sections. 
 
4.6.2 Analysis of fixed response data 
Simple descriptive statistics were generated using the statistical analysis package SPSS 
22 [IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, 
NY: IBM Corp.], were used for the majority of the data obtained from the questionnaire. 
Response bias was assessed by comparing baseline characteristics of responders and 
non-responders provided in the original data requested from Binleys. This included 
number of partners in the the participants practice and the practice list size. For the 
majority of descriptive analyses, results will be presented as means, frequencies and 
percentages. Some questions asked participants to assign a graded importance of a sign, 
symptom or impact on life. These results are presented on radar plots of modal 
responses. Radar plots are an effective way to present and compare multiple values for 
multiple variables. The modal response was used as it conveys the most common 
response from participants. To investigate associations between respondent 
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characteristics and reported diagnosis and management strategies, logistic regression 
analyses were used.   
 
4.6.3 Analysis of open response data 
Open response questions can be challenging to analyse given that the range of 
responses can vary from just a few words to long, extended paragraphs. Two common 
methods of analysing this type of data are content analysis and thematic analysis. 
Thematic analysis is discussed in detail in Chapter 6, as this method will be used to 
analyse the qualitative GP interviews that form the second half of this thesis. 
 
4.6.3 Content Analysis 
Krippendorf (1989) defined content analysis as “A research technique for making 
replicable and valid inferences from data to their context.” [Krippendorff 1989 p403] At 
its most basic level it is a method of analysis that involves assessing the occurrence and 
frequency of a subject of interest within the available data. This may be something as 
simple as a single word but can be more complex involving general themes or processes. 
Thematic content analysis goes beyond analysing the simple frequencies of events of 
interest by developing themes from emerging the data. This method allows both 
representations of the impact of a particular issue (using simple frequencies) but also an 
element of superficial interpretation of text with subsequent development of simple 
categories to create global themes. [Krippendorf 1989]       
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4.6.4 Content analysis versus thematic analysis 
Content analysis has its origins as a quantitative research method and was principally 
developed for use in media research. However qualitative approaches have been used 
and developed for other areas of research including medicine and psychology, allowing 
the interpretation of data as well as calculating the actual frequency of an issue or 
subject. [Krippendorf 1989, Vaismoradi et al 2013] Issues remain over some of the 
concepts of qualitative content analysis [Graneheim and Lundman 2004, Vaismoradi et 
al 2013] and its comparisons with thematic analysis. Table 4.4 summarises the different 
approach to analysis with these two methods. Quotes from the open responses are 
labelled with the participants’ anonymised survey identification number, their age, 
length of time practising as a GP, their gender and their seniority/role.   
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Table 4.4 Comparisons between thematic analysis and content analysis 
Thematic Analysis 
[Braun and Clarke 2006] 
 
Content Analysis  
[Elo and Kyngas 2008] 
 
Familiarisation with the data 
Immersion in the data by transcription, reading and 
re-reading in an “active” way to search for patterns 
and meaning. 
Preparation 
Immersion in the data, making sense of it as a 
whole and deciding upon the what will be 
analysed 
Generating initial codes 
Creating codes that relate to features in the data 
that are interesting and grouping data that is 
relevant to each code. 
 
Organising 
Data analysis by content, development of codes 
and grouping of codes to create categories and 
sub-categories 
Searching for themes 
Grouping codes to develop general themes 
 
 
Reviewing themes 
Re-assessing the identified themes to ensure that 
they are supported by the data 
 
 
Defining and naming themes 
The final detailed analysis and review of each theme 
and its story. How do the identified themes relate to 
each other and does the data support this.  
 
 
Producing the report 
Final analysis and overall presentation of the data in 
a final report 
Reporting 
Reporting the analytical process, the results of 
that process and the overarching story that 
emerges from the data 
 
 
4.7 Summary 
A key difference between a thematic approach and content analysis lies in the type of 
data resulting from the open response questions. Thematic analysis usually requires a 
certain level of interpretation of in depth and detailed data that is often obtained from a 
limited number of individuals. Emerging themes are not usually quantifiable but are 
something important that is deemed to relate to the overall research question. In 
content analysis a theme may develop simply as a result of the frequency of its 
occurrence in the data. Additionally, owing to the limited length of responses in the 
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survey and therefore, the lack of overall context of the response, the amount of 
interpretation that can be made is limited, unlike for example thematic analysis of in-
depth interviews.  
A thematic content analysis was therefore chosen to analyse the open response data 
given the number of responders and the brevity and often superficial detail of which the 
open response data consists. The importance of each emerging theme can be assessed 
quantitatively in relation to the frequency with which that the theme occurs. NVivo is 
software package often used for analysing qualitative data [NVivo qualitative data 
analysis Software; QSR International Pty Ltd. Version 10, 2012]. It allows data to be 
coded into themes. NVivo 10 was used to analyse the open response data by allocating 
responses into relevant categories.  
 
4.8 Conclusions 
This chapter summarises and justifies the methods used in developing the national PMR 
questionnaire survey of GPs along with the strengths and limitations of the approach 
used. The analysis methods used for the quantitative survey and the methods used for 
the free text part of the survey are also described. The following chapter describes the 
results of the data obtained from the survey
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Chapter 5: PMR National Cross-sectional Survey: Results  
 
5.1 Introduction 
This chapter presents the results from the national PMR GP cross sectional survey, the 
methodology of which is described in detail in Chapter 4. The postal questionnaire 
included fixed and open response questions around GPs’ diagnosis and management of 
PMR, both of which are presented in this chapter under headings focusing on the 
diagnosis (Section 5.3), management (section 5.4), impact and challenges (Section 5.5) 
associated with PMR in primary care. Each section of results references the related 
question(s) from the survey questionnaire. First the characteristics of responders and 
non-responders are compared. 
 
5.2 Response and baseline characteristics of responders 
5000 questionnaires were mailed to potentially eligible participants, and 1258 (25.2%) 
completed questionnaires were received. Nine responses were found to be duplicates 
resulting in 1249 (25.0%) unique, completed questionnaires for use in analyses 
Figure 5.1 presents the response rates at selected points of the questionnaire mail-out 
process, the proportion of participants completing the questionnaire on-line and those 
withdrawing from the study at each stage. 
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Figure 5.1 Survey flow and questionnaire response 
 
* It was found on data cleaning that some respondents had completed both paper and electronic 
questionnaires. The response with most questions answered therefore was chosen to be included for 
analysis. 8 of the duplicates that were removed were completed on-line. 
 
 
Of those responding 1132 (90.63%) completed a paper questionnaire and 126 (10.07%) 
completed the on-line version. The majority of responders were GP partners, with the 
mean duration of qualification being 13.4 years. The baseline characteristics of 
responders and the available characteristics (obtained from Binleys initial data supply) 
of non-responders are presented in Table 5.1. 
Survey Close 
5000 Questionnaires 
mailed 
Further pack sent to 
non-responders after 4 
weeks 
Reminder card sent to 
non-responders after 2 
weeks 
6 weeks to allow 
further responses 
Total 
Mailed 1132 (22.64%) 
On Line 126 (2.52%) 
Withdrawn 34 (0.68%) 
Responses: 
Postal  263 (5.26%) 
On-line  18   (0.36%)  
Withdrawn  7     (0.14%) 
Responses: 
Postal  348 (7.14%) 
On-line  58   (1.19%)  
Withdrawn  8     (0.16%) 
Responses: 
Postal  521 (11.76%) 
On-line  50   (1.13%)  
Withdrawn  19     (0.43%) 
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Table 5.1 Baseline characteristics of responders and non-responders to the PMR 
National cross-sectional survey questionnaire 
Characteristic Overall 
responders 
n=1249 
Postal 
responders 
n=1132 
Online 
responders 
n=123 
Non-
responders 
n=3749 
List size (Median, IQR)  7129 
(6463,5500) 
7098 
(6375,5500)  
7519 
(7000,5175)   
6574 
(5700,3600) 
Number of partners  
(Median, IQR) 
3.78 (4,3) 3.76 (4,3) 4.02 (4, 3) 3.24 (3, 4) 
Age  
(year) (Mean, SD)  
44.05 (9.25) 44.48 (9.45) 40.8 (7.73) n/a 
Female (n, %) 649 (52) 598 (53) 68 (55) n/a 
Seniority (n, %)    n/a 
 Senior partner 
Partner 
Salaried 
Locum 
172 (13.8) 
757 (60.6) 
260 (20.8) 
31 (2.5) 
165 (14.7) 
673 (59.8) 
234 (20.8) 
29 (2.6) 
7 (5.7) 
83 (67.5) 
26 (21.1) 
2 (1.6) 
n/a 
n/a 
n/a 
n/a 
Years qualified as a doctor 
(Median, IQR) 
20.1 (18,15) 20.4 (18, 24) 16.3 (15,9) n/a 
Years qualified as a GP  
(Median, IQR) 
13.5 (11,14) 13.8 (11, 15) 9.5 (15,9) n/a 
SD – standard deviation; IQR – interquartile range, n/a – not available 
 
The mean age of survey postal responders was 44 years, which is lower than the 
national mean GP age of 47 years. 73.8% of responders were GP partners which is 
comparable to the UK national demographic where 75.7% of GPs are partners [GP Data 
HSCIC (Health and Social Care Information Centre)]. Study participants were more likely 
to work in slightly larger practices. Additionally they worked in practices with more GP 
partners when compared to non-responders. 
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The regional variation in response is illustrated in Table 5.2. 
Table 5.2 Regional variation in questionnaire response 
Region 
 
Mailed 
 
Responders 
 
n % of total n % of all 
responders 
 
% of baseline 
London 
Midlands & Eastern 
North 
Northern Ireland 
Scotland 
South  
Wales  
793 
1197 
1265 
21 
500 
964 
260 
15.9 
23.9 
25.3 
0.4 
10.0 
19.3 
5.2 
139 
296 
325 
6 
141 
322 
60 
10.8 
23.0 
25.2 
0.5 
10.9 
25.0 
4.6 
17.5 
24.7 
25.7 
28.6 
28.2 
33.4 
23.1 
 
 
The region with the highest response was the South of the UK, whilst London had the 
poorest response. 
 
5.3 Diagnosis 
This section presents the results focusing on making an accurate diagnosis of PMR. The 
following section summarises the fixed response data. 
 
5.3.1 Age (Question 1) 
Table 5.3 summarises the ages below which GPs would exclude the possibility of PMR. 
The findings from the survey suggest that GPs would not necessarily exclude PMR based 
solely on age, although the majority of GPs (72.5%) would appropriately exclude PMR in 
patients under the age of 50 years.  
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Table 5.3. Age below which PMR would be excluded 
Age Category (years) n 
 
(%) 
Less than 30 208 (16.7) 
Less than 40 264 (21.1) 
Less than 50 434 (34.7) 
Less than 60 156 (12.5) 
Less than 70 102 (8.2) 
 
 
5.3.2 Use of investigations  
5.3.2.1 Inflammatory markers (Question 3) 
Raised inflammatory markers support a diagnosis of PMR. The majority of respondents 
(n=1118 (89.5%)) reported checking the erythrocyte sedimentation rate (ESR) whilst 683 
respondents (54.7%) routinely request C-reactive protein (CRP). Table 5.4 illustrates the 
actions of responding GPs in cases where inflammatory markers are normal. 392 (31.4%) 
report that they would refer such patients for specialist review, whilst a quarter of 
responders (25.2%) reported that they would exclude a diagnosis of PMR. Half of 
respondents (50.7%) stated that they would consider a trial of treatment.  
Table 5.4 Actions taken in suspected PMR when inflammatory markers are normal 
Action taken 
 
n * (%) * 
Exclude PMR as potential diagnosis 315  (35.2) 
Recheck bloods 468 (37.5) 
Refer to specialist 392 (31.4) 
Offer treatment trial 633 (50.7) 
Other 101 (8.1) 
 
*Participants were not limited in the number of boxes that could be checked and so totals are greater than the 
number of participants and percentages add up to greater than 100 
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Responses from the open response questions highlight that diagnosing PMR in the 
context of normal inflammatory markers was a challenge. Respondents suggested that 
the overall clinical context relating to clinical presentation, signs, symptoms and 
investigation results had to be considered, although it was highlighted that normal 
inflammatory markers did make the diagnosis of PMR less likely, resulting in GPs more 
actively considering alternative and differential diagnoses. 
 “basically care would be individual, if history was highly suggestive of PMR, 
patient 60 who is not diabetic or osteopenic where steroid treatment could help I 
would be happy to go ahead and treat, if more complex may seek second 
opinion”  Participant 1665 (11, F, P)  
Key: [time qualified as a GP (years), gender (male/Female), seniority/role (S:salaried, 
L:locum, P:partner, SP: senior partner)] 
 
5.3.2.2 Other blood tests (Question 6) 
Whilst inflammatory markers (97.8%) and full blood count (95.9%) are almost 
universally performed, other recommended screening investigations were not routinely 
undertaken.  The investigations reported to be routinely undertaken by participating 
GPs are illustrated in Table 5.5 
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Table 5.5 Investigations routinely undertaken by GPs 
Investigation GP undertaking the 
investigation routinely  
 
 n % 
Full blood count (FBC) 1198 95.9 
Erythrocyte sedimentation rate/c-reactive protein (ESR/CRP) 1222 97.8 
Rheumatoid factor (RhF) 730 58.6 
Glucose 520 41.6 
Anti-nuclear antibodies (ANA) 412 33.0 
Urea and electrolytes (U&E) 866 69.3 
Creatinine Kinase (CK) 579 46.4 
Liver function tests (LFT) 806 64.5 
Thyroid function tests (TFT) 801 64.1 
Bone 670 53.6 
Serum electrophoresis 250 20.0 
Bence Jones  protein 211 16.9 
Anti-cyclic citrullinated peptide antibody (Anti CCP) 99 7.9 
Prostate specific antigen (PSA) 137 11.0 
X-Ray 161 12.9 
Ultra sound scan (USS) 22 1.8 
Other Imaging 18 1.4 
Urinalysis 195 15.6 
None 5 0.4 
Other 30 2.4 
 
 
Plasma viscosity was a commonly indicated “other” investigation and its use appears to 
be largely dependent on regional availability of inflammatory markers and local clinical 
guidance.   
 
5.3.3 Exclusion of PMR differential diagnoses (Question 5) 
The majority of responders reported that they actively try to exclude giant cell arteritis 
(GCA) when diagnosing PMR (80.1%). However exclusion of other causes for symptoms 
was not routine (Table 5.6). In particular, only 66.3% of respondents reported routinely 
excluding infections, and only 54.6% reported routinely trying to exclude malignancy.  
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Table 5.6 Routine exclusion of disorders that can mimic PMR 
Disorder 
 
n (%) 
Giant Cell Arteritis  1001  (80.1) 
Rheumatoid arthritis 864  (69.2) 
Active infection 828  (66.3) 
Drug induced myalgia 814  (65.2) 
Relevant rheumatological disorders 759  (60.8) 
Osteoarthritis 745  (59.6) 
Malignancy 682  (54.6) 
Relevant endocrine disorders 348  (27.9) 
Relevant neurological disorders 285  (22.8) 
 
 
5.3.4 Clinical features (Question 2) 
Participants were asked to rate the importance of selected clinical features associated 
with PMR from a provided list that was generated from the literature review presented 
in Chapter 3 (some of which were typical of PMR and others that were atypical). 
Participants were asked to rate the importance of each feature between one and five 
with five being “highly important” and one the “least important”. The median score for 
each feature was calculated with the results illustrated in Figure 5.2.  
Bilateral shoulder pain, raised inflammatory markers and response to treatment were 
rated as the most important features in diagnosing PMR, with muscle pain, morning 
stiffness and hip girdle pain as additional important features.  
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Figure 5.2. Radar plot depicting median scores relating to participant rating of 
importance of presenting clinical features used to diagnose PMR 
 
 
5.3.4.1 Open response questions to symptoms used for identifying PMR (Question 2) 
As well as rating the listed features offered in the questionnaire, participants were 
offered the opportunity to add other features they felt were important in identifying 
PMR. These are summarised in Table 5.7. 
 
 
 
1
2
3
4
5
Arm Pain
Muscle Pain
Morning Stiffness
Neck Pain
Bilateral Shoulder Pain
Shoulder Limitation
Hip Limitation
Raised Inflammatory
Markers
Response to initial
treatment
Leg Pain
Generalised joint ache
Hip Girdle Pain
Unilateral Shoulder
Pain
Joint Stiffness
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Table 5.7 Content analysis of open responses of presenting features of PMR 
Category 
 
Theme Count 
Constitutional Symptoms 89 
Symptoms of GCA 28 
Reduced mobility 20 
Muscle weakness 19 
Muscle joint aches 18 
Depression/low mood 16 
Overall global picture 14 
Muscle tenderness 7 
Other 3 
 
  
General constitutional symptoms, (including fatigue, tiredness and lethargy) was the 
main theme that emerged from the free text content analysis.  Fatigue was the 
predominant feature highlighted. Weakness reported as both generalised and muscular 
was another feature reported by some GPs although there was no indication as to 
whether this was objective or subjective weakness. Some respondents also suggested 
that it is more the overall global assessment that is important and the combination of 
signs, symptoms and investigation findings, rather than individual components in 
diagnosing or excluding PMR. 
 
5.3.4 Analysis of responder characteristics and associations with guideline appropriate 
diagnosis (Question 5) 
UK Clinical guidelines recommend excluding a range of conditions prior to diagnosing 
PMR. [Dasgupta et al 2010] These include the exclusion of GCA, active infection and 
cancer as a cause for the symptoms. Logistic regression analysis was undertaken to 
determine the characteristics of responders (experience measured by years since 
qualification, gender and the use of medical information resources) who were less likely 
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to undertake these recommended steps. No significant associations were found that 
identified a particular group that were not undertaking appropriate exclusions.  
 
5.3.6 Challenges surrounding the diagnosis of PMR (Question 14) 
Three general themes were identified surrounding challenges related to diagnosis. 
These included atypical presentations, overall uncertainty and other issues regarding 
diagnosis. These are summarised in Table 5.8. 
Table 5.8 Results of thematic content analysis of open response question relating to 
challenges surrounding diagnosis 
Category 
 
Theme Count 
Normal Inflammatory markers  284 
Possible mimicking disorders  183 
Diagnostic uncertainty/fear of misdiagnosis 112 
Non-specific presentation  108 
Atypical presentation  87 
Co / multi-morbidity  55 
Poor initial treatment response  50 
Long term glucocorticoid use  32 
No Challenges  24 
Giant cell arteritis  24 
Lack of diagnostic gold test  22 
 
 
5.3.6.1 Atypical Presentation 
This theme relates to the varying symptoms, signs and features with which patients 
suspected of having PMR first present. Classically symptoms include bilateral shoulder 
pain and/ or hip girdle pain, morning stiffness and muscle aches with raised 
inflammatory markers. However, patients often do not present like this, and it is the less 
typical presentations that cause diagnostic difficulty. 
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“Diagnosis often more difficult than the text book suggests, would love to always 
have patients that report classical symptoms and have elevated inflammatory 
markers and respond well to treatment, this happens rarely”  
Participant 3063 (29, M, SP)  
 
Atypical presentations can vary from abnormal distributions of symptoms to unusual 
joint involvement and can be made more challenging as it can be difficult for patients to 
express exactly the type and character of pain or stiffness. This is especially difficult for 
patients with illnesses such as dementia which has an increasing prevalence with 
increasing age. 
“Dementia patients and PMR, uncertainty re history, sought advice from 
secondary care”  
Participant 2378 (9, F, S) 
 
Atypical presentations also include situations where a patient may have typical features 
of PMR but without confirmatory raised inflammatory markers. As illustrated in Table 
5.8, normal inflammatory markers were the most commonly quoted factor contributing 
to diagnostic uncertainty. 
 “Typical symptoms but normal ESR would make me under confident to diagnose 
and may result in a referral to rheumatology. A rheumatologist diagnosed one of 
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my patients as above and I felt happy to treat with steroids with a normal ESR” 
Participant 3174 (7, F, P)  
 
5.3.6.2 Uncertainty of diagnosis 
General uncertainty and fear of misdiagnosis was a common issue expressed by 
responders but whilst an atypical presentation may be one element contributing to 
diagnostic uncertainty there were other specific areas where for PMR, diagnosis was 
reported to be difficult. PMR has an extensive differential diagnosis with many disorders 
that can present clinically in a similar way, and as there is no gold standard diagnostic 
test for PMR it can be very difficult to separate PMR from mimicking disorders. 
“there is no diagnostic test so it’s a clinical diagnosis with suggestive blood 
results which can be hard to feel certain about and hard to convey convincingly 
to the patient, also there being lots of other conditions with similar presentations 
makes this even harder”   
Participant 4814 (2, F, S) 
 
A significant response to glucocorticoid treatment is a well-recognised feature of PMR 
although its usefulness in classification criteria has been recently challenged. [Dasgupta 
et al 2012] As such this feature was often used to confirm the diagnosis by participants. 
However, when response to treatment was suboptimal, it caused uncertainty. 
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“Classic presentation, raised ESR but no response to steroids - actually had 
metastatic cancer”  
Participant 1029 (2, M, P)  
 
Finally respondents reported the non-specific way in which PMR can present to be 
especially difficult. This was particularly thought to be a problem in older patients with 
comorbidity where pre-existing symptoms could confuse the clinical picture. 
“often symptoms in older patients with multiple co-morbidities, difficult 
sometimes to distinguish between any related symptoms including osteoarthritis 
and fibromyalgia”  
Participant 1955 (17, F, P) 
 
5.3.6.3 Other diagnosis themes identified  
This theme encompasses those areas of diagnosis that whilst expressed less frequently 
than the above themes, may represent important aspects that need considering. These 
include the difficulties in making a diagnosis where there is the possibility of an inter-
current illness, which may be accounting for the raised inflammatory markers.   
“inter-current illness (chest infection) confusing inflammatory marker 
interpretation”  
Participant 1922 (5, F, P) 
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Additional challenges expressed included the problem that PMR is relatively unusual 
and depends on the practice population, and role of the individual GP. Exposure to PMR 
can be very dependent on the demographic of the practice population which will impact 
on the relative experience of an individual GP and therefore the confidence in 
diagnosing and managing it. 
“I have not seen many patients with PMR I work mainly in a practice for homeless 
people which is a younger population and as an academic GP, maybe I'm missing 
some diagnoses”  
Participant 3106 (8, M, L)  
 
Finally there is sometimes difficulty in patients accepting the diagnosis or uncertainty 
amongst patients who are concerned they may have a different diagnosis. 
“often getting patients to accept diagnosis and the need for steroid treatment…. 
coming to terms with diagnosis, addressing secondary depression”   
Participant 1588 (7, M, P)  
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5.4 Management of PMR 
The following section focuses on the treatment and management of PMR with a specific 
focus on prednisolone dosing and the management of the potential adverse effects of 
long term treatment with glucocorticoids. 
 
5.4.1 Initial Treatment (Question 6) 
UK National guidelines suggest an initial dose of 15mg of prednisolone [Dasgupta et al 
2010] for managing PMR followed by a gradual dose tapering. The median initiating 
dose of prednisolone was found to be 20mg with a most frequent initiating dose of 
15mg (Figure 5.3). 704 (56.4%) responders would initially treat PMR as per guideline 
recommendation with either 15mg or 20mg of prednisolone. Three further dosing peaks 
are noted with a starting dose of 30mg, 40mg and 60mg of prednisolone. 
 
Figure 5.3 Initiating prednisolone dose (mg) 
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373 (29.9%) responders would exclude PMR as a diagnosis based on a poor response to 
glucocorticoids, although the majority (68.4%) would consider specialist referral in this 
scenario. Two main themes emerged from a review of the open response question 
related to this topic. First, a poor response to initial treatment would lead to 
consideration of an alternative diagnosis rather than completely excluding PMR. This is 
also dependant on the confidence the general practitioner had in the initial clinical 
presentation. Second, a poor treatment response would prompt additional 
investigation, further reviewing of patients and consideration of a referral for specialist 
review. 
“depends on clinical context. If my suspicion was high I would seek specialist 
advice. If lower index of suspicion, I'd probably exclude PMR and cast round for 
alternative explanations (which may also include referral depending on context) 
perhaps by casting a wider investigative net.”  
Participant 1132 (17, M, P) 
 
Some responders indicated that they would try physiotherapy and/or alternative 
medications such as anti-inflammatories or analgesics to improve symptom control. 
Stopping treatment with prednisolone in situations of poor response however was a 
common theme in the open response questions, although some responders indicated 
that they would increase the dose of prednisolone and one responder indicated they 
would do this to a maximum of 60mg. 
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Intramuscular methylprednisolone is an alternative treatment option to oral 
prednisolone but was not commonly used amongst responders. 54 responders (4.4%) 
reported that they had used it to treat PMR. In general, responders who had used 
methylprednisolone found that patients had a good response to treatment.  
“patient reports excellent resolution of disabling symptoms”  
Participant 382 (23, F, P) 
 
A common theme in those that had experience of treating PMR with 
methylprednisolone was that it was usually administered after gaining advice from 
specialists. 
“therapeutic trial [of methylprednisolone] on one occasion in someone without 
raised ESR, that rheumatologist felt had PMR - wouldn't use routinely”  
Participant 991 (23, F, P) 
 
5.4.2 Long term management and monitoring of PMR patients 
Long term follow up of PMR patients is usually conducted in primary care. This involves 
glucocorticoid dose tapering and focused assessments for the development of GCA, 
potential other mimicking disorders and adverse effects of treatment (for example 
osteoporosis and diabetes).  
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5.4.2.1 Adjuvant Treatment (Question 10) 
As discussed in Chapter 1, osteoporosis prophylaxis in the form of calcium and vitamin D 
supplements, and bisphosphonates (if indicated) is advised for PMR patients being 
treated with long term glucocorticoids [Dasgupta et al 2010]. Current guidance does not 
advocate the use of routine gastric protection, but should be considered in at risk 
groups, (for example previous peptic ulcer disease or patients taking other medications 
(for example aspirin) that may increase the risk peptic ulceration)  as gastric symptoms 
are a common adverse effect in patients taking low to medium dose glucocorticoids. 
[Hoes et al 2009] Survey findings are illustrated in Table 5.9 and suggest that the 
majority of respondents routinely offer bone protection including calcium supplements 
and bisphosphonates (81.3%) and that gastric protection is also commonly offered 
(68.9%).  
 
Table 5.9 Summary of the results surrounding the long-term management and follow up 
of PMR 
 
Adjunctive therapy routinely offered to PMR patients 
 
n (%) 
Routinely offer bone protection  1016  81.3 
Routinely offer gastric protection 860    68.9 
Routinely offer analgesia 688    55.1 
Routinely offer physiotherapy 177    14.2 
Routinely offer alternative therapies 66      5.3 
Routinely offer referral to secondary care 149    11.9 
Routinely offer joint injection 19      1.5 
Routinely offer information leaflet 757    60.6 
Routinely offer website information 356    28.5 
Routinely offer support group 84      6.7 
Routinely offer none 8        0.6 
Routinely offer non-steroidal anti inflammatory 29      2.3 
 
 
 
 
 133 
 
0 
A review of the responses to the open question relating to this topic indicated that 
participants sometimes offered alternative therapies to help treat PMR. This most often 
involved a referral for a course of acupuncture, but other respondents indicated that 
hydrotherapy and aromatherapy were other alternatives. 
 
5.4.2.2 Indications for specialist review (Question 11) 
The most common reasons cited by respondents for referral for specialist review were 
diagnostic uncertainty (87.1%) and poor response to treatment (79.3%). 6.4% of 
respondents indicated that they referred all PMR patients to secondary care as a matter 
of routine. These results are summarised in Table 5.10 
Table 5.10 Indications for referral for specialist review 
Indications for referral for specialist review 
 
n (%) 
Diagnostic uncertainty 1088  87.1 
Poor response to treatment with glucocorticoids 991  79.3 
Request of patient 554  44.4 
Young patients 543  43.5 
Medication complications 446  35.7 
Normal inflammatory markers 399  31.9 
 
 
5.4.2.3 Management of PMR flares (Question 12) 
PMR symptoms may at any time flare up. The most common course of action in the case 
of a PMR flare was to recheck inflammatory markers (72.5%), whilst 46.4% of 
responders reported increasing glucocorticoids to the previously effective dose and 
62.6% increasing dose until symptoms were controlled. The full results from this 
question are illustrated in Table 5.11 
 134 
 
0 
 
Table 5.11 Management of PMR flares 
Action undertaken to manage a PMR symptom 
flare 
 
n (%) 
Increase glucocorticoid until symptoms controlled  777  62.2 
Recheck inflammatory markers 906  72.5 
Increase glucocorticoid only if ESR raised 199  15.9 
Increase glucocorticoid by 5mg 144  11.5 
Increase glucocorticoid even if ESR normal 265  21.2 
Refer to secondary care 209  16.7 
Increase glucocorticoid to previous effective dose 579  46.4 
 
 
5.4.3 Challenges experienced when managing PMR patients (Question 15) 
The open question identified a number of challenges related to treatment in the 
management of PMR (Table 5.12), which are discussed in turn below. 
Table 5.12 Frequency of challenges regarding PMR treatment 
Category 
 
Theme Count 
Prednisolone titration and reduction 295 
Glucocorticoid adverse events 285 
Symptom relapse 111 
Overall duration of treatment 89 
Adjuvant medication 85 
Stopping steroids 63 
Poor response to initial treatment 63 
Comorbidity and polypharmacy 58 
Compliance to treatment 55 
Regular monitoring 30 
Initiating dose of prednisolone 27 
Patient self -reducing medications too quickly 14 
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5.4.3.1 Challenges of long-term treatment with glucocorticoids 
The predominant theme relating to treatment challenges surrounded the use and 
potential adverse-effects of glucocorticoids. Some responders expressed issues 
surrounding unclear advice on initiating doses of prednisolone as well as treatment 
tapering which was reported as an area of considerable challenge for GPs treating PMR, 
and for patients given the potential for adverse effects balanced against the fear of 
symptom recurrence.  
“Main challenge is coming off steroids most patients are completely delighted 
when their symptoms resolve after a week on steroids but become despondent 
and anxious when they start to experience steroid side effects (e.g. weight gain) 
and discover when they try to step down off their steroids their symptoms re-
occur”  
Participant 1665 (11, F, P)  
 
Compliance with treatment was a notable issue for GPs responding to the survey and for 
patients with PMR this was related to both over treatment and adhering to dose 
reduction regimens. 
“frequent input with steroid regimes/doses especially when they struggled with 
dose reduction, no matter how slowly it was done - some patients feel dependent 
on steroids and will end up taking more (without consulting you) to control 
symptoms even when perhaps their symptoms might not be due to PMR” 
Participant 818 (4, M, P)  
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Finally, stopping treatment was reported to be challenging for both physical and 
psychological reasons. 
“those difficult to wean off - seem to become physically or psychologically 
dependent on steroids”  
 Participant 1228 (21, M, SP) 
 
5.4.3.2 Co/multimorbidity and multi-pharmacy 
The second theme identified from the free text responses relates to the impact that 
PMR treatment has on other illnesses, interactions with existing medications and the 
need in some cases to try and prevent any potential side effects and complications of 
long term glucocorticoid treatment. 
“Main problems are with anticoagulated patients (dabigatran will help) and 
patients with osteoporosis, heart failure, frailty, renal failure etc.”  
Participant 253 (17, M, S)  
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Glucocorticoid treatment was also noted to impact on PMR patients other comorbidities 
which tend to be more common in older age groups.  Diabetes was the predominant 
illness being reported to be affected by PMR treatment. 
 “one patient was diabetic and blood sugar control with oral steroids was a 
challenge”   
Participant 3849 (11, F, S)  
 
Treatment for PMR also involves the consideration of the prevention of potential 
adverse effects associated with long term glucocorticoids. This in itself can present 
challenges with respect to multi-pharmacy and compliance. 
 “complicated meds regime with need for bone prophylaxis and PPI as well as 
steroids”  
Participant 2227 (9, F, P)  
 
“having to take bone protection as well tolerating it” 
 Participant 4756 (12, F, S)  
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5.4.3.3 Practicalities of treatment and other challenges 
 
The final theme surrounds the practicalities of treating PMR and other challenges which 
although not frequently cited pose interesting challenges that are worthy of further 
consideration. The following quotes give some examples of the type of practical issues 
that GPs reported. 
 “keeping follow up and reduction in steroids - not enough appointments to bring 
back routinely patient need to be aware of plan and proactive if arranging tests 
and symptoms review”  
Participant 3529 (5, F, S)  
 
 “practicalities adjusting dosette boxes which are prepared few weeks ahead with 
need to change steroid dose regularly”  
Participant 211 (8, F, S)  
 
 “often housebound and no easy mechanism for review”  
Participant 3558 (17, F, P) 
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5.5 General challenges surrounding PMR (Question 16) 
The final open question explored any further or general challenges experienced by GPs 
that were not associated with diagnosis or management. Table 5.13 shows the 
frequency of the various categories from the data relevant to this question. Diagnosis 
and treatment with glucocorticoids were still identified as the predominant challenges 
expressed for this question and have been discussed in detail already, whilst giant cell 
arteritis will be discussed in Chapter 7. Other themes not already identified will be 
discussed in this section in more detail. 
Table 5.13 Other challenges of PMR in primary care 
Category 
 
Theme Count 
Diagnosis 467 
Treatment with glucocorticoids 265 
Follow up and monitoring 111 
Chronic condition 43 
Relapse and flare 39 
Few or none  39 
Multi-morbidity and polypharmacy 25 
Giant cell arteritis 21 
Access to specialists 17 
Lack of guidance 11 
 
 
The third predominant category after diagnosis and treatment surrounded the practical 
issues associated with follow up, monitoring and the pressure on availability of 
appointments.  
“diagnosis not always straightforward. Easy for patients to be lost to follow up if 
stable. May end up on steroids for years without proper monitoring, especially if 
change of surgery due going into nursing home for instance”  
Participant 814 (23, F, SP)  
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Finally some participants expressed issues surrounding the lack of rapid access to 
specialist input and inconsistencies surrounding available guidelines. 
“long term steroid complications require careful and frequent follow up, national 
and local guidelines and actual practice muddled with agreement, difficult access 
to secondary care, concern they mix up diagnosis timeline”   
Participant 3927 (18, F, SP) 
 
Figure 5.6 summarises the challenges described by participants in the questionnaire 
postal survey, including the points where treatments are added or changed during the 
treatment period.  
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Figure 5.6 Treatment timeline for PMR and management challenges during the treatment timeline 
Treatment initiation Adjuvant Medication Prednisolone reduction Treatment end Treatment of flare 
Poor initial response 
Best starting dose 
Flare management 
Is it a PMR flare? 
Prednisolone titration 
- Doctor centred 
- Patient centred 
Stopping 
prednisolone 
 
Glucocorticoid adverse effects Need for regular monitoring 
  Factors surrounding chronic disease 
management 
 Compliance to: 
 Glucocorticoid treatment 
 Adjuvant medications 
 Existing medications 
Loss to Follow up Burden on resources 
  
Multi-morbidity Polypharmacy and medication interaction Impact on existing illness 
  
Treatment timeline 
  
  
0 months 12 months 24 months 
Permanent complications 
1
41
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5.6 Perceived impact of PMR on patient’s lives (Question 13) 
The questionnaire also asked participants about how they perceived PMR impacted on 
their patients’ lives. GPs were asked to rate the importance of various PMR features (5 
being very important and 1 being least important) that may impact on well-being and 
function (Figure 5.7). 
These results suggest that GPs perceive the greatest PMR related issues that patients 
have to be pain and limitation of activity, followed by sleep issues, stiffness and concerns 
surrounding side effects and complications of long term treatment. 
Figure 5.7 Radar plot of median scores of perceived impact of PMR on patients 
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5.7 Discussion 
This large cross-sectional survey is the first to explore the views of GPs towards the 
diagnosis, management and challenges that PMR poses in primary care settings. The 
results suggest that PMR is a very challenging disorder to convincingly diagnose and 
manage effectively in primary care.  
The quote below summarises in a participants own words many of the issues identified 
from the results of the questionnaire survey in diagnosing and managing PMR in general 
practice.  
 “There are challenges to make the diagnosis with the resources and time GPs have 
i.e. 10 minute consultations, lack of immediate blood results, time and resources, 
patients require regular review, blood tests, specific advice, management of side 
effects of treatment can be sometimes difficult in primary care”  
Participant 2506 (4, F, P)  
 
5.7.1 Summary of findings 
Issues regarding accurate diagnosis remain the predominant challenge associated with 
PMR for general practitioners. First, the wide range of differential diagnoses, sometimes 
vague presentation and atypical features can make identifying PMR patients very difficult. 
Added to this, patients in the typical PMR age-range often have multi-morbidity which 
can confuse the presenting picture and complicate treatment regimens. A PMR diagnosis 
will result in long-term treatment with glucocorticoids with its associated potential 
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adverse effects which can also impact on comorbidity. An accurate diagnosis is therefore 
imperative.  
GPs responding to this cross sectional survey appear to be identifying patients with PMR 
using widely accepted clinical features, although there may be some over-reliance on 
response to treatment, both with respect to making or excluding a PMR diagnosis. Multi-
morbidity and/or poly-pharmacy increases with age [Uijen and Van De Lisdonk 2008] and 
so is a particular issue for diagnosing PMR (given that PMR is rare under the age of 60), as 
it may impact on the clarity of PMR symptoms, which will contribute to the diagnostic 
challenge. Multi-morbidity and/or polypharmacy also therefore relates to the challenges 
of excluding mimicking disorders which may be responsible for symptoms. It is an area 
that is clearly causing concern amongst responding participants, but is especially 
important in light of evidence that suggests an excess in malignancy diagnosed in the first 
six months after being diagnosed with PMR may be attributed to misdiagnosis. [Muller et 
al 2013] A clear process of exclusion of alternative diagnoses and on-going surveillance 
represents an area where improvements in practice could be made. Analysis of the open 
response questions relating to this issue suggested that there was not a set standard of 
investigations participants were routinely performing and has been found in other 
research in this area. [Helliwell et al 2013] This could be a reflection of a lack of 
awareness of the current guidance and advised investigation set, or, that GPs are simply 
choosing not to follow guidance. A process of exclusion of mimicking disorders however is 
an important and essential aspect of diagnosis and represents and area where practice 
could be improved. This could be achieved through focused dissemination of the current 
guidance through educational initiatives and relevant literature for practising GPs.  
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Normal inflammatory markers have been shown to occur in up to a 22.5% of cases. [Ellis 
et al 1983] However diagnosis has to be carefully considered in cases where inflammatory 
markers are normal, and should prompt a referral for specialist review for possible 
alternative diagnoses. [Dasgupta et al 2010] Over half of responders indicated that they 
would initially offer a trial of treatment. This is a significant potential pitfall, given that the 
symptoms of some disorders including inflammatory arthritis, non-inflammatory 
musculoskeletal disease and some malignancies will temporarily improve with oral 
prednisolone reinforcing that a systematic exclusion of other causes for symptoms does 
not appear to be routine practice. 
However, whilst guidelines are helpful and advocate the exclusion of all other potential 
causes for symptoms they do not often address issues surrounding multi-morbidity [Muth 
et al 2014] and the possibility that more than one condition may contribute to the 
presenting symptoms. Accounting for this is often dependent on clinician experience, 
which may be difficult to accrue with uncommon disorders like PMR. In the absence of a 
robust diagnostic protocol or gold standard diagnostic test, accurate diagnosis will still 
depend on the experience of the clinician in conjunction with vigilant follow-up and 
support from specialist services aided by accepted guidelines. 
PMR management in terms of treatment with glucocorticoids remains a source of on-
going concern for clinicians with regards to side effects, complications, appropriate dose 
reduction, monitoring, effects on co-morbidity and interactions with other concomitant 
medication. These are understandable given that in PMR patients, cumulative 
glucocorticoid dose is associated with fragility fracture (OR 1.4) and duration of treatment 
is associated with the development of osteoporosis (OR 1.02) and arterial hypertension 
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(OR 1.03). [Mazzantini et al 2012] Overall management of PMR in primary care appears to 
be broadly in-line with UK BSR/BHPR guidance however some responders felt that 
guidance was not clear on the initiating dose of prednisolone and is reflected in the 
finding that almost 40% of responders are initially treating PMR with inappropriately high 
doses of prednisolone. The BSR/BHPR UK guidance, however is clear on the initiating 
prednisolone dose (15mg of prednisolone which can be increased to 20mg if the clinical 
picture is convincing and a response to treatment is sub-optimal) and may suggest that 
guidance has not been disseminated yet to the wider GP population or GPs are simply not 
following the advised guidance. [Dasgupta et al 2010] 
What is less clear in the guidance is the reduction of treatment from this initial dose. 
Whilst there is also an advised prednisolone reduction regimen, in practise, prednisolone 
reduction can be more variable and may depend on multiple factors which as yet have 
not been investigated. For example inter-current illness, co-morbidity, severity of disease, 
genetic predisposition, gender, age at onset and pre-morbid state may all affect the dose 
reduction regimen. Dose reduction therefore is a much more complicated process and 
not one that could necessarily follow a fixed timeline.  
Appropriate bone prophylaxis is reported to be routinely offered by the majority of 
responders which contrasts with observed findings that suggests that prophylaxis is not 
routinely offered. [Helliwell et al 2013] However many factors may impact on whether it 
is finally prescribed or not, for example polypharmacy, interactions, adverse effects and 
patient choice, and may account for this discrepancy.  
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The final significant challenge that PMR poses surrounds the significant amount of 
resources that are needed for regular follow up and the associated specialist support that 
may be needed in certain cases. Ensuring appropriate follow up for patients and for 
patients to remember to arrange further assessment can add to the challenge of on-going 
monitoring and is an area where, if not carefully considered, loss to follow up could be an 
issue and may result in inappropriately prolonged treatment. Excessively long treatment 
could result in inappropriate exposure to risks of treatment which additionally, may not 
be identified if not followed up regularly. 
 
5.7.2 Factors contributing to the challenges associated with PMR 
Musculoskeletal disorders account for around one in seven consultations in general 
practice, [Jordan et al 2010] yet confidence in diagnosis and management of 
musculoskeletal disorders remains consistently low. [Goff et al 2014] This was thought to 
be related to the differences in case mix that GP trainees are exposed to with trainees 
seeing younger patients with more minor and or acute problems. [Eccles et al 1994] 
However, Goff (2014) showed that this was not the case specifically for musculoskeletal 
disorders but rather the lack of provision of specific musculoskeletal training in general, 
even at to undergraduate level. [Goff et al 2014] 
 A survey of GP trainees demonstrated that the rheumatology training was insufficient, 
that the training they did have depended on whether they had been posted on 
rheumatology placements, and online resources [personal correspondence with Louise 
Warburton 23/11/2015].  
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The age-adjusted incidence of PMR in the UK has been shown to be 8.4 per 10,000 
patient years and a fulltime GP can expect to see 4 or 5 PMR patients per year [Jordan 
2010], of which 1 or 2 patients may be newly presenting with PMR. [Smeeth et al 2006] In 
comparison, a full-time GP can expect to see approximately 45 patients with 
osteoarthritis, [Jordan 2010] and around 25 new cases of community acquired 
pneumonia per year. [Millet et al 2013] PMR therefore, is relatively rarely encountered in 
general practice despite being one of the most common inflammatory rheumatic 
disorders. For trainee general practitioners, exposure to PMR in a twelve month GP 
registrar training placement is likely to be extremely limited even if it does occur. Also, 
given the non-specific initial presenting features, it may not be immediately recognised 
when patients present early or atypically especially for practitioners with less experience 
of the condition.  
The most recent BSR/BHPR PMR guidance advises on indications for referral for specialist 
review particularly in cases of atypical features and treatment dilemmas. [Dasgupta et al 
2010] Rapid access for specialist PMR review remains an issue particularly if treatment 
has been initiated, as it can affect how a patient presents at their specialist review adding 
to diagnostic difficulty and challenge for the assessing specialist, especially when the 
appointment is weeks or even months after treatment has been started. [Quick and 
Kirwan 2012] Rapid access for specialist review for potential PMR patients presenting 
atypically would be an optimum solution for this, ideally with patients being seen prior to 
the initiation of treatment so that the clinical features are not affected  
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The PMR guidelines currently available represent a much needed baseline reference 
resource for clinicians. Previously, no unified guidance was available, however, no 
guideline can cover every aspect of an illness and this is a particular problem for PMR 
given the range of presenting features. Furthermore, the guidance does not consider the 
impact of multi-morbidity which is a significant problem in older patients. Finally, these 
guidelines were published in a rheumatology specialist journal and may therefore not be 
accessed by GPs, although the guidelines have been disseminated to primary care in a 
number of publications including the British Journal of General Practice [Helliwell et al 
2012] and the Arthristis Research UK “Hands on” series, which is sent to all GPs in the 
country. [Mallen et al 2014] The following Section discusses some of the potential 
strengths and weakness of the survey findings.  
 
5.7.3 Potential sources of biases 
This section discusses potential sources of bias that may be relevant to this study 
including response bias, recall bias, social desirability bias and volunteer bias. 
 
5.7.3.1 Response bias 
The questionnaire response was 24.98%. This is comparable to similar musculoskeletal 
related GP surveys undertaken recently within the Research Institute (for example 
[Clarson et al 2013]), but is lower than mean response in published articles using survey 
methods. [Creavin et al 2011] Generally, response rates to surveys in primary care appear 
to be declining. [Creavin et al 2011] There may however, be specific reasons why the 
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response rate for this study is lower than expected. Although a single prize of champagne 
has been shown to be an effective incentive [Thomson et al 2004] this may have been 
insufficient to promote response for this study.  
Workload can impact on decisions to participate in surveys. [Kaner et al 1998, McAvoy 
and Kaner 1996] GP workload has significantly increased over the past 5 years and may be 
a factor contributing to the overall reduction in research participation. Many GPs may 
simply have been too busy to participate, or the disruption to workload too great to 
complete a questionnaire. PMR is a relatively uncommon condition and may not have 
been a sufficiently interesting topic for many GP’s. Equally some may not have known 
much about the subject and so lacked confidence in participating. A lack of interest in the 
subject is a well-recognised factor that can impact on decisions about taking part in 
surveys or not and would have impacted on survey response. [McAvoy and Kaner 1996] 
Study participants however, may have had a special interest in musculoskeletal medicine 
which could result in them having an increased awareness of the issues and challenges 
that are associated with this condition or they may be more likely to report clinical 
practice in line with best practice guidelines. Given the previously described results, 
demonstrating marked deviation from some areas of current clinical guidelines it is 
unlikely that the results presented in this chapter are heavily skewed to those with an 
interest in this area. 
 
Low response creates concern due to the potential for bias and the lack of 
generalisability. However this is only the case if the responding participants are 
significantly different from the population sampled.  Despite the limited data that is 
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available on non-responders it is possible to make some observations. Responders to this 
survey appear to work in slightly larger practices with a greater number of partners than 
non-responders. However, responder demographics relating mean age, gender, and GP 
role were comparable to national demographics. [GP Data. www.hscic.gov.uk/]  
 
5.7.3.2 Recall Bias 
Recall bias defined as a “Systematic error due to differences in accuracy or completeness 
of recall to memory of past events or experiences” [Dictionary of epidemiology 2014]. 
Recall bias has been shown to increase with rare disorders. [Sackett 1979] Recall of 
events and critical details is a complex process and can significantly affect responses to 
survey questions. Recall declines with increased time lapse since the exposure or 
experience, emotional or personal experiences associated with an event, and the number 
of previous exposures. [Bradburn et al 1987] Given the infrequency with which GPs 
encounter PMR, recall issues may have been an issue for some participants impacting as a 
result on the accuracy of the data provided. 
 
5.7.3.3 Social desirability bias 
Phillips defined social desirability bias as “tendency of people to deny socially undesirable 
traits or qualities and to admit to socially desirable ones”. [Phillips and Clancy 1972] This 
can be a particular issue with questionnaire surveys as they rely on responders to 
accurately respond to questions in an honest and truthful way to reflect their opinions, 
experiences and knowledge. Social desirability bias tends to impact more on studies 
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relating to sensitive topics. [Gregson et al 2002] Whilst this survey did not ask sensitive 
questions, participants may equally not want their lack of knowledge to be known 
irrespective of how anonymised the study is. Questionnaire surveys cannot control or 
prevent participants from reviewing guidance or reporting best practice. Some 
participants to the PMR questionnaire survey may well have revised current guidelines 
whilst completing the questionnaire or may not have answered in a way that reflected 
their true practice. However, given the wide range of responses this is unlikely to have 
had a major impact on this study. 
 
5.7.3.4 Volunteer Bias 
Heiman (2002) suggested that volunteer bias is a form of bias that arises from the fact 
that a particular sample of participants will comprise of those are actually willing to 
participate and those who find the topic interesting. [Heiman 2002] Volunteers that 
participate have been shown to be different from non-volunteers in that they can be 
more educated, more intelligent, desire a need for approval and are more social. 
[Rosenthal and Rosnow 1975] This form of bias relates closely to the concept that 
responding to surveys is closely related to the level of interest that the participant has in 
the survey and needs to be acknowledged.  
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5.7.4 Strengths and weaknesses 
5.7.4.1 Strengths 
This is the first large scale national survey of general practitioners focusing on PMR 
diagnosis and management in primary care. This is an area where evidence is lacking. This 
large data-set provides a unique insight into PMR diagnosis and management in primary 
care from the GP perspective and thus adds to our knowledge of PMR and identifies 
targets that could help to improve care for patients. The survey was conducted using 
rigorous clinical trials unit (CTU) approved protocols, monitoring and quality checks to 
ensure a high quality data set is generated. In conducting this survey, standard operating 
procedures (SOPs) relating to survey management were used. This strives to ensure 
governance, quality and research excellence by including data entry checking processes 
and quality review processes of all paperwork by all members of the study team and lay 
advisors. The survey was developed using current guidance, and identified issues from 
previous primary care research [Helliwell et al 2013], as well as including input from 
practising rheumatologists and general practitioners. It was also piloted amongst a 
number of practising GPs and amended based on their recommendations. My 
involvement in this study and the recognition of this work has resulted in me contributing 
to the OMERACT (Outcome Measures in Rheumatology And Clinical Trials) PMR special 
interest group (as an OMERACT fellow) to develop a standard outcome measure set for 
PMR research. This work was also endorsed by the national PMR charity, PMRGCAUK who 
recognise this as an area of importance.  
 154 
 
0 
 
5.7.4.2 Weaknesses 
Whilst there are limitations and biases that will apply to most questionnaire surveys and 
relate to survey methodology in general [Choi and Pak 2005], the main weakness of this 
survey relates to the suboptimal response and therefore the potential lack of 
generalisability of the data and the conclusions that can be made from it.   
The questionnaire used in this study was designed specifically to investigate the primary 
care diagnosis and management of PMR and did not use predetermined and validated 
items or instruments. However, the questionnaire was developed using existing literature 
to support maximising response rates and was piloted amongst general practitioners and 
rheumatologists to assess usability and quality and to improve face validity. 
 
5.8 Conclusions  
This is the largest study to date investigating the management of PMR and GCA in general 
practice. Although issues surrounding response are evident, the findings highlight several 
issues that could contribute to improving care for patients with PMR including 
improvements in GP training, accessibility of appropriate and relevant guidance and 
access to specialist support if needed. 
With a wide differential diagnosis and in the absence of robust diagnostic criteria or gold 
standard diagnostic tests, PMR remains a very challenging illness to diagnose. Clinical 
features, laboratory findings, previous experience, trials of treatment and vigilance to 
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ensure that there are no other causes for symptoms, all have to be drawn upon, for 
clinicians to diagnose PMR in primary care. This needs to be in conjunction with careful, 
on-going follow up to ensure that no other mimicking disorder becomes apparent. 
Response to treatment with low to medium dose glucocorticoids has long been suggested 
a typical feature of PMR [Dasgupta et al 2010] and is a highly rated feature of PMR 
amongst general practitioners (see Figure 5.2). Over-reliance on this feature is however, a 
significant potential pitfall, especially as recent research findings question the diagnostic 
usefulness of this approach [Dasgupta et al 2012] and it is known that significant 
mimicking disorders, for example cancer, [Muller et al 2013]  may be missed. Also, what 
constitutes an adequate treatment response? Guidance suggests that an adequate 
response is a patient reported global improvement of seventy percent or more but do 
GPs use such guidance when reviewing patients? [Dasgupta et al 2010] Perhaps, in order 
to improve diagnostic accuracy when considering response to treatment, a more formal 
approach to assess response or alternative approaches to initial treatment like a 
“treatment sandwich”, where patients with PMR are treated for a period of time with 
glucocorticoids but then treatment is withdrawn and then restarted after a short period 
of time. [Quick and Kirwan 2012] Initial treatment dosing remains a controversial area in 
PMR and is an area where further research is needed. 
Vigilant follow-up over time is key to ensuring a correct diagnosis and to screen and 
manage any associated treatment adverse effects (such as diabetes) or associations (for 
example GCA). A formal protocol or template driven review, as is undertaken for other 
disorders in primary care (for example epilepsy and asthma) may improve diligence in 
reviews given its rarity and so help to improve outcomes for patients. Issues still remain 
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and so the final objective of this thesis was to undertake a semi-structured telephone 
interview study of GPs to explore some of these issues and challenges in much greater 
depth. The methods and results of this study will be presented in the following chapter.
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Chapter 6. A qualitative study investigating the diagnostic and 
management challenges of PMR in primary care 
“It wrecks lives doesn’t it? You get people that are, kind of, you know, really active, 
and then all of a sudden they’ve got this awful thing. And then they get the 
treatment for it that, you know, improves them” GP 22 (15, M, P) 
 
Key: [time qualified as a GP (years), gender (male/Female), seniority/role (S:salaried, 
L:locum, P:partner, SP: senior partner)] 
 
6.1 Introduction 
This chapter presents the qualitative interview study conducted as part of this PhD, 
allowing a more in-depth understanding of the data collected and presented in chapter 5. 
The first section of the chapter introduces and justifies the qualitative methods utilised, 
including recruitment and analysis. The second section presents the findings and 
conclusions of the in-depth GP interviews. 
 
6.1.1 How a qualitative study fits in to this multi-methods thesis  
Qualitative research methods seek to provide a more complete understanding of the 
research problem and are ideal for investigating in depth the complexity of a subject. 
[Howitt and Cramer 2008] A qualitative study may often be undertaken to inform a much 
 158 
 
0 
larger quantitative study so that appropriate areas of focus are identified and not missed. 
Qualitative studies are often also used to validate quantitative research findings and 
results.  
The key characteristic however for this aspect of the PhD, is the depth and richness of 
data that can be obtained using qualitative methods in health research. This is particularly 
important for under researched disorders such as PMR where clinical presentation and 
management can be highly variable.   
Qualitative research methods were therefore chosen to explore the current practice, 
challenges and barriers to effective care encountered by general practitioners managing 
patients with PMR in the community. The data from these interviews will help to build on 
the results and further explore some of the issues identified from the cross sectional 
survey described in Chapter 5. This approach will complement the results of the cross-
sectional survey in several ways. These include: 
 Providing a more experiential and detailed source of data that will allow a 
thorough exploration of key issues identified in the survey 
 Allowing the opportunity to discuss potential solutions to help overcome any 
barriers identified 
 Identifying new areas for future research or investigation 
 
6.2 Methods 
The following section describes and justifies the methods used in conducting the 
qualitative study that forms part of this thesis. 
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6.2.1 Interviews 
“Interviews facilitate the collection of detailed personal data that provides a high degree 
of response quality and the opportunity for probing deeply into issues” 
[Block and Erskine 2012 p429] 
Interviews remain the predominant method for data collection in qualitative studies in 
health care settings and can be semi-structured (incorporating open ended questions that 
focus and direct the participant to the area of interest) or in-depth (where possibly only 
one or two topics are discussed in thorough detail where the interviewer’s role is to help 
probe and clarify information as it emerges). [Pope and Mays 2000] 
The cross sectional study described in chapters 4 and 5 provided a large amount of data 
that identified numerous challenges and areas of potential focus for in-depth study. 
Therefore, this interview study aimed to explore in more depth, issues and challenges 
relating to PMR that were identified from the survey data. Formal in-depth interviews 
would not allow the exploration of the range of issues that have been identified and 
therefore a semi-structured interview process was chosen to allow exploration of specific 
challenges guided by the interviewer, whilst allowing sufficient depth of questioning to 
thoroughly explore the related issues. 
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6.2.2 Data Collection 
In qualitative studies, data can be collected in numerous ways from the analysis of video 
and audio consultation data, to text analysis from a range of different types of media. 
Interviews with participants are a commonly employed method of data generation and 
were used for this study. 
Semi-structured telephone interviews with clinically active general practitioners were 
undertaken. Face to face interviews are often viewed as the best way to interview 
participants, [Novick 2008] as they provide additional visual cues that enhance the 
contextual quality of the data. Telephone interviews have certain advantages over face to 
face interviews, depending on the study and the type of data that is being sought. These 
are summarised in Table 6.1. 
Table 6.1 Summary of advantages and disadvantages of telephone interviews 
 
Advantages Disadvantages 
 
Cost effectiveness Lack of rapport building 
Time efficient Loss of visual and non-verbal cues 
Increased access to a widely dispersed 
geographical or inaccessible population  
Unable to use visual aids 
Relative anonymity Potentially poorer quality data. 
Safety (both for researcher and participant) Potentially lower response rate 
 
Table developed from [Block and Erskine 2012] 
 
One of the major limitations surrounding telephone interviews concerns the quality and 
richness of data resulting from the loss of visual cues and non-verbal and contextual data. 
It is also argued that rapport building with the participant and the ability of the 
interviewer to probe and elaborate on themes developing through the interview is not as 
effective with telephone interviews. However, these findings have not been formally 
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demonstrated and may not be relevant when researching certain populations, provided 
appropriate preparations have been made. [Novick 2008] This includes the provision of 
prior information to the participants and the development of appropriate topic guides 
which include specific questions to be asked in the interview. [Block and Erskine 2012, 
Sturges and Hanrahan 2004, Stephens 2007] 
Despite the potential drawbacks of telephone interviews, they were chosen for data 
collection for the study for several reasons. Firstly, telephone interviews have the benefit 
of reaching a broad and geographically diverse cohort of participants, important as this 
was a UK wide study. Telephone interviews provide a convenient (for both interviewer 
and interviewee) and cost efficient opportunity to interview a broad range of participants. 
This convenience has the potential to improve participation of this study population given 
that GPs are often busy with limited available time to be interviewed. Telephone 
interviews also provide a certain amount of anonymity to the participant which is 
important to ensure that participants do not feel judged or tested by the interviewer, 
particularly important when the interviewer is from the same professional group as the 
interviewee, as in this case. 
 
6.2.3 Participant Recruitment 
6.2.3.1 Study population 
General practitioners are the first line of contact for most patients developing symptoms 
of PMR and will often be involved in the on-going management and monitoring of the 
diseases. [Dasgupta et al 2010] Hence interviews with GPs were undertaken to provide a 
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more personal experience of PMR from a GP's perspective. This enabled the exploration 
of some previously unknown perspectives on the diagnosis, management and monitoring 
of PMR in a primary care setting. 
 
6.2.3.2 Sampling Methodology 
The postal survey (described in Chapters 4 and 5) provided a sampling frame for 
identifying participants. GPs responding to the postal survey were given the opportunity 
to consent to further contact from the research group. A total of 659 participants agreed 
to further contact. Potential participants were then purposively sampled from this 
database and sent a study pack inviting them to take part in the qualitative study.  
 
6.2.3.3 Purposive Sampling 
Silverman describes purposive sampling as: 
“a method that allows us to choose a case because it illustrates some feature or process in 
which we are interested.” [Silverman 2010 p148] 
 
This sampling method, often used in qualitative research, does not aim to identify 
participants in order to produce data that is widely generalisable. Instead the method 
identifies participants that will potentially contribute the most information and so for this 
study, participants were specifically identified in order to generate data rich in variation 
of views and experience. Additionally, recruiting participants from different geographical 
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areas is essential to investigate regional variations in clinical practice and pathways of 
care. 
To reflect as broad a range of practitioner experience as possible we purposively 
identified potential participants based on years of experience (more or less than 11 years 
(the median years of experience reported in the survey) of clinical experience as a GP), 
gender and seniority (locum, partner, salaried). 29 locum doctors responding to the 
original survey agreed to be contacted again. This group, in view of the transient nature 
of the work were expected to be a hard to reach group and so all of the identified locums 
were sent a study pack to take part in the study. 
 
6.2.3.4 Sample Size 
Interviews were conducted until data saturation is achieved. Data saturation is described 
by Strauss (1998) as the point when no new information, concepts or ideas are being 
found from the data. [Strauss 1998] 
Estimating when saturation will occur remains controversial and difficult to predict and 
will vary depending on the study design, topic being researched, the participants and 
methods of interview. [Bazely 2014] Estimations for the number of participants required 
are often needed however in order to plan for study costs, project administration and 
work time allocation. Guest  demonstrated using qualitative interview data from their 
study exploring social desirability bias, that 12 interviews was sufficient to achieve data 
saturation [Guest et al 2006] whilst other studies advise data saturation for the type of 
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study described in this thesis to occur after approximately 20 to 30 interviews. [Welsh et 
al 2012, Ryan and Bernard2000] 
While the number of interviews required can be estimated, often the number of 
participants that need to be approached to achieve the required number of interviews is 
greater. Experience at the Keele University Research Institute of Primary Care and Health 
Sciences, based on previous studies purposively recruiting GPs for qualitative telephone 
interviews, found that approximately 130 general practitioners would need to be 
approached in order to recruit 30 participants for interview [e.g. Welsh et al 2012]. 
Figure 6.1 illustrates the process undertaken for recruiting GPs into the qualitative study. 
After purposively identifying potential participants to take part, study packs were sent by 
post after confirming that identified participants had agreed to further contact. 
Study packs contained a covering letter of introduction, participant information leaflet 
and participant consent form. These documents can be reviewed in Appendix 5 and were 
designed using templates obtained from the Keele University Institute of Primary Care 
and Health Sciences Standard Operating Procedure 7 [SOP 7 - Document Design and 
Development]. 
Participants responding to the study pack were logged on a mailing database developed 
for the study. Those who provided consent to take part in an interview were then 
contacted by their preferred method (telephone or email) to formally arrange a 
convenient time for telephone interview. 
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6.2.3.5 Reimbursement of participants 
A reimbursement of £50 was offered to participants for taking part in the study. The 
amount was calculated based on typical hourly payment rates for locum GPs, and was 
provided as an acknowledgement of the time that the GP had given up to take part, 
rather than as an incentive to participate. 
 
6.2.4 Topic guide development 
A topic guide was developed to maintain interview structure, to ensure essential 
administrative procedures were undertaken (including checking consent, discussing       
reimbursement, confirming that the interviews would be recorded and transcribed) and 
to ensure that all relevant topics surrounding PMR and GCA were discussed. Topics to be 
discussed were informed by areas of interest from the findings of the quantitative cross 
sectional survey and relevant areas of interest from the wider PMR literature. The topic 
guide was reviewed and refined with feedback from GPs, rheumatologists and qualitative 
researchers. This process is summarised in Appendix 5. 
As transcripts were reviewed, and as experience was gained from the interviews 
undertaken, the topic guide was modified to focus on themes that started to emerge 
from the interviews. The final topic guide can be seen in Appendix 6. 
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Figure 6.1 Flow Chart illustrating GP recruitment        
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6.2.5 Interviewer training 
TH undertook specific qualitative interview training, attending the Oxford University 
‘Introduction to qualitative interviews’ course. A pilot interview was also undertaken with 
an independent GP volunteer. The pilot interview was reviewed by a senior qualitative 
research supervisor (JR- Dr Jane Richardson) with expertise in qualitative interviewing and 
specific feedback was given. This focused on conducting the interview to allow the 
participant to tell their story, to develop techniques on how to encourage the interviewee 
to really explore the topic being discussed and how to interview GP colleagues objectively 
given the relative expertise that the interviewer has. 
 
6.2.6 Practical consideration in performing telephone interviews 
The interviews were conducted by TH at times convenient to the participants. Owing to 
the busy schedules and limited time that GPs have to undertake such interviews, the 
maximum amount of flexibility was offered resulting in interviews being conducted 
throughout the day and sometimes late in the evening. 
Interviews were digitally recorded and the resulting interviews were uploaded to a 
secure, password protected folder. Interviews were then transcribed verbatim by an 
approved transcription company (The Transcription Company, 
http://thetranscription.co.uk/) used by Keele University Research Institute of Primary 
Care and Health Sciences. Resulting transcripts were then screened to remove any 
identifying information prior to analysis. 
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Analysis of the transcripts was managed by using NVivo (NVivo10) [NVivo qualitative data 
analysis Software; QSR International Pty Ltd. Version 10, 2012]-a qualitative data analysis 
software package analysed using a thematic analysis, described in Chapter 4. 
 
6.2.7 Methods of qualitative data analysis 
6.2.7.1 Thematic and framework analysis 
Thematic analysis is one of the most common forms of analysis used in qualitative 
studies. Braun and Clarke argue that it is an analysis in its own right [Braun and Clarke 
2006],  but thematic analysis does have its critics, not so much related to the method but 
more related to a lack of, or superficial methodological detail reporting and theory 
development [Bazely 2014]. Braun described six phases in thematic analysis. These are 
illustrated and summarised in Table 6.2 and this framework was used to analyse the 
transcribed interviews.  
TH undertook thematic analysis training through the Oxford University “analysing 
qualitative interview course”. Additionally, as quality control, an inter-rater exercise was 
undertaken in which three other researchers (SM, SH, JR) were asked to independently 
analyse and identify general themes relating to an interview to compare with findings by 
TH. 
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Table 6.2 The Six phases of thematic analysis 
Phase Description  
 
Phase 1: Familiarisation This may occur during the process of 
transcription or initial reading of 
transcribed interviews  
 
Phase 2: Generating initial codes Systematic coding of interesting features 
and gathering all relevant data to develop 
any potential themes 
 
Phase 3: Searching for themes among codes Grouping codes into potential themes 
Developing a thematic map 
 
Phase 4: Reviewing themes Confirming that identified themes relate to 
coded extracts and the relevant codes 
across the data set  
 
Phase 5: Defining and naming themes Formalise the specific themes and how 
they relate to the overall story 
 
Phase 6: Producing the report Final check on the overall themes relating 
to the overall story and related literature 
 
[Braun and Clarke 2006] 
 
Pope also discusses a “framework” approach to analysis which is a development of 
thematic analysis which was developed specifically for applied or policy relevant 
qualitative research where the objectives are known prior to the study being conducted, 
relative to the needs of the researching body (e.g. a health authority). Pope describes 5 
stages of data analysis including:  
1) Familiarisation,  
2)  Identifying a thematic framework,  
3) Indexing, 
4) Charting 
5) Mapping and interpretation. 
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This method is based on both the findings from the original data obtained from 
participants and the aims and objectives already set for the study [Pope and Mays 2000]. 
A thematic analysis was therefore used but was influenced by some aspects of framework 
analysis given the thematic analysis was influenced by the survey findings. 
 
6.2.7.2 The physical process of data analysis 
The analysis process began as early as undertaking the pilot interview. Although not a 
formal participant whose interview would be used for analysis it did start the process of 
understanding where and what the potential themes surrounding PMR and GCA might 
be. Feedback from a senior qualitative researcher (JR) helped me to understand how best 
to explore issues better for future interviews without making the interviewer feel judged 
by phrasing questions based on what other GPs had said or the findings of the survey. 
Analysis began after transcribing the two initial interviews. Although time consuming and 
not being expert in transcription techniques this process was extremely useful as it 
allowed a thorough familiarisation with the data which enabled me to identify and reflect 
on initial codes, themes and subthemes. For all other transcripts that were transcribed 
professionally, an initial read through and anonymization or removal of identifiable data 
was undertaken. Whilst this had a pragmatic justification it also allowed familiarisation 
with the data to reflect on possible codes and to review the field notes to see if there was 
a particular focus or specific agenda for the participant being interviewed. Interview eight 
was chosen to be reviewed and coded by my supervisors (JR, SM, SH). This interview was 
chosen as it contained broad variety of issues, and was undertaken after gaining some 
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experience in interviewing and analysis whilst not being too far through the analysis 
process so any issues could be identified and addressed for future transcripts. 
Thorough analysis of each transcript was then undertaken by identifying initial codes to 
develop into sub themes and themes. Coding was undertaken using NVivo 10 which is a 
qualitative data analysis software package. Whilst I encountered many benefits and some 
frustrations in using this software, it did make the task of analysis with subsequent code 
generation much easier than analysing transcripts using hard copies of the interviews. In 
particular, coding and the development of sub-themes and themes was straightforward 
through the development of nodes (a method of categorising in NVivo) that could be 
accessed to add relevant text for each transcript. Also, text searching and cross 
referencing was straight forward and rapid to perform which was of particular help when 
emerging themes and subthemes were being developed. These functions allowed 
comparison of data from the interviews with particular codes or themes to see if 
similarities existed. Finally, node related data was another helpful feature of this 
software. Whilst qualitative methods do not necessarily call for frequencies to assign 
relative importance, knowing how often a code is used can give an idea of the impact and 
importance of that code. 
The predominant challenge that I encountered during the analysis phase was the 
preconceived ideas that I had, given that I am a GP as well as having research experience 
in PMR and the findings from the PMR cross-sectional survey that was informing the 
interview topic guide.  
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Qualitative analysis requires a considerable amount of interpretation and so I had to be 
mindful and reflective of my preconceptions and be vigilant and sensitive to identifying 
other issues that may emerge. In some ways, being aware of the issues could be an 
advantage for this study as it allowed me to be able to recognise early potential areas of 
enquiry that had not been identified in the usual literature or from the survey.  
 
6.3 Results of qualitative interview study 
The following section describes the baseline demographics of the interviewed sample and 
reports the findings from the qualitative interview study of GPs. 
 
6.3.1 Participant Recruitment 
659 participants who had agreed to further contact regarding future research were 
identified from the cross-sectional postal survey and used for the sampling frame to 
recruit GPs for the qualitative interview study. Study packs were mailed to purposively 
identified potential participants, initially in batches of 30. The number of packs mailed 
was subsequently increased to batches of 60 after an initially poor response from GPs. A 
total of 327 study packs were mailed to GPs over a period of nine months.  Table 6.3 
illustrates the breakdown of who was sent study packs relative to our purposive sampling 
framework. 
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Table 6.3 Purposive Sampling Breakdown of categories 
Gender Experience Seniority n (%) 
 
Female Less than 11 years Partner  98 (44%) 
Male  Less than 11 years  Partner 124 (56%) 
Female Less than 11 years Salaried 64 (70%) 
Male  Less than 11 years Salaried 27(30%) 
Female More than 11 years  Partner 105 (43%) 
Male  More than 11 years  Partner 139 (47%) 
Female More than 11 years  Salaried 32 (71%) 
Male  More than 11 years  Salaried 13 (29%) 
 
Locums 
   
29 
Total female    299 
Total male   303 
 
n= number in this category 
 
61 (18.7%) contacts were received from GPs. 45 of these agreed to be contacted again 
and participate in the interview study, resulting in 24 (7.3% of total mailed study packs) 
completing interviews. The remaining GPs did not respond to further contact regarding 
the interview study, despite repeated attempts using their preferred method (e.g. 
telephone, email). This process is summarised in Figure 6.2. 
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Figure 6.2 GP recruitment process for the telephone interview study 
 
 
 
6.3.2 Characteristics of Interview Participants 
The characteristics of participants who completed a telephone interview are illustrated in 
Table 6.4. Unfortunately no locum participants responded to our survey packs, which is 
perhaps not surprising, as this group was expected to be hard to reach (e.g. moving to 
work in a different practice or geographical area), especially given the time interval 
between the initial survey and mail out for the qualitative study. 
 
 
 
 
659 survey participants who had agreed to 
take part in further PMR research  
327 Study Packs sent to GPs  
61 (18.7%) contacts from GPs received 
•45 (13.8%) agreed to further contact 
•16 did not wish to take part  
11 study packs returned 
•reasons included: GP retired, unwell or had left the 
practice 
Total of 24 (7.3%) interviews conducted  
•21 GPs were un-contactable despite several attempts 
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Table 6.4 Characteristics of GPs participating in the PMR qualitative interview study 
GP Identification Gender Years Qualified as 
a GP 
Seniority Region 
GP1 F 13 Partner Eastern 
GP2 F 29 Partner South West 
GP3 M 9 Partner London 
GP4 M 6 Partner South West 
GP5 F 15 Partner South East 
GP6 F 20 Partner South west 
GP7 M 10 Partner Scotland 
GP8 F 10 Salaried London 
GP9 M 19 Partner Wales 
GP10 F 12 Salaried Yorkshire 
GP11 F 10 Partner Eastern 
GP12 F 15 Salaried Yorkshire 
GP13 F 5 Salaried Yorkshire 
GP14 F 9 Partner Derbyshire 
GP15 F 25 Partner Cumbria 
GP16 M 17 Partner Midlands 
GP17 F 11 Partner North Scotland 
GP18 M 22 Salaried Midlands 
GP19 F 8 Salaried South East 
GP20 M 17 Partner Midlands 
GP21 F 7 Salaried Surrey 
GP22 M 15 Partner South East 
GP23 F 13 Salaried Eastern 
GP23 F 12 Salaried Eastern 
GP24 F 12 Salaried Midlands 
 
F: Female 
M: Male 
 
There was a good geographical spread of participants with a range of overall experience 
in terms of years qualified as a GP. Figure 6.3 depicts the areas where the GP participants 
were located. Verbatim quotes are presented in the same manner as in Chapter 5, 
illustrating their experience (duration of qualification as a GP), gender and seniority/role 
and are presented in the following format using the following key. 
Key: [time qualified as a GP (years), gender (male/Female), seniority/role 
(S:salaried, L:locum, P:partner, SP: senior partner)] 
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Figure 6.3 Geographical locations of GP participants. 
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6.3.3 Results of thematic analysis of GP interviews 
 
The two main areas of interest surrounding PMR that were identified from the GP cross 
sectional survey concerned diagnosis and treatment. Information concerning the themes 
that was identified from the transcript data will be presented under these two broad 
headings, although they should not be viewed as mutually exclusive. Initial treatment 
plays an integral part in the diagnostic process for PMR, as there is considerable inter-
linking between these two areas. The connection between making the diagnosis and then 
testing the likelihood of the diagnosis (by assessing response to glucocorticoid treatment) 
coupled with knowing the impact of long term treatment will have for the patient, has 
considerable influences on how clinicians make their initial diagnosis.  
“Well they always get a response because everything responds to steroids and so 
it’s much more the problem the other way round, that you’re not very sure 
whether they’ve had a response because they’re generally achy and this magic 
makes everything better.  So I’ve never encountered somebody who didn’t feel 
better on steroids and sometimes I’m not really convinced that it’s the magic cure 
that they think it is.  And so I mean I must say I would always err on the side of 
trying to not use steroids as my, you know in the end I think the patients are 
usually quite happy to be on steroids until they realise what a dreadful sentence it 
is really”   
GP17 (11, F, P) 
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6.3.3.1 Diagnosis 
“I mean, nobody ever comes in saying that they think they’ve got PMR……except 
those that have had it before. Or those that have got, you know, a close relative.”  
GP 22 (15, M P) 
Relating to diagnosis there were two identified overarching themes. The first, “developing 
the diagnosis” relates to how patients present and how a GP may identify and diagnose 
patients with PMR. Response to initial treatment is specifically discussed in this section as 
a common feature of PMR is the rapid and significant response to glucocorticoids. The 
second, theme, “contributors to diagnostic uncertainty” relates to a range of factors that 
affect diagnostic confidence. Again these two themes are inherently connected.  
 
6.3.3.2 Developing the diagnosis 
The following section describes the sub-themes that contribute to the theme relating to 
developing a diagnosis. 
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Awareness of PMR 
This sub theme is relevant to both patients and clinicians. For many patients some of the 
symptoms of PMR may almost be an expected part of aging and so patients may not 
(initially) recognise that there is anything wrong and subsequently may not seek medical 
help. This may especially be the case for patients with a gradual onset of symptoms or 
those with milder disease  
“I think a lot of the time it’s much older people, and they’ve just, kind of, gone, 
‘Well, it’s part of getting old. I’m a lot achier than I was this time last year and they 
don’t realise that it’s necessarily something we could perhaps help with.”  
GP23 (13, F, S) 
 
PMR may not be at the forefront of GPs’ minds for several reasons, as it is infrequently 
encountered in general practice. [Smeeth et al 2006, Jordan et al 2010] 
“Well, I suppose, quite unusual, maybe the GPs aren’t aware of it. Or, you know, 
it’s not something that you see all the time….”  
GP8 (10, F, S) 
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Clinical Features 
Respondents in general used the ‘classical textbook’ features to try and identify patients 
who may have PMR but were acutely aware that it can sometimes present clinically in an 
atypical way. 
“I think the majority of the time people do come in with what’s described as the 
classic symptoms; talking about pain mainly around shoulders and hips.  I think 
those are the classic things that would make me think of it fairly quickly.  I suppose 
there are then people who come in with much more generalised non-specific aches 
and pains, and it can then take a little bit longer for PMR to come to the forefront 
of your mind when seeing them.  I suppose systemic features as well; so if people 
have aches and pains but it also comes on fairly rapidly, with them initially often 
feeling generally unwell with it as well, that would make me think about it”  
GP13 (5, F, S) 
GPs often however, related the symptoms of PMR to the functional impact on patients, as 
patients often recognise that there is a problem because of certain tasks that they have 
problems with. 
“Typically, when they’re complaining of shoulder pain, and they say, ‘I’ve had real 
trouble washing my hair or brushing my hair.’ And there’s difficulty with getting up 
out of the chair because of the leg pain, you know, the, sort of, ones that give you 
the high index of suspicion.”  
GP23 (12, F, S) 
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Investigations 
Guidance suggests a range of blood tests and investigations to undertake when 
diagnosing PMR to confirm the diagnosis and exclude common differential diagnoses. 
[Dasgupta et al 2010] All participants reported undertaking blood tests to measure an 
inflammatory response. Several factors directed other investigations that would be 
requested depending on the degree of diagnostic certainty, presenting features or 
associated features of concern.  
“I mean obviously the cardinal things I’m looking for are raised inflammatory 
markers so CRP and the ESR would be the two that I would be sort of looking at.  
However I would be doing a full blood count because it’s not uncommon that I’d 
find a mild anaemia, a chronic disease.  I’d do renal function because I’m going to 
be sticking them on drugs potentially, similarly liver function tests, I want a 
baseline glucose and potentially an HbA1c if I think that’s going to be abnormal.  I 
may want to do a CK [creatinine kinase] because there’s often sort of myalgia.  If 
there's been any weight loss already or any other sort of slightly sort of more sort 
of red flag symptoms I’d be considering things like an auto immune profile or 
myeloma screen, tend to do a chest X-ray at baseline when I’m starting with the 
steroids but earlier than that if there's any other systemic features, yeah so I think 
that's probably about it.”  
GP6 (20, F, S) 
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Factors causing diagnostic uncertainty  
A recurrent finding indicated by GPs was that patients can present atypically, especially 
older patients. Normal inflammatory markers with typical clinical features of PMR, was 
found to be a particular area that can cause diagnostic dilemmas. 
“I had a colleague here when we were considering a diagnosis of somebody and 
we looked it all up in the book again and it said, basically you know you have to 
have X out of Y symptoms don’t you there’s like a list.  And you can have a normal 
CRP it doesn’t preclude it and so I don’t know it’s just - words fail one really”  
GP17 (11, F, P) 
 
However, various options were volunteered by participants on how to manage patients 
who had typical features normal inflammatory markers. Referral for specialist review was 
one strategy reported but often subsequent management very much depended on how 
‘convincing’ the symptoms were and the level of confidence in the diagnosis. 
“I’m probably more inclined to refer now.  I’ve actually seen two people recently 
who I’ve referred – which is quite unusual having seen two in quite quick 
succession – who had reasonably convincing symptoms but their inflammatory 
markers were entirely normal.  They fitted the right demographic and their 
symptoms were quite convincing but I wasn’t convinced enough, so on the basis of 
normal inflammatory markers I’ve referred them to rheumatology”  
GP13 (5, F, S) 
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 Watchful waiting or a trial of treatment, if there was sufficient diagnostic confidence 
were other strategies employed when inflammatory markers were normal. 
“I might give it a watchful waiting in that case, and, sort of, see how they go over 
the next couple of weeks or so. I may even repeat the bloods, because sometimes 
there’s a bit of a lag isn’t there? And I suppose if I’d got enough clinical conviction, 
and I couldn’t think of anything else that I was missing, then I might go for a 
clinical, kind of, trial of steroids.”  
GP 24 (12, F, S) 
 
The final feature that causes diagnostic concern surrounds a less than dramatic response 
to initial treatment with glucocorticoids which often leads to GPs re-visiting their original 
diagnosis. 
“And occasionally also there’s people who have a good response but not dramatic 
response and you start thinking about is this actually rheumatoid or some kind of 
inflammatory arthritis. And again we’ll try and get someone clever on board but 
the problem is if they do have a response to steroids and don’t like reducing them 
because their symptoms come back”  
GP16 (17, M, P) 
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6.3.3.3 Contributors to diagnostic uncertainty 
This theme concerns other factors that contribute to the diagnostic challenges associated 
with PMR. The two main subthemes that contribute to this theme adding to diagnostic 
uncertainty include “multi-morbidity” and “disorders that mimic PMR”. 
 
Multimorbidity 
Multimorbidity is defined as “the co-occurrence of two or more chronic medical conditions 
in one person” [http://www.multimorbidity.net/, accessed 11/12/15]. Multimorbidity can 
impact on the challenge of diagnosing PMR in several ways, most notably when there is 
an overlap of symptoms (for example thyroid disease or osteoarthritis).   
“I think it impacts at every stage, doesn’t it?  It makes diagnosis harder because 
people often have conditions where symptoms overlap and so it makes it harder to 
assess.  If their function is limited by something else then the usual things you 
might look for are already affected by their other things, so you can’t use your 
normal clues when going through their history.  Often you see people who are on 
several other painkillers or who are maybe on steroids for something else, so it 
makes it difficult.”  
GP12 (15, F, S) 
 
The presence of multimorbidity may also alter confidence for making the diagnosis. Given 
the long term treatment with steroids and the impact steroid treatment may have on 
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other conditions, GPs may become more reluctant to confidently make the diagnosis in 
people with multimorbidity.  
“I think it makes my threshold for starting steroids a lot higher, and again I 
suppose that makes you want to be even more certain about the diagnosis, which I 
think is always just a difficult area really.”  
GP13 (5, F, S) 
 
Disorders mimicking PMR 
The differential diagnosis of PMR is extensive with a range of disorders that can present in 
a similar way to PMR. Guidelines advise clinicians to exclude GCA, infections and 
malignancy specifically, (amongst a long list of differential diagnoses) prior to diagnosing 
PMR. [Dasgupta et al 2010] Whilst easy to write in a guideline, excluding malignancy (for 
example) is extremely challenging, especially if the patient does not present any 
diagnostic clues.  
There is clearly a certain amount of anxiety among GPs in missing the diagnosis. There is 
also an awareness that other disorders can mimic the symptoms of PMR. This lesson is 
often learned through previous experience. 
“Other things you know occasionally something else will be going on and kind of 
odd rheumatological things kind of I don’t know, where you’ve got cross over 
symptoms, vitamin D deficiency’s one that I’ve found where someone, we live in 
the west of the country which is a bit cloudier and white people are getting 
significant vitamin D deficiency who don’t go out very much and that can cause 
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very similar symptoms.  B12 deficiency again is something that I’ve picked up on 
the odd occasion and kind of I can’t think now what the, how that’s happened but 
I’ve certainly had to review the diagnosis.”   
GP16 (17, M, P) 
 
Most participants had experience, or were aware of cases, where an alternative diagnosis 
to PMR was made, including serious/malignant conditions  
“Yes, it does. And also ruling out other causes. I had a patient a few years ago who 
presented with really barn-door polymyalgic symptoms, with shoulder pain and hip 
pain, morning stiffness improved as the day goes on, raised inflammatory markers, 
normocytic anaemia, that all seemed very much like polymyalgia, improved within 
a couple of days of the steroids. But it seemed that she had a, sort of, 
paraneoplastic thing. She actually had a – oh, what do you call it? A 5HIAA 
secreting tumour, serotonin-secreting tumour. And so it was, like, paraneoplastic, 
and so that makes me also more reluctant to jump to a diagnosis of polymyalgia, 
because that did behave just as you would expect the polymyalgia to. It was just 
that we happened… It was difficult to try and find out the cause of her anaemia, 
which was presumed to be due to the polymyalgia, but then, because her iron 
levels were always normal, because of the inflammatory response. And so it made 
it very difficult, but within a couple of months we found out that it was actually 
more of an iron deficiency anaemia, and then she had the colonoscopy, and then 
that was how the diagnosis was made so, I’m always very, very vigilant with my 
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patients with polymyalgia, just to make sure nothing is going a bit awry, because 
other things can masquerade in a very similar way.”   
GP21 (7, F, S) 
 
This awareness and fear of missing other diagnoses creates a certain level of vigilance and 
searching for other illnesses at subsequent follow up consultations. 
“So I end up, every so often, doing a bit of an extended MOT on them, diabetes, 
you know, and just check their thyroids, because, as you say, a lot of them are on 
other things for other illnesses as well. And, yeah, often I see that the white counts 
have gone up a bit, so, you know, in the back of my mind there’s always the horror 
of some kind of you know, a leukaemia type of thing.”  
GP22 (15, M, P)  
 
6.3.3.4 Summary of findings relating to diagnosis 
The diagnostic processes for PMR used by the GPs interviewed appear to be holistic and 
patient centred with a clear recognition of the complexities of this illness. A broad 
spectrum of experience was found among the GPs interviewed. Participants indicated 
that they were responsive to individual clinical presentations and aware of variety of ways 
that patients can present. Taking into account multimorbidity as a confounding factor 
when making a diagnosis was a key area identified as was concern about missing serious 
differential diagnoses such as malignancy. Guidelines can aid the clinician in making the 
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diagnosis but can potentially be over-simplistic giving the impression of a standard 
phenotype for PMR that is easily recognisable. For PMR however, and especially in 
general practice, where patients may present very early in the disease course, multiple 
consultations over an extended period of time are often required to build a diagnostic 
picture using a wide variety of clinical and laboratory features based on both experience 
and guidance.  
 
6.3.3.5 Treatment and long term management of PMR 
 “They love it. They absolutely love it. They come back – and it’s a really satisfying 
thing to treat, you know, if you’ve got the diagnosis right, and they come back a 
couple of days later and you should see it in their face, that they’re absolutely 
transformed.”  
GP22 (15, M, P) 
 
Treatment and long term management for PMR was identified from the cross sectional 
survey as the second most challenging area for GPs. Treatment is usually with 
prednisolone (an oral glucocorticoid), with current national guidance providing clear 
instructions in terms of initiating doses and the advised dose reduction regimen. 
[Dasgupta et al 2010] The two broad themes identified from the interviews concerning 
treatment are discussed in the following section. The predominant theme surrounded the 
“implications of treatment”, will be discussed first. The second theme “practical 
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considerations” concerns more GP-related practical aspects of treating patients with 
PMR. 
 
Implications of treatment 
Several clear subthemes were identified relating to this theme, including the effects of 
treatment on patients, preventing and monitoring adverse effects and the impacts of 
treatment on existing co-morbidity. The lack of alternative treatment options was often 
also highlighted. 
“The lack of other options, really……and that nothing else does seem to work 
particularly well for it, and you’re a little bit stuck if, for any reason, they can’t 
tolerate the steroids, and aren’t getting on with them. You are a little bit stuck 
with what else to suggest. Yes, it’s not exactly a nice option.”  
GP24 (12, F, S) 
 
Adverse effects of treatment 
GPs reported their own concerns surrounding the potential adverse events associated 
with the long term treatment with glucocorticoids, as well as concerns often expressed by 
their patients. Some participants had had patients that had experienced adverse events 
first hand. 
“In terms of starting steroids, people in most cases don’t seem too resistant to that 
idea initially.  I suppose it’s because they’re in pain and they think it’ll make them 
better.  It’s later on, when they’re on them and getting side-effects, that they have 
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more concerns about it […..] Yes, I’ve certainly got a lady who developed diabetes 
for the first time whilst she was on steroids.  Not by me, I saw her later down the 
route, but she had been started on them for PMR.  Whether she was going to go 
on and develop diabetes anyway, she may well have done, but certainly she 
developed it whilst she was on the steroids.  She’s now off steroids but still on 
some low dose Metformin for her diabetes.  She’s still labelled as diabetic, which 
she certainly blames on the steroids.  I think the other thing is GI side effects; that’s 
what you actually see people complaining of mainly. Then weight gain is a big 
one”  
GP13 (5, F, S) 
However, whilst the potential adverse effects of glucocorticoid treatment are well known, 
participants weren’t always specific about the problems that treatment caused nor were 
they entirely sure that the adverse effects were definitely related to treatment. 
“but do you know I can’t think off hand of somebody in whom I’ve thought well 
that’s the cause of this.  But then as you say it doesn’t happen that often so 
maybe, I can’t really think of instances where I’ve had, like I say there’s just the 
sense of people that were quite well old people turning in to people who suddenly 
have a lot of problems and they’re on more medication and they’re just not as well 
at the end as they were at the beginning.  But I don’t know I think I am very 
negative about the diagnosis and so probably I am very negative about the 
treatment as well.”  
GP17 (11, F, P) 
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Prevention of adverse effects and drug prophylaxis 
 
“So, then I say ‘And here’s another tablet for you. I’m sorry.’ ‘And, actually, here’s 
a PPI [proton pump inhibitor (drug to prevent gastrointestinal complications)] as 
well.’”  
GP 24 (12, F, S) 
 
This sub-theme relates to efforts often made by GPs to try and prevent the development 
of adverse events using prophylactic medications. Currently national guidance 
recommends prophylactic treatment for patients at high risk of fractures due to 
osteoporosis and patients susceptible to gastro-intestinal complications. 
“Yes. If I’m going to be committing someone to a long course of steroids, I will 
often start them on a PPI, to prevent them from getting gastrointestinal side 
effects. And, also, I often start them on a bisphosphonate as well, providing they’re 
able to tolerate it, and calcium supplements.”  
GP22 (15, M, P) 
 
There is a certain amount of confusion surrounding certain aspects of prophylactic 
treatment particularly surrounding osteoporosis prevention, especially as these 
medications are poorly tolerated. GPs seemed to take a more collaborative approach in 
deciding whether or not prophylaxis was appropriate involving patients, providing more 
information and possibly undertaking further investigations before making any final 
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decisions. However none of the participants indicated that they would use any formal 
fracture risk assessment for example FRAX or QFracture. [Kanis et al 2015] 
“But, yes, of course. So, yes, so, you know, interestingly, whether to DEXA scan 
people or just treat them, I think our local guidelines say just treat. But I think I 
probably, personally, don’t put people on something from the word go, because it 
seems all a bit, sort of, over the top to start on day one. So I think, in practice, I’d 
probably discuss it with them, you know, a month in, or maybe a bit more. Yeah. 
No, I do think I don’t forget that, yes, in practice”.  
GP12 (15, F, S) 
 
This reinforces the holistic approaches taken by GPs. Guidance can sometimes be very 
inflexible, yet treatment plans need to be individualised to account for multi-morbidity, 
multi-pharmacy, treatment risks and  benefits and the patient’s wishes. 
 
Impact of treatment on existing co-morbidity 
Barnett (2012) demonstrated that multimorbidity is significantly related to increasing age. 
Most of their sample over the age of 65, were suffering with multimorbidity. [Barnett et 
al 2012] Given that PMR occurs in older patients it is likely also that multimorbidity is 
common. Long term treatment with glucocorticoids may well result in significant adverse 
effects but could impact also on existing co-morbidity. Diabetes was the predominant 
disorder noted to be affected by concomitant treatment for PMR. 
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“Oh, definitely, yes, their diabetes control, definitely. I mean, they’ve usually got 
type 2 diabetes…so they don’t run into any crises, but definitely, their diabetes 
control gets worse.”  
GP 24 (12, F, S) 
 
Blood pressure control was a common disorder that was cited as being potentially 
affected by treatment although there was an awareness that the control of some chronic 
co-morbidities can deteriorate with time irrespective of treatment with glucocorticoids. 
 “I suppose it’s a bit similar with blood pressure, isn’t it?  You see people who are 
already hypertensive and on treatment and then also on steroids.  You see them 
and their blood pressure is a little bit worse and you think, Should I adjust their 
medication or as we’re reducing their steroids should we just leave it and see?  
That’s always another discussion with the patient, isn’t it?  I always feel a bit 
uncertain about how much of an impact the steroids are actually having, or 
whether the control is getting worse for whatever reason.”  
GP12 (15, F, S) 
 
6.3.3.6 Practical implications of treatment and monitoring for PMR 
 
This theme moves away from the direct consequences of treatment to the more 
pragmatic challenges that GPs face when treating PMR. The sub-themes are discussed in 
 194 
 
0 
the following sections and relate to the resource impact and follow up of patients with 
PMR and issues surrounding tapering and stopping treatment all-together. 
 
Long term monitoring of PMR 
 
Current guidance recommends a follow up plan for patients diagnosed with PMR and 
outlines aspects of care that should be monitored to exclude possible mimicking disorders 
and associations. [Dasgupta et al 2010] A clear challenge identified from the survey 
results surrounded the difficulties and resources needed for this, and was reinforced in 
the interview study. 
“I think that clearly the initial diagnosis and the follow up can often be weekly for a 
bit isn’t it, depending on the response and monitoring response, so depending on 
how well it’s going in terms of rechecking inflammatory markers you're probably 
looking at the nurse doing that a couple of weeks down the line and depending if 
the sugars are going off that’s going to throw in some more blood tests so yes, it is 
immediately creating a number of consultations with myself and the practice nurse 
really, yes.”  
GP6 (20, F, P)  
 
Varying types of follow up were discussed by the GPs interviewed and this largely 
depended on the level of confidence that the GP had in their patient managing their own 
illness balanced against the perceived need for close monitoring by the GP for various 
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reasons including compliance, ability to self-manage and concerns about the original 
diagnosis. Unfortunately given the structure of practices, availability of appointments and 
sometimes unforeseen circumstances, patients are sometimes lost to follow up. 
“Yes, again, sometimes people do get lost to follow-up, with all the will in the 
world, don’t they? So I had one lady who had been seeing me very regularly. We 
were bringing it [steroids] down. Something else cropped up with her, and she 
ended up, sort of, seeing somebody else for a while about another thing. And then 
she just had been left on this dose of prednisolone” GP24 (12, F, S) 
 
Treatment dose tapering 
The final sub-theme surrounds the process of slowly reducing the dose of treatment over 
time and was highlighted as a significant area of challenge from the PMR questionnaire 
survey. Although guidance on prednisolone tapering is presented in the PMR guidelines, 
[Dasgupta et al 2010] it can be challenging.  
“Yeah oh definitely and then you try and get them off them and they get, I don’t 
know it seems to me that they get very attached to the steroids in a funny way and 
they, if they start to ache again they come back and say oh I think I should increase 
my steroids which is maybe the right thing to do but it’s just as I say woolly, oh I so 
dislike it.”  
GP17 (11, F, P) 
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Numerous approaches to the long-term and ongoing reduction in prednisolone dose were 
volunteered by interviewees. Some participants were very specific in terms of the way 
that they advised patients to wean down their glucocorticoid treatment. 
“So if the patient is sensible I’ll explain to them what I’m expecting to do with the 
reduction and often will then only follow them up, you know we have people book 
phone appointments and I’ll tell them to book a phone appointment every eight 
weeks after an intervening reduction.  And again if it’s me and the patient that’s 
fine, the problem comes where there are other people and you need to be very 
clear then if there’s other doctors involved you need to be very clear about kind of 
making plans and making sure that the numbers are written down because 
otherwise you can have reducers plans but it’s actually not very clear what the 
plan is and you know it’s not always easy to pick up what those people are on.”  
GP16 (17, M, P) 
 
Other GPs were less specific and allowed their patients to self-manage and wean their 
doses of prednisolone in a less formal way. 
“I mean, I like my PMR patients because they are fairly straightforward.  There’s a 
kind of loose structure of reducing this drug, seeing how they respond.  I will kind 
of go clinically; I don’t push them to have blood tests every month.  I mean, it just 
seems pointless.  I judge their response by symptoms, not inflammatory markers.”  
GP18 (22, M, S) 
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“I’ve tended more to allow, the ones who can, to self-manage, and then just got 
them back for a review intermittently. I’ve not found any great benefit in bringing 
them back for frequent reviews when, especially if they’re still working.”  
GP23 (12, F, S) 
 
6.3.3.7 Summary of themes relating to treatment 
It is clear from the interviews conducted that there are significant concerns surrounding 
the long-term treatment of patients who have PMR. This relates mainly to the potential 
adverse events associated with glucocorticoids and given that this is currently the only 
treatment option available to most GPs, it is an area of significant challenge.  
A variety of approaches to on-going management were undertaken and volunteered by 
participants. Initial treatment is often very effective with patients responding with a 
significant and rapid improvement in most of their symptoms. However, on-going 
treatment becomes more challenging and has to be negotiated in order to balance the 
beneficial effects of the treatment (improved function) against the long term potential 
adverse effects, which become more prevalent with duration of treatment, and may need 
additional treatment to prevent/manage. The GP’s interviewed tended to take a shared 
management approach that was individualised for each patient. GPs were aware of how 
the treatment could affect their patients given any co-existing morbidity and multi-
pharmacy. They were also balancing confidence in the patient and the patient’s own 
confidence to self-managing their illness with the additional burdens of compliance and 
adverse events of prophylactic treatments. 
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6.4. Challenges and influences impacting on the findings of the qualitative interviews 
The following section briefly describes some reflections on the specific challenges 
encountered in conducting this qualitative study, including a discussion surrounding 
factors that may have influences on the overall findings and conclusions. 
 
6.4.1 Practical Challenges 
Recruitment 
Recruitment was the main challenge encountered with this study. 61 (18.7% of the total 
number of study packs sent out) GPs returned responses agreeing to participate in the 
interview study. On trying to arrange an interview date, a further 16 GPs withdrew. A 
further 21 GPs were unable to be contacted despite repeated efforts. The study 
recruitment period ran from September 2014 to May 2015. This period included two 
parts of the year where GPs are particularly busy, Christmas and the closing of the 
financial year in April, where practice financial issues and enhancing the Quality and 
Outcomes Framework (QOF) assessments are made. This timing may have affected GP 
willingness to participate although the timing of the study was not intentional and it was 
not foreseen that recruitment to this study would take so long. 
Furthermore time constraints on GPs may have affected recruitment. This was reflected 
by some of the interviews being undertaken in the evening and in the participants’ spare 
time.  
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Finding a mutually agreeable time to conduct the interviews was at times challenging and 
in some cases had to be re-scheduled because of unforeseen events. To some extent, this 
had an impact on the time taken to complete all of the interviews. 
 
Translating interviews into data for analysis (equipment failure) 
Three of the interviews that were conducted were not transcribed. This was because the 
participants’ voices could not be heard and was likely due to setting up the equipment 
incorrectly. Unfortunately the field notes did not contain enough detail to use them to 
contribute data to the study. After discovering this problem, the equipment was double 
checked by doing a testing check to ensure it had been set up correctly. The transcription 
services used for this study worked flawlessly and efficiently.  
 
6.4.2 Factors that potentially influenced findings 
Qualitative methods may be used to identify, clarify and explore areas of interest, 
possibly for further research. Qualitative methodology focuses on validity, credibility and 
methodological transparency in order to attempt to describe the truth. [Silverman 2010, 
Bazeley 2014] The following sections describe possible aspects of this study which may 
have influenced some of the study findings and have to be acknowledged. 
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6.4.3 Sampling frame 
The sampling frame described in Section 6.2.3 was used in order to identify participants 
that would potentially convey data from a broad range of experience. Pragmatically, and 
owing to the poor response, interviews were conducted with anyone who agreed to 
participate irrespective of their underlying characteristics or experience. The 
characteristics of participants in medical survey research are reviewed in Chapter 4. It is 
likely that those agreeing to take part in further research on a particular subject followed 
by completing an interview will be highly motivated and interested in the subject, 
resulting in a highly selected cohort of participants.       
The effect of the characteristics of “the volunteer” has to be considered as it can 
influence the data obtained and affect the conclusions made. Rosenthal investigated “the 
volunteer subject” and highlighted that volunteers tend to be better educated, more 
intelligent, more sociable and more conforming. [Rosenthal and Rosnow 1975] It became 
apparent during the interviews that some participants had clear PMR “intelligence”, with 
experience and specialist interest in PMR and musculoskeletal disorders. However, this 
was certainly not a universal experience, with some GPs having a seemingly minimal 
awareness of the illness and others had apparently agreed to take part to express their 
discontent surrounding the poor diagnostic processes and lack of good treatment options 
for PMR. Whilst this group of participants may be highly selective they also are more 
aware of associated issues and so were ideal for the aims of this study in investigating the 
challenges associated with PMR. 
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6.4.4 Influence of the interview method on findings 
A pilot interview was undertaken with a non-academic GP volunteer in order to 
determine potential technical issues with using the recording equipment and to gain 
feedback and advice from expert research supervisors on the conduct and performance 
of the interview. This interview was not included in the analysis. Several areas for 
improvement were identified. There was a tendency to over-explain and over-elaborate 
points which could be misinterpreted as critical of interviewee responses. To help with 
this, placing enquiries in the context of what other participants have been saying was a 
particularly helpful strategy to put participants at ease. There were also clear 
opportunities where I should have allowed the interviewee to fully talk and to avoid over 
talking.  
The type of interview and the way in which an interview is conducted can have specific 
effects on the data obtained and this will be dependent on both the experience and skill 
of the interviewer and their perceived status. This was of a particular issue for this 
telephone interview study, given that the interviewer was both a peer and expert in the 
subject area. Participants who are interviewed by professional peers may feel that they 
are being tested or that their professional integrity is being scrutinised. [Coar and Sim 
2006] However, interviews conducted by peers may also result in broader and richer 
accounts of clinical practice. [Chew-Graham et al 2002]  As such, every effort was made to 
ensure that the participant did not feel judged. It was explained both in the participant 
information leaflet, and as part of the formal checking process prior to starting the 
interviews, that this was not a test of knowledge, but a discussion of experiences, and 
that honest views were being sought. On-going reassurance was provided throughout the 
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interview, whilst building rapport and empathically acknowledging shared personal 
challenges and experiences. 
Given the volunteer status of participants that completed an interview, it is likely that this 
issue did not have a detrimental effect on the data gained from the interview. As 
identified by Chew-Graham (2002), an expert peer interviewer can also have its benefits 
and for this study it is particularly applicable as a background awareness of the issues 
allowed a focus and recognition of potential challenges to be explored reflexively and 
efficiently, given the limited time opportunity for interviewing. [Chew-Graham et al 2002] 
One of the main criticisms surrounding telephone interviews is the obvious lack of visual 
cues that result from not being able to see the participant. For this study, it is likely that 
visual cues would not have impacted significantly on the data obtained. This is because of 
the type of data being sort that was largely factual and medically based often on personal 
experience with an expected level of intellect and background knowledge. Visual cues 
maybe important in studies where behaviour is being challenged or an in-depth 
exploration of a participant’s experiences, knowledge or beliefs is being undertaken and 
visual responses may significantly add to the meaning of the data and conclusions. Equally 
for investigations of sensitive or traumatic subjects, rapport and visual encouragement 
may be essential to fully obtain the best data. However, a potential issue related to 
expert peers undertaking interviews may extend from the concept of social desirability 
bias where participants answer questions in the way that they think the interviewer 
wants them answered. For telephone interviews there is nothing to stop a participant 
preparing for an interview or having clinical guidelines available whilst doing the 
interview.  
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6.4.5 Analytical issues influencing findings 
Some of the criticisms of qualitative research stem from the interpretive analytical 
techniques used. As such, qualitative analytical processes have been developed to try and 
improve the validity and reliability of the analytical process. It has also been noted that 
there are factors that can influence the data at the interview stage. For example the 
direction of the interview and the skill of the interviewer can affect the quality and or 
focus of the interview and subsequent transcribed data and so although the transcripts 
represent raw data at the analysis stage, the data may already be “contaminated”.  
Analysing this data myself and having a significant prior knowledge was a potential issue 
with data interpretation in this study. Drawing on my experience as a clinical general 
practitioner and pre-identified areas of interest, significant analyser influences should be 
less of an issue but must be recognised and cannot be completely eliminated. The draw-
back of having a pre-conception of the issues is the potential to miss important new 
information. However, a knowledge of the issues and a focus on those issues can improve 
trustworthiness.  
Inter-rater analysis is a method that can be used to try and improve the reliability and 
trust-worthiness of the findings from analysis. Supervisors were given a copy of a 
transcript of an interview and asked to identify the broad themes that they felt were 
emerging from the interview. These were then compared with my own, although no 
formal inter-rater reliability analysis was undertaken. Studying inter-rater reliability can 
be helpful to ensure quality in the identification of broader themes, but is less reliable in 
demonstrating how these themes are developed and packaged. [Armstrong et al 1997] 
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In conclusion, eliminating all pre-conceptions in qualitative research can be challenging, 
and is not necessary. It is well recognised as an issue and is acknowledged here. However, 
for this study some of areas of interest were identified through data obtained from a 
national survey which informed and directed the interviews. The purpose of undertaking 
this qualitative study was to explore these identified areas in depth, and a pre-awareness 
of the issues, it may be argued, could enhance this by knowing when and where to 
explore issues and to help identify new and previously unrecognised problems.   
 
6.5 Conclusion 
“I think it can be managed in primary care, as long as there are sufficient resources 
out there; educational information and support in terms of being able to refer or to 
ask questions where there is uncertainty.  I feel I’ve seen enough cases over the 
years not all diagnosed by me, because you obviously see people who are being 
treated for it more regularly than you see people on whom you’ve initiated 
treatment.  I feel I’ve seen enough people where management seems to have been 
perfectly reasonable, where they’ve started on it with a good history and have got 
on fine and have reduced down and come off their steroids appropriately.  I don’t 
think it’s necessary for all of those people to be seen in secondary care, but 
obviously the support does need to be there because there is a significant amount 
of uncertainty for quite a lot of people.”   
GP13 (5, F, S) 
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Successful diagnosis and treatment of PMR relies on an effective collaboration between 
patients and their GP, having a good understanding of the illness (both for doctor and 
patient) and appropriate access and follow up to ensure the right diagnosis and good on-
going treatment concordance. As PMR does not have a gold standard diagnostic test, 
accurate diagnosis can take time, and varies with emerging symptoms, laboratory tests 
and the absence of red flag symptoms. This picture is somewhat at odds with a typical 
guideline that may give the impression that diagnosis and treatment is straight-forward 
and follows a set and clear pattern and can be achieved after an initial encounter and 
follow up with requested investigation results. 
Generally participants felt that PMR should remain a predominantly primary care focused 
disorder providing there were the resources and access to specialist reviews if required.  
The GPs interviewed for this qualitative study appear to be alert to the common 
diagnostic pitfalls and challenges that PMR poses, taking a reflexive and holistic approach 
to diagnosis whilst being aware that other disorders can present in very similar ways, and 
acting accordingly.  On-going treatment and monitoring is often undertaken in primary 
care, which is appropriate as patients potentially can have regular or rapid access to a 
clinician when problems arise. Patients can also be regularly monitored which, is less 
feasible for secondary care settings. Finally, as general practitioners are trained to and 
indeed do encounter a very wide spectrum of illness, they are well placed to recognise, 
manage and monitor any developing potential adverse events from treatment with 
glucocorticoids. 
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Chapter 7: Giant Cell Arteritis 
 
 “I don’t think I have ever diagnosed it although I’ve looked at it a few times and 
again it’s just horrifying isn’t it because it’s like polymyalgia except there’s this 
fear about if you miss it then the patient will go blind and it will be your fault.  
But the same diagnostic problems [as PMR] and you send people for biopsies and 
it’s a horrible thing to have done and then it’s negative and then they say, oh but 
that doesn’t rule it out and so you end up treating them anyway.”  
GP 17 (11, F, P) 
 
7.1 Introduction 
As highlighted in Chapter 1, giant cell arteritis (GCA) has a close association with PMR. 
Although not the main focus of the thesis, this chapter will briefly introduce GCA and 
illustrate its relationship to PMR. The remainder of the chapter will present GCA related 
results from both the GP National PMR questionnaire survey and the GP qualitative 
interview study. 
 
7.2 History and background 
Sir Johnathan Hutchinson has been attributed as the first clinician to describe a definite 
case of GCA in 1890 but it was not until the early 1930s that a case series with associated 
temporal artery biopsies and typical giant cell vascular infiltrates was formally described 
by Dr Bayard Horton. [Boes 2007] The potential association between GCA and PMR was 
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made in 1960 by Drs Paulley and Hughes in their description of a case series of 71 
patients with GCA, 32 of which were described as having “anarthritic rheumatism”. 
[Paulley and Hughes 1960] More recent research has shown that up to 60% of GCA 
patients report PMR type symptoms during their illness with between 16 and 21% of PMR 
patients developing GCA. [Salvarani et al 2008] Gonzalez-Gay (2001) demonstrated that 
9% of patients with isolated PMR had histological evidence of GCA on temporal artery 
biopsy. [Gonzalez Gay et al 2001]  
Like PMR, GCA is rare in younger patients (<60 years old) and classically presents with 
features of new onset headache or head pain. This may be accompanied by jaw or tongue 
claudication. Visual disturbances, including amaurosis fugax and transient diplopia, are 
also associated and are signs of imminent visual loss which should be treated as a medical 
emergency. [Dasgupta (GCA) et al 2010]  
Unlike PMR, GCA has more robust and accepted range of diagnostic tests that can be 
useful in making a definitive diagnosis. Temporal artery biopsy remains the gold standard 
diagnostic test with some studies demonstrating 100% specificity. [Vilaseca et al 1987] 
However its sensitivity is affected by the presence of “skip” lesions (sections of artery 
where typical histological findings are absent), the experience and technique of the 
surgeon performing the biopsy, the length of biopsy taken and the duration of treatment 
with glucocorticoids prior to the biopsy being taken. [Mahr et al 2006, Gonzalez Gay et al 
2005] Temporal artery ultrasound is increasingly becoming recognised as a useful tool in 
diagnosis also, [Dasgupta (GCA) et al  2010] although to date it is not widely available in 
non-research settings. Table 7.1 summarises the clinical features of biopsy positive GCA 
and highlights the wide variation of symptoms with which patients can present. 
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Table 7.1. Clinical features of temporal artery biopsy positive patients with GCA 
Clinical Feature Percentage of biopsy proven  
Cases with the feature 
 
Temporal Headache 52 
Any Headache 76 
Scalp Tenderness 31 
Jaw Claudication 34 
Any visual Symptom 37 
Unilateral Visual Loss 24 
Diplopia 9 
Myalgia 39 
Previous diagnosis of PMR 34 
Weight loss 43 
Fever 42 
Absent temporal pulse 45 
Any abnormality on palpation of the temporal artery 65 
Erythrocyte sedimentation rate normal 4 
Erythrocyte sedimentation rate greater than 50mm/hr 83 
 
 [Smetana et al 2002] 
GPs remain the first point of medical contact for most patients. Given the risks of 
irreversible visual loss in patients in whom treatment is delayed [Ezeonyeji et al 2011] GPs 
need to be able to identify potential GCA patients early and initiate prompt, appropriate 
steroid treatment before referral for definitive diagnosis under specialist care.  
 
7.3 Aims and objectives 
The overall aim of this chapter is to describe the diagnosis, management and associated 
challenges of GCA in primary care. This will be achieved through the following objectives: 
1. To investigate the clinical signs and symptoms used by GPs to identify GCA and 
any accompanying laboratory or imaging investigations used to confirm the 
diagnosis 
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2. To describe the usual management processes undertaken by GPs including 
initial treatment and associated specialist referral practices 
3. To ascertain diagnostic and management challenges associated with GCA and 
to identify possible solutions to these challenges. 
 
The methods used to achieve these objectives will be discussed in the following section. 
 
7.4 Methods 
The design and execution of the cross-sectional survey used to collect data on the 
diagnosis and management of GCA was described in Chapter 4. These questions included 
fixed response questions on management and general experience of GCA. The section 
also includes open response questions on signs and symptoms used to identify GCA, initial 
corticosteroid dosing and any associated diagnostic and management challenges 
encountered. The full questions can be reviewed in the PMR questionnaire in Appendix 3. 
The relevant domains are summarised in table 7.2 
Table 7.2 Domains relating to GCA in the GP National PMR questionnaire survey 
Question Number Domain 
 
18 Have you ever managed a patient with GCA? 
19 What symptoms would lead you to suspect GCA? 
20 What signs would lead you to suspect GCA? 
21 Management and referral pathways for suspected  GCA  
22 Specialist to who suspected GCA patients are referred 
23 Initiating dose of prednisolone 
 
 
Within the qualitative phase of the study, GCA was included as described in Chapter 6. 
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Verbatim quotes, as in chapter 6 are labelled in the same way using the following key. 
Key: [time qualified as a GP (years), gender (male/Female), seniority/role (S:salaried, 
L:locum, P:partner, SP: senior partner)] 
 
7.5 Results 
The following section presents the findings from the cross-sectional survey and 
qualitative study that are specifically related to GCA. Responder characteristics to the 
questionnaire survey and details of participants in the qualitative study were presented in 
Chapters 5 and 6. The results will be presented in a similar format to the PMR results 
under the broad themes of diagnosis and management and each result relating to the 
questionnaire survey will be referenced to the relevant question. 
 
7.5.1 Identification and diagnosis  
Although GCA is the most common large vessel vasculitis it is still a rare disorder and is 
infrequently encountered in general practice.  Full time general practitioners can expect 
to see one case at most every one to two years. [Barraclough et al 2012] Of our survey 
responders only 879 (70.4%) indicated that they had managed a patient with GCA 
reflecting its rarity  
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Symptoms used to identify patients with potential GCA (Question 18) 
To ascertain how GPs were identifying patients with GCA a free text open response 
question was used to ask all participants to describe how they made a diagnosis of GCA. 
This question was analysed using quantitative content analysis, with the results 
summarised in Table 7.3. 
Table 7.3 Table demonstrating the features used by responders to identify GCA 
GCA Feature Theme Frequency 
 
Headache/Head Symptoms 1071 
Visual disturbances 671 
Scalp Tenderness 468 
Jaw Symptoms 420 
PMR symptoms 69 
Systemic Symptoms 65 
Fatigue 29 
Joint/Muscle symptoms 20 
Tongue symptoms 12 
 
 
The predominant clinical feature used to diagnose GCA is headache, along with visual 
disturbance and scalp tenderness. Survey responders indicated that they often used a 
combination of features when making a new diagnosis. To illustrate this, the most 
commonly reported symptoms are presented as a Venn diagram in Figure 7.2, which 
highlights the overlap of the combinations of symptoms used to diagnose GCA. Of 
particular note was that 21.9% of responders indicated that they only use headache to 
identify GCA.  
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Figure 7.2 Venn diagram of symptoms used to diagnose GCA 
 
 
 
  
  
7.5.2 Thematic analysis of qualitative interviews relating to GCA diagnosis  
“I would say, a GPs role in this I think is in considering the diagnosis because you 
know you miss it [making a GCA diagnosis] in like about a fifth of them can go 
blind so you know my main thing is making the diagnosis.”  
GP7 (10, M, P) 
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Diagnostic confirmation through referral to specialists will be addressed in the later 
section which discusses the management of GCA. Two predominant themes surrounding 
GCA identification were identified. The first, “presenting features of GCA” is closely 
related to the second theme “fears of missing a diagnosis of GCA” 
 
Presenting features of GCA 
When asked about GCA symptoms in the interviews, participants often gave textbook 
descriptions of classical features of GCA. 
 “Well I mean again I'm looking for the headaches, the sort of cardinal signs, 
headache in someone over 55 you think giant cell arteritis really, that's my 
mantra, new different headache, classically unilateral but not always, focused 
around the temple, potentially some tenderness there, possibly protruding 
temporal artery, classically tender when they're combing their hair, but also 
looking for things like jaw claudication or tongue symptoms, it's not always the 
sort of classic but I've had someone with “oh my tongue just feels odd Doc”  with 
or without PMR symptoms as well really and obviously the dread of visual 
disturbance as well really which can be anything really and can be very fleeting so 
I remember a patient that I had diagnosed had no visual symptoms at onset and 
then she rang a partner of mine at the practice and said I'd had just literally 10, 
15 seconds of a sudden visual cloud and then gone again and actually she went 
on to get visual complications as well”  
GP6 (20, F, P) 
 214 
 
0 
While textbook descriptions of classical GCA were given, there was recognition that some 
of these features may be difficult to recognise or link to GCA.  
“jaw claudication is interesting, because I know at the time, my colleague and 
myself, kind of, looked a bit more up about GCA and he said, ‘I’ve never heard of 
jaw claudication.’ And, actually, I had, and will ask about it, but I’m not sure I’ve 
ever heard anybody say they’ve got it.”  
GP15 (25, F, P) 
 
However some GPs highlighted how the wide range of symptoms associated with GCA 
meant that atypical presentations were not unusual.  
“He came in before Christmas one year, probably about three or four years ago 
now, just with a vague headache, and hadn’t had any visual disturbance at that 
point in time. And he didn’t really have a lot of temporal artery tenderness. So, I 
said, ‘Well, look. Let’s try some ibuprofen or paracetamol,’ you know. ‘Come back 
in a week if it’s not any better’. He came back in a week. It wasn’t really better. We 
did some bloods at that point, and the ESR and CRP were normal. At the time he 
was already under the care of an ophthalmologist for something else, and a 
rheumatologist for something else. So, he had appointments with both of those 
departments, not specifically about his headache and, kind of, nothing different 
done. And he kept complaining about this, and then he lost his vision… I wrote in 
the notes at the time, ‘Excludes GCA”……which, having read a bit more about it 
since, after this happened, doesn’t totally exclude it. But he really didn’t have any 
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of the typical symptoms that would ring alarm bells. He wasn’t, you know, tender 
or anything. And that was really upsetting for us all, I think, because, well, that’s a 
devastating consequence isn’t it? And, yeah, I think that really made us sit up and 
take note, and I’m quite sure we do more ESRs and CRPs than anybody else. And 
I’m quite sure we put people on steroids quicker, but perhaps bring them off 
steroids quicker, as well, if it doesn’t, you know, if it doesn’t solve the problem. I 
think it’s made us a little bit, kind of, hypersensitive to the possibility. So, that’s, 
kind of, what that one was about.”  
GP 15 (25, F, P) 
 
Fear of missing case of GCA 
Participants expressed considerable fear about missing a diagnosis of GCA as a missed 
diagnosis has the potential to result in irreversible visual loss which might be prevented 
with appropriate and timely treatment. 
 “I find it, sort of, trickier, I think, to diagnose. I worry about it more. I worry about 
missing it. And I feel far less confident about treating it. I think when I was first 
qualified as a GP I think I thought somebody had got it every week. Anybody 
who’d got a headache, you know”  
GP 24 (12, F, S) 
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There is recognition that some of the symptoms of GCA can be non-specific, vague and 
occur commonly amongst patients in the older age group which can lead to diagnostic 
and treatment dilemmas. 
“Well the most recent one that we went down this futile track was an elderly lady 
who was having headaches and kind of pain around her eyes and I’m trying to 
think what other symptoms she had, general misery really.  And it sort of came and 
went and came and went and she didn’t really have any visual problems which is 
good and when you said to her, “Does it hurt to chew?” she’d say, “Oh yes I think it 
does”.  And so yes all of that so in the end I started, I did discuss it with our local 
physicians because just in that situation where you don’t want to miss it but on the 
other hand it doesn’t seem like it’s probably the most likely diagnosis.  And we got 
as far as them saying, “Well if it’s maybe a possibility then go ahead and treat with 
steroids”, at which point she said, “No I’m feeling much better thank you”. And 
that was that until she started complaining about it again another few months 
later”  
GP17 (11, F, P) 
 
Whilst participants seemed aware of the typical presentations of GCA, atypical 
presentations could result in referrals to the wrong speciality as GCA had not been 
recognised leading to delay in diagnosis. 
“I had another one, a long, long, long time ago, you know, complaining of earache, 
and I referred him to Ear, Nose, and Throat. He reckons that he more or less said 
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he was malingering. And then I did an ESR and it was something like 100 or 
something. And, you know, I think he responded quite well to steroids. But, again, 
it was 15 years ago. And he’d been going on for about a year or so, you know, to 
people. Yeah, and I think that turned out to be temporal arteritis.”  
GP22 (15, M, P) 
 
7.5.3 The management of GCA (Questions 20, 21 and 22) 
For general practitioners, management is intimately associated with diagnosis as 
suspected GCA patients require urgent specialist referral for definitive diagnosis and 
treatment. [Dasgupta (GCA) et al 2010] However, key to the prevention of the visual 
complications of GCA, is the initiation of high dose glucocorticoids. Current guidance 
advises early treatment with 40-60mg of prednisolone and 60mg in the presence of 
ischaemic features whilst urgent admission for intravenous methylprednisolone is 
indicated in patients with threatened or evolving visual loss. [Dasgupta (GCA) et al 2010] 
Figure 7.3 illustrates the initiating doses that responders indicated that they use in the 
initial treatment of potential GCA patients. As can be seen the most common initiating 
dose of prednisolone was 60 mg with 78.7% (n=983) indicating that they would initiate 
suspected GCA patients with an appropriate dose of prednisolone that was somewhere 
between 40 and 60mg in-line with current guidance. 
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Figure 7.3 Initiating prednisolone dose in suspected GCA 
 
 
The graph indicates almost 10% of responders indicating an “other” dose. This was done 
for practical reasons as some responders indicated a dosing range (for example 30 to 
80mg). Some responders indicated that they did not have a standard dose to mind as 
illustrated by the free text responses presented in Box 7.1 
Box 7.1. Free text examples for other initiating prednisolone dose  
 
 
 
Irrespective of the response to general practice initiated treatment, patients with GCA 
should usually be referred for specialist review and diagnostic confirmation. [Dasgupta 
(GCA) et al 2010] Table 7.4 outlines the usual actions of responders when faced with a 
patient with suspected GCA. 
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Table 7.4 Action taken by responders for cases of suspected GCA. 
Action 
 
n (%) 
Refer to hospital immediately without  
investigation 
244 19.5 
Do urgent blood tests and refer to hospital immediately if elevated 201 16.1 
Do urgent blood tests, initiate steroids and 
refer for out-patients review urgently if blood tests positive 
554 44.4 
Do urgent blood tests, initiate steroids and refer for out-patients 
review routinely 
66 5.3 
Other 74 5.9 
 
 
Responders indicated that they referred suspected cases of GCA to a variety of different 
specialties. Table 7.5 illustrates the various specialities to which potential GCA patients 
are referred by responding GPs whilst a few responders indicated that they did not refer 
patients at all. 
 “Do not routinely refer as no advantage gained in management usually.”  
Participant 3049 (23, M, P) 
 
Table 7.5 Table of specialties to which GCA patients are referred by participating GPs 
Speciality Frequency  (%) 
Rheumatology 478 38.3 
Ophthalmology 366 29.3 
General Medicine 144 11.5 
Accident and Emergency 35 2.8 
Neurology 12 1.0 
Elderly Care 9 0.7 
Other 41 3.3 
 
 
Whilst rheumatology was the most common speciality to refer suspected GCA patients to, 
Table 7.5 highlights that patients are being referred to a range of different specialities. 
This variation in specialty to which suspected GCA patients are referred probably reflects 
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regional variations in local policy and the availability of relevant expertise but may add to 
confusion for GPs unless referral pathways are clear. 
 
Analysis of free text data 
Qualitative content analysis of the free text responses relating to specialist referral 
revealed three notable themes. 
The first theme surrounds non-emergency referrals and referral pathways to gain access 
to temporal artery biopsy. This most commonly included vascular surgeons but also, 
general surgeons, maxillofacial surgeons and ophthalmologists.  
“This is a problem locally, I have found myself struggling to get a specialist to take 
responsibility. I try for eyes if eye symptoms and rheumatology if not but the need 
for temporal artery biopsy by a surgeon tends to cloud the issue”  
Participant 4161 (16, F, P) 
 
Secondly, for some, it very much depended on the presentation of the patient as to who 
they would refer to. Older patients may be referred to elderly care services whilst 
patients with visual symptoms would be urgently referred for immediate assessment to 
specialities according to local availability, usually ophthalmology or acute services such as 
accident emergency or acute medicine.  
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“this will depend on what symptoms dominate at presentation i.e. if acute visual 
loss….ophthalmology”  
Participant 2645 (21, M, P) 
 
The final theme surrounded the lack of an urgent and co-ordinated care pathway for 
patients with GCA, causing a potential delay in diagnosis. 
“Local issue regarding whether ophthalmology or vascular surgery will perform 
temporal artery biopsy, reliability of this procedure and steroid response whilst 
waiting for the biopsy” 
Participant 2506 (4, 2, P) 
 
7.5.4 Thematic analysis of qualitative interview data relating to GCA management 
 
Two main themes were found from the interviews and these relate to “Referral for 
definitive diagnostic confirmation by specialist” and “Initial and on-going management 
challenges”. These themes largely echo the findings from the content analysis of the 
quantitative data presented above but provide more depth to these findings.  
 
7.5.4.1 Referral for definitive diagnostic confirmation by specialist 
Issues related to specialist referral was the dominant and recurring issue relating to GCA 
expressed by the general practitioners interviewed. Several sub-themes were identified 
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relating to which speciality the patient was referred, the process of arranging a temporal 
artery biopsy and the timeliness and other issues surrounding biopsy. 
 
Speciality to which suspected GCA should be referred 
For this sub-theme, there was clear regional variation in how and to whom suspected 
GCA patients were referred. For some participants the referral route was well established. 
“If their history was suspicious and their inflammatory markers were raised, I 
would then contact…well we’ve had this issue between rheumatology and 
ophthalmology and who to contact, and the line seems to be that if they’ve got 
any visual symptoms then they go to ophthalmology and if they haven’t then they 
go to rheumatology.  But I would certainly discuss it that day if I thought 
somebody did have it.”  GP13 (5, F, S) 
 
However for some respondents in other regions it was less clear as to how or to whom 
suspected patients with GCA should be referred. 
“But, generally, you speak to the on-call medical team, and they will advise me to 
speak to someone else. And then they advise me to speak to someone else. So you 
end up making loads of phone calls to try and find out which route you go in, which 
is frustrating and time-consuming.” 
 GP21 (7, F, S) 
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Arranging temporal artery biopsy 
Several participants reported that when they suspected GCA the GP was expected to 
arrange the temporal artery biopsy. However, this was not always straight-forward, with 
often varying specialities performing the biopsy. 
“we would try and get a temporal artery biopsy fairly promptly. It has been a bit 
difficult in the past, and you know, you’re supposed to get it done within a day or 
two. We traipse round the ophthalmologists, who say, ‘No, speak to the vascular 
people.’ Who say, ‘No, speak to the general surgeons.’ Well, we tried, initially, 
referring to the ophthalmologist, and they just aren’t keen at all. So, at the 
moment we’ve had, a general surgery team who have done a temporal artery 
biopsy for us, and the vascular surgeons have. But our local vascular surgery team 
is now in *******, which is quite some way away. So, again, if that situation crops 
up, I think we’d try the general surgeons first and see if they would do that. But it 
still took a week, from us seeing a patient, to getting the temporal artery biopsy, 
last time it happened. And you’ve, kind of, got to make a decision by then, haven’t 
you?”  
GP15 (25, F, P) 
 
Challenges surrounding the urgency for GCA patients having temporal artery biopsy 
Most GPs interviewed considered GCA to be a medical emergency. However, this was not 
always reflected by local referral policies. 
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“you refer them under a two-week wait, and it’s not that much of an emergency, 
whereas we all thought you referred them acutely, because it was that much of an 
emergency. So there was a big discrepancy of views between what we felt we’d 
been taught about it, and what other people were now doing.”  
GP23 (12, F, S) 
 
Equally there was recognition that some patients had been experiencing symptoms for 
some time before a diagnosis is made without coming to harm,  resulting in participants 
questioning how urgent referrals need to be and how quickly treatment needs to be 
initiated. 
“I know we, kind of, all get it drummed into us, you know, we should all get these 
things sent in on the day. But I think, well, one of them was hanging round for a 
year, and he didn’t really come to any harm, except undue pain and distress that 
he had. And the other one was hanging round for a couple of months, you know. 
And they were both proved – as I say, I’m turning the clock back 15 years - but I 
think they were both proven to be temporal arteritis. It maybe isn’t that, kind of, 
you know, you must get them in on the day, as I thought as a medical student, you 
know”  
GP22 (15, M, P) 
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Delays in patients being seen by specialist services, given that GCA is considered a medical 
emergency was a recurring issue with confusion surrounding to whom patients should be 
referred and who would take ownership and responsibility for definitive care.  For most 
GPs, this related to initial diagnosis and often created dilemmas surrounding decisions on 
initial treatment. 
“And, certainly, in the past, twice that I’ve done it, in the past couple of years, 
we’ve started them on steroids first, because, kind of, getting anybody to see them 
quickly, you know, within a day or two, not been possible, which doesn’t seem very 
ideal to me. And we’ve taken the view if it turns out to be wrong, we can stop it, 
but if we don’t start it, there might be a problem before they get the biopsy. So 
that’s, kind of, what we’ve done here.”  
GP15 (25, F, P) 
 
Delays in specialist assessment also created confusion around the likelihood of a positive 
temporal artery biopsy, especially when treatment had been initiated. 
“The patient that I referred on the NHS, she ended up having a biopsy before she 
saw a consultant rheumatologist. So, yes, it was done that way round. The biopsy, 
of course, came back negative because the two week delay before getting it done 
meant the steroids had treated it. So, I mean, obviously, you can get the negative 
biopsies because of the nature of it all, but she had pretty convincing symptoms, 
and I’m pretty certain that, if the biopsy would have been done at bit earlier, it 
would have had a better chance of yielding a positive result. And the other patient 
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who went privately, he got his biopsy done within a couple of days of starting the 
steroids, it came back positive”.  
GP21 (7, F, S) 
 
Delays in patients being reviewed by specialist services had for some resulted in no biopsy 
being done at all, creating great uncertainty and cautious reduction in treatment. 
“what then happens in secondary care, it's less than ideal, they seem to rotate who 
might do a temporal artery biopsy between vascular ophthalmology and general 
surgery I think and they see to it on a sort of rotation but it all feels a little bit hit 
and miss really but the patient generally is having that temporal biopsy before 
ever seeing a rheumatologist and the timeliness of that temporal artery biopsy is 
not ideal so the most recent patient where there was diagnostic uncertainty I had 
actually, she had raised inflammatory markers, she had a headache but was fit but 
not a great response to steroids after about a week so I had a phone conversation 
with the rheumatologist who said refer her up, we'll get a temporal artery biopsy, 
the date for that just missed the window by two or three weeks to the point where 
it was not going to be a useful process to put her through so she didn't have that, 
then she got seen in clinic some weeks later by which time I'd had further 
telephone conversations with rheumatology and we were starting to tail her off 
the steroids really but very slowly because of the diagnostic uncertainty so yeah, 
not ideal.”  
GP6 (20, F, P) 
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There were doubts expressed by participants about the benefit of doing a biopsy at all 
given that a negative result does not entirely exclude the illness, due to the presence of 
skip lesions and that patients may be unwilling to undergo an invasive procedure.  
“I suppose, that you do the biopsy because it doesn’t really change the 
management much because if it’s negative, I suppose you could potentially wean 
down the steroids faster but if it’s there, you’re going to continue the steroids.”   
GP19 (8, F, S) 
 
No GPs interviewed demonstrated any awareness of the possibility of temporal artery 
ultrasound as an alternative to biopsy. Although it was not a specific topic for discussion, 
it may represent an effective investigation given its non-invasive simplicity which will 
benefit patients who cannot undergo biopsy. 
 
7.5.3.2 Initial and on-going management of GCA 
Two main sub-themes were identified surrounding the initial and on-going management 
of GCA. The first sub-theme surrounds the initial treatment with prednisolone. The 
second larger sub-theme relates to the on-going management. 
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Initial treatment with glucocorticoids 
Guidance suggests that “high-dose glucocorticoid therapy should be initiated immediately 
when clinical suspicion of GCA is raised” usually with a dose of between 40 and 60 mg of 
prednisolone. [Dasgupta (GCA) et al 2010] Some GPs indicated that they would start 
treatment themselves. 
“Okay so I've had the conversation with them already that the worrying feature of 
this condition is visual loss so I give them lots of safety netting about how to deal 
with that and I am then involving secondary care so I'm keeping them on 40mg 
and I'm involving secondary care”  
GP6 (20, F, P) 
 
Others however would gain specialist advice prior to initiating treatment. The reasons for 
this were not always clear, but were often because it had been a long time since the GP 
had seen a case and confidence in management may have been low. 
“I think the rheumatologists would say start the 60[mg] and I will see them in 
clinic.”  
GP4 (6, M, P) 
 
Given the rarity of the disorder though, some GPs could not remember the initiating dose 
and indicated that they would have to look it up. 
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“I would probably look up the current guidance and find out what sort of duration 
of steroids is recommended initially and go from there but yeah, I would definitely 
– if I had a patient acutely, I would have to review that.”  
GP19 (8, F, S) 
 
On-going management 
Several issues regarding on-going management were identified from the interviews. Like 
PMR there were concerns regarding the adverse effects of long term treatment with 
glucocorticoids. These concerns were greater for GCA compared to PMR given the higher 
doses suggested for treatment.   
“Well, it’s a good two years of treatment with steroids and all the complications 
and side effects that they carry with them. So, yes, and high doses of it, which have 
been poorly tolerated with the patients. […..] One patient, she had diabetes, and 
she was started on the steroids, and she was struggling with awful side effects 
from the steroids. She developed, well, lots of depressive symptoms. Her blood 
sugars went all over the place. She got a lot of pitting oedema of the legs, which 
was hampering her mobility. She got unsteadiness due to the steroids. She got all 
sorts of side effects. So it does make me, after seeing patients like that, more 
reluctant to just jump in and start on the steroids, because you’re committing to 
such a long course of treatment.”  
GP21 (7, F, S) 
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The on-going management of GCA patients is usually shared between specialists and GPs 
(when compared to PMR which is mainly managed by GPs). The amount of specialist 
follow up will depend on any associated complications of the disease such as visual 
impairment or clinical comorbidity. Unfortunately in some cases, this resulted in a 
blurring of who was responsible for the patient leading to confusion. 
“Yes again just I think in terms of the ongoing management really because my 
experience with another patient, the one that ended up with visual disturbance, 
she sort of then fell between ophthalmology and rheumatology without either 
necessarily taking full responsibility for her and actually she was a patient of a 
partner of mine so he was kind of following her up but his experience was that he 
was piggy in the middle really, the patient on 60mg of prednisolone, herself quite 
confused as to who was taking responsibility for sorting her out really so again it is 
the secondary care element of this is difficult, yeah…”  
GP 6 (20, F, P) 
 
7.6 Discussion 
Baseline characteristics, issues surrounding recruitment, bias, challenges and other 
aspects that relate to both the cross sectional survey and qualitative study described 
earlier in chapters  4, 5 and 6 apply equally to the results found for GCA as the data was 
obtained from the same participants and so will not be discussed again here.  
The diagnosis of GCA can be challenging especially in view of the rarity of the disorder 
and the wide variation in its presentation. It appears that GPs responding to the survey 
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rely overly on headache when diagnosing GCA. Given that almost half of patients do not 
present with a classical temporal headache and that 24% of patients with proven GCA 
have no headache symptoms at all, [Smetana et al 2002] excluding GCA on the basis of no 
headache has the potential to miss a significant proportion of patients with GCA. Some 
symptoms, like headache, are common [Boardman et al 2005] with over half of over 65 
year olds having had a headache in the previous 12 months, [Prencipe et al 2001] but 
serious pathology is rare in general practice. For some participants their usual practice 
had been affected by experiences where GCA patients had had unfavourable outcomes 
[GP15]. Indeed for some participation in the qualitative study may have been an attempt 
to voice disquiet about adverse experiences that they had had.   
The group of patients with no headache are recognised to be at higher risk of permanent 
visual loss as a result of delayed diagnosis. [Ezeonyeji et al 2011] Therefore, if alternative 
presentations are not recognised by GPs they will continue to remain a high risk group. 
Educating clinicians about other presenting symptoms and atypical presentations is 
essential to optimise diagnosis and reduce delays in instigating appropriate treatment 
and referral, which could reduce the potential for visual loss and serious long term 
complications for this patient group. 
The initial referral is critical and identifying patients with GCA and not missing the 
diagnosis was a predominant theme amongst the GP responders. However, the dominant 
issue that came from the data is what happens once a suspected GCA, patient has been 
identified. There are great regional variations in practice with regards to who GCA 
patients are referred, how definitive diagnosis is made and who arranges and performs 
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temporal artery biopsy. Streamlining patient pathways would reduce the diagnostic 
confusion and perhaps improve outcomes for patients 
Whilst the majority of responders seem to be prescribing appropriate doses of 
glucocorticoids to patients with suspected GCA the subsequent management is more 
variable. Rheumatology remains the predominant speciality to whom GPs refer, however 
some responders indicated that there do not appear to be robust clinical pathways for 
patients who have been identified with possible GCA and need further specialist follow 
up. Given the rarity of GCA and variation in its presentation, the potential for 
misdiagnosis is high. In regions where temporal artery biopsy is arranged by the general 
practitioner or undertaken before seeing the relevant specialist there is the possibility 
that a significant amount of unnecessary biopsies are being performed that could be 
avoided if patients with suspected GCA are reviewed first by a clinician with significant 
experience in diagnosing and identifying suspected  GCA. No participant discussed 
temporal artery ultrasound. Further studies will be needed to determine whether 
availability and accuracy of temporal artery ultrasound will alter requirements for biopsy. 
However, it may be a preferred option for those with significant co-morbidities or too frail 
to undergo biopsy. Additionally, it is less invasive and would be more conducive to being 
embedded in an acute care pathway for the rapid assessment of GCA.   
Delays in assessment for definitive diagnosis, creates several conundrums surrounding 
initial treatment. Current guidance is clear that treatment should not be delayed and 
should be initiated in all patients with suspected GCA although the sensitivity of temporal 
artery biopsy declines the longer treatment has been given before biopsy. [Pieri et al 
2013] Additionally the American College of Rheumatology criteria for GCA suggests that a 
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positive temporal artery biopsy is not essential to diagnose GCA. [Hunder et al 1990] High 
dose glucocorticoid treatment may have a significant impact on symptoms by the time 
they present to the reviewing specialist and therefore definitive diagnosis for patients 
who have had a negative biopsy is extremely challenging. Accurate diagnosis is critical 
however. A decision to stop treatment in patients with true GCA could result in visual loss 
but equally a decision to continue treatment in someone who does not have GCA will 
expose that patient to an inappropriate prolonged treatment course with glucocorticoids 
and all its associated potential adverse effects. Pieri (2013) demonstrated that in almost 
half of patients with suspected GCA, treatment was continued despite a negative 
temporal artery biopsy. [Pieri et al 2013]  
The quantitative data suggested that almost half of participants would not initiate 
treatment prior to referral. However, not initiating prednisolone may be in part a matter 
of local policy rather than poor or inappropriate GP management. 
“Locally this gets referred to ophthalmology[…..] and our practice is actually within 
the grounds of the hospital so we’ve got no issues really in terms of administering 
steroids you know before they were seen, they would be seen within an hour by an 
ophthalmologist. But I’m aware that if I worked in another place that waiting for 
an assessment by an ophthalmologist you shouldn’t delay the administration of 
sort of high dose steroids.”  
GP 7 [10, M, P] 
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Whilst an increased focus on education and awareness of GCA (given its rarity and the 
range of presenting features that GCA may present) may aid better identification of 
potential GCA patients, significant challenges with GCA remain in primary care, some of 
which need to be addressed in conjunction with specialist settings. Guidance advises that 
GCA is a medical emergency, yet there are regions in the UK where specialists local policy 
or referral pathways do not reflect the same urgency. This dissidence clearly causes 
confusion and conflict in GPs decision making which could unfortunately result in a less 
urgent approach by GPs resulting in potential adverse outcomes for patients with GCA.   
The question of the effect of glucocorticoids on the sensitivity of temporal artery biopsy 
and newer and experimental imaging modalities like ultrasound and PET scanning 
remains controversial. A pragmatic way to eliminate this issue would be to undertake 
these further investigations as an emergency prior to treatment or within a minimal time 
frame after initiating therapy. Also, the availability of related specialist services may not 
exist in all regions, particularly in more remote areas. However, in order to improve 
outcomes for potential GCA patients, robust and nationally accepted standard referral 
pathways need to be developed and in place for effective onward investigation and 
timely management. 
This qualitative study was undertaken as part a wider project of two complementary 
studies investigating PMR. The wider conclusions of this study will be discussed in 
conjunction with the questionnaire survey in Chapter 8.
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Chapter 8: Summary of thesis conclusions and areas for future research 
8.1 Introduction 
The overall aim of this PhD was to describe the current diagnostic and management 
practices used by general practitioners caring for patients with polymyalgia rheumatica 
(and the allied condition giant cell arteritis), to identify the barriers to effective care and 
determine targets for future interventions and educational initiatives that could lead to 
improvements in patient care. This chapter summarises the main findings of the thesis, 
discusses the implications of these findings for clinical practice and makes suggestions for 
further research. 
 
8.2 Summary of key PMR findings 
The systematic review (Chapter 3) highlighted the lack of primary care focused research, 
identifying a range of PMR studies conducted predominately in secondary care settings 
and on highly selected patient populations. Despite emerging evidence on the role of 
biomarkers and imaging, making an accurate diagnosis is still dependent on identifying 
the classical cluster of clinical signs and symptoms described in published classification 
criteria.     
Current clinical practice was investigated using two complementary methodological 
approaches, a large cross-sectional survey (Chapters 4, 5 and 7) and semi-structured 
interviews of general practitioners (Chapters 6 and 7). Whilst GPs reported using well 
recognised features of PMR to make a diagnosis they found the condition challenging, 
especially when it presented in an atypical way.  Misdiagnosis was a recurring concern, 
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with GPs anxious about alternative (and more sinister) diagnoses and the implications of 
inappropriate treatment with glucocorticoids. Despite this, adequate exclusion of 
alternative diagnoses does not routinely happen in UK primary care, representing a 
missed opportunity to improve clinical care. Likewise, there was limited awareness of the 
full range of investigations that are suggested in current guidance [Dasgupta et al 2010] 
prior to making a diagnosis of PMR, with an over reliance on the role of inflammatory 
markers. 
Despite response to glucocorticoid treatment not being included as part of the 
classification criteria for PMR, GPs still rely on this feature when making a diagnosis. 
Doses of glucocorticoids prescribed are frequently not in line with national guidance, with 
40% of GPs using higher than recommended doses.   
Whilst many chronic diseases (e.g. diabetes, asthma) have well formulated systems for 
on-going medical review, this does not appear to be the case for patients with PMR who 
frequently suffer from a lack of coordinated or structured follow-up. This not only impacts 
on treatment for PMR but also presents challenges for medication titration and for active 
surveillance of both the disease its sequelae (e.g. coronary heart disease) and its adverse 
treatment outcomes (e.g. diabetes, hypertension, and osteoporosis). Despite guidelines 
advocating frequency of follow up for PMR patients this study would suggest that a more 
structured follow up with glucocorticoid tapering and active surveillance for common 
complications could improve outcome for PMR patients. 
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8.3 Summary of GCA findings 
Findings from the cross-sectional survey and semi-structured telephone interviews 
illustrated the challenges faced by general practitioners diagnosing and managing patients 
with GCA. GCA is a diagnosis that GPs worry about missing, because of the risk of serious 
adverse long term patient outcomes in cases with diagnostic delay or where the diagnosis 
has been missed. Whilst GPs were comfortable with classical presentation patterns, they 
over relied on headache as a trigger to diagnose and had limited awareness of the full 
range of symptoms associated with GCA. Current clinical guidelines and treatment 
recommendations were not widely known, with a significant proportion indicating that 
they would not routinely initiate treatment with high dose glucocorticoids before a 
specialist diagnosis was made. This however, may in part, reflect varying regional policies 
and care pathways. In general, GCA was not viewed as a medical emergency, with regional 
referral pathways being highly variable and difficult to navigate.  
 
 
8.4 Clinical Implications and research recommendations  
This PhD has highlighted a number of implications for clinical practice, many of which 
have associated research recommendations. These are discussed in the section below.  
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8.4.1 Improving the diagnosis of PMR and GCA in primary care 
Diagnosis of both PMR and GCA are challenging in primary care. Both conditions are 
relatively unusual and as such it is currently possible for general practice trainees to not 
have any exposure these patients during their training. Furthermore, specialist 
placements in rheumatology in vocational training programmes and exposure to 
musculoskeletal training in traditional ‘half day’ release programmes is patchy and 
suboptimal [Warburton, personal correspondences  December 2015]. The findings from 
both the cross-sectional survey and semi-structured interviews highlight the need for 
improved education into the management of these neglected and often sub-optimally 
managed conditions. Current clinical guidelines are published in high impact speciality 
journals including Rheumatology (British Society for Rheumatology guidelines), Annals of 
the Rheumatic Diseases and Arthritis and Rheumatology (joint European League Against 
Rheumatism and American College of Rheumatology guidelines). GPs have limited 
awareness of these publications and often have limited access to the articles published in 
them. I have been active in trying to improve the dissemination of high-quality evidence 
into clinical practice, authoring a brief guideline summary on PMR [Helliwell et al 2012] 
and co-authoring a similar article on GCA [Barraclough et al 2012] both of which were 
published in the British Journal of General Practice, a journal that is distributed monthly 
to all members of the Royal College of General Practitioners [Appendix 7]. Furthermore, I 
have written a book chapter on ‘PMR in general practice’ (Oxford University Press, release 
date Easter 2016), co-authored an Arthritis Research UK ‘Hands on’ guide to PMR which 
was mailed to all general practitioners in the UK [Appendix 8] and helped to develop the 
‘Map of Medicine’ for PMR. Whilst these initiatives are no substitute for high quality and 
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on-going clinical education, they demonstrate my ongoing commitment to improving care 
for patients with PMR and GCA and highlights the willingness of journals and publishers to 
further knowledge in these areas for GPs. 
Some areas where future educational initiatives could be targeted need to be informed by 
research. Whilst it is evident that patients presenting with classical symptoms are 
diagnosed relatively quickly, there is a lack of awareness of atypical presentations. These 
potential presentations are highlighted in clinical guidelines, but many of these symptoms 
are vague and not specific. Future work quantifying the predictive value of individual and 
groups of symptoms could improve diagnostic accuracy and support GP decision making. 
This would help with the over reliance GPs have on certain characteristics such as 
headache (for GCA) and response to glucocorticoids (for PMR).  
GPs responding to both the cross-sectional survey and participating in the semi-structured 
interviews highlighted the need for improving diagnostic technology, expressing the lack 
of a ‘gold standard’ test as a key barrier to effective management. Further research is 
needed in this area which should be particularly focussed to a primary care setting, where 
patients will have a different spectrum of clinical symptoms. One potentially important 
innovation is the introduction of ultrasound, yet to date the utility of this modality has not 
been investigated in a primary care setting. Consideration also has to be given to the 
availability of laboratory tests and or imaging for use in primary care as some biomarkers 
may not be readily available and the availability of high-quality musculoskeletal 
ultrasound is limited in primary care and as such it is unlikely to have a major impact on 
clinical care in the foreseeable future.  
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Existing classification criteria have been extrapolated into proxy diagnostic criteria for 
clinical use but there are several issues surrounding the use of classification criteria for 
clinical practice. Classification criteria are designed to identify a standard patient with a 
high probability of PMR for research purposes, and as such do not account for patients 
with co and multi-morbidity, polypharmacy and atypical presentations, all of whom are 
managed in primary care. Further research is needed to support GPs in making an 
accurate diagnosis in a “real-life” primary care population rather than an ‘artificial’ 
research setting.   
Response to treatment with glucocorticoids remains controversial yet it is clear that GPs 
rely on this feature when assessing accuracy of diagnosis. Recently published classification 
criteria suggest that treatment response should not be relied upon when classifying PMR 
for research purposes, [Dasgupta et al 2012] yet the majority of patients included in this 
study were from secondary care. This patient group typically represents diagnostic 
uncertainty or lack of response to treatment, hence the need to refer to secondary care. 
Response to treatment could be a useful diagnostic aid in primary care, yet to date this 
has not been formally evaluated. One approach that has been advocated is the use of 
‘steroid sandwich’ in which patients receive glucocorticoids in week one, placebo in week 
two and glucocorticoid in week three. [Quick et al 2012] This allows a more objective 
assessment of response to treatment.   
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8.4.2.  Improving the management of PMR and GCA in primary care 
Guidance on glucocorticoid treatment is conflicting, with different clinical guidelines 
providing different advice. Furthermore, guidance is based largely on expert secondary 
care consensus, rather than high quality research evidence. Recently published guidance 
from the ACR/EULAR advocate using a minimum effective initiating dose of glucocorticoid 
of between 12.5mg and 25 mg of prednisolone, with precise dose being guided by the 
presence of other morbidities, risk of relapse and risk of adverse effects. [Dejaco et al 
2015]  Such a wide dosing range is likely to cause confusion rather than reassurance to 
clinicians. 40% of responders to the questionnaire postal survey indicated that they were 
initiating PMR patients on doses of prednisolone of 30mg or more, a level that is 
highlighted in the guideline as being inappropriate. [Dejaco et al 2015] It is unclear why 
this dose of prednisolone is being used and no research has ever indicated that this was 
an appropriate dose to use with Boyle and Beaty (1961) advocating low dose 
glucocorticoids over 50 years ago. [Boyle and Beaty 1961]  
Evidence on the optimal dosing regimen, and the associated titration in response to 
treatment, is largely based on limited, low quality, secondary care trials. There continues 
to be a need for a large pragmatic primary care based trial to provide GPs with the 
evidence needed to optimise the management of PMR patients.   
For many patients, PMR and GCA represent a long term condition, yet many GPs do not 
recognise or treat these diseases in this way. Optimal management of long term 
conditions requires patient self-management supported by regular monitoring from 
health care professionals. For PMR and GCA this is especially important, as patients not 
only risk long term consequences from their PMR/GCA (e.g. vascular disease, visual loss) 
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but also adverse events (e.g. osteoporosis, hypertension) related to their treatment.  Such 
concepts are currently lacking in clinical guidance but are a core feature of high quality 
primary care. General practice needs to develop systems to support integrating new 
innovations into patient care and to support patients to self-manage. Asymptomatic 
patients could be provided with clear instructions and supported to reduce glucocorticoid 
dose and to monitor for potential side effects and complications. Many long term diseases 
(for example asthma and diabetes) are monitored by a wider multidisciplinary team 
including practice nurses using standard structured assessments and associated input 
from doctors when needed. This approach could be implemented for intermittent follow 
up and monitoring of PMR patients to ensure continuity and to achieve a standard of best 
practice. 
The cross-sectional survey and semi-structured interviews highlighted the lack of 
consistency in referral pathways and the problems GPs face when trying to refer to 
appropriate specialist care.  One recommendation to improve care for patients with GCA 
would be the introduction of a nationwide standardised fast-track pathway for patients 
with suspected GCA. [Patil et al 2015] Patients would be able to access appropriate 
diagnostic tests (e.g. ultrasound, temporal artery biopsy) and have improved confidence 
in the accuracy of their diagnosis. Key windows of opportunity exist for patients with GCA. 
The accuracy of temporal artery biopsy reduces with increased duration of glucocorticoid 
treatment making prompt assessment important. Fast track pathways have already been 
introduced in some parts of the country (e.g. Southend, Bristol). Lessons in introducing 
fast track pathways can be learnt from other important areas, such as the two week wait 
referrals currently used to improve cancer care. One key feature that is important to 
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consider is the sensitivity and specificity of symptoms triggering referral. More work is 
needed in this area, as the predictive value of many GCA symptoms is currently unknown. 
Future research developing a risk prediction score (such as the Wells score currently used 
to predict the likelihood of deep vein thrombosis and pulmonary embolism) would be 
beneficial to primary care. 
 
8.5 Conclusion 
PMR and GCA remain challenging disorders and whilst medical technologies have 
progressed and can contribute to more effective processes of exclusion of mimicking 
disorders, the diagnosis of PMR and GCA still relies largely on the clinical expertise of the 
diagnosing physician. For the majority of patients initial identification and long term 
management of PMR and GCA will be undertaken by their GP. Whilst this thesis 
contributes to the research evidence, a concerted focus of further research in this setting 
is needed in order to improve diagnosis and outcomes for patients. 
 
“Polymyalgia rheumatica remains an enigma, one and one quarter centuries after 
its first recognisable description in a medical publication It is now known that it is 
more common in women than in men; there is a dramatic response to 
corticosteroids and there is clear evidence of synovitis, bursitis and tendinitis in the 
proximal limb girdles. Apart from these few additional facts, almost nothing has 
been added to the astute clinical observations about the disease by Bruce in 1888.”  
[Rooney 2014 p225]
 244 
 
0 
References 
 
POLYMYALGIA rheumatica. 1957. British medical journal, 2(5059), pp. 1483-1484. 
ALDRIDGE, A., LEVINE, K., 2001. Survey the social world. University press Buckingham. 
ARMSTRONG D., GOSLING A., WEINMAN J., MARTEAU T, 1997.The Place of Inter-Rater 
Reliability in Qualitative Research: An Empirical Study. Sociology 31 (3), pp. 597-606 
ANDREWS, F.M., 1965. Polymyalgia rheumatica: a biopsy and follow-up study. Annals of 
the Rheumatic Diseases, 24(5), pp. 432-438. 
ARNOLD, M.H., CORRIGALL, V.M., PITZALIS, C. and PANAYI, G.S., 1993. The sensitivity and 
specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia 
rheumatica/giant cell arteritis. Clinical and experimental rheumatology, 11(6), pp. 629-
634. 
BAHLAS, S., RAMOS-REMUS, C. and DAVIS, P., 2000. Utilisation and costs of investigations, 
and accuracy of diagnosis of polymyalgia rheumatica by family physicians. Clinical 
rheumatology, 19(4), pp. 278-280. 
BARBER, H.S., 1957. Myalgic syndrome with constitutional effects; polymyalgia 
rheumatica. Annals of the Rheumatic Diseases, 16(2), pp. 230-237. 
BARCLAY, S., TODD, C., FINLAY, I., GRANDE, G. and WYATT, P., 2002. Not another 
questionnaire! Maximizing the response rate, predicting non-response and assessing non-
response bias in postal questionnaire studies of GPs. Family practice, 19(1), pp. 105-111. 
BARNETT, K., MERCER, S.W., NORBURY, M., WATT, G., WYKE, S. and GUTHRIE, B., 2012. 
Epidemiology of multimorbidity and implications for health care, research, and medical 
education: a cross-sectional study. Lancet (London, England), 380(9836), pp. 37-43. 
BARRACLOUGH, K., LIDDELL, W.G., DU TOIT, J., FOY, C., DASGUPTA, B., THOMAS, M. and 
HAMILTON, W., 2008. Polymyalgia rheumatica in primary care: a cohort study of the 
diagnostic criteria and outcome. Family practice, 25(5), pp. 328-333. 
BARRACLOUGH, K., MALLEN, C.D., HELLIWELL, T., HIDER, S.L. and DASGUPTA, B., 2012. 
Diagnosis and management of giant cell arteritis. The British journal of general practice : 
the journal of the Royal College of General Practitioners,62(599), pp. 329-330. 
BAZELY, P., 2014. Qualitative data analysis Practical strategies, Sage. 2014. 
 
 245 
 
0 
BINARD, A., LEFEBVRE, B., DE BANDT, M., BERTHELOT, J.M., SARAUX, A. and CLUB 
"RHUMATISMES ET INFLAMMATION", 2009. Validity of the polymyalgia rheumatica 
activity score in primary care practice. Annals of the Rheumatic Diseases, 68(4), pp. 541-
545. 
BIRD, H.A., ESSELINCKX, W., DIXON, A.S., MOWAT, A.G. and WOOD, P.H., 1979. An 
evaluation of criteria for polymyalgia rheumatica. Annals of the Rheumatic 
Diseases, 38(5), pp. 434-439. 
BIRD, H.A., LEEB, B.F., MONTECUCCO, C.M., MISIUNIENE, N., NESHER, G., PAI, S., PEASE, 
C., ROVENSKY, J. and ROZMAN, B., 2005. A comparison of the sensitivity of diagnostic 
criteria for polymyalgia rheumatica. Annals of the Rheumatic Diseases, 64(4), pp. 626-9. 
BLOCK, E., ERSKINE, L., 2012. Interviewing by Telephone: Specific Considerations, 
Opportunities, and Challenges. International Journal of Qualitative Methods, 11(4), pp. 
428-445 
BOARDMAN, H.F., THOMAS, E., MILLSON, D.S. and CROFT, P.R., 2005. One-year follow-up 
of headache in an adult general population. Headache, 45(4), pp. 337-345. 
BOES, C.J., 2007. Bayard Horton's clinicopathological description of giant cell (temporal) 
arteritis. Cephalalgia : an international journal of headache, 27(1), pp. 68-75. 
BOHAN, A., 1988. History and classification of polymyositis and dermatomyositis. Clinics 
in dermatology, 6(2), pp. 3-8. 
BOIARDI, L., SALVARANI, C., MACCHIONI, P., CASADEI MALDINI, M., MANCINI, R., 
BELTRANDI, E. and PORTIOLI, I., 1996. CD8 lymphocyte subsets in active polymyalgia 
rheumatica: comparison with elderly-onset and adult rheumatoid arthritis and influence 
of prednisone therapy. British journal of rheumatology, 35(7), pp. 642-648. 
BONEVSKI, B., MAGIN, P., HORTON, G., FOSTER, M. and GIRGIS, A., 2011. Response rates 
in GP surveys - trialling two recruitment strategies. Australian Family Physician, 40(6), pp. 
427-430. 
BOYLE, A.C. and BEATTY, D.C., 1961. Polymyalgia Rheumatica. Proceedings of the Royal 
Society of Medicine, 54(8), pp. 681-684. 
BRADBURN, N.M., RIPS, L.J. and SHEVELL, S.K., 1987. Answering autobiographical 
questions: the impact of memory and inference on surveys. Science (New York, 
N.Y.), 236(4798), pp. 157-161. 
BRAUN, V. and CLARKE, V., 2006. Using thematic analysis in psychology. Qualitative 
Research in Psychology, 3(2), pp. 77-101. 
BREALEY, S.D., ATWELL, C., BRYAN, S., COULTON, S., COX, H., CROSS, B., FYLAN, F., 
GARRATT, A., GILBERT, F.J., GILLAN, M.G., HENDRY, M., HOOD, K., HOUSTON, H., KING, D., 
MORTON, V., ORCHARD, J., ROBLING, M., RUSSELL, I.T., TORGERSON, D., WADSWORTH, V. 
 246 
 
0 
and WILKINSON, C., 2007. Improving response rates using a monetary incentive for 
patient completion of questionnaires: an observational study. BMC medical research 
methodology, 7, pp. 12. 
BREUER, G.S., NESHER, R. and NESHER, G., 2008. Negative temporal artery biopsies: 
eventual diagnoses and features of patients with biopsy-negative giant cell arteritis 
compared to patients without arteritis. Clinical & Experimental Rheumatology, 26(6), pp. 
1103-6. 
BRUCE, W., 1888. Senile Rheumatic Gout. British medical journal, 2(1450), pp. 811-813. 
BUCKINGHAM, B., SAUNDERS, P., 2009. The survey methods workbook. Polity press, 
Cambridge 
BUTTGEREIT, F., SPIES, C.M. and BIJLSMA, J.W., 2015. Novel glucocorticoids: where are we 
now and where do we want to go? Clinical and experimental rheumatology, 33(4 Suppl 
92), pp. S29-33. 
CANTINI, F., NICCOLI, L., NANNINI, C., PADULA, A., OLIVIERI, I., BOIARDI, L. and 
SALVARANI, C., 2005. Inflammatory changes of hip synovial structures in polymyalgia 
rheumatica. Clinical and experimental rheumatology, 23(4), pp. 462-468. 
CANTINI, F., SALVARANI, C., OLIVIERI, I., BAROZZI, L., MACCHIONI, L., NICCOLI, L., PADULA, 
A., PAVLICA, P. and BOIARDI, L., 1999. Remitting seronegative symmetrical synovitis with 
pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance 
imaging study. Annals of the Rheumatic Diseases, 58(4), pp. 230-236. 
CANTINI, F., SALVARANI, C., OLIVIERI, I., NICCOLI, L., MACCHIONI, P., BOIARDI, L., 
MASTROROSATO, M., CIANCIO, G., PADULA, A., BOZZA, A. and RUBINI, F., 2001. Inflamed 
shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation 
rate. Arthritis and Rheumatism, 44(5), pp. 1155-1159. 
CANTINI, F., SALVARANI, C., OLIVIERI, I., NICCOLI, L., PADULA, A., MACCHIONI, L., BOIARDI, 
L., CIANCIO, G., MASTROROSATO, M., RUBINI, F., BOZZA, A. and ZANFRANCESCHI, G., 
2001. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-
control study. The Journal of rheumatology, 28(5), pp. 1049-1055. 
CAPORALI, R., MONTECUCCO, C., EPIS, O., BOBBIO-PALLAVICINI, F., MAIO, T. and 
CIMMINO, M.A., 2001. Presenting features of polymyalgia rheumatica (PMR) and 
rheumatoid arthritis with PMR-like onset: a prospective study. Annals of the Rheumatic 
Diseases, 60(11), pp. 1021-1024. 
CARR, L.T., 1994. The strengths and weaknesses of quantitative and qualitative research: 
what method for nursing? Journal of advanced nursing, 20(4), pp. 716-721. 
CATS, H.A., TERVAERT, J.W., VAN WIJK, R., LIMBURG, P.C. and KALLENBERG, C.G., 1993. 
Anti-neutrophil cytoplasmic antibodies in giant cell arteritis and polymyalgia 
rheumatica. Advances in Experimental Medicine and Biology, 336, pp. 363-366. 
 247 
 
0 
CECCATO, F., ROVERANO, S., BARRIONUEVO, A., RILLO, O. and PAIRA, S., 2006. The role of 
anticyclic citrullinated peptide antibodies in the differential diagnosis of elderly-onset 
rheumatoid arthritis and polymyalgia rheumatica. Clinical rheumatology, 25(6), pp. 854-
857. 
CHAKRAVARTY, K., POUNTAIN, G., MERRY, P., BYRON, M., HAZLEMAN, B. and SCOTT, D.G., 
1995. A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant 
cell arteritis. The Journal of rheumatology, 22(9), pp. 1694-1697. 
CHANTLER, I.W., DAVIE, M.W., EVANS, S.F. and REES, J.S., 2003. Oral corticosteroid 
prescribing in women over 50, use of fracture prevention therapy, and bone densitometry 
service. Annals of the Rheumatic Diseases, 62(4), pp. 350-2. 
CHEW-GRAHAM, C.A., MAY, C.R. and PERRY, M.S., 2002. Qualitative research and the 
problem of judgement: lessons from interviewing fellow professionals. Family 
practice, 19(3), pp. 285-289. 
CHOI, B.C. and PAK, A.W., 2005. A catalog of biases in questionnaires. Preventing chronic 
disease, 2(1), pp. A13. 
CHUANG, T.Y., HUNDER, G.G., ILSTRUP, D.M. and KURLAND, L.T., 1982. Polymyalgia 
rheumatica: a 10-year epidemiologic and clinical study. Annals of Internal Medicine, 97(5), 
pp. 672-80. 
CIMMINO, M.A., 1997. Genetic and environmental factors in polymyalgia 
rheumatica. Annals of the Rheumatic Diseases, 56(10), pp. 576-577. 
CIMMINO, M.A. and ZACCARIA, A., 2000. Epidemiology of polymyalgia 
rheumatica. Clinical and experimental rheumatology, 18(4 Suppl 20), pp. S9-11. 
CLARSON, L.E., NICHOLL, B.I., BISHOP, A., EDWARDS, J.J., DANIEL, R. and MALLEN, C.D., 
2013. Monitoring Osteoarthritis: A Cross-sectional Survey in General Practice. Clinical 
medicine insights.Arthritis and musculoskeletal disorders,6, pp. 85-91. 
COAR, L. and SIM, J., 2006. Interviewing one's peers: methodological issues in a study of 
health professionals. Scandinavian journal of primary health care, 24(4), pp. 251-256. 
COOMES, E.N., ELLIS, R.M. and KAY, A.G., 1976. A prospective study of 102 patients with 
the polymyalgia rheumatica syndrome. Rheumatology and rehabilitation, 15(4), pp. 270-
279. 
CORRIGALL, V.M., DOLAN, A.L. and PANAYI, G.S., 1995. The value of percentage of CD8+ T 
lymphocyte levels in distinguishing polymyalgia rheumatica from early rheumatoid 
arthritis. The Journal of rheumatology, 22(6), pp. 1020-1024. 
CREAVIN, S.T., CREAVIN, A.L. and MALLEN, C.D., 2011. Do GPs respond to postal 
questionnaire surveys? A comprehensive review of primary care literature. Family 
practice, 28(4), pp. 461-467. 
 248 
 
0 
CUTOLO, M., MONTECUCCO, C.M., CAVAGNA, L., CAPORALI, R., CAPELLINO, S., 
MONTAGNA, P., FAZZUOLI, L., VILLAGGIO, B., SERIOLO, B. and SULLI, A., 2006. Serum 
cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset 
rheumatoid arthritis. Annals of the Rheumatic Diseases, 65(11), pp. 1438-1443. 
DASGUPTA, B., BORG, F.A., HASSAN, N., BARRACLOUGH, K., BOURKE, B., FULCHER, J., 
HOLLYWOOD, J., HUTCHINGS, A., KYLE, V., NOTT, J., POWER, M., SAMANTA, A. and BSR, 
B.S.R.B.H.P.R.,GROUP, 2010. BSR and BHPR guidelines for the management of 
polymyalgia rheumatica. Rheumatology, 49(1), pp. 186-90. 
DASGUPTA, B., BORG, F.A., HASSAN, N., ALEXANDER, L., BARRACLOUGH, K., BOURKE, B., 
FULCHER, J., HOLLYWOOD, J., HUTCHINGS, A., JAMES, P., KYLE, V., NOTT, J., POWER, M., 
SAMANTA, A. and BSR AND BHPR STANDARDS, GUIDELINES AND AUDIT WORKING 
GROUP, 2010. BSR and BHPR guidelines for the management of giant cell arteritis. 
Rheumatology (Oxford, England), 49(8), pp. 1594-1597. 
DASGUPTA, B., CIMMINO, M.A., MARADIT-KREMERS, H., SCHMIDT, W.A., SCHIRMER, M., 
SALVARANI, C., BACHTA, A., DEJACO, C., DUFTNER, C., JENSEN, H.S., DUHAUT, P., POOR, 
G., KAPOSI, N.P., MANDL, P., BALINT, P.V., SCHMIDT, Z., IAGNOCCO, A., NANNINI, C., 
CANTINI, F., MACCHIONI, P., PIPITONE, N., AMO, M.D., ESPIGOL-FRIGOLE, G., CID, M.C., 
MARTINEZ-TABOADA, V.M., NORDBORG, E., DIRESKENELI, H., AYDIN, S.Z., AHMED, K., 
HAZLEMAN, B., SILVERMAN, B., PEASE, C., WAKEFIELD, R.J., LUQMANI, R., ABRIL, A., 
MICHET, C.J., MARCUS, R., GONTER, N.J., MAZ, M., CARTER, R.E., CROWSON, C.S. and 
MATTESON, E.L., 2012. 2012 provisional classification criteria for polymyalgia rheumatica: 
a European League Against Rheumatism/American College of Rheumatology collaborative 
initiative. Annals of the Rheumatic Diseases, 71(4), pp. 484-92. 
DASGUPTA, B., DOLAN, A.L., PANAYI, G.S. and FERNANDES, L., 1998. An initially double-
blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in 
the treatment of polymyalgia rheumatica. British journal of rheumatology, 37(2), pp. 189-
95. 
DASGUPTA, B. and PANAYI, G.S., 1990. Interleukin-6 in serum of patients with polymyalgia 
rheumatica and giant cell arteritis. British journal of rheumatology, 29(6), pp. 456-458. 
(GCA) 
DASGUPTA, B., SALVARANI, C., SCHIRMER, M., CROWSON, C.S., MARADIT-KREMERS, H., 
HUTCHINGS, A., MATTESON, E.L. and MEMBERS, P.M.R.,PMR, 2008. Developing 
classification criteria for polymyalgia rheumatica: comparison of views from an expert 
panel and wider survey. Journal of Rheumatology, 35(2), pp. 270-7. 
DEAL, C.L., MEENAN, R.F., GOLDENBERG, D.L., ANDERSON, J.J., SACK, B., PASTAN, R.S. and 
COHEN, A.S., 1985. The clinical features of elderly-onset rheumatoid arthritis. A 
comparison with younger-onset disease of similar duration.Arthritis and 
Rheumatism, 28(9), pp. 987-994. 
 249 
 
0 
DEJACO, C., SINGH, Y.P., PEREL, P., HUTCHINGS, A., CAMELLINO, D., MACKIE, S., ABRIL, A., 
BACHTA, A., BALINT, P., BARRACLOUGH, K., BIANCONI, L., BUTTGEREIT, F., CARSONS, S., 
CHING, D., CID, M., CIMMINO, M., DIAMANTOPOULOS, A., DOCKEN, W., DUFTNER, C., 
FASHANU, B., GILBERT, K., HILDRETH, P., HOLLYWOOD, J., JAYNE, D., LIMA, M., MAHARAJ, 
A., MALLEN, C., MARTINEZ-TABOADA, V., MAZ, M., MERRY, S., MILLER, J., MORI, S., NEILL, 
L., NORDBORG, E., NOTT, J., PADBURY, H., PEASE, C., SALVARANI, C., SCHIRMER, M., 
SCHMIDT, W., SPIERA, R., TRONNIER, D., WAGNER, A., WHITLOCK, M., MATTESON, E.L. 
and DASGUPTA, B., 2015. 2015 Recommendations for the management of polymyalgia 
rheumatica: a European League Against Rheumatism/American College of Rheumatology 
collaborative initiative. Annals of the Rheumatic Diseases, 74(10), pp. 1799-1807. 
DIAMANTOPOULOS, A.P., HAUGEBERG, G., LINDLAND, A. and MYKLEBUST, G., 2015. The 
fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces 
permanent visual impairment: towards a more effective strategy to improve clinical 
outcome in giant cell arteritis? Rheumatology (Oxford, England),. 
DILLMAN, D. A., 2007. Mail and internet surveys - the tailored design method, 2nd ed. 
New York. Wiley 
DORAN, M.F., CROWSON, C.S., O'FALLON, W.M., HUNDER, G.G. and GABRIEL, S.E., 2002. 
Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted 
County, Minnesota, USA. The Journal of rheumatology, 29(8), pp. 1694-1697. 
ECCLES, M., BAMFORD, C., STEEN, N. and RUSSELL, I., 1994. Case mix and content of 
trainee consultations: findings from the north of England study of standards and 
performance in general practice. The British journal of general practice : the journal of the 
Royal College of General Practitioners, 44(387), pp. 437-440. 
EDWARDS, P., ROBERTS, I., CLARKE, M., DIGUISEPPI, C., PRATAP, S., WENTZ, R. and KWAN, 
I., 2002. Increasing response rates to postal questionnaires: systematic review. BMJ 
(Clinical research ed.), 324(7347), pp. 1183. 
EDWARDS, P.J., ROBERTS, I., CLARKE, M.J., DIGUISEPPI, C., WENTZ, R., KWAN, I., COOPER, 
R., FELIX, L.M. and PRATAP, S., 2009. Methods to increase response to postal and 
electronic questionnaires. The Cochrane database of systematic reviews, (3):MR000008. 
doi(3), pp. MR000008. 
ELLING, H., ELLING, P. and OLSSON, A., 1989. CD8+ lymphocyte subset in polymyalgia 
rheumatica and arteritis temporalis. Inverse relationship between the acute hepatic 
phase reactants and the CD8+ T-cell subset. Clinical & Experimental Rheumatology, 7(6), 
pp. 627-30. 
ELLIS, M.E. and RALSTON, S., 1983. The ESR in the diagnosis and management of the 
polymyalgia rheumatica/giant cell arteritis syndrome. Annals of the Rheumatic 
Diseases, 42(2), pp. 168-170. 
ELO, S. and KYNGAS, H., 2008. The qualitative content analysis process. Journal of 
advanced nursing, 62(1), pp. 107-115. 
 250 
 
0 
EZEONYEJI, A.N., BORG, F.A. and DASGUPTA, B., 2011. Delays in recognition and 
management of giant cell arteritis: results from a retrospective audit. Clinical 
rheumatology, 30(2), pp. 259-262. 
FALSETTI, P., ACCIAI, C., VOLPE, A. and LENZI, L., 2011. Ultrasonography in early 
assessment of elderly patients with polymyalgic symptoms: a role in predicting diagnostic 
outcome? Scandinavian journal of rheumatology, 40(1), pp. 57-63. 
FALSETTI, P., FREDIANI, B., STORRI, L., BISOGNO, S., BALDI, F., CAMPANELLA, V., ACCIAI, 
C., FILIPPOU, G., CHELLINI, F. and MARCOLONGO, R., 2002. Evidence for synovitis in active 
polymyalgia rheumatica: Sonographic study in a large series of patients. Journal of 
Rheumatology, 29(1), pp. 123-130. 
FAUCHALD, P., RYGVOLD, O. and OYSTESE, B., 1972. Temporal arteritis and polymyalgia 
rheumatica. Clinical and biopsy findings. Annals of Internal Medicine, 77(6), pp. 845-852. 
FREDIANI, B., FALSETTI, P., STORRI, L., BISOGNO, S., BALDI, F., CAMPANELLA, V., ACCIAI, 
C., FILIPPOU, G., CHELLINI, F., COSENTINO, R. and MARCOLONGO, R., 2002. Evidence for 
synovitis in active polymyalgia rheumatica: sonographic study in a large series of 
patients. The Journal of rheumatology, 29(1), pp. 123-130. 
FRIES, J.F., HOCHBERG, M.C., MEDSGER, T.A.,JR, HUNDER, G.G. and BOMBARDIER, C., 
1994. Criteria for rheumatic disease. Different types and different functions. The 
American College of Rheumatology Diagnostic and Therapeutic Criteria 
Committee. Arthritis and Rheumatism, 37(4), pp. 454-462. 
GAMEZ-NAVA, J.I., GONZALEZ-LOPEZ, L., DAVIS, P. and SUAREZ-ALMAZOR, M.E., 1998. 
Referral and diagnosis of common rheumatic diseases by primary care physicians. British 
journal of rheumatology, 37(11), pp. 1215-9. 
GARCIA-UNZUETA, M.T., MARTINEZ-TABOADA, V.M., AMADO-SENARIS, J.A. and 
RODRIGUEZ-VALVERDE, V., 2006. Plasma adrenomedullin levels in patients with 
polymyalgia rheumatica and giant cell arteritis. Clinical and experimental 
rheumatology, 24(2 Suppl 41), pp. S6-9. 
GLIDEWELL, L., THOMAS, R., MACLENNAN, G., BONETTI, D., JOHNSTON, M., ECCLES, M.P., 
EDLIN, R., PITTS, N.B., CLARKSON, J., STEEN, N. and GRIMSHAW, J.M., 2012. Do incentives, 
reminders or reduced burden improve healthcare professional response rates in postal 
questionnaires? two randomised controlled trials. BMC health services research, 12, pp. 
250-6963-12-250. 
GOFF, I., WISE, E.M., COADY, D. and WALKER, D., 2014. Musculoskeletal training: are GP 
trainees exposed to the right case mix for independent practice? Clinical rheumatology, . 
GONZALEZ-GAY, M.A., 2005. The diagnosis and management of patients with giant cell 
arteritis. The Journal of rheumatology, 32(7), pp. 1186-1188. 
 251 
 
0 
GONZALEZ-GAY, M.A., GARCIA-PORRUA, C., RIVAS, M.J., RODRIGUEZ-LEDO, P. and 
LLORCA, J., 2001. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: 
trend over an 18 year period. Annals of the Rheumatic Diseases, 60(4), pp. 367-371. 
GONZALEZ-GAY, M.A., GARCIA-PORRUA, C., VAZQUEZ-CARUNCHO, M., DABABNEH, A., 
HAJEER, A. and OLLIER, W.E.R., 1999. The spectrum of polymyalgia rheumatica in 
Northwestern Spain: Incidence and analysis of variables associated with relapse in a 10 
year study. Journal of Rheumatology, 26(6), pp. 1326-1332.  
GONZALEZ-GAY, M.A., GARCIA-PORRUA, C. and VAZQUEZ-CARUNCHO, M., 1998. 
Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different 
subset but differs from isolated polymyalgia rheumatica. The Journal of 
rheumatology, 25(9), pp. 1750-1755. 
GONZALEZ-GAY, M.A., RODRIGUEZ-VALVERDE, V., BLANCO, R., FERNANDEZ-SUEIRO, J.L., 
ARMONA, J., FIGUEROA, M. and MARTINEZ-TABOADA, V.M., 1997. Polymyalgia 
rheumatica without significantly increased erythrocyte sedimentation rate. A more 
benign syndrome. Archives of Internal Medicine, 157(3), pp. 317-320. 
GORDON, I., 1960. Polymyalgia rheumatica. A clinical study of 21 cases. The Quarterly 
journal of medicine, 29, pp. 473-488. 
GRAN, J.T. and MYKLEBUST, G., 2000. The incidence and clinical characteristics of 
peripheral arthritis in polymyalgia rheumatica and temporal arteritis: a prospective study 
of 231 cases. Rheumatology (Oxford, England), 39(3), pp. 283-287. 
GRAN, J.T. and MYKLEBUST, G., 1997. The incidence of polymyalgia rheumatica and 
temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-
94. Journal of Rheumatology, 24(9), pp. 1739-43. 
GRANEHEIM, U.H. and LUNDMAN, B., 2004. Qualitative content analysis in nursing 
research: concepts, procedures and measures to achieve trustworthiness. Nurse 
education today, 24(2), pp. 105-112. 
GRAVA-GUBINS, I. and SCOTT, S., 2008. Effects of various methodologic strategies: survey 
response rates among Canadian physicians and physicians-in-training. Canadian family 
physician Medecin de famille canadien, 54(10), pp. 1424-1430. 
GREENHALGH, T., 1997. How to read a paper. Getting your bearings (deciding what the 
paper is about). BMJ (Clinical research ed.), 315(7102), pp. 243-246. 
GREGOIRE, G., DERDERIAN, F. and LE LORIER, J., 1995. Selecting the language of the 
publications included in a meta-analysis: is there a Tower of Babel bias? Journal of clinical 
epidemiology, 48(1), pp. 159-163. 
GREGSON, S., ZHUWAU, T., NDLOVU, J. and NYAMUKAPA, C.A., 2002. Methods to reduce 
social desirability bias in sex surveys in low-development settings: experience in 
Zimbabwe. Sexually transmitted diseases, 29(10), pp. 568-575. 
 252 
 
0 
GUEST, G., BUNCE, A., JOHNSON, L., 2006. How Many Interviews Are Enough? An 
Experiment with Data Saturation and Variability. Field Methods, 18(1), pp. 59-82 
 
HACHULLA, E., SAILE, R., PARRA, H.J., HATRON, P.Y., GOSSET, D., FRUCHART, J.C. and 
DEVULDER, B., 1991. Serum amyloid A concentrations in giant-cell arteritis and 
polymyalgia rheumatica: a useful test in the management of the disease. Clinical and 
experimental rheumatology, 9(2), pp. 157-163. 
HANCOCK, A.T., MALLEN, C.D., MULLER, S., BELCHER, J., RODDY, E., HELLIWELL, T. and 
HIDER, S.L., 2014. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ : 
Canadian Medical Association journal = journal de l'Association medicale canadienne,. 
HEIMAN, G. W., (2002). Research Methods in Psychology. 3rd Ed. Boston & New York. 
Houghton Mifflin Company 
HELFGOTT, S.M. and KIEVAL, R.I., 1996. Polymyalgia rheumatica in patients with a normal 
erythrocyte sedimentation rate. Arthritis and Rheumatism, 39(2), pp. 304-307. 
HELLIWELL, T., BROUWER, E., PEASE, C.T., HUGHES, R., HILL, C.L., NEILL, L.M., HALLS, S., 
SIMON, L.S., MALLEN, C.D., BOERS, M., KIRWAN, J.R. and MACKIE, S.L., 2016. 
Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from 
the OMERACT 12 Polymyalgia Rheumatica Working Group. The Journal of 
rheumatology, 43(1), pp. 182-186. 
HELLIWELL, T., HIDER, S.L., BARRACLOUGH, K., DASGUPTA, B. and MALLEN, C.D., 2012. 
Diagnosis and management of polymyalgia rheumatica. The British journal of general 
practice : the journal of the Royal College of General Practitioners, 62(598), pp. 275-276. 
HELLIWELL, T., HIDER, S.L. and MALLEN, C.D., 2013. Polymyalgia rheumatica: diagnosis, 
prescribing, and monitoring in general practice. The British journal of general practice : 
the journal of the Royal College of General Practitioners,63(610), pp. 361-366. 
HEWLETT, S., COCKSHOTT, Z., BYRON, M., KITCHEN, K., TIPLER, S., POPE, D. and HEHIR, 
M., 2005. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, 
uncontrollable, ignored. Arthritis and Rheumatism, 53(5), pp. 697-702. 
HOES, J.N., JACOBS, J.W., VERSTAPPEN, S.M., BIJLSMA, J.W. and VAN DER HEIJDEN, G.J., 
2009. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory 
diseases: a meta-analysis. Annals of the Rheumatic Diseases,68(12), pp. 1833-1838. 
HOHWU, L., LYSHOL, H., GISSLER, M., JONSSON, S.H., PETZOLD, M. and OBEL, C., 2013. 
Web-based versus traditional paper questionnaires: a mixed-mode survey with a Nordic 
perspective. Journal of medical Internet research, 15(8), pp. e173. 
HOSIE, G.A., 2000. Teaching rheumatology in primary care. Annals of the Rheumatic 
Diseases, 59(7), pp. 500-503. 
 253 
 
0 
HOUSSIAU, F.A., DEVOGELAER, J.P., VAN DAMME, J., DE DEUXCHAISNES, C.N. and VAN 
SNICK, J., 1988. Interleukin-6 in synovial fluid and serum of patients with rheumatoid 
arthritis and other inflammatory arthritides. Arthritis and Rheumatism, 31(6), pp. 784-
788. 
HOWITT D, CRAMER D.(2008). Introduction to Research Methods in Psychology. 2nd 
ed.Pearson Education 
HUANG, C.Y., LIAO, H.Y. and CHANG, S.H., 1998. Social desirability and the clinical self-
report inventory: methodological reconsideration. Journal of clinical psychology, 54(4), 
pp. 517-528. 
HUMMERS-PRADIER, E., SCHEIDT-NAVE, C., MARTIN, H., HEINEMANN, S., KOCHEN, M.M. 
and HIMMEL, W., 2008. Simply no time? Barriers to GPs' participation in primary health 
care research. Family practice, 25(2), pp. 105-112. 
HUNDER, G.G., 2006. The early history of giant cell arteritis and polymyalgia rheumatica: 
first descriptions to 1970. Mayo Clinic proceedings, 81(8), pp. 1071-1083. 
HUNDER, G.G., BLOCH, D.A., MICHEL, B.A., STEVENS, M.B., AREND, W.P., CALABRESE, L.H., 
EDWORTHY, S.M., FAUCI, A.S., LEAVITT, R.Y. and LIE, J.T., 1990. The American College of 
Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis and 
Rheumatism, 33(8), pp. 1122-1128. 
JENKINS, P., SCHEIM, C., WANG, J.T., REED, R. and GREEN, A., 2004. Assessment of 
coverage rates and bias using double sampling methodology. Journal of clinical 
epidemiology, 57(2), pp. 123-130.  
JONES, J.G. and HAZLEMAN, B.L., 1981. Prognosis and management of polymyalgia 
rheumatica. Annals of the Rheumatic Diseases, 40(1), pp. 1-5. 
JORDAN, K.P., KADAM, U.T., HAYWARD, R., PORCHERET, M., YOUNG, C. and CROFT, P., 
2010. Annual consultation prevalence of regional musculoskeletal problems in primary 
care: an observational study. BMC musculoskeletal disorders,11, pp. 144-2474-11-144. 
JORDAN, K. 2010. Consultations for selected diagnoses and regional problems. 
Musculoskeletal matters. Bulletin 2. 
JUNI, P., HOLENSTEIN, F., STERNE, J., BARTLETT, C. and EGGER, M., 2002. Direction and 
impact of language bias in meta-analyses of controlled trials: empirical 
study. International journal of epidemiology, 31(1), pp. 115-123. 
KANER, E.F., HAIGHTON, C.A. and MCAVOY, B.R., 1998. 'So much post, so busy with 
practice--so, no time!': a telephone survey of general practitioners' reasons for not 
participating in postal questionnaire surveys. The British journal of general practice : the 
journal of the Royal College of General Practitioners, 48(428), pp. 1067-1069. 
 254 
 
0 
KANIS, J.A., COMPSTON, J., COOPER, C., HARVEY, N.C., JOHANSSON, H., ODEN, A. and 
MCCLOSKEY, E.V., 2015. SIGN Guidelines for Scotland: BMD Versus FRAX Versus 
QFracture. Calcified tissue international, . 
KARASSA, F.B., MATSAGAS, M.I., SCHMIDT, W.A. and IOANNIDIS, J.P., 2005. Meta-
analysis: test performance of ultrasonography for giant-cell arteritis. Annals of Internal 
Medicine, 142(5), pp. 359-369. 
KASSIMOS, D., KIRWAN, J.R., KYLE, V., HAZLEMAN, B. and DIEPPE, P., 1995. Cytidine 
deaminase may be a useful marker in differentiating elderly onset rheumatoid arthritis 
from polymyalgia rheumatica/giant cell arteritis. Clinical and experimental 
rheumatology, 13(5), pp. 641-644. 
KIMURA, M., TOKUDA, Y., OSHIAWA, H., YOSHIDA, K., UTSUNOMIYA, M., KOBAYASHI, T., 
DESHPANDE, G.A., MATSUI, K. and KISHIMOTO, M., 2012. Clinical characteristics of 
patients with remitting seronegative symmetrical synovitis with pitting edema compared 
to patients with pure polymyalgia rheumatica. The Journal of rheumatology, 39(1), pp. 
148-153. 
KREMERS, H.M., REINALDA, M.S., CROWSON, C.S., ZINSMEISTER, A.R., HUNDER, G.G. and 
GABRIEL, S.E., 2005. Direct medical costs of polymyalgia rheumatica. Arthritis & 
Rheumatism, 53(4), pp. 578-84. 
KREMERS, H.M., REINALDA, M.S., CROWSON, C.S., ZINSMEISTER, A.R., HUNDER, G.G. and 
GABRIEL, S.E., 2005. Use of physician services in a population-based cohort of patients 
with polymyalgia rheumatica over the course of their disease. Arthritis Care and 
Research, 53(3), pp. 395-403. 
KRIPPENDORF, K., 1989. Content analysis. In: BARNOUW E., GERBNER G., W., SCHRAMM, 
T. L., Worth, & L. Gross (Eds.), International encyclopedia of communication 1, pp. 403-
407. New York, NY: Oxford University Press. 
KYLE, V., SILVERMAN, B. and SILMAN, A., 1985. Polymyalgia rheumatica/giant cell arteritis 
in a Cambridge general practice. British medical journal, 291(6492), pp. 385-387. 
LANGE, U., PIEGSA, M., TEICHMANN, J. and NEECK, G., 2000. Ultrasonography of the 
glenohumeral joints--a helpful instrument in differentiation in elderly onset rheumatoid 
arthritis and polymyalgia rheumatica. Rheumatology international, 19(5), pp. 185-189. 
LANGE, U., TEICHMANN, J., STRACKE, H., BRETZEL, R.G. and NEECK, G., 1998. Elderly onset 
rheumatoid arthritis and polymyalgia rheumatica: ultrasonographic study of the 
glenohumeral joints. Rheumatology international, 17(6), pp. 229-232. 
LAWRENCE, R.C., FELSON, D.T., HELMICK, C.G., ARNOLD, L.M., CHOI, H., DEYO, R.A., 
GABRIEL, S., HIRSCH, R., HOCHBERG, M.C., HUNDER, G.G., JORDAN, J.M., KATZ, J.N., 
KREMERS, H.M., WOLFE, F. and NATIONAL ARTHRITIS DATA WORKGROUP, 2008. 
Estimates of the prevalence of arthritis and other rheumatic conditions in the United 
States. Part II. Arthritis and Rheumatism, 58(1), pp. 26-35. 
 255 
 
0 
 
LEECE, P., BHANDARI, M., SPRAGUE, S., SWIONTKOWSKI, M.F., SCHEMITSCH, E.H., 
TORNETTA, P., DEVEREAUX, P.J. and GUYATT, G.H., 2004. Internet versus mailed 
questionnaires: a randomized comparison (2). Journal of medical Internet research, 6(3), 
pp. e30. 
LI, W.L., LO, Y., LEUNG, M.H., WONG, W.S. and MOK, M.Y., 2010. The clinical course of 
polymyalgia rheumatica in Chinese. Clinical rheumatology, 29(2), pp. 199-203. 
LITTLE, M.A., NAZAR, L. and FARRINGTON, K., 2004. Polymyalgia rheumatica preceding 
small-vessel vasculitis: changed spots or misdiagnosis? QJM : monthly journal of the 
Association of Physicians, 97(5), pp. 289-292. 
LOPEZ-HOYOS, M., RUIZ DE ALEGRIA, C., BLANCO, R., CRESPO, J., PENA, M., RODRIGUEZ-
VALVERDE, V. and MARTINEZ-TABOADA, V.M., 2004. Clinical utility of anti-CCP antibodies 
in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia 
rheumatica. Rheumatology (Oxford, England), 43(5), pp. 655-657. 
LUSK, C., DELCLOS, G.L., BURAU, K., DRAWHORN, D.D. and ADAY, L.A., 2007. Mail versus 
internet surveys: determinants of method of response preferences among health 
professionals. Evaluation & the health professions, 30(2), pp. 186-201. 
MACKIE, S., HELLIWELL, T., HUGHES, R., BROUWER, E., PEASE, C.T., MALLEN, C., BOERS, 
M. and KIRWAN, J.R., 2014. Core Outcome Domains and Potential Measurement 
Instruments in polymyalgia Rheumatica (PMR) Using Omeract Filter 2.0, ARTHRITIS & 
RHEUMATOLOGY 2014, WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 
pp. S1208-S1209. 
MACKIE, S.L. and PEASE, C.T., 2013. Diagnosis and management of giant cell arteritis and 
polymyalgia rheumatica: challenges, controversies and practical tips. Postgraduate 
medical journal, 89(1051), pp. 284-292. 
MAHR, A., SABA, M., KAMBOUCHNER, M., POLIVKA, M., BAUDRIMONT, M., BROCHERIOU, 
I., COSTE, J. and GUILLEVIN, L., 2006. Temporal artery biopsy for diagnosing giant cell 
arteritis: the longer, the better? Annals of the Rheumatic Diseases, 65(6), pp. 826-828. 
MALLEN, C., HELLIWELL, T., O’BRIEN, A., MACKIE S., 2014. Polymyalgia rheumatic.  ARUK 
reports on the Rheumatic Diseases, Series 7, Spring 2014. Hands On No 4 
MALLEN, C.D., DUNN, K.M., THOMAS, E. and PEAT, G., 2008. Thicker paper and larger font 
increased response and completeness in a postal survey. Journal of clinical 
epidemiology, 61(12), pp. 1296-1300. 
MALLEN, C.D., PEAT, G., THOMAS, E., DUNN, K.M. and CROFT, P.R., 2007. Prognostic 
factors for musculoskeletal pain in primary care: a systematic review. The British journal 
of general practice : the journal of the Royal College of General Practitioners, 57(541), pp. 
655-661. 
 256 
 
0 
MAZZANTINI, M., TORRE, C., MICCOLI, M., BAGGIANI, A., TALARICO, R., BOMBARDIERI, S. 
and DI MUNNO, O., 2012. Adverse events during longterm low-dose glucocorticoid 
treatment of polymyalgia rheumatica: a retrospective study.The Journal of 
rheumatology, 39(3), pp. 552-557. 
MCAVOY, B.R. and KANER, E.F., 1996. General practice postal surveys: a questionnaire too 
far? BMJ (Clinical research ed.), 313(7059), pp. 732-3; discussion 733-4. 
MCCARTHY, E.M., MACMULLAN, P.A., AL-MUDHAFFER, S., MADIGAN, A., DONNELLY, S., 
MCCARTHY, C.J., MOLLOY, E.S., KENNY, D. and MCCARTHY, G.M., 2013. Plasma fibrinogen 
is an accurate marker of disease activity in patients with polymyalgia 
rheumatica. Rheumatology, 52(3), pp. 465-71. 
MCCARTY, D.J., 1976. Calcium pyrophosphate dihydrate crystal deposition disease--
1975. Arthritis and Rheumatism, 19 Suppl 3, pp. 275-285. 
MCDOUGALL, F.A., KVAAL, K., MATTHEWS, F.E., PAYKEL, E., JONES, P.B., DEWEY, M.E., 
BRAYNE, C. and MEDICAL RESEARCH COUNCIL COGNITIVE FUNCTION AND AGEING 
STUDY, 2007. Prevalence of depression in older people in England and Wales: the MRC 
CFA Study. Psychological medicine, 37(12), pp. 1787-1795. 
MCDOUGALL, F.A., MATTHEWS, F.E., KVAAL, K., DEWEY, M.E. and BRAYNE, C., 2007. 
Prevalence and symptomatology of depression in older people living in institutions in 
England and Wales. Age and Ageing, 36(5), pp. 562-568. 
MCGAURAN, N., WIESELER, B., KREIS, J., SCHULER, Y.B., KOLSCH, H. and KAISER, T., 2010. 
Reporting bias in medical research - a narrative review. Trials, 11, pp. 37-6215-11-37. 
MICHET, C.J. and MATTESON, E.L., 2008. Polymyalgia rheumatica. BMJ (Clinical research 
ed.), 336(7647), pp. 765-769. 
MILLETT, E.R., QUINT, J.K., SMEETH, L., DANIEL, R.M. and THOMAS, S.L., 2013. Incidence 
of community-acquired lower respiratory tract infections and pneumonia among older 
adults in the United Kingdom: a population-based study.PloS one, 8(9), pp. e75131. 
MULLER, S., HIDER, S., HELLIWELL, T., BAILEY, J., BARRACLOUGH, K., COPE, L., DASGUPTA, 
B., FOSKETT, R., HUGHES, R., MAYSON, Z., PURCELL, C., RODDY, E., WATHALL, S., 
ZWIERSKA, I. and MALLEN, C.D., 2012. The epidemiology of polymyalgia rheumatica in 
primary care: a research protocol. BMC musculoskeletal disorders, 13, pp. 102-2474-13-
102. 
MULLER, S., HIDER, S.L., BELCHER, J., HELLIWELL, T. and MALLEN, C.D., 2013. Is cancer 
associated with polymyalgia rheumatica? A cohort study in the General Practice Research 
Database. Annals of the Rheumatic Diseases. 
 
 257 
 
0 
MULLER, S., WYNNE-JONES, G., DANIEL, R., CREAVIN, S.T., BISHOP, A. and MALLEN, C.D., 
2012. There is no association between a measure of clinical care and the response rate of 
GPs to postal surveys: a methodological study. The European journal of general 
practice, 18(3), pp. 154-158. 
MUTH, C., KIRCHNER, H., VAN DEN AKKER, M., SCHERER, M. and GLASZIOU, P.P., 2014. 
Current guidelines poorly address multimorbidity: pilot of the interaction matrix 
method. Journal of clinical epidemiology, 67(11), pp. 1242-1250. 
NAKASH, R.A., HUTTON, J.L., JORSTAD-STEIN, E.C., GATES, S. and LAMB, S.E., 2006. 
Maximising response to postal questionnaires--a systematic review of randomised trials in 
health research. BMC medical research methodology, 6, pp. 5. 
NARVAEZ, J., NOLLA-SOLE, J.M., NARVAEZ, J.A., CLAVAGUERA, M.T., VALVERDE-GARCIA, J. 
and ROIG-ESCOFET, D., 2001. Musculoskeletal manifestations in polymyalgia rheumatica 
and temporal arteritis. Annals of the Rheumatic Diseases, 60(11), pp. 1060-1063. 
NIEDERKOHR, R.D. and LEVIN, L.A., 2007. A Bayesian analysis of the true sensitivity of a 
temporal artery biopsy. Investigative ophthalmology & visual science, 48(2), pp. 675-680. 
NOBUNAGA, M., YOSHIOKA, K., YASUDA, M. and SHINGU, M., 1989. Clinical studies of 
polymyalgia rheumatica. A proposal of diagnostic criteria. Japanese journal of 
medicine, 28(4), pp. 452-6. 
NOVICK, G.  2008. Is there a bias against telephone interviews in qualitative research? 
Research in Nursing & Health, 31(4), pp. 391-398 
OLIVO, D., D'AMORE, M., MATTACE-RASO, F. and MATTACE, R., 1996. Clinical and 
laboratory features at onset of polymyalgia rheumatica (PMR) and elderly onset of 
rheumatoid arthritis in PMR-like presentation: a comparison of two groups of 
patients. Archives of Gerontology and Geriatrics, 22 Suppl 1, pp. 527-533. 
PANNUCCI, C.J. and WILKINS, E.G., 2010. Identifying and avoiding bias in research. Plastic 
and Reconstructive Surgery, 126(2), pp. 619-625. 
PATIL, P., WILLIAMS, M., MAW, W.W., ACHILLEOS, K., ELSIDEEG, S., DEJACO, C., BORG, F., 
GUPTA, S. and DASGUPTA, B., 2015. Fast track pathway reduces sight loss in giant cell 
arteritis: results of a longitudinal observational cohort study. Clinical and experimental 
rheumatology, 33(2 Suppl 89), pp. S-103-6. 
PAULLEY, J.W. and HUGHES, J.P., 1960. Giant-cell arteritis, or arteritis of the aged. British 
medical journal, 2(5212), pp. 1562-1567. 
PAWLOWSKI, T., AESCHLIMANN, A., KAHN, M.F., VAITH, P., MACKIEWICZ, S.H. and 
MUELLER, W., 1990. Microheterogeneity of acute phase proteins in the differentiation of 
polymyalgia rheumatica from polymyositis. The Journal of rheumatology, 17(9), pp. 1187-
1192. 
 258 
 
0 
PEASE, C.T., HAUGEBERG, G., MONTAGUE, B., HENSOR, E.M., BHAKTA, B.B., THOMSON, 
W., OLLIER, W.E. and MORGAN, A.W., 2009. Polymyalgia rheumatica can be distinguished 
from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective 
study. Rheumatology (Oxford, England), 48(2), pp. 123-127. 
PEASE, C.T., HAUGEBERG, G., MORGAN, A.W., MONTAGUE, B., HENSOR, E.M. and 
BHAKTA, B.B., 2005. Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, 
and temporal arteritis in patients presenting with polymyalgic symptoms. A prospective 
longterm evaluation. The Journal of rheumatology, 32(6), pp. 1043-1046. 
PEGO-REIGOSA, J.M., RODRIGUEZ-RODRIGUEZ, M., HURTADO-HERNANDEZ, Z., GROMAZ-
MARTIN, J., TABOAS-RODRIGUEZ, D., MILLAN-CACHINERO, C., HERNANDEZ-RODRIGUEZ, I. 
and GONZALEZ-GAY, M.A., 2005. Calcium pyrophosphate deposition disease mimicking 
polymyalgia rheumatica: a prospective followup study of predictive factors for this 
condition in patients presenting with polymyalgia symptoms. Arthritis and 
Rheumatism, 53(6), pp. 931-938. 
PHILLIPS, D.L., CLANCY, K.J., 1972. Some Effects of "Social Desirability" in Survey Studies 
American Journal of Sociology, 77(5), pp. 921-940 
PIERI, A., MILLIGAN, R., HEGDE, V. and HENNESSY, C., 2013. Temporal artery biopsy: are 
we doing it right? International journal of health care quality assurance, 26(6), pp. 559-
563. 
POPE, C., MAYS, N., 2000. Qualitative research in health care BMJ books 
PORCHERET, M., HUGHES, R., EVANS, D., JORDAN, K., WHITEHURST, T., OGDEN, H., 
CROFT, P. and NORTH STAFFORDSHIRE GENERAL PRACTICE RESEARCH NETWORK, 2004. 
Data quality of general practice electronic health records: the impact of a program of 
assessments, feedback, and training. Journal of the American Medical Informatics 
Association : JAMIA, 11(1), pp. 78-86. 
PRENCIPE, M., CASINI, A.R., FERRETTI, C., SANTINI, M., PEZZELLA, F., SCALDAFERRI, N. and 
CULASSO, F., 2001. Prevalence of headache in an elderly population: attack frequency, 
disability, and use of medication. Journal of neurology, neurosurgery, and 
psychiatry, 70(3), pp. 377-381. 
PRIETO-GONZALEZ, S., DEPETRIS, M., GARCIA-MARTINEZ, A., ESPIGOL-FRIGOLE, G., 
TAVERA-BAHILLO, I., CORBERA-BELLATA, M., PLANAS-RIGOL, E., ALBA, M.A., HERNANDEZ-
RODRIGUEZ, J., GRAU, J.M., LOMENA, F. and CID, M.C., 2014. Positron emission 
tomography assessment of large vessel inflammation in patients with newly diagnosed, 
biopsy-proven giant cell arteritis: a prospective, case-control study. Annals of the 
Rheumatic Diseases, 73(7), pp. 1388-1392. 
PROVEN, A., GABRIEL, S.E., O'FALLON, W.M. and HUNDER, G.G., 1999. Polymyalgia 
rheumatica with low erythrocyte sedimentation rate at diagnosis. The Journal of 
rheumatology, 26(6), pp. 1333-1337. 
 259 
 
0 
PULSATELLI, L., MELICONI, R., BOIARDI, L., MACCHIONI, P., SALVARANI, C. and FACCHINI, 
A., 1998. Elevated serum concentrations of the chemokine RANTES in patients with 
polymyalgia rheumatica. Clinical and experimental rheumatology, 16(3), pp. 263-268. 
QUICK, V. and KIRWAN, J.R., 2012. Our approach to the diagnosis and treatment of 
polymyalgia rheumatica and giant cell (temporal) arteritis. The journal of the Royal 
College of Physicians of Edinburgh, 42(4), pp. 341-349. 
RAPHAEL, K., 1987. Recall bias: a proposal for assessment and control. International 
journal of epidemiology, 16(2), pp. 167-170. 
REA, L.M., PARKER, R.A., 2005. Designing and conducting Survey research a 
comprehensive Guide, 3rd ed2005 Wiley San Francisco 
ROONEY, P.J., ROONEY, J., BALINT, G. and BALINT, P., 2014. Polymyalgia rheumatica: 125 
years of progress? Scottish medical journal, 59(4), pp. 220-228. 
ROSENTHAL, R. and ROSNOW, L., Rosnow. 1975. The volunteer subject Robert Rosenthal 
New York: Wiley 
RYAN, G.W., and BERNARD H.R., 2000. Handbook of Qualitative Research, 2nd ed, Sage 
SACKETT, D.L., 1979. Bias in analytic research. Journal of chronic diseases, 32(1-2), pp. 51-
63. 
SALAFFI, F., DE ANGELIS, R., GRASSI, W., MARCHE PAIN PREVALENCE and INVESTIGATION 
GROUP (MAPPING) STUDY, 2005. Prevalence of musculoskeletal conditions in an Italian 
population sample: results of a regional community-based study. I. The MAPPING 
study. Clinical and experimental rheumatology, 23(6), pp. 819-828. 
SALVARANI, C., BOIARDI, L., MACCHIONI, P., CASADEI MALDINI, M., MANCINI, R., 
BELTRANDI, E., ROSSI, F. and PORTIOLI, I., 1994. Serum soluble CD4 and CD8 levels in 
polymyalgia rheumatica. The Journal of rheumatology, 21(10), pp. 1865-1869. 
SALVARANI, C., CANTINI, F. and HUNDER, G.G., 2008. Polymyalgia rheumatica and giant-
cell arteritis. Lancet, 372(9634), pp. 234-245. 
SALVARANI, C., CANTINI, F., MACCHIONI, P., OLIVIERI, I., NICCOLI, L., PADULA, A. and 
BOIARDI, L., 1998. Distal musculoskeletal manifestations in polymyalgia rheumatica: a 
prospective followup study. Arthritis and Rheumatism,41(7), pp. 1221-1226. 
SALVARANI, C., MACCHIONI, P., ZIZZI, F., MANTOVANI, W., ROSSI, F., CASTRI, C., 
CAPOZZOLI, N., BARICCHI, R., BOIARDI, L. and CHIARAVALLOTI, F., 1991. Epidemiologic 
and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern 
Italy. Arthritis and Rheumatism, 34(3), pp. 351-356. 
 260 
 
0 
SCHAUFELBERGER, C., BENGTSSON, B.A. and ANDERSSON, R., 1995. Epidemiology and 
mortality in 220 patients with polymyalgia rheumatica. British journal of 
rheumatology, 34(3), pp. 261-264. 
SILVERMAN, D., 2010. Doing qualitative research. 3rd ed Sage 
SMEETH, L., COOK, C. and HALL, A.J., 2006. Incidence of diagnosed polymyalgia 
rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Annals of the 
Rheumatic Diseases, 65(8), pp. 1093-1098. 
SMETANA, G.W. and SHMERLING, R.H., 2002. Does this patient have temporal 
arteritis? Jama, 287(1), pp. 92-101. 
STEPHENS, N., 2007. Collecting data from elites and ultra-elites: telephone and face-to-
face interviews with macroeconomists. Qualitative Research, 7(2), pp. 203-216 
STOCKS, N. and GUNNELL, D., 2000. What are the characteristics of general practitioners 
who routinely do not return postal questionnaires: a cross sectional study. Journal of 
epidemiology and community health, 54(12), pp. 940-941. 
STRAUSS, A., 1998. Basics of Qualitative research. Techniques and procedures for 
developing Grounded Theory. 2nd ed Sage 
STURGES, J.E., Hanrahan, K.J., 2004. Comparing Telephone and Face-to-Face Qualitative 
Interviewing: a Research Note. Qualitative Research 4(1), pp.  107-118 
THOMSON, C.E., PATERSON-BROWN, S., RUSSELL, D., MCCALDIN, D. and RUSSELL, I.T., 
2004. Short report: encouraging GPs to complete postal questionnaires--one big prize or 
many small prizes? A randomized controlled trial. Family practice, 21(6), pp. 697-698. 
THORPE, C., RYAN, B., MCLEAN, S.L., BURT, A., STEWART, M., BROWN, J.B., REID, G.J. and 
HARRIS, S., 2009. How to obtain excellent response rates when surveying 
physicians. Family practice, 26(1), pp. 65-68. 
TURNER, R.M., 1983. Polymyalgia rheumatica: a general practice experience. The Journal 
of the Royal College of General Practitioners, 33(248), pp. 167-170.  
TWOHIG, H., MITCHELL, C., MALLEN, C., ADEBAJO, A. and MATHERS, N., 2015. "I suddenly 
felt I'd aged": a qualitative study of patient experiences of polymyalgia rheumatica 
(PMR). Patient education and counseling, 98(5), pp. 645-650. 
UDDHAMMAR, A., ROOS, G., NASMAN, B. and DAHLQVIST, S.R., 1995. Peripheral blood 
lymphocyte subsets in polymyalgia rheumatica. Clinical rheumatology, 14(1), pp. 62-7. 
UDDHAMMAR, A., SUNDQVIST, K.G., ELLIS, B. and RANTAPAA-DAHLQVIST, S., 1998. 
Cytokines and adhesion molecules in patients with polymyalgia rheumatica. British 
journal of rheumatology, 37(7), pp. 766-769. 
 261 
 
0 
UIJEN, A.A. and VAN DE LISDONK, E.H., 2008. Multimorbidity in primary care: prevalence 
and trend over the last 20 years. The European journal of general practice, 14 Suppl 1, pp. 
28-32. 
VAISMORADI, M., TURUNEN, H. and BONDAS, T., 2013. Content analysis and thematic 
analysis: Implications for conducting a qualitative descriptive study. Nursing & health 
sciences, 15(3), pp. 398-405. 
VILASECA, J., GONZALEZ, A., CID, M.C., LOPEZ-VIVANCOS, J. and ORTEGA, A., 1987. Clinical 
usefulness of temporal artery biopsy. Annals of the Rheumatic Diseases, 46(4), pp. 282-
285. 
WELLS, P.S., HIRSH, J., ANDERSON, D.R., LENSING, A.W., FOSTER, G., KEARON, C., WEITZ, 
J., D'OVIDIO, R., COGO, A. and PRANDONI, P., 1995. Accuracy of clinical assessment of 
deep-vein thrombosis. Lancet (London, England),345(8961), pp. 1326-1330. 
WELSH, V.K., MALLEN, C.D., WYNNE-JONES, G. and JINKS, C., 2012. Exploration of GPs' 
views and use of the fit note: a qualitative study in primary care. The British journal of 
general practice : the journal of the Royal College of General Practitioners, 62(598), pp. 
e363-70. 
 
 262 
 
0 
Appendix 1 Search terms for Medline and Embase and search history for 
the literature review of diagnostic and classification criteria for 
PMR and their use in clinical practice 
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Medline  
1. Polymyalgia Rheumatica/ 
2. polymyalgia.mp. 
3. (senile adj2 gout).mp. 
4. (rheumatic adj2 gout).mp. 
EMBASE 
1. exp rheumatic polymyalgia/ 
2. (polymyalgia adj2 rheumatic$).mp. 
3. (senile adj2 gout).mp. 
4. (rheumatic adj2 gout).mp. 
 
Search History:  
1. MEDLINE; POLYMYALGIA RHEUMATICA/; 2057 results.  
7. MEDLINE; CLASSIFICATION/; 8375 results.  
8. MEDLINE; exp BOOK CLASSIFICATION/ OR exp CLASSIFICATION/ OR exp 
INTERNATIONAL CLASSIFICATION OF DISEASES/; 122178 results.  
9. MEDLINE; (classification AND criteria).ti,ab; 16448 results.  
2. MEDLINE; (polymyalgia AND rheumatica).ti,ab; 1878 results.  
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3. MEDLINE; polymyalgia.ti,ab; 2019 results.  
12. MEDLINE; (diagnostic AND criteria).ti,ab; 48001 results.  
13. MEDLINE; "diagnostic criteria".ti,ab; 25551 results.  
14. MEDLINE; exp DIAGNOSIS/; 6043572 results.  
15. MEDLINE; 12 OR 13 OR 14; 6065754 results.  
16. MEDLINE; criteria.ti,ab; 310343 results.  
5. MEDLINE; (rheumatic adj2 gout).mp; 23 results.  
18. MEDLINE; 6 AND 11; 21 results.  
19. MEDLINE; 6 AND 15; 1307 results.  
20. MEDLINE; 6 AND 16; 132 results.  
21. MEDLINE; 19 [Limit to: English Language and Humans and (Age Groups All Adult 19 
plus years)]; 735 results.  
6. MEDLINE; 1 OR 2 OR 3 OR 4 OR 5; 2564 results.  
23. MEDLINE; 18 [Limit to: English Language and Humans and (Age Groups All Adult 19 
plus years)]; 11 results.  
24. MEDLINE; 21 OR 22 OR 23 [Limit to: English Language and Humans and (Age Groups 
All Adult 19 plus years)]; 754 results.  
4. MEDLINE; ((senile adj2 gout)).ti,ab; 4 results.  
11. MEDLINE; 7 OR 8 OR 9 OR 10; 138145 results.  
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17. MEDLINE; CRITERIA/; 0 results.  
10. MEDLINE; "classification criteria".ti,ab; 1926 results.  
22. MEDLINE; 20 [Limit to: English Language and Humans and (Age Groups All Adult 19 
plus years)]; 73 results.  
25. AMED; "POLYMYALGIA RHEUMATICA".ti,ab; 11 results.  
26. AMED; pmr.ti,ab; 73 results.  
32. AMED; 28 OR 29; 51433 results.  
33. AMED; 30 OR 31; 2820 results.  
34. AMED; 27 AND 32; 20 results.  
35. AMED; 27 AND 33; 0 results.  
36. AMED; 34 OR 35; 20 results.  
31. AMED; exp CLASSIFICATION/; 839 results.  
27. AMED; 25 OR 26; 81 results.  
37. AMED; 36 [Limit to: (Languages English)]; 18 results.  
29. AMED; exp DIAGNOSIS/; 48040 results.  
30. AMED; classification.ti,ab; 2498 results.  
28. AMED; diagnosis.ti,ab; 7253 results.  
40. CINAHL; (rheumatic AND gout).ti,ab; 34 results.  
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44. CINAHL; exp DIAGNOSIS/; 594031 results.  
45. CINAHL; 43 OR 44; 629885 results.  
46. CINAHL; classification.ti,ab; 16413 results.  
39. CINAHL; exp POLYMYALGIA RHEUMATICA/; 211 results.  
43. CINAHL; diagnosis.ti,ab; 77582 results.  
49. CINAHL; 42 AND 45; 212 results.  
50. CINAHL; 42 AND 48; 9 results.  
51. CINAHL; 49 OR 50; 215 results.  
52. CINAHL; 51 [Limit to: (Language English) and (Age Groups All Adult)]; 137 results.  
48. CINAHL; 46 OR 47; 28330 results.  
38. CINAHL; "polymyalgia rheumatica".ti,ab; 199 results.  
41. CINAHL; PMR.ti,ab; 142 results.  
42. CINAHL; 38 OR 39 OR 40 OR 41; 386 results.  
47. CINAHL; exp CLASSIFICATION/; 14012 results.  
53. EMBASE; exp RHEUMATIC POLYMYALGIA/; 3349 results.  
58. EMBASE; 53 OR 54 OR 55 OR 56 OR 57; 5195 results.  
67. EMBASE; 65 OR 66; 2213 results.  
60. EMBASE; exp DIAGNOSIS/; 4038737 results.  
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66. EMBASE; 58 AND 64; 297 results.  
57. EMBASE; (rheumatic adj2 gout).mp; 23 results.  
65. EMBASE; 58 AND 61; 2087 results.  
64. EMBASE; 62 OR 63; 1023293 results.  
63. EMBASE; exp CLASSIFICATION/; 912220 results.  
61. EMBASE; 59 OR 60; 4494654 results.  
68. EMBASE; 67 [Limit to: Human and English Language and (Human Age Groups Adult 18 
to 64 years or Aged 65+ years)]; 882 results.  
59. EMBASE; diagnosis.ti,ab; 1177342 results.  
55. EMBASE; (polymyalgia adj2 rheumatic$).mp; 3710 results.  
54. EMBASE; pmr.ti,ab; 2116 results.  
62. EMBASE; classification.ti,ab; 205984 results.  
56. EMBASE; (senile adj2 gout).mp; 3 results. 
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Appendix 2  Data extraction form and quality assessment criteria 
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Systematic Review Paper Assessment 
Objective
 ………………………………………………………………………………….. 
 
 ………………………………………………………………………………….. 
 
 ………………………………………………………………………………….. 
Method
 ………………………………………………………………………………….. 
 
 ………………………………………………………………………………….. 
 
 ………………………………………………………………………………….. 
Results
 ………………………………………………………………………………….. 
 
 ………………………………………………………………………………….. 
   
Conclusion
 ………………………………………………………………………………….. 
 
 ………………………………………………………………………………….. 
 
 ………………………………………………………………………………….. 
Other 
 ………………………………………………………………………………….. 
   
Quality Assessment 
Criteria  
Clearly defined study objective  
Appropriate design for study question  
Inclusion and exclusion criteria clear and appropriate  
Representative sample (and comparison)  
Sample size calculation presented  
Appropriate selection of outcome  
Appropriate measurement of outcome  
Standardised collection of data  
Adequate length of follow up for research question  
Baseline participation >70% (all groups)  
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Losses and drop outs <20%  
Adequate description of losses and completers  
Appropriate analysis of outcomes measured  
Numerical description of important outcomes given  
Adjusted and unadjusted calculations provided (with CI if appropriate)  
Total  
 
 
Diagnostic Indicator Sens/Spec etc Significance 
1)   
2)   
3)   
4)   
5)   
6)   
 
 
Classification criteria Used if any: 
1) 
2) 
3) 
4) 
5) 
6) 
7)
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Appendix 3 Development of questions for the PMR questionnaire survey
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Development of questions relating to diagnosis 
Relevant theme 
derived from 
systematic review and 
other existing 
literature 
Relevant area of UK 
PMR guideline  
Process of 
stakeholder 
questionnaire 
review and 
refinement 
Question in survey questionnaire 
    
Classification criteria 
studies 
 Section 3.4.3 
Section 1 (i) Core 
inclusion criteria 
 Age >50 years 
 Question 1 Age at which the diagnosis of 
PMR would be excluded? 
Classification criteria 
studies 
 Section 3.4.3 
Clinical features 
studies 
 Section 3.4.4 
Section 1 (i) Core 
inclusion criteria 
 Bilateral 
shoulder or 
pelvic girdle 
aching 
 Morning 
stiffness 
 Evidence of an 
acute phase 
response 
 Question 2 Importance of key features  
 
Classification criteria 
studies 
 Section 3.4.3 
Laboratory 
investigations and 
unique biomarkers 
 Section 3.4.5 
 
 
Section 1 (i) Core 
inclusion criteria 
 Evidence of an 
acute phase 
response 
Section 2  
 Laboratory 
investigations 
before 
commencement 
of steroid 
therapy 
 Question 3 Use of inflammatory markers 
 
Classification criteria 
studies 
 Section 3.4.3 
Section 1 (i) Core 
inclusion criteria 
 “PMR can be 
diagnosed with 
normal 
inflammatory 
markers” 
 
 Question 4 Actions undertaken if 
inflammatory markers are normal 
 
All sections relevant as 
studies identified to 
exclude other causes 
for symptoms and 
discriminate PMR 
from other mimicking 
disorders 
 Section 3.4.3 
 Section 3.4.4 
 Section 3.4.5 
 Section 3.4.6 
Section 1 (ii) Core 
Exclusion criteria 
 Active infection 
 Active cancer 
 Active GCA 
Other exclusions 
 Other 
inflammatory 
rheumatic 
diseases 
 Drug induced 
myalgia 
 Chronic pain 
syndromes 
 Question 5 Disorders routinely excluded 
before making a diagnosis 
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 Endocrine 
disease 
 Neurological 
disease 
Laboratory 
investigations and 
unique biomarkers 
 Section 3.4.5 
 
Section 2  
 Laboratory 
investigations 
before 
commencement 
of steroid 
therapy 
 
 
 
 Question 7 Investigations routinely 
performed 
 
All sections relevant as 
studies not able to 
definitively identify 
gold standard 
diagnostic criteria or 
tests  
• Section 3.4.3 
• Section 3.4.4 
• Section 3.4.5 
• Section 3.4.6 
  Question 15 Challenges of PMR diagnosis 
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Development of questions relating to treatment 
Relevant theme 
derived from 
systematic review and 
other existing 
literature 
Relevant area of UK 
PMR guideline 
[Dasgupta 2010] 
Process of 
stakeholder 
questionnaire 
review and 
refinement 
Question in survey questionnaire 
    
Helliwell et al 2013 Section 1 (iv) and 
Section 5 
 Initial 
standardised 
dose 15mg 
 Question 6 Initial dose of prednisolone 
used 
 Section 4 
 Incomplete, 
poorly sustained 
or non-response 
to 
corticosteroids 
 Question 8. Action undertaken if 
response to treatment is poor 
 Section 5 
 Intramuscular 
methylprednisol
one may be used 
in milder cases 
(i.m. 
depomedrone) 
 Question 9 Previous use of 
methylprednisolone 
 Section 7 
 Recommended 
vigilant 
monitoring 
 Question 10 Follow up of PMR patients 
Helliwell et al 2013 Section 6 
 Recommended 
bone protection 
 Question 11Additional interventions or 
medications offered 
 Section 4 
 Recommendatio
ns for early 
referral 
 Question 12 Indications for referral 
 Section 8 
 Recommendatio
ns for the 
management of 
relapse 
 Question 13 Management of relapse 
OMERACT 12 
Helliwell et al 2016 
 
  Question 14 Perceived Impact on 
patients’ lives 
 
Helliwell et al 2013 
 
  Question 16 Challenges of PMR 
treatment 
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Development of questions relating to GCA 
Relevant theme 
derived from 
systematic review 
and other existing 
literature 
Relevant area of UK 
GCA guideline 
[Dasgupta (GCA) 
2010] 
Process of 
stakeholder 
questionnaire 
review and 
refinement 
Question in survey questionnaire 
    
Rarity of the disorder 
[Barraclough et al 
2008] 
  18) Have you ever managed a patient 
with GCA? 
 
 
 Section 1 
 Symptoms 
 19 )What symptoms would lead you to 
suspect GCA 
 Section 1 
 Signs 
 20) What signs would lead you to 
suspect GCA? 
 
 Section 1 
 Recommended 
investigations 
Section 2 
 Urgent referral 
for specialist 
evaluation  
Section 4a 
 Immediate 
initiation of 
high-dose 
glucocorticoid 
 
 
 
 
 
 
21) Management and referral pathways 
for suspected  GCA  
 
 Section 2 
 Urgent referral 
for specialist 
evaluation 
 22) Specialist to who suspected GCA 
patients are referred 
 Section 4a 
 Immediate 
initiation of 
high-dose 
glucocorticoid 
 23) Initiating dose of prednisolone 
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Appendix 4 PMR National cross-sectional survey documents 
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23 January 2012 
 
Dr Toby Helliwell 
Arthritis UK Primary Care Centre 
Primary Care Sciences 
Keele University 
 
Dear Toby 
 
Re:  ‘The challenges of diagnosis and management of polymyalgia rheumatic in 
primary care: a GP survey’ 
 
Thank you for submitting your revised project for review. 
 
I am pleased to inform you that your project has been approved by the Ethics Review 
Panel. 
 
If the fieldwork goes beyond the date stated in your application (June 2012) you must 
notify the Ethical Review Panel via Michele Dawson.  
 
If there are any other amendments to your study you must submit an ‘application to 
amend study’ form to Michele Dawson.  This form is available from Michele (01782 
733588) or via http://www.keele.ac.uk/researchsupport/researchethics/ 
 
If you have any queries, please do not hesitate to contact Michele Dawson in writing to 
m.dawson@uso.keele.ac.uk 
 
Yours sincerely 
 
 
 
 
 
Dr Roger Beech 
Chair – Ethical Review Panel 
 
CC RI Manager 
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PMR National Cross-sectional Survey Questionnaire 
 
 
Thank you for taking a few moments of your time to fill in this questionnaire. 
If it is more convenient, a link to an online version of the questionnaire can 
be found (your unique identifier can be found on the back of this 
questionnaire, password pmrstudy). 
 
www.keele.ac.uk/pmr/ 
 
 
The first section looks at the identification of PMR 
 
1) At what age would you consider excluding a diagnosis of PMR? 
(Please tick one box only) 
 
<30… □  <40… □  <50… □  <60… □  <70… □  Other………. 
 
 
2) Please circle how important the following features are to you in making 
the diagnosis of PMR (1 being the least important and 5 being the 
most important) 
(please circle one number on each line only)  
 
 
     Least Important    Most 
important  
Arm pain    1 2 3 4 5 
Muscle Pain    1 2 3 4 5 
Morning stiffness    1 2 3 4 5 
Neck Pain             1 2 3 4 5 
Bilateral shoulder pain    1 2 3 4 5 
Shoulder limitation  1 2 3 4 5 
Hip Limitation    1 2 3 4 5 
Raised inflammatory markers 1 2 3 4 5  
Response to corticosteroids 1 2 3 4 5 
Leg pain      1 2 3 4 5 
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Generalised joint pain   1 2 3 4 5 
Hip girdle pain    1 2 3 4 5 
Unilateral Shoulder pain   1 2 3 4 5 
Joint Stiffness   1 2 3 4 5 
 
Other (Please Specify)
 ........................................................................................................ 
  
 ........................................................................................................ 
3) Please indicate which inflammatory marker you routinely use and what 
you would consider to be raised/positive in order for you to consider 
PMR as a diagnosis. (Please tick as many boxes that apply and give 
a figure for each that you would consider significant in PMR) 
 
ESR……….... □ 
 
CRP……….... □ 
................... 
mm/hr 
            
  
 
 
..................... mg/l  
 
4) If the inflammatory markers were normal would you:- 
(Please tick as many boxes as apply) 
 
Exclude diagnosis of PMR.... □  Recheck blood test... □ 
Offer a trial of treatment……. □  Refer to specialist…. □ 
Other □         Please specify ................................................... 
 
 
 
5) Which of the following would you routinely try to exclude as part of 
diagnosing PMR. (Please tick as many boxes that apply) 
 
Active infection…………………………. □  Active cancer…………………. □ 
Raised/Positive 
 value 
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Active Giant Cell/Temporal Arteritis…. □  Rheumatoid arthritis………….. □ 
Osteoarthritis……………………………. □  Pain syndromes………………. □ 
Other rheumatological diseases……… □  Drug induced myalgias………. □ 
Endocrine disorders……………………. □  Neurological disease………… □ 
Other □            Please specify  ….........………………………............. 
 
 
 
6) What initial dose of prednisolone do you tend to prescribe if you decide 
to treat for PMR? 
...........mg 
 
Which (if any) investigations do you perform routinely in suspected PMR? 
(please tick any of the relevant boxes that apply) 
 
Full blood count…...……………………. □  ESR/CRP…...…………………. □ 
Rheumatoid factor ……………………... □  Glucose ……………………….. □ 
Antinuclear antibodies ...………………. □  Urea & electrolytes .…………. □ 
Creatinine Kinase ……………………… □  Liver Function Tests ...………. □ 
Thyroid function Tests ..………………. □  Bone  profile ………...………... □ 
Protein electrophoresis ..……………. □  Bence Jones Protein .……….. □ 
Anti CCP antibodies.…………………... □  Prostate specific antigen ..….. □ 
Chest X-Ray ……………………………. □  Ultrasound ……………………. □ 
Other imaging …………………..……… □  Urinalysis …………...………… □ 
None ……………….……………………. □    
Other  □                       Please specify  ………………………………................. 
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The following section concerns the management of PMR 
 
 
7) Typically patients with PMR respond well to prednisolone. If the response 
was poor what would be your next step? (Please tick as many boxes 
that apply) 
 
Exclude diagnosis of PMR........... □  Continue on the same dose…….. □ 
Increase the dose of steroid……. □  Check ESR……………………….. □ 
Refer to specialist………………… □  Other...........................................                         □ 
 
   
If Other please 
specify........................................................................................................... 
 
.........................................................................................................................
...................... 
 
 
 
8) Have you ever used Intra-Muscular methylprednisolone 
(depomedrone) as a treatment for PMR?  
Yes……….... □ 
 
No……….... □ 
  
 
  
If yes, please comment on how effective you thought this treatment was. 
 
...............................................................................................................
.................... 
 
...............................................................................................................
.................... 
 
9) When do you normally follow up your patients with PMR in the first 
year after starting treatment? (please circle all that apply) 
 
Weeks 1 2 3 4 5 6      
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Months 2 3 4 5 6 7 8 9 10 11 12 
 
Other. (Please specify)……………………………………………………………… 
 
……………………………………………………………………………..…………... 
 
10) With a newly diagnosed patient with PMR what additional 
interventions do you offer routinely? (Please tick any that you offer) 
 
Bone protection (eg Bisphosphonate).. □  Gastric protection…...………... □ 
Analgesics ……………………............ □  Physiotherapy..……………….. □ 
Alternative therapies ...………………... □  Referral to secondary care .… □ 
Joint injection …………………………... □  Information leaflet ....………… □ 
Website information ..………………….. □  Support group ……...………... □ 
None ..…………………………………… □  Non-steroidal anti-inflammatory □ 
Other   □                       Please specify  
 
…………………………………………... 
 
If you have ticked alternative therapies please indicate which alternative 
therapies that you suggest. 
.........................................................................................................................
....................... 
 
……………………............................................................................................
.......................  
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11) In what circumstances would you refer a patient with PMR to a 
specialist or secondary care? (Please indicate all responses that 
are relevant to you) 
Routine (every patient)..….…...………. □  Never………………...………... □ 
Confirm diagnosis.……….……............ □  Uncertain diagnosis………….. □ 
High steroid requirements.……………. □  Poor response…………....… □ 
Medication complications….………….. □  Flare-up/relapse…....………… □ 
Patient request……...………………….. □  Normal ESR………...………... □ 
Young patient…………………………… □ Please specify age cut-off……………. 
Other……………………………………… □ 
 
Please specify…………………………. 
 
  
 
This section relates to relapse of PMR symptoms, living with PMR and 
problems that you or your patients may have experienced. 
 
 
12) How would you manage a relapse in symptoms?  
(Please tick what you feel are the most appropriate boxes) 
Increase steroid until symptoms 
controlled..….….................................... □  
Re-check inflammatory markers 
……...….................................. □ 
Increase steroid dose only if ESR 
raised.……….……................................ □  Increase steroid by 5mg……... □ 
Increase steroid dose even if ESR was 
normal.………………………….............. □  
Refer patient to secondary 
care……………………………... □ 
Increase steroid to previous effective 
dose ….…………………………………... □  Other.......................................    □ 
                      
 
 
 
If Other please 
specify............................................................................................................. 
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.........................................................................................................................
....................... 
 
.........................................................................................................................
....................... 
 
13) Thinking about patients that you have seen with PMR, how would you 
rate the importance to your patients of the following factors? 
(Please circle one number on each line only) 
 
       Least Important    Most 
important 
Pain     1 2 3 4 5   
Stiffness    1 2 3 4 5  
Limitation of activity  1 2 3 4 5 
Sleep     1 2 3 4 5 
Mood     1 2 3 4 5  
Intimate relationship issues 1 2 3 4 5  
Medications    1 2 3 4 5  
Side effects/Complications 1 2 3 4 5  
Relapse    1 2 3 4 5  
Worries about diagnosis  1 2 3 4 5  
 
Other (Please specify) 
................................................................................................. 
 
                   
................................................................................................. 
 
 
14) Thinking about patients with PMR that you have seen before what 
challenges regarding their diagnosis did you encounter? 
 
.........................................................................................................................
.......................  
 
.........................................................................................................................
....................... 
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15) Thinking about patients with PMR that you have seen before, what 
challenges regarding their treatment did you encounter? 
 
.........................................................................................................................
.......................  
 
.........................................................................................................................
....................... 
 
16) Generally, what challenges (if any) do you believe PMR poses to 
general practice?  
 
.........................................................................................................................
.................... 
 
.........................................................................................................................
.................... 
 
Giant cell (GCA) or temporal arteritis (TA) is a common association 
with PMR. The following section relates to GCA 
 
17) Have you ever managed a patient with GCA? 
 
Yes……….... □ 
 
No……….... □ 
 
 
18) What symptoms would lead you to suspect GCA? 
.........................................................................................................................
....................... 
 
.........................................................................................................................
....................... 
 
 
19) What signs would lead you to suspect GCA? 
.........................................................................................................................
....................... 
 
.........................................................................................................................
....................... 
 
 
20) Considering the management of GCA, would you… 
(Please tick one of the following) 
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Refer to hospital immediately as 
an emergency without 
investigation?................................. □  
Do urgent blood tests and refer to 
hospital immediately if 
elevated?……................................ □ 
 
Do urgent bloods, initiate steroids 
and refer for outpatient specialist 
review urgently if bloods positive? □  
Do urgent bloods, initiate steroids 
and refer for outpatient specialist 
review routinely?..………….…..... □ 
 
Other   □                Please specify  
 
………………...……………........................ 
 
21) Who would you routinely refer to?  
(Please tick the 1 box that is most relevant to you) 
A&E…………………………………. □  Elderly care………………………… □ 
Rheumatology……………………… □  Opthamology………………………. □ 
General medicine………………….. □  Neurology…………………………... □ 
Other   □                Please specify  
 
………………...……………........................ 
 
22) If you were to initiate prednisolone what initial dose would you 
prescribe? 
 
..........mg 
 
The following section asks a few questions about you and your 
practice. 
 
Age ………....years 
 
Gender: Female……….... □ 
 
Male……….... □ 
 
Current role Salaried....□    Locum....□      Partner....□     Senior partner....□  
   
 
What year did you qualify as a doctor? ………................ 
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What year did you qualify as a GP? ………………...... 
  
How many patients do you have on your practice list? …………………… 
 
  
Are there any resources or guidelines that you refer to, to help you manage 
patients with PMR or GCA 
Yes……….... □ 
 
No……….... □ 
 
(Please 
specify)............................................................................................................
......... 
 
.........................................................................................................................
....................... 
 
Would you be happy to be contacted in the future to discuss PMR in 
more depth?  
 
Yes……….... □ 
 
No……….... □ 
 
 
Thank you for taking the time to fill in this questionnaire 
and help with this important research. 
 
 
 
 
 
 
 
 
Address label 
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PMR National Cross-sectional Survey: Reminder Card 
 
 
 
 
 
 
 
 
 289 
 
0 
PMR National Cross-sectional Survey: covering letter 
 
 
Polymyalgia Rheumatica GP Survey 
                      
 
 
 
 
 
 
PMR GP Survey 
 
Dear Colleague,  
 
My name is Dr Toby Helliwell and I am a GP working at Keele University and also 
in practice in Newcastle-Under-Lyme, North Staffordshire. As part of my GP 
training I undertook a small project looking at the management of polymyalgia 
rheumatica (PMR) in general practice. PMR is the commonest inflammatory 
rheumatological disorder of the elderly and on average a full-time GP will see 4 to 
5 cases of PMR per year. Work done by Dr Kevin Barraclough, a GP based in 
Gloucestershire, showed that over 80% of patients with PMR are managed solely 
by their GP. Despite this the majority of PMR research has been conducted in 
secondary care, where the patients may be different from those we manage in 
primary care.  
 
Diagnosing and managing PMR in primary care can sometimes be challenging. To 
try to better understand this, we have developed a short questionnaire, which we 
would be very grateful if you could complete. As a GP I know that we are asked to 
fill in many questionnaires, and, that time is precious, but it should only take a few 
minutes of your time to complete and a pre-paid return envelope is included. Your 
views are important and could help to direct future research in this area. If you feel 
it would be more convenient for you the questionnaire can be completed on-line 
via the link below using the unique identifier on your address label and the link 
(password pmrsurvey): 
www.keele.ac.uk/pmr/ 
 
Participants returning a completed questionnaire will be entered into a prize 
draw to win a bottle of 2002 vintage Dom Perignon Champagne. We hope our 
findings will go on to help develop primary care orientated guidance and 
management strategies and so improve outcomes for this common disorder.  
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Thank you for your help. 
 
Dr Toby Helliwell MRCGP 
GP research Fellow 
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Appendix 5  Development of topic guide used for the qualitative telephone       
             interview study 
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Diagnosis 
“How would you diagnose PMR?” 
Expand/probe/challenge, typical symptoms for 
you, normal inflammatory markers, young 
patients, response to treatment, role of blood 
tests or investigations, multimorbidity, 
challenges experienced 
Management 
“How do you treat PMR?” 
Expand/probe/challenge, initial dose, response 
to treatment, do you offer any other treatment, 
prophylaxis, manage relapse, challenges 
experienced referral 
Challenges 
“What other general challenges do disorders 
like PMR pose in general practice?” 
Expand/probe/challenge, overall role of GP, 
fears, thoughts on how to improve, what would 
be the ideal, how could that be achieved, 
barriers encountered 
GCA 
“What features would make you think of GCA?” 
“How do you treat GCA?” 
Expand steroid dose, investigations, referral, 
what features would worry you 
Topic guide questions 
PMR Diagnosis literature BSR/BHPR PMR guidelines 
 [Dasgupta et al 2010] 
Classification criteria studies, Section 3.4.3 Section 1 (i) Core inclusion criteria 
Age >50 years 
Classification criteria studies, Section 3.4.3 
Clinical features studies, Section 3.4.4 
Section 1 (i) Core inclusion criteria 
Classification criteria studies, Section 3.4.3 
Laboratory investigations and unique 
biomarkers, Section 3.4.5 
 
Section 1 (i) Core inclusion criteria, Evidence 
of an acute phase response 
Section 2, Laboratory investigations before 
commencement of steroid therapy 
Classification criteria studies, Section 3.4.3 Section 1 (i) Core inclusion criteria “normal 
inflammatory markers” 
Exclude other causes for symptoms  
Section 3.4.3, Section 3.4.4, Section 3.4.5, 
Section 3.4.6 
Section 1 (ii) Core Exclusion criteria 
Other causes for symptoms 
Laboratory investigations and unique 
biomarkers, Section 3.4.5 
Section 2 Laboratory investigations before 
commencement of steroid therapy 
All sections relevant as studies not able to 
definitively identify gold standard diagnostic 
criteria or tests  
Section 3.4.3, Section 3.4.4, Section 3.4.5, 
Section 3.4.6 
 
 
Systematic review and guidelines used to develop questionnaire 
PMR Management literature BSR/BHPR PMR guidelines 
 [Dasgupta et al 2010] 
Helliwell et al 2013 Section 1 (iv) and Section 5 
Initial standardised dose 15mg 
 Section 4. Incomplete, poorly sustained or non-response to 
corticosteroids 
 Section 5.Intramuscular methylprednisolone may be used in 
milder cases (i.m. depomedrone) 
 Section 7. Recommended vigilant monitoring 
Helliwell et al 2013 Section 6. Recommended bone protection 
 Section 4. Recommendations for early referral 
 Section 8. Recommendations for the management of relapse 
OMERACT 12 
[Helliwell et al 2016] 
Life Impact 
 BSR/BHPRGCA guidelines 
[Dasgupta (GCA) et al 2010] 
Section 1, GCA Symptoms 
Section 1, GCA Signs 
Section 1, Recommended investigations 
Section 2, Urgent referral for specialist evaluation  
Section 4a, Immediate initiation of high-dose glucocorticoid 
Section 2, Urgent referral for specialist evaluation 
Section 4a, Immediate initiation of high-dose glucocorticosteroid 
 
Features used by 
GPs for PMR 
identification 
Section 5.3 
Challenges: 
Atypia 
Diagnostic uncertainty 
Mimicking disorders 
Multimorbidity 
Section 5.3.6 
Advised  
Investigations not 
routinely performed 
Sections 5.3.2.1,  
5.3.2.2 
Importance of 
excluding mimicking 
disorders  
Section 5.3.3 
Initial prednisolone 
dose 
Section 5.4.1 
Adjuvant treatment 
Section 5.4.2.1 
Management of 
relapse/flares 
Section 5.4.2.2 
Specialist referral 
Diagnostic uncertainty 
Atypia 
Section 5.4.2.2 
Challenges: 
Dose reduction 
Adverse effects 
Treatment duration 
Section 5.4.3 
GCA symptoms and 
signs 
Section7.5.1 
GCA Management 
Initiating dose 
Referral 
Challenges 
Section 7.5.3 
Findings of questionnaire survey 
2
92
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Appendix 6 Qualitative study investigating the diagnostic and 
management challenges of PMR and GCA in primary care 
documents 
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A qualitative study investigating the diagnostic and management 
challenges of PMR in primary care: Topic guide 
 
 
Polymyalgia Rheumatica: A qualitative Investigation 
Topic Guide 
 
 
 
 
Introduction 
 Introduce myself and the study aims, introduce interview (length, tape 
recording) 
 Discuss reimbursement  
 Explain voluntary nature of participation, right to withdraw & confidentiality 
 Ask if participant has any questions 
Background and initial open PMR questions 
 Discuss current job, practice, seniority, interests 
Keep brief 
 “Tell me about your professional experiences with PMR” 
“Tell me about the last case of PMR that you saw” 
 
Diagnosis 
 “How would you diagnose PMR in your day to day practice” 
Expand/probe/challenge,  
- Typical symptoms for you  
- normal inflammatory markers 
- young patients 
- response to treatment 
- role of blood tests or investigations 
- multimorbidity 
- challenges experienced 
 
Management 
 “How do you treat PMR” 
Expand/probe/challenge,  
- Initial dose 
- How important is response to treatment 
- Do you offer any other treatment 
Aim: To explore in-depth the views of general practitioners towards the diagnosis and 
management of polymyalgia rheumatic in primary care and to identify perceived barriers to 
effective diagnosis and management 
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- Do you offer prophylaxis 
- How do you manage relapse 
- Challenges experienced 
- Referral 
 
Challenges 
 “We have talked about several challenges with regards to diagnosis and 
management of PMR by GPs, what other general challenges do disorders 
like PMR, that aren’t often encountered pose in general practice” 
 
Expand/probe/challenge 
- Overall role of GP 
- Fears 
- Thoughts on how to improve 
- What would be the ideal 
- How could that be achieved 
- Barriers encountered 
GCA 
Dependent on time available and if brought up by interviewee 
 What features would make you think of GCA 
 How do you treat GCA 
- Expand steroid dose, investigations, referral 
 What features would worry you 
 
Summary 
 Any other thoughts that you would like to discuss or share 
 Re-check consent 
 Thank participant for their time 
 Any questions for me 
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A qualitative study investigating the diagnostic and management 
challenges of PMR in primary care: reply slip 
 
 
Version 1.0 10/10/13 Researchers: T Helliwell, S Muller, J Richardson, S Hider, C Mallen 
 
 
Reply slip for research study- 
PMR in general practice: A qualitative study 
 
 
 
Yes, I would like to take part in the study  
 
   
No, I do not wish to take part in the study 
 
 
 
Name:………………………………………………………………………………….. 
 
Address:……………………………………………………………………………….. 
………………………………………………………………………………………….. 
………………………………………………………………………………………….. 
………………………………………………………………………………………….. 
 
Contact number:……………………………………………………………………… 
 
Email:………………………………………………………………………………….. 
 
Preferred contact method to arrange a suitable time for interview: 
 
Telephone 
 
Email 
 
 
Please return the form in the pre-paid envelope provided. 
 
Thank you for your help with this research study 
 
 
Dr Toby Helliwell 
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A qualitative study investigating the diagnostic and management 
challenges of PMR in primary care: consent form 
 
Version 1.0 10/10/13 Researchers: T Helliwell, S Muller, J Richardson, S Hider, C Mallen 
 
CONSENT FOR TAKING PART IN THE STUDY 
 
PMR in general practice: A qualitative study 
 
1. I confirm that I have read and understand the information sheet  
and have had the opportunity to ask questions……………………………………. 
 
2. I understand that my participation is voluntary, that I can refuse 
to answer a question or withdraw my consent at any time, without  
giving reason and without my professional role being compromised……………. 
 
3. I understand that the interview will be recorded and transcribed verbatim  
and that recording will be stored in a secure location, but will bear no  
identifying information. I also understand that the recordings may be kept  
for up to 20 years and after this time they will be destroyed………………………. 
 
4. I understand that, should I Iose the capacity to consent to be in  
the study, the research centre would retain any information collected 
prior to this point, but would not involve me in any further part of the study……… 
 
5. I understand that the data collected during the study may be looked 
at by individuals from Primary Care Sciences, from regulatory authorities 
or from the NHS Trust, where it is relevant to my taking part in this  
research. I give permission to these individuals to have access to my records….. 
 
6. I understand that quotations from the interview may be included in reports  
or publications from this study, but that these will be anonymous and I will  
not be identifiable.………………………………………………..................................  
  
I  DO want to see all quotations obtained during my interview before  
publication…………………………………………………………………………………..  
 
I DO NOT want to see the quotations obtained during this interview before 
publication……………………………………………………………………………….. 
 
 
7. I agree to take part in the study………………………………………………………….. 
 
Please sign and date: 
 
 
 
Name of participant     Date    Signature 
 
 
 
Name of researcher    Date    Signature 
 
Thank you for your help with this research project 
For any further information about this study, please telephone: Dr Toby Helliwell (01782 734895) 
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A qualitative study investigating the diagnostic and management 
challenges of PMR in primary care: covering letter 
 
Version 1.0 10/10/13 Researchers: T Helliwell, S Muller, J Richardson, S Hider, C Mallen 
 
PMR in general practice: A qualitative study 
 
Participant information leaflet 
 
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disorder 
seen in older patients. The majority of patients with the disorder are identified, diagnosed 
and managed exclusively by general practitioners yet the majority of research to date has 
focused on secondary care. As such little is known about the management and diagnostic 
challenges that PMR poses in primary care. 
This leaflet explains what will happen if you decide to take part in the study. If there is 
anything that is not clear, or you require further information, please contact the research 
team: 
 
Mondays and Thursdays: Dr Toby Helliwell 01782 734829 
Tuesdays, Wednesdays, Fridays  
Alternatively, email t.helliwell@keele.ac.uk 
 
What is the purpose of the study? 
This study aims to explore in depth the beliefs, challenges and experiences of GPs on the 
management and diagnosis of PMR in the community. We are particularly interested in 
your views on what typical features you use to diagnose PMR and any diagnostic or 
management challenges that you have faced. This is particularly pertinent for general 
practitioners as they are often the first clinicians approached by patients and, as no 
commonly agreed diagnostic criteria nor gold standard test exists for PMR, diagnosis can 
be difficult. GPs too, are often intimately involved in the on-going management and 
monitoring of the majority of PMR patients. This remains an area where there has 
historically been little research focus. Your opinions will help direct further research 
initiatives and identify areas where GPs could be better supported in diagnosing and 
managing PMR. 
 
Do I have to take part? 
We are writing to you because, when you completed a questionnaire as part of the ‘PMR 
National GP survey’ study, you agreed to further contact. We would like to carry out some 
follow-up research to explore some of the issues raised in more detail and wondered if 
you could help again. You are, of course, entirely free to choose whether or not to 
take part. If you decide to take part, you will be asked to sign a consent form entitled 
‘consent for taking part in the study and use of quotes’. After giving consent, you are still 
free to withdraw at any time without giving reason. Your decision to take part in the study, 
or to withdraw, will not affect any legal rights. If you would like to take part, please return 
the enclosed reply slip and consent form and we will contact you. 
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What will happen to me if I agree to take part? 
If you agree to take part, you will be contacted by telephone to arrange a subsequent 
telephone interview, at a time most convenient for you. The interview will last 
approximately 20-30 minutes and it will focus on your experiences on diagnosis and 
management of PMR. Since we are interested in your opinions, there are no right or 
wrong answers. No preparation for the interview is necessary and this is not a test about 
your knowledge. We would like to record the interview and will check that this is 
acceptable to you prior to the interview. The interview will then be transcribed into text. 
Both the recording and the text will be stored in a secure location, only accessed by the 
research team. Both the recording and the text will contain no personal identifiable 
information. We will ask if you would like a copy of the transcribed interview for your 
records. We will store the recordings securely for 20 years, after which they will be 
destroyed. 
 
During the interview, you can choose not to answer questions, or to end the interview at 
any time. You will be asked at the end of the interview if you are still happy to be included 
in the study. If you decide that you would like to withdraw your consent, your interview will 
not be used. In order to convey the attitudes and beliefs of participants, we would like to 
use direct quotations from the interview. On the consent form we have included a section 
specifically for the use of direct quotations. We would be grateful if you could complete 
this section also, however if you do not wish quotes to be used please check the relevant 
box. You will be asked at the end of the interview again if you would still be willing to allow 
quotes to be used if you had agreed on the initial consent form. 
 
Any information you give in the interview will not be passed on to anyone else without 
your permission. If your interview contains comments that might identify a third party (e.g. 
GP, surgery, hospital), we will ensure that the person or institution cannot be identified in 
any account or published report of this study.  
 
What are the possible benefits and risks of taking part? 
There are no direct risks relating to medical treatment in this study, neither are there any 
intended direct medical benefits. There may be an indirect benefit to patients from the 
insights we gain, but of course, we cannot guarantee this. 
Occasionally during interviews like these, some people may feel some distress, perhaps a 
topic may prompt unhappy memories or distressing thoughts. If this happens and you do 
not wish to discuss this further, the topic will not be followed up again during the interview. 
The study is not intended to be of any educational benefit. 
 
Who is organising and funding the research, and is it ethical? 
This study is part of a programme of work being conducted by the Arthritis Research 
Campaign National Primary Care Centre at Keele University. It is 
funded by the National Society of Primary Care Research and ethical approval has been 
obtained from the Keele University Ethical Review Panel. 
 
Thank you for your time    
 
 
 
Dr Toby Helliwell 
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Appendix 7 HELLIWELL, T., HIDER, S.L., BARRACLOUGH, K., DASGUPTA, B. 
and MALLEN, C.D., 2012. Diagnosis and management of 
polymyalgia rheumatica. The British journal of general practice 
: the journal of the Royal College of General 
Practitioners, 62(598), pp. 275-276. 
BARRACLOUGH, K., MALLEN, C.D., HELLIWELL, T., HIDER, S.L. 
and DASGUPTA, B., 2012. Diagnosis and management of giant 
cell arteritis. The British journal of general practice : the 
journal of the Royal College of General Practitioners,62(599), 
pp. 329-330. 
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Toby Helliwell, DRCOG, MRCGP, GP, NIHR inpractice research fellow and Samantha L Hider, 
PhD, FRCP, senior lecturer & honorary consultant rheumatologist 
Kevin Barraclough, MA, FRCP, MRCGP, AFOM, LLB, GP, Painswick Surgery 
Bhaskar Dasgupta, MD, FRCP, consultant rheumatologist, honorary professor 
Christian D Mallen, MMedSCi, MPhil, PhD, MRCGP, professor of general practice, director of 
academic general practice, director of clinical academic training, Arthritis Research UK clinician 
scientist, GP 
Author information ► Article notes ► Copyright and License information ► 
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INTRODUCTION 
Polymyalgia rheumatica (PMR) is the commonest inflammatory rheumatic disorder 
affecting older people.1Patients typically present with bilateral shoulder pain, morning 
stiffness, raised inflammatory markers, and have a rapid response to low-dose 
corticosteroids. There is no gold standard diagnostic test and despite being first 
described in 1888, controversies still exist as to its defining characteristics. PMR 
carries a lifetime risk of 2.4% for females and 1.7% for males.2 The incidence in the 
UK has been shown to be 8.42 per 10 000 person years.3 In the UK, the majority of 
patients are managed exclusively in primary care4 with an average full-time GP seeing 
five new cases of PMR per year.5 Accurate diagnosis can be challenging even for 
specialists, but is essential as many serious illnesses can mimic PMR. Guidelines for 
the diagnosis and management of PMR have recently been published by the British 
Society of Rheumatologists (BSR) and British Health Professionals in Rheumatology 
(BHPR).6 
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DIAGNOSIS 
Consider PMR in patients over the age of 50 years with: 
 ≥2 weeks of bilateral shoulder and/or pelvic girdle ache; 
 morning stiffness; and 
 raised inflammatory markers. 
Subsequent clinical assessment and investigations should be directed towards 
excluding disorders that can mimic PMR (Box 1). Suggested initial investigations 
include full blood count, renal, thyroid, and liver function, inflammatory markers 
(erythrocyte sedimentation rate [ESR]/C-reactive protein [CRP]), bone, protein 
electrophoresis, rheumatoid factor, urinary Bence Jones protein, creatinine kinase, and 
dipstick urinalysis. Additional investigations if clinically appropriate include 
antinuclear antibodies, anti-cyclic citrullinated peptide antibodies, and chest X-ray. 
Ultrasound of the shoulders and/or hips may show characteristic lesions such as sub-
deltoid bursitis, bicipital tenosynovitis, and joint fluid.7 
Box 1. Disorders that can mimic polymyalgia rheumatica 
Rheumatological disorders 
Inflammatory 
 Late-onset rheumatoid arthritis, spondylo-arthritides, psoriatic arthritis, systemic 
lupus erythematosus, scleroderma, Sjögren's syndrome, vasculitis, inflammatory 
myopathies 
Non-inflammatory 
 Osteoarthritis, rotator cuff disorders, frozen shoulder 
Infection 
 Tuberculosis, bacterial endocarditis, osteomyelitis, septic arthritis, other 
infections, for example, urinary tract infections 
Malignancies 
 Lymphoma, myeloma, and leukaemia. Solid tumours, and metastases, for 
example, prostate, bowel, lung, breast, and renal 
Other 
 Endocrine disorders (for example, hypo/hyperthyroidism, 
hyper/hypoparathyroidism) 
 Drug induced myalgia (for example, statins) 
 Parkinson's disease 
Giant cell arteritis (GCA) is a serious association of PMR. The latest guidance is 
summarised in an associated article.8 
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TREATMENT 
A rapid response to low dose prednisolone (15 mg) is typical. However, a poor 
response should prompt further assessment for an alternative diagnosis or consideration 
for a specialist review. Patients taking long-term corticosteroids are at high risk of 
developing osteoporosis. Current guidance suggests offering osteoporosis prophylaxis 
(bisphosphonate and calcium/vitamin D supplementation) to those who are at high risk 
of fracture (≥65 years or prior fragility fracture).6 In other individuals calcium/ vitamin 
D supplementation and a dual-emission X-ray absorptiometry scan is 
recommended.6 Although not part of this latest guidance, gastric symptoms, are 
commonly reported among patients with PMR.9 Gastric protection should therefore be 
strongly considered especially in at-risk patients. 
 
ONGOING MANAGEMENT 
Robust clinical evidence for corticosteroid tapering is lacking. An initial dose of 15 mg 
of prednisolone coupled with a slow reduction in dose is effective at maintaining 
remission.10 Guidance suggests 15 mg of prednisolone for 3 weeks, followed by 12.5 
mg for 3 weeks, then 10 mg for 4–6 weeks, and finally a reduction in dose of 1 mg 
every 4–8 weeks. After initial diagnosis, follow-up to assess response within 1 week is 
suggested. Subsequently a review of symptoms, progress, adverse side effects, 
complications of treatment, atypical features, and an assessment for GCA is suggested 
in weeks 3 and 6 and again, 3, 6, 9, and 12 months after diagnosis. This treatment and 
follow-up regimen serves only as a guide and should be modified according to 
individual patients' response and ongoing progress. Relapses should be assessed by 
clinical symptoms rather than being guided by laboratory results (such as ESR and 
CRP). Management of relapse should involve an increase of prednisolone to the 
previously higher dose that controlled symptoms, followed by reassessment.6 Recurrent 
relapses (more than two) are an indication for specialist referral for consideration of 
steroid sparing agents such as methotrexate. 
PATIENT EDUCATION AND SELF-MANAGEMENT 
All patients should be provided with written information on PMR and corticosteroid 
treatments. They should also be given information on range-of-motion exercises for the 
shoulder and provided with contacts to their local Polymyalgia Rheumatica & Giant 
Cell Arteritis UK patient support group.11 
REFERRAL 
A wide range of illnesses can mimic PMR, some of which respond to corticosteroid 
therapy. Accurate diagnosis is therefore essential, ongoing management can usually 
continue in primary care once diagnosis has been confirmed. In cases of diagnostic 
uncertainty early referral for specialist review is essential. Some examples of 
indications for early referral are summarised in Box 2. 
Box 2. Indications for early referral to specialist 
Atypical features 
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 Age <60 years 
 Chronic onset 
 Lack of shoulder involvement 
 Lack of inflammatory stiffness 
 Red flag features (prominent systemic features, weight loss, night pain, 
neurological signs) 
 Features of peripheral arthritis, muscle disease, and other autoimmune/systemic 
diseases 
 Very high or normal inflammatory markers 
Treatment dilemmas 
 Poor/incomplete response to corticosteroids 
 Inability to reduce corticosteroid therapy 
 Recurrent relapse 
 Contraindications to corticosteroid therapy 
 Prolonged treatment duration (>2 years) 
CONCLUSION 
PMR is a commonly-seen disorder that is often managed exclusively in primary care. 
The BSR/BHPR guidance brings together the best evidence and extensive expert 
opinion to provide a much needed safe approach to the identification and ongoing 
management of this common inflammatory rheumatological disorder. Accurate 
diagnosis is key. Further early expert review should be sought in situations where 
diagnosis is uncertain. The guidance reinforces a more holistic approach to PMR 
emphasising the need to consider the prevention and management of potential side 
effects and complications of treatment. Dissemination of this guidance to general 
practice, where the majority of patients are managed, will hopefully facilitate accurate 
diagnosis and improve the ongoing management and, therefore, outcomes for patients 
with PMR. 
 
Notes 
Provenance 
Freely submitted; not externally peer reviewed. 
Discuss this article 
Contribute and read comments about this article on the Discussion 
Forum: http://www.rcgp.org.uk/bjgp-discuss 
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INTRODUCTION 
Giant cell arteritis (GCA) is the commonest form of large-vessel vasculitis and affects 
branches of the external carotid artery but also the ciliary and retinal arteries. The 
symptoms are caused by local ischaemia due to endovascular damage and cytokine-
mediated systemic illness. There is considerable overlap with polymyalgia rheumatica 
(PMR): 16–21% of patients with PMR have GCA on temporal artery biopsy, and 
symptoms of PMR are present in 40–60% of patients with GCA.1 GCA occurs in 2.2 
per 10 000 patient-years in the UK.2 A full-time GP may expect to see one new case 
every 1–2 years. It is virtually unknown in people aged under 50 years. Early 
recognition is critical to prevent visual loss, that otherwise occurs in up to 20% of 
cases.3 Once high-dose corticosteroids are started, visual loss is extremely rare. 
Guidelines for the diagnosis and management of GCA, have recently been published by 
the British Society of Rheumatologists and British Health Professionals in 
Rheumatology.4 
DIAGNOSIS 
A 2002 systematic review analysed the presenting clinical features in a mixture of 
studies, with a total of 1435 cases of giant cell arteritis.5 The mean duration of 
symptoms at diagnosis was 3.5 months.5 The results in Table 1 demonstrate the 
somewhat protean manifestations of this condition. 
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Table 1 
Manifestations of giant cell arteritis 
The sensitivity of individual clinical features was relatively low: 24% of cases had no 
headache at all, and only 52% had a temporal headache. The diagnosis is easily missed 
when systemic symptoms (such as low-grade fever or weight loss), ischaemic 
symptoms (jaw claudication or transient visual symptoms), or polymyalgic symptoms 
(proximal myalgia or morning stiffness) predominate over the well-known hallmark of 
temporal headache. Unfortunately, there is some evidence that this subgroup (without 
headache as the dominant symptom) may be at increased risk of visual loss. A recent 
audit of 65 patients with GCA showed that 44 had had unrecognised visual disturbance, 
visual loss, or stroke in the mean of 35 days between onset of symptoms and diagnosis 
(range 2–336 days).6 Eleven of these patients presented without headache or scalp 
tenderness, and 10 of these had visual loss. 
Only 4% of patients with GCA have a completely ‘normal’ erythrocyte sedimentation 
rate (ESR) but nearly one-fifth have an ESR >50 mm/hour. 
There is some evidence that GCA may be underdiagnosed. A 1971 Swedish study 
examined 1097 consecutive autopsies, with temporal artery examination carried out in 
each of them. Sixteen cases of undiagnosed GCA were identified (1.5% of the study 
population). Retrospective analysis of the case notes documented typical features of 
undiagnosed GCA in nine.7 
Localities need to have a clear pathway for suspected GCA because GPs are often 
uncertain whether to refer to rheumatologists, ophthalmologists, or vascular surgeons. 
Temporal artery ultrasound may become more used in diagnosis. A meta-analysis of 
studies of temporal artery ultrasound against a gold standard of temporal artery biopsy 
found a sensitivity of 69% and a specificity of 82%.8 
BIOPSY 
Urgent referral for specialist assessment and temporal artery biopsy is suggested for all 
patients with suspected GCA, although this should not delay initiation of immediate 
corticosteroid treatment. The biopsy can retain the characteristic giant cell histology for 
2–6 weeks after initiation of treatment but should ideally be done within 2 weeks. The 
biopsy may be negative in 13% of true cases (possibly because of ‘skip lesions’).9 If the 
clinical features are typical, the patients should, nevertheless, be treated. 
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TREATMENT 
High-dose glucocorticosteroid therapy should be initiated immediately the diagnosis is 
suspected. There are few risks in starting treatment erroneously (the treatment can 
always be stopped) and delayed treatment can result in sudden visual loss. In the 
absence of ischaemic symptoms (jaw claudication or visual symptoms), it is reasonable 
to start on 40 mg prednisolone daily orally. If the patient has jaw claudication, the risk 
of visual loss is high and 60 mg prednisolone should be used. If the patient already has 
visual symptoms of any sort, then immediate admission for 3 days of intravenous 
methylprednisolone is necessary to preserve vision. 
The initial dose of oral prednisolone is maintained until symptoms have resolved and 
inflammatory mediators have normalised. The dose can then be reduced by 10 mg at 2-
week intervals until the patient is taking 20 mg daily, and then reduced by 2.5 mg steps 
each 2 weeks to 10 mg. Thereafter, a reduction of 1 mg per month every 4–8 weeks is 
recommended, as with PMR. Most patients have stopped treatment by 2 years. Review 
with measured inflammatory markers is initially weekly, tapering to monthly, and then 
3-monthly. 
Low-dose aspirin should be considered in those patients without contraindications and 
bisphosphonates with calcium and vitamin D supplementation are recommended for all 
patients on long-term corticosteroids. 
Relapse is usually, but not always, associated with a rise in inflammatory markers. 
Rarely, patients may develop a more widespread vasculitis of the aortic arch and its 
branches. Upper-limb claudication, absent pulses, or widening of the mediastinum on a 
chest X-ray should prompt urgent specialist evaluation. 
PATIENT EDUCATION AND SELF-MANAGEMENT 
Patients should receive written information on GCA (such as the Arthritis Research 
Campaign booklet on GCA), together with instructions about seeking urgent review in 
the event of any return of symptoms. Support can be obtained from the local 
Polymalgia Rheumatica and Giant Cell Arteritis UK (PMRGCAUK) patient support 
group (http://www.pmrgcauk.com/). 
CONCLUSION 
GCA is the commonest form of vasculitis. A GP will encounter a new case roughly 
once every 1–2 years. Early recognition and treatment with high-dose corticosteroids is 
crucial to preventing the visual loss that occurs in 20% of patients. There is evidence 
that the risk of visual loss is higher in patients with jaw claudication and in patients 
who do not have the typical temporal headache. The starting dose for prednisolone is 
40 mg to 60 mg. Specialist referral is advised and temporal artery biopsy should ideally 
occur within 2 weeks. 
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Notes 
Provenance 
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Editorial 
Polymyalgia rheumatica (PMR) is a condition that is commonly seen in older 
patients in primary care. It is known that there is wide variation in clinical practice 
with respect to diagnosis and management. The challenges include having no gold 
standard test for it, the possibility of atypical presentation and the existence of other 
conditions that can mimic it. 
Having made the diagnosis it is important to balance treatment efficacy against 
potential side-effects. Patients vary in their response to steroids and the rate at 
which their treatment can be tapered. 
Patients with PMR are likely to already have co-morbidities or to be at risk of 
developing them due to steroid treatment. Primary care has a key role in screening 
and monitoring for hypertension, diabetes and bone health. Again it is known that 
there is often room for improvement here. 
The authors of this report address these challenges with a very practical and useful 
guide to how assessment and management can be improved. This is definitely 
something to keep to hand as you see patients with PMR. 
Simon Somerville, Medical Editor  
Introduction 
Polymyalgia rheumatica (PMR) is the commonest inflammatory rheumatological disorder of older 
people, with an incidence of 8.4/10,000 person-years (95% CI 8.3 to 8.6) and a lifetime risk of 2.4% for 
women and 1.7% for men.1,2 It is characterised by bilateral pain and stiffness of the hips and shoulders 
and is often associated with profound disability. The majority of patients with PMR are exclusively 
managed in the community, yet diagnosis can be difficult, especially for those with an atypical 
presentation. A recent analysis of GP consultation databases suggests that current primary care 
management may be suboptimal and that patient care could be improved.3 The aim of this edition of 
Hands On is to provide an evidence-based overview to the successful diagnosis and management of 
patients with PMR in general practice settings. 
Making the diagnosis 
PMR is uncommon in those under 60 years. For many patients, the onset of PMR is abrupt and may 
start with fevers or chills (‘the flu that does not go away’). Patients complain of pain in the shoulders and 
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hips that is associated with stiffness, especially in the morning. They often report that they rapidly 
deteriorate over a period of 1–2 weeks, becoming so disabled that they are no longer able to get off the 
toilet without help or turn over in bed. Patients usually have elevated inflammatory markers (e.g. ESR, 
CRP or where available plasma viscosity, PV) and may report systemic features such as malaise and 
fatigue. Treatment with low-dose glucocorticoids (e.g. prednisolone) produces a dramatic response in 
around 80–90% of patients. 
The lack of a ‘gold standard’ (100% specific) diagnostic test makes diagnosing PMR challenging even 
for experts.4 As such a thorough and systematic diagnostic work up is essential in primary care to 
exclude other conditions that commonly present with a polymyalgic syndrome. These commonly include 
both rheumatological and non-rheumatological disorders, some of which may initially improve with 
glucocorticoid treatment, and so response to treatment is not diagnostic of PMR.4 Therefore patients 
who do not have a rapid, complete response (see below for definition) warrant re-consideration of the 
diagnosis. 
A number of ‘core’ investigations are recommended by the British Society for Rheumatology.5 These are 
intended to help guide the diagnostic process and are presented in Box 1. 
 
Specialist imaging such as musculoskeletal ultrasound of the shoulders and hips is now used in some 
hospitals to aid the diagnosis of rheumatic disease; however, its role in primary care remains to be 
defined. In some patients a chest X-ray is indicated if respiratory pathology is suspected or if the patient 
has prominent systemic symptoms. 
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How to treat and monitor PMR 
For most patients with PMR the mainstay of treatment is with glucocorticoids, usually oral prednisolone, 
although there is limited trial evidence to support the use of injectable glucocorticoids (such as 
intramuscular methylprednisolone) in patients with mild or localised symptoms. The mechanism of action 
of glucocorticoids in PMR is not fully understood, but high doses (30 mg prednisolone or more) should 
not be required. There is no role for the routine use of non-steroidal anti-inflammatory drugs. 
The response to the initial glucocorticoid treatment could be viewed as an (admittedly imperfect) 
diagnostic test for PMR. This ‘test’ is most specific for PMR as patients feel completely better (‘magic’ or 
‘miracle’ effects) after 3 days of 15 mg prednisolone. Sensitivity of the ‘trial of steroids’ is probably 
improved, at the cost of some loss in specificity, if patients are allowed longer (1–2 weeks) to achieve a 
70% reduction in symptom scores, or if they are given higher doses (e.g. 20–25 mg prednisolone). 
After the initial response, the glucocorticoid dose is tapered gradually. The average length of treatment 
in hospital-based cohorts is around 2 years but with wide variation. There is little evidence to help decide 
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how to taper the dose. Some patients need a much slower taper than others, and some patients develop 
significant glucocorticoid toxicity. To reduce the risks of treatment, it is usually recommended to try the 
quicker taper first, but to slow this taper down if need be to keep the PMR symptoms under control. 
Individualised treatment and shared decision-making should be the rule rather than the exception. 
The aim of PMR treatment is to achieve acceptable control of PMR symptoms while minimising the risks 
and side-effects of treatment. Therefore, if a patient feels their PMR is well controlled, there is no need 
to re-check inflammatory markers before reducing the dose. A transient (<1 week) increase in PMR-like 
symptoms after dose reduction is common and usually manageable if patients are forewarned. 
 
A key role of the GP is to regularly monitor patients, checking for alternative diagnoses and assessing 
the risks and side-effects of glucocorticoids, which are common in PMR6 and are a major consideration 
when making decisions on tapering rates. Risks and side-effects such as weight gain, skin fragility, 
changes in physical appearance, infections, glaucoma, steroid myopathy, osteoporosis/fracture, 
avascular necrosis, hypertension, diabetes, psychiatric morbidity, and peptic ulcers should all be 
considered as appropriate for each individual patient. Consider adding calcium, vitamin D and perhaps 
bisphosphonate according to local guidelines. It may be wise to monitor blood glucose and blood 
pressure intermittently. Patients should be offered a ‘steroid card’ and access to support and information 
about their condition. 
 
Rheumatologists often see the atypical cases, those with incomplete glucocorticoid response and those 
with difficulty in stopping glucocorticoids. Some rheumatologists use methotrexate or other drugs but 
most of the evidence comes from rheumatoid arthritis rather than PMR. If used, methotrexate also 
requires monitoring for potential toxicity. 
Non-pharmacological treatments have not been formally evaluated although many patients self-manage 
pain and stiffness with heat packs and simple analgesia. Whilst physiotherapy interventions have not yet 
been formally investigated the maintenance of joint ranges around the shoulders and hips with gentle 
exercise is prudent and patients anecdotally report improvements in stiffness and pain as well as 
function. Additional strengthening exercises can be added to a daily programme to maximise general 
activities of daily living and mobility. Effective physiotherapy exercise can be enhanced by general 
advice relating to keeping active, optimal posture, diet, the use of heat, minimising the risk of falls, 
pacing strategies as well as being alert to headaches or other potential related symptoms. 
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Patient education forms an essential part of management for patients with PMR. Written information 
should be provided giving details of the natural history of the condition, along with information on 
treatment, side effects and ‘red flags’ (including giant cell arteritis). In addition to our resources for 
PMR, PMRGCAuk is a registered charity that provides a range of services, including a telephone 
helpline, for patients and their families. 
 
Do not miss giant cell arteritis 
Perhaps 5–10% of patients with PMR are also diagnosed with giant cell arteritis (GCA); in some cases 
the GCA only appears later.1 Untreated GCA can result in permanent visual loss or stroke, and as such 
is a ‘must not miss’ diagnosis. Tell patients with PMR to look out for headache, scalp tenderness, jaw 
pain/claudication and visual disturbance. GCA symptoms may need high glucocorticoid doses (usually at 
least 30–40 mg/day prednisolone) so the risk of steroid-associated side-effects is high. Patients 
suspected as having GCA should be urgently referred to local specialist services (usually rheumatology 
or ophthalmology, but this is dependent on local care pathways). 
 
Specialist referral 
Many patients with suspected PMR can be safely diagnosed and managed in general practice. Referral 
is usually indicated for one of two reasons: diagnostic uncertainty and lack of response to primary care 
treatment. 
The British Society for Rheumatology recommends referral in the following situations4: 
 younger age (usually less than 60 years) 
 no shoulder involvement 
 lack of inflammatory stiffness 
 insidious onset 
 normal or very high inflammatory markers 
 red flag features (e.g. prominent systemic features, weight loss, night pain, neurological signs) 
 suspicion of co-existing giant cell arteritis 
 poor or incomplete response to glucocorticoids 
 difficulty reducing steroids dose 
 recurrent relapse 
 contraindication to glucocorticoid treatment. 
  
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